WO2018065182A1

WO2018065182A1 - Reduced quinoline compounds as antifuni agents

Info

Publication number: WO2018065182A1
Application number: PCT/EP2017/073098
Authority: WO
Inventors: Bernd Mueller; Erica CAMBEIS; Jan Klaas Lohmann; Ana Escribano Cuesta; Antje Wolf; Nadine RIEDIGER; Marcus Fehr; Violeta TERTERYAN-SEISER; Wassilios Grammenos; Christian Winter
Original assignee: Basf Se
Priority date: 2016-10-04
Filing date: 2017-09-14
Publication date: 2018-04-12

Abstract

The present invention relates to compounds (I) wherein the variables are defined as given in the description and claims. The invention further relates to uses, processes and intermediates for compounds (I).

Description

REDUCED QUINOLINE COMPOUNDS AS ANTIFUNI AGENTS

Description

The present invention relates to quinoline compounds and the N-oxides and the salts thereof for combating phytopathogenic fungi, and to the use and methods for combating phytopathogenic fungi and to seeds coated with at least one such compound. The invention also relates to processes for preparing these compounds, intermediates, processes for preparing such intermediates, and to compositions comprising at least one compound I.

In many cases, in particular at low application rates, the fungicidal activity of the known fungicidal compounds is unsatisfactory. Based on this, it was an object of the present invention to provide compounds having improved activity and/or a broader activity spectrum against phytopathogenic harmful fungi.

Surprisingly, this object is achieved by the use of the inventive quinoline compounds of formula I having favorable fungicidal activity against phytopathogenic fungi.Accordingly, the present invention relates to the c

wherein

m is 0, 1 , 2, 3 or 4;

R¹ is in each case independently selected from halogen, OH, CN, NO2, SH, N H₂,

NH(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂, NH-S0₂-R^x, Ci-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆- alkynyl, Ci-C6-alkoxy, C3-C6-cycloalkyl, five- or six-membered heteroaryl and aryl; wherein the heteroaryl contains one, two or three heteroatoms selected from N, O and S; and wherein

R^x is Ci-C₄-alkyl, Ci-C₄-halogenalkyl, unsubstituted aryl or aryl that is substituted by one, two, three, four or five substituents R^x1 independently selected from Ci-C₄-alkyl;

wherein the acyclic moieties of R¹ are not further substituted or carry one, two, three or up to the maximum possible number of identical or different groups R^1a which independently of one another are selected from:

R^1a halogen, OH, CN, Ci-C6-alkoxy, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, Ci- C₄-halogenalkoxy, Ci-C6-alkylthio and phenoxy, wherein the phenyl group is unsubstituted or carries one, two, three, four or five substituents R^11a selected from the group consisting of halogen, OH, Ci-C₄-alkyl, Ci-C₄-halogenalkyl, Ci- C₄-alkoxy and Ci-C₄-halogenalkoxy;

wherein the cycloalkyi, heteroaryl and aryl moieties of R¹ are not further substituted or carry one, two, three, four, five or up to the maximum number of identical or different groups R^{1 b} which independently of one another are selected from:

R^{1 b} halogen, OH, CN, Ci-C₄-alkyl, Ci-C₄-alkoxy, Ci-C₄-halogenalkyl, C₃-C₆- cycloalkyl, C3-C6-halogencycloalkyl, Ci-C₄-halogenalkoxy and Ci-C6-alkylthio; n is 0, 1 or 2;

R² is in each case independently selected from the substituents as defined for R¹ , wherein the possible substituents for R² are R^2a and R^2b , respectively, which correspond to R^1a and R^{1 b}, respectively;

are independently selected from halogen, OH, CN, NO2, SH, Ci-C6-alkylthio, NH2,

NH(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂, NH-S0₂-R^x, Ci-C₆-alkyl,_Ci-C₆-halogenalkyl, C₂-C₆- alkenyl, C2-C6-halogenalkenyl, C2-C6-alkynyl, C2-C6-halogenalkynyl, Ci-C6-alkoxy, Ci-C6-halogenalkoxy, C2-C6-alkenyloxy, C2-C6-alkynyloxy, CH(=0), C(=0)Ci-C6- alkyl, C(=0)0(d-C₆-alkyl), C(=0)NH(C C₆-alkyl), C(=0)N(Ci-C₆-alkyl)₂,

CR'=NOR", a saturated or partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbocycle or heterocycle, wherein in each case one or two CH2 groups of the carbo- and heterocycle may be replaced by a group independently selected from C(=0) and C(=S), five- or six-membered heteroaryl and aryl; wherein the heterocycle and the heteroaryl contain independently one, two, three or four heteroatoms selected from N, O and S; and wherein R' and R" are independently selected from H, Ci-C₄-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, saturated or partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbo- and heterocycle, five- or six-membered heteroaryl or aryl; wherein the heterocycle or heteroaryl contains one, two or three heteroatoms selected from N, O and S, and wherein R' and R" are independently unsubstituted or substituted by R'" which is independently selected from halogen, OH, CN, NO2, SH, NH2, NH(Ci-C₄- alkyl), N(Ci-C₄-alkyl)₂, NH-S0₂-R^x, Ci-C₆-alkyl, Ci-C₆-halogenalkyl, C₂-C₆-alkenyl, C2-C6-halogenalkenyl, C2-C6-alkynyl, C2-C6-halogenalkynyl, Ci-C6-alkoxy, C1-C6- halogenalkoxy, C₃-C6-cycloalkyl, C₃-C6-halogencycloalkyl and phenyl; or wherein the acyclic moieties of R³ and R⁴ are independently not further substituted or carry one, two, three or up to the maximum possible number of identical or different groups R^3a or R^4a, respectively, which independently of one another are selected from:

R^3a,R ^a halogen, OH, CN, N0₂, SH, NH₂, NH(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂,

NH(C(=0)Ci-C₄-alkyl), N(C(=0)Ci-C₄-alkyl)₂, NH-S0₂-R^x, Ci-C₆-alkoxy, Ci-C₄-halogenalkoxy, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, C1-C6- alkylthio, C C₆-halogenalkylthio, S(0)_z-CrC₆-alkyl, S(0)_z-Ci-C₆- halogenalkyl, S(0)_z-aryl, CH(=0), C(=0)Ci-C₆-alkyl, C(=0)0(Ci-C₆-alkyl), C(=0)NH(Ci-C₆-alkyl), C(=0)N(Ci-C₆-alkyl)₂, CR'=NOR", a saturated or partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten- membered carbocycle or heterocycle, five-, six- or ten-membered het- eroaryl, aryl, phenoxy; wherein in each case one or two CH₂ groups of the carbocycle and heterocycle may be replaced by a group independently selected from C(=0) and C(=S); wherein the heterocycle and heteroaryl contain independently one, two, three or four heteroatoms selected from

N, O and S; wherein the carbocyclic, heterocyclic, aryl, phenyl and heteroaryl groups are independently unsubstituted or carry one, two, three, four or five substituents selected from the group consisting of halogen, OH, CN, N0₂, SH, NH₂, NH(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂, NH(C(=0)Ci-C₄- alkyl), N(C(=0)Ci-C₄-alkyl)₂, NH-S0₂-R^x, Ci-C₆-alkylthio, Ci-C₄-alkyl, Ci-

C₄-halogenalkyl, Ci-C₄-alkoxy, Ci-C₄-halogenalkoxy and S(0)_z-Ci-C6- alkyl;

z is 0, 1 and 2;

wherein the carbocyclic, heterocyclic, heteroaryl and aryl moieties of R³ and R⁴ are independently not further substituted or carry one, two, three, four, five or up to the maximum number of identical or different groups R^3b or R^4b, respectively, which independently of one another are selected from:

R^3b,R^4b halogen, OH, CN, N0₂, SH, NH₂, NH(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂,

NH(C(=0)Ci-C₄-alkyl), N(C(=0)Ci-C₄-alkyl)₂, NH-S0₂-R^x, Ci-C₄-alkyl, Ci- C₄-alkoxy, Ci-C₄-halogenalkyl, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl,

Ci-C₄-halogenalkoxy, Ci-C6-alkylthio, Ci-C6-halogenalkylthio, S(0)_z-Ci- C6-alkyl, Ci-C₄-alkoxy-Ci-C₄-alkyl, phenyl and phenoxy, wherein the phenyl groups are unsubstituted or carry one, two, three, four or five substituents selected from the group consisting of halogen, OH, Ci-C₄-alkyl, Ci- C₄-halogenalkyl, Ci-C₄-alkoxy and Ci-C₄-halogenalkoxy;

and wherein R^x R' and R" is as defined above;

3, R⁴ together with the carbon atom to which they are bound (marked with ^* in formula I) form a saturated or partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbocycle or heterocycle; wherein the heterocycle contains one, two, three or four heteroatoms selected from N, O and S, wherein the heteroa- tom N may carry one substituent R^N selected from CrC₄-alkyl, CrC₄-halogenalkyl and S0₂Ph, wherein Ph is unsubstituted phenyl or phenyl that is substituted by one, two or three substituents selected from Ci-C₄-alkyl, and wherein the heteroatom S may be in the form of its oxide SO or S0₂, and wherein the carbocycle or heterocy- cle is unsubstituted or carries one, two, three or four substituents R³⁴ independently selected from halogen, OH, CN, N0₂, SH, NH₂, Ci-C₆-alkyl, Ci-C₆-halogenalkyl, Ci- C6-alkoxy, Ci-C6-halogenalkoxy, Ci-C6-alkylthio, Ci-C6-halogenalkylthio, C1-C4- alkoxy-Ci-C₄-alkyl, phenyl and phenoxy, wherein the phenyl groups are unsubstituted or carry one, two, three, four or five substituents R^34a selected from the group consisting of CN, halogen, OH, Ci-C₄-alkyl, Ci-C₄-halogenalkyl, Ci-C₄-alkoxy and

Ci-C₄-halogenalkoxy; and wherein in each case one or two CH₂ groups of the carbo- or heterocyde may be replaced by a group independently selected from C(=0) and C(=S);

R⁵ is hydrogen, halogen, OH, CN, N0₂, SH, NH₂, NH(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂, NH- S0₂-R^x, C₂-C₆-alkyl, substituted d-Ce-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, Ci-C₆- alkoxy, C3-C6-cycloalkyl, saturated or partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered heterocyde, five- or six-membered heteroaryl or aryl; wherein the heterocyde or heteroaryl contains one, two or three heteroa- toms selected from N, O and S; and wherein R^x is defined above; and

wherein the acyclicmoieties of R⁵ are not further substituted or carry one, two, three or up to the maximum possible number of identical or different groups R^5a which independently of one another are selected from:

R^5a halogen, OH, CN, Ci-Ce-alkoxy, Cs-Ce-cycloalkyl, Cs-Ce-halogencycloalkyl, Ci- C₄-halogenalkoxy, Ci-C6-alkylthio and phenoxy, wherein the phenyl group is unsubstituted or carries one, two, three, four or five substituents R^55a selected from the group consisting of halogen, OH, CrC₄-alkyl, CrC₄-halogenalkyl, Ci-

C₄-alkoxy and Ci-C₄-halogenalkoxy;

wherein the cycloalkyi, heterocyde, heteroaryl and aryl moieties of R⁵ are not further substituted or carry one, two, three, four, five or up to the maximum number of identical or different groups R^5b which independently of one another are selected from:

R^5b halogen, OH, CN, Ci-C₄-alkyl, Ci-C₄-alkoxy, Ci-C₄-halogenalkyl, Cs-Ce- cycloalkyl, C3-C6-halogencycloalkyl, CrC₄-halogenalkoxy and Ci-C6-alkylthio;

R⁶ is independently selected from the substituents as defined for R⁵, wherein the

possible substituents for R⁶ are R^6a, R^66a and R^6b, respectively, which correspond to R^5a, R^55a and R^5b, respectively;

or R⁵ and R⁶ together with the carbon atom to which they are bound (marked with C^** in formula I) form a saturated or partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbo- or heterocyde; wherein the heterocyde contains one, two, three or four heteroatoms selected from N, O and S, wherein the heteroatom N may carry one substituent R^N selected from CrC₄-alkyl, Ci-C₄- halogenalkyl and S0₂Ph, wherein Ph is unsubstituted phenyl or phenyl that is substituted by one, two or three substituents selected from Ci-C₄-alkyl, and wherein the heteroatom S may be in the form of its oxide SO or S0₂, and wherein the carbocycle or heterocyde is unsubstituted or carries one, two, three or four substituents R⁵⁶ independently selected from halogen, OH, CN, N0₂, SH, NH₂, Ci-

C6-alkyl, Ci-C6-halogenalkyl, Ci-C6-alkoxy, Ci-C6-halogenalkoxy, Ci-C6-alkylthio, Ci- C6-halogenalkylthio, Ci-C₄-alkoxy-Ci-C₄-alkyl, phenyl and phenoxy; wherein the phenyl groups are unsubstituted or carry one, two, three, four or five substituents R^56a selected from the group consisting of CN, halogen, OH, Ci-C₄-alkyl, Ci-C₄- halogenalkyi, Ci-C₄-alkoxy and Ci-C₄-halogenalkoxy; and wherein in each case one or two CH₂ groups of the carbo- or heterocyde may be replaced by a group independently selected from C(=0) and C(=S); and

R⁷ and R⁸ together with the carbon atoms to which they are bound form a five- or six- membered heteroaryl; wherein the heteroaryl contains one, two or three

heteroatoms selected from N , O and S, and wherein the heteroaryl carries zero, one, two, three or four substituents (R⁷⁸)₀, wherein

o is 0, 1 , 2 or 3; and

R⁷⁸ are independently selected from halogen, OH , CN , NO2, SH , N H₂,

N H(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂, N H(C(=0)Ci-C₄-alkyl), N(C(=0)Ci-C₄- alkyl)₂, N H-S0₂-R^x, CH(=0), C(=0)Ci-C₆-alkyl, C(=0) N H(Ci-C₆-alkyl), CR'=NOR", d-Ce-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, Ci-C₆-alkoxy, Ci- C6-halogenalkoxy, C₂-C6-alkenyloxy, C₂-C6-alkynyloxy, C3-C6-cycloalkyl, C3-C6-cycloalkenyl, S(0)z-Ci-C6-alkyl, three-, four-, five- or six-membered saturated or partially unsaturated heterocycle, five- or six-membered heteroaryl and phenyl; wherein the heterocycle or heteroaryl contains one, two or three heteroatoms selected from N , O and S; wherein the heterocycle or heteroaryl contains one, two or three heteroatoms selected from N , O and S; wherein z, R' and R" is as defined above;

wherein the acyclic moieties of R⁷⁸ are not further substituted or carry one, two, three or up to the maximum possible number of identical or different groups R^78a which independently of one another are selected from:

R^78a halogen, OH , CN , Ci-C₆-alkoxy, C₃-C₆-cycloalkyl, C₃-C₆- cycloalkenyl, C₃-C6-halogencycloalkyl, C₃-C6-halogencycloalkenyl, Ci-C₄-halogenalkoxy, Ci-C6-alkylthio, five- or six-membered heteroaryl, phenyl and phenoxy, wherein the heterorayl, phenyl and phenoxy group is unsubstituted or carries one, two, three, four or five substituents R^78a' selected from the group consisting of halogen, OH , Ci-C₄-alkyl, Ci-C₄-halogenalkyl, Ci-C₄-alkoxy and Ci-C₄- halogenalkoxy;

wherein the cyclic, phenyl, heterocyclic and heteroaryl moieties of R⁷⁸ are not further substituted or carry one, two, three, four, five or up to the maximum number of identical or different groups R^78b which independently of one another are selected from:

R^78b halogen, OH , CN , Ci-C₄-alkyl, Ci-C₄-alkoxy, Ci-C₄-halogenalkyl, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, Ci-C₄-halogenalkoxy and Ci-C6-alkylthio;

R⁹ is in each case independently selected from hydrogen, OH , CH(=0), C(=0)Ci-C6- alkyl, C(=0)C₂-C₆-alkenyl, C(=0)C₂-C₆-alkynyl, C(=0)C₃-C₆-cycloalkyl, C(=0)0(Ci- Ce-alkyl), C(=0)0(C₂-C₆-alkenyl), C(=0)0(C₂-C₆-alkynyl), C(=0)0(C₃-C₆- cycloalkyl), C(=0) N H(C C₆-alkyl), C(=0) N H(C₂-C₆-alkenyl), C(=0)N H(C₂-C₆- alkynyl), C(=0)N H(C₃-C₆-cycloalkyl), C(=0) N(Ci-C₆-alkyl)₂, C(=0) N(C₂-C₆- alkenyl)₂, C(=0)N(C₂-C₆-alkynyl)₂, C(=0)N(C₃-C₆-cycloalkyl)₂, CH(=S), C(=S)Ci-C₆- alkyl, C(=S)C₂-C₆-alkenyl, C(=S)C₂-C₆-alkynyl, C(=S)C₃-C₆-cycloalkyl, C(=S)0(Ci- Ce-alkyl), C(=S)0(C₂-C₆-alkenyl), C(=S)0(C₂-C₆-alkynyl), C(=S)0(C₃-C₆- cycloalkyl), C(=S)NH(Ci-C₆-alkyl), C(=S)NH(C₂-C₆-alkenyl), C(=S)NH(C₂-C₆- alkynyl), C(=S)NH(C₃-C₆-cycloalkyl), C(=S)N(Ci-C₆-alkyl)₂, C(=S)N(C₂-C₆-alkenyl)₂, C(=S)N(C₂-C₆-alkynyl)₂, C(=S)N(C₃-C₆-cycloalkyl)₂, Ci-C₆-alkyl, Ci-C₄-halogenalkyl,

C₃-C6-cycloalkyl, C₃-C6-halogencycloalkyl, Ci-C₄-alkoxy, Ci-C₄-halogenalkoxy, OR^Y, CrC6-alkylthio, Ci-C6-halogenalkylthio, C₂-C6-alkenyl, C₂-C6-halogenalkenyl C₂-C₆-alkynyl, C₂-C₆-halogenalkynyl, S(0)z-Ci-C₆-alkyl, S(0)_z-Ci-C₆-halogenalkyl, S(0)_z-Ci-C₆-alkoxy, S(0)_z-C₂-C₆-alkenyl, S(0)_z-C₂-C₆-alkynyl, S(0)_zaryl, S0₂- NH(Ci-C₆-alkyl), S0₂-NH(Ci-C₆-halogenalkyl), S0₂-NH-aryl, tri-(Ci-C₆ alkyl)silyl and di-(Ci-C6 alkoxy)phosphoryl), five- or six-membered heteroaryl and aryl;

wherein the heteroaryl contains one, two or three heteroatoms selected from N, O and S; wherein the aryl groups are unsubstituted or carry one, two, three, four or five substituents selected from the group consisting of CN, halogen, OH, Ci-C₄- alkyl, Ci-C₄-halogenalkyl, Ci-C₄-alkoxy and Ci-C₄-halogenalkoxy;

R^Y is Ci-C6-alkyl, Ci-C6-halogenalkyl, C₂-C6-alkenyl, C₂-C6-halogenalkenyl, C₂-C6- alkynyl, C₂-C6-halogenalkynyl, C₃-C6-cycloalkyl, C₃-C6-halogencycloalkyl, phenyl and phenyl-Ci-C6-alkyl; wherein the phenyl groups are unsubstituted or carry one, two, three, four or five substituents selected from the group consisting of CN, halogen, OH, Ci-C₄-alkyl, Ci-C₄-halogenalkyl, Ci-C₄-alkoxy and Ci-C₄- halogenalkoxy;

wherein the acyclic moieties of R⁹ are not further substituted or carry one, two, three or up to the maximum possible number of identical or different groups R^9a which independently of one another are selected from:

R^9a halogen, OH, CN, Ci-C₆-alkoxy, C₃-C₆-cycloalkyl, C₃-C₆- cycloalkenyl, C₃-C6-halogencycloalkyl, C₃-C6-halogencycloalkenyl, Ci-C₄-halogenalkoxy, Ci-C6-alkylthio, five- or six-membered heteroaryl, phenyl and phenoxy, wherein the heterorayl, phenyl and phenoxy group is unsubstituted or carries one, two, three, four or five substituents R^78a' selected from the group consisting of halogen, OH, Ci-C₄-alkyl, Ci-C₄-halogenalkyl, Ci-C₄-alkoxy and Ci-C₄- halogenalkoxy;

wherein the alicyclic, phenyl, heterocyclic and heteroaryl moieties of R⁹ are not further substituted or carry one, two, three, four, five or up to the maximum number of identical or different groups R^9b which independently of one another are selected from:

R^9b halogen, OH, CN, Ci-C₄-alkyl, Ci-C₄-alkoxy, Ci-C₄-halogenalkyl, C₃-C6-cycloalkyl, C₃-C6-halogencycloalkyl, Ci-C₄-halogenalkoxy and Ci-C6-alkylthio; and the N-oxides and the agriculturally acceptable salts thereof.

The numbering of the ring members in the compounds of the present invention is as given in formula I above:

Compounds of formula I, when R⁹ is not proton, can be accessed e.g. starting from compounds of the formula 1-1 (R⁹ is proton) A skilled person will realize that compounds of type i can be reacted via reaction with a reactive group R⁹-X. Reactive groups are preferably a Iky I halides, alkenyl halides, alkynyl halides, benzyl halides, aldehydes, ester, acid chlorides, amides, sulfates, silyl halides or phosphates, e.g. carboxylic acid (X = OH), aldehydes (X=H), acid chloride (X = CI), or halides (X=halogen), amides (Χ=Ν Μβ2) or phosphates (X=OCH3). In the following schemes, the optionally substituted heteroaryl framed by R⁷ and R⁸ is sketched by a circle named "heteroaryl":

1-1

Typically the reaction is performed in a range between 0 °C and ambient temperature in the presence of an reactive group and organic base. Suitable base preferably NEt.3, pyridine NaOH, TEBAC, K2CO3, NaCOs or KOH. Most preferably solvents are THF, DMF, DMSO, MeOH or water (see for example, Journal of Medicinal Chemistry, 1989, 32(6), 1242-1248; European Journal of Medicinal Chemistry, 2009, 44(10), 4034-4043).

Compounds of formula 1-1 can be accessed e.g. starting from compounds of the formula II via a reduction agent in an organic solvent (see for example WO2009095253, WO2008143263). Re- duction agent can be for example NaBH₄ or NaCNBH₃. Typically the reaction is performed in a range between 0°C, room temperature and 60°C in an organic solvent, such as THF, dichloro- methane or acetonitrile, most preferably MeOH or EtOH.

1-1

Compounds of formmula II can be also reduced to 1-1 via hydrogenation by using a metal catalyst in an organic solvent, water or a mix of water and organic solvent (see for example Chem- CatChem, 5(10), 2939-2945; 2013; Organic Letters, 17(12), 2878-2881 ; 2015). As metal cata- lyst can be used for example Ru, Ir, and Pd, with or without ligands such as phosphines, phosphates, cyclooactadiene, diamines and imidazoles. The reaction can take place at temperatute from 0°C to 100 °C. Preferable organic solvent are methanol, acetone, dichloromethane, 2,2,2- trifluoroethanol or DMF. The reaction can also take place the presence of an acid for example HCO2H , trifluooroacetic acid and acetic acid.

Compounds of the formula II can be provided e.g. starting from alcohols of type III with nitriles of type IV in the presence of an acid in an organic solvent (see for example US 2008/0275242 or WO2005/070917). Preferably, sulfuric acid or a sulfonic acid, in particular triflic acid, are used as acid. Most suitable solvents are h drocarbons, preferably benzene or dichloromethane.

Depending on the nature of the starting materials, the reaction is performed at a temperature from -40°C to 200°C, in particular from -10°C to 120°C, more specifically from 0°C to 100°C, even more specifically from room or ambient temperature (about 23°C) to 80°C.

Nitriles of type IV are either commercially available or can be prepared by a skilled person from the corresponding halides following literature precedures (see, for example Journal of Organic Chemistry, 76(2), 665-668; 201 1 ; Angewandte Chemie, International Edition, 52(38), 10035- 10039; 2013; WO2004/013094).

Alcohols of type III can be prepared as described below. A skilled person will realize that compounds of type IV can be reacted with organometallic reagents, preferably alkyl Grignard or al- kyl-Lithium reagents, in ethereal solvents, preferably THF at low temperatures and under inert conditions to furnish compounds of type III.

Alternatively, alcohols of type III can be prepared from epoxydes IVa and compounds VII (see below):

The metallation reaction may preferably be carried out using Lithium-organic compounds, such as for example n-butyl lithium, sec-butyl lithium or tert-butyl lithium to result in an exchange of halogen by lithium. Also suitable is the reaction with magnesium resulting in the formation of the respective Grignard reagents. A further possibility is the use of other Grignard reagents such as isopropyl-magnesium-bromide instead of Mg.

A typical preparation of compounds of type IV can be achieved by reacting compounds of type V with organometallic reagents, preferably alkyl Grignard or alkyl-Lithium reagents, in ethereal solvents, preferably THF at low temperatures and under inert conditions to furnish compounds of type IV as previously reported (see for example WO2012051036; WO201 1042918).

Compounds of type V can be accessed by reacting a carbonyl compound of type VI, preferably a carboxylic acid (X = OH) or an acid chloride (X = CI), with NH(OR')R", wherein R' and R" are selected from (Ci-C4)-alkyl, most preferably being methyl, in an organic solvent, preferably THF or dichloromethane. Typically the reaction is performed in a range between 0 °C and ambient temperature in the presence of an organic base, preferably NEt.3 or pyridine (see e.g. US 20130324506; Tetrahedron: Asymmetry, 17(4), 508-51 1 ; 2006). If X = OH, the addition of an activating reagent, preferably a carbodiimide, may be preferred (see for example

ChemMedChem, 7(12), 2101 -21 12; 2012; 201 1038204; Journal of Organic Chemistry, 76(1 ), 164-169; 201 1 ).

If required, compounds of type VI can be prepared from the corresponding aryl halides of type VII (Hal is halogen, preferably Br or I). As described (Tetrahedron, 68(9), 21 13-2120; 2012; Chemical Communications (Cambridge, United Kingdom), 49(60), 6767-6769; 2013), aryl hal- ides will react with compounds of type VII in the presence of a transition metal catalyst, preferably a copper(l) salt, in an organic solvent, preferably DMF or DMSO, at elevated temperatures. Typically a base, preferabl potassium phosphate, is added.

VII

If appropriate, compounds of type III can be prepared as follows. A known or commercially available compound of type IX can be reacted with an organometallic reagent of type X, preferably a Grignard or an organolithium reagent, readily prepared by a skilled person. Preferably, the reaction is performed in a temperature range from -78 °C to room temperature under inert conditions in an ethereal solvent.

IX Alternatively compounds II can be prepared via intramolecular reaction of amide XI with an electron-rich heterocycle. The intramolecular cyclization will take place in the presence of a dehydrating agent in an organic solvent (WO 2008143263, Synthetic Communications 2007, 37, 1331-1338.). Preferably, phosphoryl chloride (POCI₃), POCI3/P2O5, H3PO4/P2O5, SnCI₄ or BF₃ are used as dehydrating agent. Most suitable solvents are hydrocarbons, preferably benzene, toluene or acetonitrile. Alternatively halogenated solvents can be used, for example dichloro- methane, chloroform or chlorobenzene.

Depending on the nature of starting materials, the reaction is performed at temperature from - 40°c to 200 °C, in particular from -10°C to 120°C, more specifically from 0°C to 100°C, even more specifically from room temperature to 100°C.

Amides of type XI can accessed by reacting a carbonyl of type XII, preferably a carboxylic acid (X = OH) or an acid chloride (X = CI), with an amines of type XIII in an organic solvent, preferably THF or dichloromethane. Typically the reaction is performed in a range between 0°C and room temperature in the presence of an organic base, preferably N(C2H5)3 or pyridine (see e.g. WO 8303968). If X = OH, the addition of an activating agent, preferably a carbodiimide or acid chloride, may be preferred (see e.g Bioorganic & Medicinal Chemistry, 2010, 18, 3088-31 15).

XIII

If required, compounds of type XIII can be synthesized from the correspond nitriles. As described Synlett. 2007, 4 652-654 or Tetrahedron 2012, 68, 2696-2703, nitriles will react with organometallic agents, preferably Grignard or Lithium reagent, in ethereal solvents, preferably THF at low temperature and under inert conditions to furnish compounds of type XIII. The synthesis of compounds of type XIII can take place in two steps or one pot.

It may be preferred to access compounds I, where R⁵ and R⁶ are F (named compounds I-2) from corresponding compouds 11-1 via reduction and optionally reaction with a reactive group R⁹-X.

Compounds 11-1 can be synthesized from the respective keto compound (named compounds 11 A.) as follows based on a literature precedent (US 2008/0275242). A skilled person will realize that compounds 11-1 can be formed using a suitable halogenation agent, preferably diethyl ami- nosulfur trifluoride or phosphorus trihalides in an organic solvent, preferably a chlorinated hy- drocarbon such as dichloromethane at, e.g., room temperature. If appropriate, the reaction can be performed at elevated temperatures.

Compounds of type 11 A. can be accessed by reacting compounds of type II-2 (where R⁵ and R⁶ are halogen substituents (Hal'), in particular bromo) under aqueous or mildly acidic conditions an organic solvent.

II-2

Said compounds II-2 can be prepared from compounds 11—3 (where R⁵ and R⁶ are both hydrogen) by reaction with a halide source, preferably N-bromosuccinimide or 1 ,3-dibromo-5,5- dimethylhydantoin, in an organic solvent, preferably a hydrocarbon such as toluene or benzene, in the presence of an initiator, preferably azo-bis-isobutyronitrile, at elevated temperatures (see for example WO 2008/035379).

II-3

Alternatively, as described elsewhere (WO 2013/047749), compounds 11-1 can be prepared directly from compounds 11— 3. To this end, compounds 11—3 are reacted with hydrogen fluoride tri- ethyl amine (HF NEt₃) in an organic solvent, preferably an aromatic hydrocarbon and at elevat- ed temperatures.

Alternatively compounds II can be synthesized from heteroaryls XIV, which are commercially available or can be synthesized according to procedures known in literature, in which X¹ denotes for hydrogen or halogen (CI, Br, I) and X² denotes for halogen (CI, Br, I) or C1-C6- alkoxycarbonyl.

Compounds XIV can be metalated with Grignard-reagents (X³ denotes for CI, Br or I), for example methyl magnesium-X³, ethyl magnesiue-X³, isopropyl-magnesium-X³ and phenyl magnesium X³ among others, or lithium organic reagents like methyl-lithium, ethyl-lithium, butyl-lithium and phenyl-lithium among others, and reacted with compounds XlVa to yield derivatives XV, whereas R³¹ and R⁴¹ independently from each other denote for Ci-C6-alkyl, C2-C6-alkenyl, C2- C6-alkynyl, a saturated or partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carboc cle or heterocycle, five- or six-membered heteroaryl and aryl.

Subsequently compounds XV (X²=CI, Br, I) can be reacted with carbon monoxide yielding esters XVI following published literature (Science of Synthesis (2014), 2, 67-93; Comprehensive Inorganic Chemistry II (2013), 6, 1 -24; RSC Catalysis Series (2015), 21 (New Trends in Cross- Coupling), 479-520; Metal-catalyzed Cross-Coupling Reactions and More (Editor: A. De Mei- jere) (2014), 1 , 133-278; Domino Reactions (Editor L. Tietze) (2014), 7-30; Synthesis 2014, 46 (13), 1689-1708; RSC Advances (2014), 4 (20), 10367-10389), for example using Pd-catalyst (i.e. Pd(dppf)Cl2 ([1 ,1 '-bis(diphenylphosphino)ferrocene]dichloropalladium(ll)) and sodium methanolat in methanol under elevated pressure (10-200 bar) of carbon monoxide.

Compounds XVI can be hydrolyzed using acidic or basic conditons, for example hydrochloric or sulfuric acid, or sodium or potassium carbonate, hydrogen carbonate or hydroxide in water or solvent mixtures with water and alcoholic solvents (preferably methanol, ethanol, isopropanol), or acetonitrile, acetone, dimethylformamide or N-methyl pyrrolidine, at temperatures from 0°C to 100°C yielding intermediates XVI I .

Intermediates XVI I can be activitated with reagents like HATU (1 -

[Bis(dimethylamino)methylene]-1 Η-Λ ,2,3-triazolo[4,5-£]pyridinium 3-oxid hexafluorophosphate), CDI (1 , 1 '-Carbonyldiimidazole), DCC (/V,/V-Methanetetraylbis[cyclohexanamine]) and others known in literature (Eur. JOC 2013, 4325; Tetrahedron 2004, 60, 2447; Tetrahedron 2005, 61 , 10827; Chem. Soc. Rev. 2009, 38, 606; Chem. Rev. 201 1 , 1 1 1 , 6557) to further react and yield compounds XVI I I.

Furthermore compounds XVIII are oxidized with MnC>2, hypochlorite, activated DMSO, Cr(VI)- containing reagents or employing other oxidizing conditions known in literature (Korean Chemical Society (2015), 36(12), 2799; Hudlicky, Oxidations in Organic Chemistry, American Chemical Society, Washington DC, 1990; Acc. Chem. Res. 2002, 35, 774; JACS 1984, 106, 3374; Tetrahedron Letters 56 (2015) 6878; Backvall, Modern Oxidation Methods, Wiley, Weinheim 2004; Tojo, Oxidation of Alcohols to Aldehydes and Ketones, Springer 2006) to provide carbon- yl compounds XIX.

Subsequently the amides XIX can be transferred into the triflate XX by reaction of XIX with tri- fluoromethyl sulfonic anhydride in an inert solvent, like dichloromethane, chloroform, carbon tetrachloride, benzene, toluene or chlorobenzene in the presence of a base, for example an organic base like pyridine, triethylamine or diisopropyl ethylamine or an aqueous base like solutions of sodium or potassium hydroxide, carbonate or hydrogen carbonate in water at tempera- tures preferably between 0°C and 100°C.

These compounds XX are reacted with fluorination reagents (Kirsch, Modern Fluoroorganic Chemistry, Wiley 2013)) like deoxo-fluor (BAST, bis(2-methoxyethyl)aminosulfur trifluoride, Journal of Fluorine Chemistry (2016), 182, 41 ; Singh, et al. Synthesis 17, 2561 , (2002)), DAST (Diethylaminoschwefeltrifluorid, Hudlicky Org. React. 35, 513, (1988)), Fluolead (4-fert-Butyl- 2,6-dimethylphenylsulfur trifluoride, WO 20131 18915; US 20080039660), Diethylaminodi- fluorosulfinium tetrafluoroborate (XtalFluor-E) or morpholinodifluorosulfinium tetrafluoroborate (XtalFluor-M) (Journal of organic chemistry (2010), 75(10), 3401 ) to yield difluoro compounds XXI.

Subsequently these triflates XXI can be reacted under Suzuki conditions (European Journal of Organic Chemistry (2008),(12),2013) with boronic acids IV^*, in which R³¹¹ and R⁴¹¹ together with the groups they are attached to form a tetramethyl-1 ,3,2-dioxaborolane-ring or independently from one an ther mean hydrogen or Ci-C6-alkyl to yield compounds II.

The N-oxides may be prepared from the inventive compounds according to conventional oxida- tion methods, e. g. by treating compounds I with an organic peracid such as metachloroper- benzoic acid (cf. WO 03/64572 or J. Med. Chem. 38(1 1 ), 1892-903, 1995); or with inorganic oxidizing agents such as hydrogen peroxide (cf. J. Heterocyc. Chem. 18(7), 1305-8, 1981 ) or oxone (cf. J. Am. Chem. Soc. 123(25), 5962-5973, 2001 ). The oxidation may lead to pure mono-N-oxides or to a mixture of different N-oxides, which can be separated by conventional methods such as chromatography.

If the synthesis yields mixtures of isomers, a separation is generally not necessarily required since in some cases the individual isomers can be interconverted during work-up for use or during application (e. g. under the action of light, acids or bases). Such conversions may also take place after use, e. g. in the treatment of plants in the treated plant, or in the harmful fungus to be controlled.

In the following, the intermediate compounds are further described. A skilled person will readily understand that the preferences for the substituents, also in particular the ones given in the tables below for the respective substituents, given herein in connection with compounds I apply for the intermediates accordingly. Thereby, the substituents in each case have independently of each other or more preferably in combination the meanings as defined herein.

The intermediate compounds of formula XI are novel. Consequently, one aspect of the present invention relates to compounds of formula XI:

XI. c wherein the substituents R¹, R², R³, R⁴, m, n, o and R⁷⁸ are as defined and preferably defined for formula I.

In the definitions of the variables given above, collective terms are used which are generally representative for the substituents in question. The term "C_n-C_m" indicates the number of carbon atoms possible in each case in the substituent or substituent moiety in question.

The term "halogen" refers to fluorine, chlorine, bromine and iodine.

The term "Ci-C6-alkyl" refers to a straight-chained or branched saturated hydrocarbon group having 1 to 6 carbon atoms, e.g. methyl, ethyl, propyl, 1-methylethyl, butyl, 1 -methylpropyl, 2- methylpropyl, 1 ,1 -dimethylethyl, pentyl, 1 -methylbutyl, 2-methylbutyl, 3-methylbutyl,

2.2- dimethylpropyl, 1-ethylpropyl, 1 ,1 -dimethylpropyl, 1 ,2-dimethylpropyl, hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1 ,1-dimethylbutyl, 1 ,2-dimethylbutyl,

1 .3- dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl,

2-ethylbutyl, 1 ,1 ,2-tri methyl propyl, 1 ,2,2-trimethylpropyl, 1 -ethyl-1 -methylpropyl and 1-ethyl-2- methylpropyl. Likewise, the term "C2-C4-alkyl" refers to a straight-chained or branched alkyl group having 2 to 4 carbon atoms, such as ethyl, propyl (n-propyl), 1-methylethyl (iso-propoyl), butyl, 1-methylpropyl (sec-butyl), 2-methylpropyl (iso-butyl), 1 ,1 -dimethylethyl (tert. -butyl).

The term "Ci-C6-halogenalkyl" refers to an alkyl group having 1 or 6 carbon atoms as defined above, wherein some or all of the hydrogen atoms in these groups may be replaced by halogen atoms as mentioned above. Examples are "CrC2-halogenalkyl" groups such as chloromethyl, bromomethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chlorofluoromethyl, dichlorofluoromethyl, chlorodifluoromethyl, 1-chloroethyl, 1 -bromoethyl, 1 - fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-chloro-2-fluoroethyl, 2-chloro- 2,2-difluoroethyl, 2,2-dichloro-2-fluoroethyl, 2,2,2-trichloroethyl or pentafluoroethyl. The term "Ci-C6-hydroxyalkyl" refers to an alkyl group having 1 or 6 carbon atoms as defined above, wherein some or all of the hydrogen atoms in these groups may be replaced by OH groups.

The term "Ci-C4-alkoxy-Ci-C4-alkyl" refers to alkyl having 1 to 4 carbon atoms (as defined above), wherein one hydrogen atom of the alkyl radical is replaced by a Ci-C4-alkoxy group (as defined above). Likewise, the term "Ci-C6-alkoxy-CrC4-alkyl" refers to alkyl having 1 to 4 carbon atoms (as defined above), wherein one hydrogen atom of the alkyl radical is replaced by a Ci-C6-alkoxy group (as defined above).

The term "C2-C6-alkenyl" refers to a straight-chain or branched unsaturated hydrocarbon radical having 2 to 6 carbon atoms and a double bond in any position. Examples are "C2-C4-alkenyl" groups, such as ethenyl, 1 -propenyl, 2-propenyl (allyl), 1 -methylethenyl, 1 -butenyl, 2-butenyl,

3- butenyl, 1-methyl-1 -propenyl, 2-methyl-1 -propenyl, 1 -methyl-2-propenyl, 2-methyl-2-propenyl.

The term "C2-C6-alkynyl" refers to a straight-chain or branched unsaturated hydrocarbon radical having 2 to 6 carbon atoms and containing at least one triple bond. Examples are "C2-C4- alkynyl" groups, such as ethynyl, prop-1 -ynyl, prop-2-ynyl (propargyl), but-1 -ynyl, but-2-ynyl, but-3-ynyl, 1 -methyl-prop-2-ynyl.

The term "Ci-C6-alkoxy" refers to a straight-chain or branched alkyl group having 1 to 6 carbon atoms which is bonded via an oxygen, at any position in the alkyl group. Examples are "C1-C4- alkoxy" groups, such as methoxy, ethoxy, n-propoxy, 1-methylethoxy, butoxy, 1 - methyl -"propoxy, 2-methylpropoxy or 1 ,1 -dimethylethoxy.

The term "Ci-C6-halogenalkoxy" refers to a Ci-C6-alkoxy radical as defined above, wherein some or all of the hydrogen atoms in these groups may be replaced by halogen atoms as mentioned above. Examples are "CrC4-halogenalkoxy" groups, such as OCH₂F, OCHF₂, OCF₃, OCH2CI, OCHCI2, OCCI3, chlorofluoromethoxy, dichlorofluoromethoxy, chlorodifluoromethoxy, 2-fluoroethoxy, 2-chloroethoxy, 2-bromoethoxy, 2-iodoethoxy, 2,2-difluoroethoxy, 2,2,2-tri- fluoroethoxy, 2-chloro-2-fluoroethoxy, 2-chloro-2,2-difluoroethoxy, 2,2-dichloro-2-fluoroethoxy, 2,2,2-trichloroethoxy, OC2F5, 2-fluoropropoxy, 3-fluoropropoxy, 2,2-difluoropropoxy,

2,3-difluoropropoxy, 2 chloropropoxy, 3-chloropropoxy, 2,3-dichloropropoxy, 2-bromopropoxy, 3 bromopropoxy, 3,3,3-trifluoropropoxy, 3,3,3-trichloropropoxy, OCH2-C2F5, OCF2-C2F5, 1- fluoromethyl-2-fluoroethoxy, 1 -chloromethyl-2-chloroethoxy, 1 -bromomethyl-2-bromoethoxy,

4- fluorobutoxy, 4-chlorobutoxy, 4-bromobutoxy or nonafluorobutoxy.

The term "C2-C6-alkenyloxy" refers to a straight-chain or branched alkenyl group having 2 to 6 carbon atoms which is bonded via an oxygen, at any position in the alkenyl group. Examples are "C2-C4-alkenyloxy" groups.

The term "C2-C6-alkynyloxy" refers to a straight-chain or branched alkynyl group having 2 to 6 carbon atoms which is bonded via an oxygen, at any position in the alkynyl group. Examples are "C2-C4-alkynyloxy" groups.

The term "C3-C6-cycloalkyl" refers to monocyclic saturated hydrocarbon radicals having 3 to 6 carbon ring members, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl. Accordingly, a saturated three-, four-, five-, six-, seven-, eight-, nine or ten-membered carbocyclyl or carbocycle is a "C3-Cio-cycloalkyl". The term "C3-C6-cycloalkenyl" refers to a monocyclic partially unsaturated 3-, 4- 5- or 6- membered carbocycle having 3 to 6 carbon ring members and at least one double bond, such as cyclopentenyl, cyclopentadienyl, cyclohexadienyl. Accordingly, a partially unsaturated three-, four-, five-, six-, seven-, eight-, nine or ten-membered carbocyclyl or carbocycle is a "C3-C10- cycloalkenyl".

The term "C3-C8-cycloalkyl-CrC4-alkyl" refers to alkyl having 1 to 4 carbon atoms (as defined above), wherein one hydrogen atom of the alkyl radical is replaced by a cycloalkyl radical having 3 to 8 carbon atoms (as defined above).

The term "Ci-Ce-alkylthio" as used herein refers to straight-chain or branched alkyl groups hav- ing 1 to 6 carbon atoms (as defined above) bonded via a sulfur atom. Accordingly, the term "Ci- C6-halogenalkylthio" as used herein refers to straight-chain or branched halogenalkyi group having 1 to 6 carbon atoms (as defined above) bonded through a sulfur atom, at any position in the halogenalkyi group.

The term "C(=0)-CrC₆-alkyl" refers to a radical which is attached through the carbon atom of the group C(=0) as indicated by the number valence of the carbon atom. The number of valence of carbon is 4, that of nitrogen is 3. Likewise the following terms are to be construed: NH(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂, NH(C₃-C₆-cycloalkyl), N(C₃-C₆-cycloalkyl)₂, C(=0)-NH(Ci-C₆- alkyl), C(=0)-N(Ci-C₆-alkyl)₂.

The term "saturated or partially unsaturated three-, four-, five-, six-, seven-, eight-, nine or ten- membered heterocyclyl or heterocycle, wherein the heterocyclyl or heterocycle contains 1 , 2, 3 or 4 heteroatoms selected from N, O and S" is to be understood as meaning both saturated and partially unsaturated heterocycles, wherein the ring member atoms of the heterocycle include besides carbon atoms 1 , 2, 3 or 4 heteroatoms independently selected from the group of O, N and S. For example:

a 3- or 4-membered saturated heterocycle which contains 1 or 2 heteroatoms from the group consisting of O, N and S as ring members such as oxirane, aziridine, thiirane, oxetane, azet- idine, thiethane, [1 ,2]dioxetane, [1 ,2]dithietane, [1 ,2]diazetidine; and

a 5- or 6-membered saturated or partially unsaturated heterocycle which contains 1 , 2 or 3 heteroatoms from the group consisting of O, N and S as ring members such as 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydrothienyl, 3-tetrahydrothienyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 3-isoxazolidinyl, 4-isoxazolidinyl, 5-isoxazolidinyl, 3-isothiazolidinyl, 4-isothiazolidinyl,

5-isothiazolidinyl, 3-pyrazolidinyl, 4-pyrazolidinyl, 5-pyrazolidinyl, 2-oxazolidinyl, 4-oxazolidinyl, 5-oxazolidinyl, 2-thiazolidinyl, 4-thiazolidinyl, 5-thiazolidinyl, 2-imidazolidinyl, 4-imidazolidinyl, 1 ,2,4-oxadiazolidin-3-yl, 1 ,2,4-oxadiazolidin-5-yl, 1 ,2,4-thiadiazolidin-3-yl, 1 ,2,4-thiadiazolidin-5- yl, 1 ,2,4-triazolidin-3-yl, 1 ,3,4-oxadiazolidin-2-yl, 1 ,3,4-thiadiazolidin-2-yl, 1 ,3,4-triazolidin-2-yl, 2,3-dihydrofur-2-yl, 2,3-dihydrofur-3-yl, 2,4-dihydrofur-2-yl, 2,4-dihydrofur-3-yl, 2,3-dihydrothien-

2- yl, 2,3-dihydrothien-3-yl, 2,4-dihydrothien-2-yl, 2,4-dihydrothien-3-yl, 2-pyrrolin-2-yl, 2-pyrrolin-

3- yl, 3-pyrrolin-2-yl, 3-pyrrolin-3-yl, 2-isoxazolin-3-yl, 3-isoxazolin-3-yl, 4-isoxazolin-3-yl, 2- isoxazolin-4-yl, 3-isoxazolin-4-yl, 4-isoxazolin-4-yl, 2-isoxazolin-5-yl, 3-isoxazolin-5-yl,

4-isoxazolin-5-yl, 2-isothiazolin-3-yl, 3-isothiazolin-3-yl, 4-isothiazolin-3-yl, 2-isothiazolin-4-yl, 3- isothiazolin-4-yl, 4-isoth iazoli n-4-y 1 , 2-isothiazolin-5-yl, 3-isothiazolin-5-yl, 4-isoth iazoli n-5-y 1 , 2,3- dihydropyrazol-1-yl, 2,3-dihydropyrazol-2-yl, 2,3-dihydropyrazol-3-yl, 2,3-dihydropyrazol-4-yl, 2,3-dihydropyrazol-5-yl, 3,4-dihydropyrazol-1-yl, 3,4-dihydropyrazol-3-yl, 3,4-dihydropyrazol-4- yl, 3,4-dihydropyrazol-5-yl, 4,5-dihydropyrazol-1-yl, 4,5-dihydropyrazol-3-yl, 4,5-dihydropyrazol- 4-yl, 4,5-dihydropyrazol-5-yl, 2,3-dihydrooxazol-2-yl, 2,3-dihydrooxazol-3-yl, 2,3-dihydrooxazol- 4-yl, 2,3-dihydrooxazol-5-yl, 3,4-dihydrooxazol-2-yl, 3,4-dihydrooxazol-3-yl, 3,4-dihydrooxazol-4- yl, 3,4-dihydrooxazol-5-yl, 3,4-dihydrooxazol-2-yl, 3,4-dihydrooxazol-3-yl, 3,4-dihydrooxazol-4- yl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 1 ,3-dioxan-5-yl, 2-tetrahydropyranyl, 4- tetrahydropyranyl, 2-tetrahydrothienyl, 3-hexahydropyridazinyl, 4-hexahydropyridazinyl, 2-hexahydropyrimidinyl, 4-hexahydropyrimidinyl, 5-hexahydropyrimidinyl, 2-piperazinyl, 1 ,3,5- hexahydrotriazin-2-yl and 1 ,2,4-hexahydrotriazin-3-yl and also the corresponding -ylidene radi- cals; and

a 7-membered saturated or partially unsaturated heterocycle such as tetra- and hexahydroaze- pinyl, such as 2,3,4,5-tetrahydro[1 H]azepin-1-,-2-,-3-,-4-,-5-,-6- or-7-yl, 3,4,5,6-tetra- hydro[2H]azepin-2-,-3-,-4-,-5-,-6- or-7-yl, 2,3,4,7-tetrahydro[1 H]azepin-1 -,-2-,-3-,-4-,-5-,-6- or-7- yl, 2,3,6,7-tetrahydro[1 H]azepin-1 -,-2-,-3-,-4-,-5-,-6- or-7-yl, hexahydroazepin-1 -,-2-,-3- or-4-yl, tetra- and hexahydrooxepinyl such as 2,3,4,5-tetrahydro[1 H]oxepin-2-,-3-,-4-,-5-,-6- or-7-yl,

2,3,4,7-tetrahydro[1 H]oxepin-2-,-3-,-4-,-5-,-6- or-7-yl, 2,3,6,7-tetrahydro[1 H]oxepin-2-, -3-,-4-,-5- ,-6- or-7-yl, hexahydroazepin-1 -,-2-,-3- or-4-yl, tetra- and hexahydro-1 ,3-diazepinyl, tetra- and hexahydro-1 ,4-diazepinyl, tetra- and hexahydro-1 ,3-oxazepinyl, tetra- and hexahydro-1 ,4- oxazepinyl, tetra- and hexahydro-1 , 3-dioxepinyl, tetra- and hexahydro-1 ,4-dioxepinyl and the corresponding -ylidene radicals.

The term "5-or 6-membered heteroaryl" refers to aromatic ring systems incuding besides carbon atoms, 1 , 2, 3 or 4 heteroatoms independently selected from the group consisting of N, O and S, for example,

a 5-membered heteroaryl such as pyrrol-1-yl, pyrrol-2-yl, pyrrol-3-yl, thien-2-yl, thien-3-yl, furan- 2-yl, furan-3-yl, pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, imidazol-1 -yl, imidazol-2-yl, imidazol-4-yl, imidazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, 1 ,2,4-triazolyl-1 -yl, 1 ,2,4-triazol-3-yl 1 ,2,4-triazol-5-yl, 1 ,2,4-oxadiazol-3-yl, 1 ,2,4-oxadiazol-5-yl and 1 ,2,4-thiadiazol-3-yl, 1 ,2,4-thiadiazol-5-yl; or

a 6-membered heteroaryl, such as pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyridazin-3-yl, pyri- dazin-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrazin-2-yl and 1 ,3,5-triazin-2-yl and 1 ,2,4-triazin-3-yl.

Agriculturally acceptable salts of the inventive compounds encompass especially the salts of those cations or the acid addition salts of those acids whose cations and anions, respectively, have no adverse effect on the fungicidal action of said compounds. Suitable cations are thus in particular the ions of the alkali metals, preferably sodium and potassium, of the alkaline earth metals, preferably calcium, magnesium and barium, of the transition metals, preferably manganese, copper, zinc and iron, and also the ammonium ion which, if desired, may carry one to four Ci-C4-alkyl substituents and/or one phenyl or benzyl substituent, preferably diisopropylammoni- urn, tetramethylammonium, tetrabutylammonium, trimethylbenzylammonium, furthermore phos- phonium ions, sulfonium ions, preferably tri(Ci-C4-alkyl)sulfonium, and sulfoxonium ions, preferably tri(Ci-C4-alkyl)sulfoxonium. Anions of useful acid addition salts are primarily chloride, bro- mide, fluoride, hydrogensulfate, sulfate, dihydrogenphosphate, hydrogenphosphate, phosphate, nitrate, bicarbonate, carbonate, hexafluorosilicate, hexafluorophosphate, benzoate, and the anions of Ci-C4-alkanoic acids, preferably formate, acetate, propionate and butyrate. They can be formed by reacting such inventive compound with an acid of the corresponding anion, prefera- bly of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid or nitric acid.

The inventive compounds can be present in atropisomers arising from restricted rotation about a single bond of asymmetric groups. They also form part of the subject matter of the present invention.

Depending on the substitution pattern, the compounds of formula I and their N-oxides may have one or more centers of chirality, in which case they are present as pure enantiomers or pure diastereomers or as enantiomer or diastereomer mixtures. Both, the pure enantiomers or dia- stereomers and their mixtures are subject matter of the present invention.

In the following, particular embodiments of the inventive compounds are described. Therein, specific meanings of the respective substituents are further detained, wherein the meanings are in each case on their own but also in any combination with one another, particular embodiments of the present invention.

Furthermore, in respect of the variables, generally, the embodiments of the compounds I also apply to the intermediates.

R¹ according to the invention is in each case independently selected from halogen, OH , CN , N0₂, SH , N H₂, N H(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂, N H-S0₂-R^x, Ci-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆- alkynyl, Ci-C6-alkoxy, C3-C6-cycloalkyl, five- or six-membered heteroaryl and aryl; wherein the heteroaryl contains one, two or three heteroatoms selected from N , O and S; and wherein

R^x is CrC₄-alkyl, CrC₄-halogenalkyl, unsubstituted aryl or aryl that is substituted by one, two, three, four or five substituents R^x1 independently selected from Ci-C₄-alkyl;

R^1a halogen, OH , CN , Ci-C6-alkoxy, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, C1-C4- halogenalkoxy, Ci-C6-alkylthio and phenoxy, wherein the phenyl group is unsubstituted or car- ries one, two, three, four or five substituents R^11a selected from the group consisting of halogen, OH , CrC₄-alkyl, Ci-C₄-halogenalkyl, Ci-C₄-alkoxy and CrC₄-halogenalkoxy;

wherein the cycloalkyl, heteroaryl and aryl moieties of R¹ are not further substituted or carry one, two, three, four, five or up to the maximum number of identical or different groups R^{1 b} which independently of one another are selected from:

R^{1 b} halogen, OH , CN , Ci-C₄-alkyl, Ci-C₄-alkoxy, Ci-C₄-halogenalkyl, C₃-C₆-cycloalkyl, C₃-C₆- halogencycloalkyl, Ci-C₄-halogenalkoxy and Ci-C6-alkylthio.

According to the invention, there can be zero, one, two, three or four R¹ present, namely for m is 0, 1 , 2, 3 or 4.

According to one embodiment, m is 0. According to a further embodiment, m is 1.

According to a further embodiment, m is 2.

According to a further embodiment, m is 2 or 3. According to one specific embodiment thereof, m is 2, according to a further specific embodiment, m is 3.

According to one embodiment of the invention, one R¹ is attached to the 5-position as numbered in formula I above. According to one specific embodiment thereof, m is 1 , according to a further specific embodiment, m is 2.

According to a further embodiment of the invention, one R¹ is attached to the 6-position as numbered in formula I above. According to one specific embodiment thereof, m is 1 , according to a further specific embodiment, m is 2.

According to a further embodiment of the invention, one R¹ is attached to the 7-position as numbered in formula I above. According to one specific embodiment thereof, m is 1 , according to a further specific embodiment, m is 2.

According to a further embodiment of the invention, one R¹ is attached to the 8-position as numbered in formula I above. According to one specific embodiment thereof, m is 1 , according to a further specific embodiment, m is 2.

According to a further embodiment of the invention, two R¹ are attached in 7, 8-position as numbered in formula I above. According to one specific embodiment thereof, m is 2, according to a further specific embodiment, m is 3.

For every R¹ that is present in the inventive compounds, the following embodiments and preferences apply independently of the meaning of any other R¹ that may be present in the ring. Furthermore, the particular embodiments and preferences given herein for R¹ apply independently for each of m=1 , m=2, m=3 and m=4.

According to one specific embodiment, R¹ is halogen, in particular Br, F or CI, more specifically F or CI.

According to a further specific embodiment, R¹ is F.

According to a further specific embodiment, R¹ is CI.

According to a further specific embodiment, R¹ is Br.

According to a further specific embodiment, R¹ is OH.

According to a further specific embodiment, R¹ is CN.

According to a further specific embodiment, R¹ is NO2.

According to a further specific embodiment, R¹ is SH.

According to a further specific embodiment, R¹ is NH2.

According to a further specific embodiment R¹ is NH(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂ or NH-S0₂-R^x, wherein R^x is Ci-C₄-alkyl, Ci-C₄-halogenalkyl, unsubstituted aryl or aryl that is substituted by one, two, three, four or five substituents R^x1 independently selected from Ci-C₄-alkyl.

According to a further specific embodiment, R¹ is Ci-C6-alkyl, in particular Ci-C₄-alkyl, such as

According to a further specific embodiment, R¹ is Ci-C6-halogenalkyl, in particular C1-C4- halogenalkyl, such as CF₃, CHF₂, CH₂F, CCI₃, CHCI2, CH₂CI, CF3CH2, CCI3CH2 or CF₂CHF₂.

According to still a further embodiment, R¹ is C2-C6-alkenyl or C2-C6-halogenalkenyl, in particu- lar C₂-C₄-alkenyl or C₂-C₄-halogenalkenyl, such as CH=CH₂, C(CH₃)=CH₂, CH=CCI₂, CH=CF₂, CCI=CCI₂, CF=CF₂, CH=CH₂, CH₂CH=CCI₂, CH₂CH=CF₂, CH₂CCI=CCI₂, CH₂CF=CF₂,

CCI₂CH=CCI₂, CF₂CH=CF₂, CCI₂CCI=CCI₂, or CF₂CF=CF₂.

According to still a further embodiment, R¹ is C2-C6-alkynyl or C2-C6-halogenalkynyl, in particular C₂-C₄-alkynyl or C₂-C₄-halogenalkynyl, such as C≡CH, C≡CCI, C≡CF, CH₂C≡CH, CH₂C≡CCI, or CH₂C≡CF.

According to a further specific embodiment, R¹ is Ci-C6-alkoxy, in particular Ci-C₄-alkoxy, more specifically Ci-C2-alkoxy such as OCH3 or OCH2CH3.

According to a further specific embodiment, R¹ is Ci-C6-halogenalkoxy, in particular C1-C4- halogenalkoxy, more specifically Ci-C2-halogenalkoxy such as OCF₃, OCHF₂, OCH₂F, OCCI3, OCHCI2 or OCH2CI, in particular OCF₃, OCHF₂, OCCI₃ or OCHCI₂.

According to a further specific embodiment R¹ is C3-C6-cycloalkyl, in particular cyclopropyl.

In a further specific embodiment, R¹ is C3-C6-cycloalkyl, for example cyclopropyl, substituted by one, two, three or up to the maximum possible number of identical or different groups R^1b as defined and preferably herein.

According to a specific embodiment R¹ is C3-C6-halogencycloalkyl. In a special embodiment R¹ is fully or partially halogenated cyclopropyl.

According to still a further specific embodiment, R¹ is unsubstituted aryl or aryl that is

substituted by one, two, three or four R^1b, as defined herein. In particular, R¹ is unsubstituted phenyl or phenyl that is substituted by one, two, three or four R^1b, as defined herein.

According to still a further specific embodiment, R¹ is unsubstituted 5- or 6-membered heteroaryl. According to still a further embodiment, R¹ is 5- or 6-membered heteroaryl that is substituted by one, two or three R^1b, as defined herein.

According to one further embodiment R¹ is in each case independently selected from halogen, OH, CN, N0₂, SH, NH₂, NH(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂, NH-S0₂-R^x, Ci-C₆-alkyl, C₂-C₆-alkenyl, C2-C6-alkynyl, Ci-C6-alkoxy and C3-C6-cycloalkyl; wherein the acyclic moieties of R¹ are not further substituted or carry one, two, three, four or five identical or different groups R^1a as defined below and wherein the cycloalkyl moieties of R¹ are not further substituted or carry one, two, three, four or five identical or different groups R^1b as defined below.

According to a further embodiment, R¹ is independently selected from halogen, OH, Ci-C6-alkyl, Ci-C6-halogenalkyl, Ci-C6-alkoxy and Ci-C6-halogenalkoxy, in particular independently selected from F, CI, Br, CN, OH, Ci-C₄-alkyl, Ci-C₄-halogenalkyl, Ci-C₄-alkoxy and Ci-C₄-halogenalkoxy.

R^1a are the possible substituents for the acyclic moieties of R¹.

R^1a according to the invention is independently selected from halogen, OH, CN, Ci-C6-alkoxy, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, Ci-C₄-halogenalkoxy, Ci-C6-alkylthio and phenoxy, wherein the phenyl group is unsubstituted or carries one, two, three, four or five substituents R^11a selected from the group consisting of halogen, OH, Ci-C4-alkyl, Ci-C4-halogenalkyl, C1-C4- alkoxy and Ci-C4-halogenalkoxy, in particular selected from halogen, Ci-C2-alkyl, C1-C2- halogenalkyl, Ci-C2-alkoxy and Ci-C2-halogenalkoxy, more specifically selected from halogen, such as F, CI and Br.

According to one embodiment R^1a is independently selected from halogen, OH, CN , C1-C2- alkoxy, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl and Ci-C2-halogenalkoxy. Specifically, R^1a is independently selected from F, CI, OH, CN, Ci-C2-alkoxy, cyclopropyl, 1-F-cyclopropyl, 1 -CI- cyclopropyl, 1 ,1 -F2-cyclopropyl, 1 ,1-Cl2-cyclopropyl and Ci-C2-halogenalkoxy.

According to one particular embodiment R^1a is independently selected from halogen, such as F, CI, Br and I , more specifically F, CI and Br.

According to a further embodiment, R^1a is independently selected from OH, C3-C6-cycloalkyl, C3- C6-halogencycloalkyl and Ci-C2-halogenalkoxy. Specifically, R^1a is independently selected from OH, cyclopropyl and Ci-C2-halogenalkoxy.

R^1b are the possible substituents for the cycloalkyl, heteroaryl and aryl moieties of R¹.

R^1b according to the invention is independently selected from halogen, OH, CN , Ci-C4-alkyl, Ci- C4-alkoxy, Ci-C4-halogenalkyl, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl and C1-C4- halogenalkoxy.

According to one embodiment thereof R^1b is independently selected from halogen, CN, C1-C2- alkyl, Ci-C2-alkoxy, Ci-C2-halogenalkyl, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl and C1-C2- halogenalkoxy. Specifically, R^1b is independently selected from F, CI, OH, CN, CH3, OCH3, cyclopropyl, 1-F-cyclopropyl, 1-CI-cyclopropyl, 1 ,1-F₂-cyclopropyl, 1 ,1-Cl2-cyclopropyl and halogenmethoxy.

According to a further embodiment thereof R^1b is independently selected from Ci-C2-alkyl, Ci- C2-alkoxy, Ci-C2-halogenalkyl, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl and C1-C2- halogenalkoxy. Specifically, R^1b is independently selected from OH, CH3, CHF2, CF3, OCH3, cyclopropyl, 1-F-cyclopropyl, 1-CI-cyclopropyl, 1 ,1-F2-cyclopropyl, 1 ,1-Cl2-cyclopropyl and halogenmethoxy, more specifically independently selected from OH, CH3, CHF2, CF3, OCH3, cyclopropyl, 1-F-cyclopropyl, 1-CI-cyclopropyl, 1 ,1 -F2-cyclopropyl, 1 ,1-Cl2-cyclopropyl and

Particularly preferred embodiments of (R¹)_m according to the invention are in Table P1 below, wherein each line of lines P1 -1 to P1-62 corresponds to one particular embodiment of the invention, wherein P1-1 to P1 -62 are also in any combination with one another a preferred embodiment of the present invention. Thereby, for every R¹ that is present in the inventive compounds, these specific embodiments and preferences apply independently of the meaning of any other R¹ that may be present in the ring:

Table P1 :

No. (R¹)m No. (R¹)m No. (R¹)m

P1-10 5-Br P1-28 7-CH3 P1-46 5-OCH2CH3

P1-11 6-Br P1-29 8-CH3 P1-47 6-OCH2CH3

P1-12 7-Br P1-30 5-CH2CH3 P1-48 7-OCH2CH3

P1-13 8-Br P1-31 6-CH2CH3 P1-49 8-OCH2CH3

P1-14 5-OH P1-32 7-CH2CH3 P1-50 5-OCF3

P1-15 6-OH P1-33 8-CH2CH3 P1-51 6-OCF3

P1-16 7-OH P1-34 5-CF3 P1-52 7-OCF3

P1-17 8-OH P1-35 6-CF3 P1-53 8-OCF3

P1-18 5-CN P1-36 7-CF3 P1-54 5-OCHF2

P1-19 6-CN P1-37 8-CF3 P1-55 6-OCHF2

P1-20 7-CN P1-38 5-CHF2 P1-56 7-OCHF2

P1-21 8-CN P1-39 6-CHF2 P1-57 8-OCHF2

P1-22 5-NO2 P1-40 7-CHF2 P1-58 5-NH-Ts

P1-23 6-NO2 P1-41 8-CHF2 P1-59 6-NH-Ts

P1-24 7-NO2 P1-42 5-OCH3 P1-60 7-NH-Ts

P1-25 8-NO2 P1-43 6-OCH3 P1-61 8-NH-Ts

P1-26 5-CHs P1-44 7-OCH3 P1-62 7,8-F₂

P1-27 6-CH3 P1-45 8-OCH3

R² according to the invention is is in each case independently selected from halogen, OH, CN, N0₂, SH, NH₂, NH(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂, NH-S0₂-R^x, Ci-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆- alkynyl, Ci-C6-alkoxy, C3-C6-cycloalkyl, five- or six-membered heteroaryl and aryl; wherein the heteroaryl contains one, two or three heteroatoms selected from N, O and S; and wherein R^x is Ci-C₄-alkyl, Ci-C₄-halogenalkyl, unsubstituted aryl or aryl that is substituted by one, two, three, four or five substituents R^x2 independently selected from Ci-C₄-alkyl; wherein the acyclic moieties of R² are not further substituted or carry one, two, three or up to the maximum possible number of identical or different groups R^2a which independently of one another are selected from:

R^2a halogen, OH, CN, Ci-C6-alkoxy, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, C1-C4- halogenalkoxy, Ci-C6-alkylthio and phenoxy, wherein the phenyl group is unsubstituted or carries one, two, three, four or five substituents R^22a selected from the group consisting of halogen, OH, Ci-C₄-alkyl, Ci-C₄-halogenalkyl, Ci-C₄-alkoxy and Ci-C₄-halogenalkoxy;

wherein the cycloalkyl, heteroaryl and aryl moieties of R² are not further substituted or carry one, two, three, four, five or up to the maximum number of identical or different groups R^2b which independently of one another are selected from:

R^2b halogen, OH, CN, Ci-C₄-alkyl, Ci-C₄-alkoxy, Ci-C₄-halogenalkyl, C₃-C₆-cycloalkyl, C₃-C₆- halogencycloalkyl, Ci-C₄-halogenalkoxy and Ci-C6-alkylthio.

According to the invention, there can be zero, one or two R² present, namely for n is 0, 1 or 2.

According to one embodiment, n is 0 or 1.

According to a further embodiment, n is 0. According to still a further embodiment, n is 1.

According to still a further embodiment, n is 2.

According to one embodiment of the invention, one R² is attached to the 2-position as numbered in formula I above. According to one specific embodiment thereof, n is 1 , according to a further specific embodiment, n is 2.

According to a further embodiment of the invention, one R² is attached to the 4-position as numbered in formula I above. According to one specific embodiment thereof, n is 1 , according to a further specific embodiment, n is 2.

According to a further embodiment of the invention, two R² are attached in 2, 4-position as numbered in formula I above.

For every R² that is present in the inventive compounds, the following embodiments and preferences apply independently of the meaning of the other R² that may be present in the ring. Furthermore, the particular embodiments and preferences given herein for R² apply independently for each of n=1 and n=2.

According to one specific embodiment, R² is halogen, in particular Br, F or CI, more specifically F or CI.

According to a further specific embodiment, R² is F.

According to a further specific embodiment, R² is CI.

According to a further specific embodiment, R² is Br.

According to a further specific embodiment, R² is OH.

According to a further specific embodiment, R² is CN.

According to a further specific embodiment, R² is NO2.

According to a further specific embodiment, R² is SH.

According to a further specific embodiment, R² is NH2.

According to a further specific embodiment R² is, NH(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂ or NH-S0₂-R^x, wherein R^x is Ci-C₄-alkyl, Ci-C₄-halogenalkyl, unsubstituted aryl or aryl that is substituted by one, two, three, four or five substituents R^x2 independently selected from Ci-C₄-alkyl.

According to a further specific embodiment, R² is Ci-C6-alkyl, in particular Ci-C₄-alkyl, such as CH₃ or CH₂CH₃.

According to a further specific embodiment, R² is Ci-C6-halogenalkyl, in particular C1-C4- halogenalkyl, such as CF₃, CHF₂, CH₂F, CCI₃, CHCI₂,CH₂CI, CF₃CH₂, CCI₃CH₂ or CF₂CHF₂.

According to still a further embodiment, R² is C2-C6-alkenyl or C2-C6-halogenalkenyl, in particular C₂-C₄-alkenyl or C₂-C₄-halogenalkenyl, such as CH=CH₂, CH=CCI₂, CH=CF₂, CCI=CCI₂, CF=CF₂, CH=CH₂, CH₂CH=CCI₂, CH₂CH=CF₂, CH₂CCI=CCI₂, CH₂CF=CF₂, CCI₂CH=CCI₂, CF₂CH=CF₂, CCI₂CCI=CCI₂, or CF₂CF=CF₂.

According to still a further embodiment, R² is C2-C6-alkynyl or C2-C6-halogenalkynyl, in particular C₂-C₄-alkynyl or C₂-C₄-halogenalkynyl, such as C≡CH, C≡CCI, C≡CF, CH₂C≡CH, CH₂C≡CCI, or CH₂C≡CF. According to a further specific embodiment, R² is Ci-C6-alkoxy, in particular Ci-C4-alkoxy, more specifically Ci-C2-alkoxy such as OCH3 or OCH2CH3.

According to a further specific embodiment, R² is Ci-C6-halogenalkoxy, in particular C1-C4- halogenalkoxy, more specifically Ci-C2-halogenalkoxy such as OCF3, OCHF2, OCH2F, OCCI3, OCHCI2 or OCH2CI, in particular OCF₃, OCHF₂, OCCI₃ or OCHCI₂.

According to a further specific embodiment R² is C3-C6-cycloalkyl, in particular cyclopropyl.

In a further specific embodiment, R² is C3-C6-cycloalkyl, for example cyclopropyl, substituted by one, two, three or up to the maximum possible number of identical or different groups R^2b as defined and preferably herein.

According to a specific embodiment R² is C3-C6-halogencycloalkyl. In a special embodiment R² is fully or partially halogenated cyclopropyl.

According to still a further specific embodiment, R² is unsubstituted aryl or aryl that is substituted by one, two, three or four R^2b, as defined herein. In particular, R² is unsubstituted phenyl or phenyl that is substituted by one, two, three or four R^2b, as defined herein.

According to still a further specific embodiment, R² is unsubstituted 5- or 6-membered heteroaryl. According to still a further embodiment, R² is 5- or 6-membered heteroaryl that is substituted by one, two or three R^2b, as defined herein.

According to one further embodiment R² is in each case independently selected from halogen, OH, CN, N0₂, SH, NH₂, NH(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂, NH-S0₂-R^x, Ci-C₆-alkyl, C₂-C₆-alkenyl, C2-C6-alkynyl, Ci-C6-alkoxy and C3-C6-cycloalkyl; wherein the acyclic moieties of R² are not further substituted or carry one, two, three, four or five identical or different groups R^2a as defined below and wherein the cycloalkyl moieties of R² are not further substituted or carry one, two, three, four or five identical or different groups R^2b as defined below.

According to a further embodiment, R² is independently selected from halogen, OH, Ci-C6-alkyl, Ci-C6-halogenalkyl, Ci-C6-alkoxy and Ci-C6-halogenalkoxy, in particular independently selected from F, CI, Br, CN, OH, Ci-C₄-alkyl, Ci-C₄-halogenalkyl, Ci-C₄-alkoxy and Ci-C₄-halogenalkoxy.

R^2a are the possible substituents for the acyclic moieties of R².

R^2a according to the invention is independently selected from halogen, OH, CN, Ci-C6-alkoxy, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, Ci-C₄-halogenalkoxy, Ci-C6-alkylthio and phenoxy, wherein the phenyl group is unsubstituted or carries one, two, three, four or five substituents R^22a selected from the group consisting of halogen, OH, Ci-C₄-alkyl, CrC₄-halogenalkyl, C1-C4- alkoxy and Ci-C₄-halogenalkoxy, in particular selected from halogen, Ci-C2-alkyl, C1-C2- halogenalkyl, Ci-C2-alkoxy and Ci-C2-halogenalkoxy, more specifically selected from halogen, such as F, CI and Br.

According to one embodiment R^2a is independently selected from halogen, OH, CN, C1-C2- alkoxy, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl and Ci-C2-halogenalkoxy. Specifically, R^2a is independently selected from F, CI, OH, CN, Ci-C2-alkoxy, cyclopropyl, 1-F-cyclopropyl, 1 -CI- cyclopropyl, 1 ,1 -F₂-cyclopropyl, 1 ,1-Cl2-cyclopropyl and Ci-C2-halogenalkoxy.

According to one particular embodiment R^2a is independently selected from halogen, such as F, CI, Br and I, more specifically F, CI and Br. According to a further embodiment, R^2a is independently selected from OH, C3-C6-cycloalkyl, C3- C6-halogencycloalkyl and Ci-C2-halogenalkoxy. Specifically, R^2a is independently selected from OH, cyclopropyl, 1 ,1-F2-cyclopropyl, 1 ,1-Cl2-cyclopropyl and Ci-C2-halogenalkoxy.

R^2b are the possible substituents for the cycloalkyl, heteroaryl and aryl moieties of R².

R^2b according to the invention is independently selected from halogen, OH, CN, Ci-C4-alkyl, Ci- C4-alkoxy, Ci-C4-halogenalkyl, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl and C1-C4- halogenalkoxy.

According to one embodiment thereof R^2b is independently selected from halogen, CN, C1-C2- alkyl, Ci-C2-alkoxy, Ci-C2-halogenalkyl, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl and C1-C2- halogenalkoxy. Specifically, R^2b is independently selected from F, CI, OH, CN, CH₃, OCH₃, cyclopropyl, 1-F-cyclopropyl, 1-CI-cyclopropyl, 1 ,1-F2-cyclopropyl, 1 ,1-Cl2-cyclopropyl and halogenmethoxy.

According to a further embodiment thereof R^2b is independently selected from Ci-C2-alkyl, Ci- C2-alkoxy, Ci-C2-halogenalkyl, C₃-C6-cycloalkyl, C₃-C6-halogencycloalkyl and C1-C2- halogenalkoxy. Specifically, R^2b is independently selected from OH, CH₃, CHF₂, CF₃, OCH₃, cyclopropyl, 1-F-cyclopropyl, 1-CI-cyclopropyl, 1 ,1-F2-cyclopropyl, 1 ,1-Cl2-cyclopropyl and halogenmethoxy, more specifically independently selected from OH, CH3, CHF2, CF3, OCH3, cyclopropyl, 1-F-cyclopropyl, 1-CI-cyclopropyl, 1 ,1-F2-cyclopropyl, 1 ,1-Cl2-cyclopropyl and Particularly preferred embodiments of (R²)_m according to the invention are in Table P2 below, wherein each line of lines P2-1 to P2-32 corresponds to one particular embodiment of the invention, wherein P2-1 to P2-32 are also in any combination with one another a preferred embodiment of the present invention. Thereby, for every R² that is present in the inventive compounds, these specific embodiments and preferences apply independently of the meaning of any other R² that may be present in the ring:

Table P2:

R³ is are independently selected from halogen, OH, CN, N0₂, SH, C C₆-alkylthio, NH₂, NH(C C₄-alkyl), N(Ci-C₄-alkyl)₂, NH-S0₂-R^x, Ci-C₆-alkyl, Ci-C₆-halogenalkyl, C₂-C₆-alkenyl, C₂-C₆- halogenalkenyl, C2-C6-alkynyl, C2-C6-halogenalkynyl, Ci-C6-alkoxy, Ci-C6-halogenalkoxy, C2-C6- alkenyloxy, C₂-C₆-alkynyloxy, CH(=0), C(=0)Ci-C₆-alkyl, C(=0)0(Ci-C₆-alkyl), C(=0)NH(Ci-C₆- alkyl), C(=0)N(Ci-C6-alkyl)₂, CR'=NOR", a saturated or partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbocycle or heterocycle, wherein in each case one or two CH2 groups of the carbo- and heterocycle may be replaced by a group independently selected from C(=0) and C(=S), five- or six-membered heteroaryl and aryl; wherein the heterocycle and the heteroaryl contain independently one, two, three or four heteroatoms selected from N, O and S; and wherein R' and R" are independently selected from H, Ci-C4-alkyl, C2-C6- alkenyl, C2-C6-alkynyl, saturated or partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbo- and heterocycle, five- or six-membered heteroaryl or aryl; wherein the heterocycle or heteroaryl contains one, two or three heteroatoms selected from N, O and S, and wherein R' and R" are independently unsubstituted or substituted by R'" which is independently selected from halogen, OH, CN, N0₂, SH, NH₂, NH(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂, NH- SC>2-R^X, Ci-C6-alkyl, Ci-C6-halogenalkyl, C2-C6-alkenyl, C2-C6-halogenalkenyl, C2-C6-alkynyl, C2- C6-halogenalkynyl, Ci-C6-alkoxy, Ci-C6-halogenalkoxy, C3-C6-cycloalkyl, C3-C6- halogencycloalkyl and phenyl; or

wherein the acyclic moieties of R³ are independently not further substituted or carry one, two, three or up to the maximum possible number of identical or different groups R^3a, respectively, which independently of one another are selected from:

R^3a halogen, OH, CN, N0₂, SH, NH₂, NH(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂, NH(C(=0)Ci-C₄-alkyl), N(C(=0)Ci-C₄-alkyl)₂, NH-S0₂-R^x, Ci-C₆-alkoxy, Ci-C₄-halogenalkoxy, C₃-C₆-cycloalkyl, C₃-C₆- halogencycloalkyl, C C₆-alkylthio, C C₆-halogenalkylthio, S(0)_z-Ci-C₆-alkyl, S(0)_z-Ci-C₆- halogenalkyl, S(0)_z-aryl, CH(=0), C(=0)C C₆-alkyl, C(=0)0(d-C₆-alkyl), C(=0)NH(C C₆- alkyl), C(=0)N(Ci-C6-alkyl)₂, CR'=NOR", a saturated or partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbocycle or heterocycle, five-, six- or ten- membered heteroaryl, aryl, phenoxy; wherein in each case one or two CH2 groups of the carbocycle and heterocycle may be replaced by a group independently selected from C(=0) and C(=S); wherein the heterocycle and heteroaryl contain independently one, two, three or four heteroatoms selected from N, O and S; wherein the carbocyclic, heterocyclic, aryl, phenyl and heteroaryl groups are independently unsubstituted or carry one, two, three, four or five substituents selected from the group consisting of halogen, OH, CN , NO2, SH , NH₂, NH(CrC₄-alkyl), N(Ci-C₄-alkyl)₂, NH(C(=0)Ci-C₄-alkyl), N(C(=0)Ci-C₄-alkyl)₂, NH-S0₂-R^x, Ci-C₆-alkylthio, Ci- C₄-alkyl, Ci-C₄-halogenalkyl, Ci-C₄-alkoxy, Ci-C₄-halogenalkoxy and S(0)_z-Ci-C6-alkyl;

z is 0, 1 and 2;

wherein the carbocyclic, heterocyclic, heteroaryl and aryl moieties of R³ are independently not further substituted or carry one, two, three, four, five or up to the maximum number of identical or different groups R^3b .respectively, which independently of one another are selected from:

R ^b halogen, OH, CN, N0₂, SH, NH₂, NH(C C₄-alkyl), N(C C₄-alkyl)₂, NH(C(=0)C C₄-alkyl), N(C(=0)Ci-C₄-alkyl)₂, NH-S0₂-R^x, C C₄-alkyl, Ci-C₄-alkoxy, C C₄-halogenalkyl, C₃-C₆- cycloalkyl, C3-C6-halogencycloalkyl, Ci-C₄-halogenalkoxy, Ci-C6-alkylthio, C1-C6- halogenalkylthio, S(0)_z-Ci-C6-alkyl, Ci-C₄-alkoxy-Ci-C₄-alkyl, phenyl and phenoxy, wherein the phenyl groups are unsubstituted or carry one, two, three, four or five substituents selected from the group consisting of halogen, OH, Ci-C4-alkyl, Ci-C4-halogenalkyl, Ci-C4-alkoxy and C1-C4- halogenalkoxy;

and wherein R^x R' and R" is as defined above.

According to one embodiment of formula I, R³ is selected from from CN, Ci-C6-alkyl, C1-C6- halogenalkyi, C2-C6-alkenyl, C2-C6-halogenalkenyl, C3-C6-cycloalkenyl, C2-C6-alkynyl, C2-C6- halogenalkynyl, C₃-C₆-cycloalkynyl, CH(=0), C(=0)C C₆-alkyl, C(=0)0(Ci-C₆-alkyl),

CR'=NOR", C3-C6-halogencycloalkyl, a saturated three-, four-, five-, six-, membered carbo- or heterocycle, a five- or six-membered heteroaryl or aryl; and Ci-C6-alkyl substituted by CN, Ci- C6-alkoxy, Ci-C4-halogenalkoxy, Ci-C6-alkylthio, S(0)_z-Ci-C6-alkyl, S(0)_z-Ci-C6-halogenalkyl, NH-S0₂-R^x, N(Ci-C₆-alkyl)₂, CH(=0), C(=0)Ci-C₆-alkyl, C(=0)0(Ci-C₆-alkyl), a saturated three-, four-, five-, six-, membered carbo- or heterocycle, aryl and heteroaryl; wherein R^x, R' and R" are defined below; and wherein the acyclic moieties of R³ are unsubstituted or substituted with identical or different groups R^3a as defined below and wherein wherein the carbo-, heterocycle and heteroaryl and aryl moieties are unsubstituted or substituted by substituents R^3b as defined be- low.

According to another embodiment of formula I, R³ is selected from Ci-C6-alkyl, C1-C6- halogenalkyl, C2-C6-alkenyl, C2-C6-halogenalkenyl, C2-C6-alkynyl, C2-C6-halogenalkynyl, C3-C6- cycloalkyl, C3-C6-halogencycloalkyl, Ci-C6-alkylaryl, Ci-C6-alkyl-five- and six-membered heteroaryl, five- and six-membered heteroaryl or aryl which is unsubstituted or substituted by halo- gen or Ci-C6-halogenalkyl, and wherein the acyclic moieties of R³ are unsubstituted or substituted with identical or different groups R^3a as defined below and wherein wherein the carbocycle, heterocycle and heteroaryl and aryl moieties are unsubstituted or substituted by substituents R^3b as defined below.

According to still another embodiment of formula I, R³ is selected from Ci-C6-alkyl, C1-C6- halogenalkyi, CN, C2-C6-alkenyl, C2-C6-halogenalkenyl, C2-C6-alkynyl, C2-C6-halogenalkynyl, C3- C6-cycloalkyl, C3-C6-halogencycloalkyl, Ci-C6-alkylaryl, Ci-C6-alkylheteroaryl, phenyl, pyridine, pyrimidine, thiophene, imidazole, triazol, oxadiazol wherein the acyclic moieties of R³ are unsubstituted or substituted with identical or different groups R^3a as defined below and wherein wherein the carbocycle, heterocycle, heteroaryl and aryl moieties are unsubstituted or substitut- ed by substituents R^3b as defined below.

According to still another embodiment of formula I, R³ is CN.

According to still another embodiment of formula I, R³ is Ci-C6-alkylthio, such as SCH3, SC2H5, Sn-propyl, Si-propyl, Sn-butyl, Si-butyl, Stert-butyl, Sn-pentyl, Si-pentyl, CH2SCH3 or

According to still another embodiment of formula I, R³ is Ci-C6-halogenalkylthio, such as SCF3, SCCI3, CH2SCF3 or CH2SCF3.

According to still another embodiment of formula I, R³ is Ci-C6-alkyl such as CH3, C2H5, n- propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl.

According to still another embodiment of formula I, R³ is Ci-C6-alkyl such as CH₃.

According to still another embodiment of formula I, R³ is Ci-C6-alkyl such as C2H5. According to still another embodiment of formula I, R³ is Ci-C6-halogenalkyl, in particular C1-C4- halogenalkyl, more specifically Ci-C2-halogenalkyl, such as CF3, CC , FCH2, CICH2, F2CH, CI2CH, CF3CH2, CCI3CH2 or CF2CHF2.

According to still another embodiment of formula I, R³ is CH2F.

According to still another embodiment of formula I, R³ is CHF2.

According to still another embodiment of formula I, R³ is CF₃.

According to still a further embodiment of formula I, R³ is C2-C6-alkenyl, in particular C₂-C₄-alk- enyl, such as CH=CH₂, CH₂CH=CH₂ or C(CH₃)C=CH₂.

According to a further specific embodiment of formula I, R³ is C2-C6-halogenalkenyl, in particular C2-C₄-halogenalkenyl, more specifically C2-C3-halogenalkenyl such as CH=CHF, CH=CHCI, CH=CF₂, CH=CCI₂, CF=CF₂, CCI=CCI₂, CH₂CH=CHF, CH₂CH=CHCI, CH₂CH=CF₂,

CH₂CH=CCI₂, CH₂CF=CF₂, CH₂CCI=CCI₂, CF₂CF=CF₂ or CCI₂CCI=CCI₂.

According to still a further embodiment of formula I, R³ is C2-C6-cycloalkenyl, in particular C2-C4- cycloalkenyl, such as CH=CH₂-cPr.

According to still a further embodiment of formula I, R³ is C2-C6-alkynyl or C2-C6-halogenalkynyl, in particular C2-C₄-alkynyl or C2-C₄-halogenalkynyl, such as C CH, C C-CI, C=C-CH₃, CH₂- C≡CH, CH₂C≡CCI or CH₂-C≡C-CH₃.

According to still a further embodiment of formula I, R³ is C2-C6-cycloalkynyl in particular C2-C4- cycloalkynyl, such as C C-cPr.

According to a further specific embodiment of formula I, R³ is Ci-C6-alkoxy, in particular C1-C4- alkoxy, more specifically Ci-C2-alkoxy such as OCH3, CH2CH3 or CH2OCH3.

According to a further specific embodiment of formula I, R³ is Ci-C6-halogenalkoxy, in particular CrC₄-halogenalkoxy, more specifically Ci-C2-halogenalkoxy such as OCF₃, OCHF₂, OCH₂F, OCCI3, OCHC or OCH2CI, in particular OCF₃, OCHF2, OCCI₃ or OCHCI₂.

According to a further specific embodiment of formula I, R³ is Ci-C6-alkyl-Ci-C6-alkoxy, in particular Ci-C₄-alkyl-Ci-C₄-alkoxy, more specifically Ci-C2-alkyl-Ci-C2-alkoxy, such as

CH₂OCH₃ or CH₂OCH₂CH₃.

According to a further specific embodiment of formula I, R³ is Ci-C6-alkyl-Ci-C6-halogenalkoxy, in particular Ci-C₄-alkyl-Ci-C₄-halogenalkoxy, more specifically Ci-C2-alkyl-Ci-C2-halogenalkoxy such as CH₂OCF₃, CH₂OCHF₂, CH₂OCH₂F, CH₂OCCI₃, CH₂OCHCI₂ or CH₂OCH₂CI, in particular CH₂OCF₃, CH₂OCHF₂, CH₂OCCI₃ or CH₂OCHCI₂.

According to a further specific embodiment of formula I, R³ is C₂-C6-alkenyloxy, in particular C₂- C₄-alkenyloxy, more specifically Ci-C₂-alkenyloxy such as OCH=CH₂, OCH₂CH=CH₂

OC(CH₃)CH=CH₂, CH₂OCH=CH₂, or CH₂OCH₂CH=CH₂.

According to a further specific embodiment of formula I, R³ is C₂-C6-alkynyloxy, in particular C₂- C₄-alkynyloxy, more specifically Ci-C₂-alkynyloxy such as OC CH, OCH₂C=CH or CH₂OC=CH

According to a further specific embodiment of formula I, R³ is CH(=0), C(=0)Ci-C6-alkyl, C(=0)0(Ci-C₆-alkyl), C(=0)NH(Ci-C₆-alkyl) or C(=0)N(Ci-C₆-alkyl)₂, wherein alkyl is CH₃, C₂H₅, n-propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl. According to a further specific embodiment of formula I , R³ is Ci-C4-alkyl-CH(=0), Ci-C₄-alkyl- C(=0)Ci-C₆-alkyl, Ci-C₄-alkyl-C(=0)0(Ci-C₆-alkyl), Ci-C₄-alkyl-C(=0)NH(Ci-C₆-alkyl) or C1-C4- alkyl-C(=0)N(Ci-C₆-alkyl)₂, especially CH₂CH(=0), CH₂C(=0)Ci-C₆-alkyl, CH₂C(=0)0(Ci-C₆- alkyl), CH₂C(=0)N H(Ci-C₆-alkyl) or CH₂C(=0)N(Ci-C₆-alkyl)₂ wherein alkyl is CH₃, C₂H₅, n- propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl.

According to a further specific embodiment of formula I , R³ is CR'=NOR" such as

C(CH₃)=NOCH₃, C(CH₃)=NOCH₂CH₃ or C(CH₃)=NOCF₃.

According to a further specific embodiment of formula I , R³ is Ci-C6-alkyl-NH(Ci-C₄-alkyl) or Ci- C6-alkyl-N(Ci-C₄-alkyl)₂, wherein alkyl is CH₃, C₂H5, n-propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl.

According to a further specific embodiment of formula I , R³ is Ci-C6-alkyl-S(0)_z-Ci-C6-alkyl, wherein alkyl is CH₃, C₂H5, n-propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl and z is 1 , 2 or 3.

According to a further specific embodiment of formula I , R³ is Ci-C6-alkyl-S(0)_z-CrC6- halogenalkyl, wherein halogenalkyl is CF₃ or CHF₂ and z is 1 , 2 or 3.

According to a further specific embodiment of formula I , R³ is Ci-C6-alkyl-S(0)_z-aryl, wherein the aryl or phenyl moiety in each case is unsubstituted or substituted by identical or different groups R^3b which independently of one another are selected from halogen, Ci-C₂-alkyl, Ci-C₂-alkoxy, Ci-C₂-halogenalkyl, Ci-C₂-halogenalkoxy and S(0)_z-Ci-C6-alkyl, in particular F, CI, Br, CH₃, OCH₃, CF₃, CHF₂, OCHF₂, OCF₃. According to one embodiment, R³ is unsubstituted phenyl. According to another embodiment, R³ is phenyl, that is substituted by one, two or three, in particular one, halogen, in particular selected from F, CI and Br, more specifically selected from F and CI.

According to a further specific embodiment of formula I , R³ is Ci-C6-alkyl-N H-S0₂-R^x wherein R^x is Ci-C₄-alkyl, Ci-C₄-halogenalkyl, unsubstituted aryl or aryl that is substituted by one, two, three, four or five substituents R^x2 independently selected from Ci-C₄-alkyl, halogen, OH, CN, Ci-C₄-halogenalkyl, Ci-C₄-alkoxy, or Ci-C₄-halogenalkoxy, such as CH₂NHS0₂CF₃ or

CH₂NHS0₂CH₃.

According to still another embodiment of formula I , R³ is selected from Ci-C6-alkyl which is sub- stituted, a saturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbocycle, in particular three-, four-, five- or six-membered, wherein the carbocycle is unsubstituted or substituted by substituents R^3b as defined below. According to one embodiment thereof, the carbocycle is unsubstituted.

According to one embodiment, R³ is selected from Ci-C6-alkyl, especially CH₂ which is substi- tuted by a 3-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R^3b. According to still another embodiment of formula I , it is substituted by R^3b.

According to one embodiment, R³ is selected from Ci-C6-alkyl, especially CH₂ which is substituted by a 4-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R^3b. According to still another embodiment of formula I , it is substituted by R^3b. According to one embodiment, R³ is selected from Ci-C6-alkyl, especially with R optionally substituted Chb which is substituted by a 5-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R^3b. According to still another embodiment of formula I, it is substituted by R^3b.

According to one embodiment, R³ is selected from Ci-C6-alkyl, especially Chb which is substituted by a 6-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R^3b. According to still another embodiment of formula I, it is substituted by R^3b.

According to a further specific embodiment of formula I, R³ is Ci-C6-alkyl, especially Chb substituted by a 4-membered saturated heterocycle which contains 1 or 2 heteroatoms, in particular 1 heteroatom, from the group consisting of N, O and S, as ring members. According to one embodiment, the heterocycle contains one O as heteroatom. For example, the formed heterocycle is oxetane. According to one embodiment thereof, the heterocycle is unsubstituted, i.e. it does not carry any substituent R^3b. According to still another embodiment of formula I, it is substituted by R³ .

According to a further specific embodiment of formula I, R³ is Ci-C6-alkyl, especially Chb substituted by a 5-membered saturated heterocycle which contains 1 , 2 or 3, in particular 1 or 2, heteroatoms from the group consisting of N, O and S, as ring members. According to one embodiment, the heterocycle contains one O as heteroatom. According to one embodiment thereof, the heterocycle is unsubstituted, i.e. it does not carry any substituent R^3b. According to still another embodiment of formula I, it is substituted by R^3b.

According to a further specific embodiment of formula I, R³ is Ci-C6-alkyl, especially CH₂ subsitited by a 6-membered saturated heterocycle which contains 1 , 2 or 3, in particular 1 or 2, heteroatoms from the group consisting of N, O and S as ring members. According to one embodiment thereof, the heterocycle is unsubstituted, i.e. it does not carry any substituent R^3b. According to still another embodiment of formula I, it is substituted by R^3b. According to one specific embodiment thereof, said 6-membered saturated heterocycle contains 1 or 2, in particular 1 , heteroatom(s) O. According to one embodiment thereof, the respective 6-membered heterocycle is unsubstituted, i.e. it does not carry any substituent R^3b. According to still another embodiment of formula I, it is substituted by R^3b.

According to a further specific embodiment of formula I, R³ is Ci-C6-alkyl, especially CH₂ substituted by a 5-membered saturated heterocycle which contains one N as ring member and optionally one or two groups Ch are replaced by C(=0).

According to still another embodiment of formula I, R³ is a partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbocycle, in particular three-, four-, five- or six-membered, wherein the carbocycle is unsubstituted or substituted by substituents R^3b as defined below. According to one embodiment thereof, the carbocycle is unsubstituted.

According to still another embodiment of formula I, R³ is a partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbocycle or heterocycle, in particular three-, four-, five- or six-membered, wherein the heterocycle contains one, two, three or four heteroatoms selected from N, O and S, and wherein the carbocycle and heterocycle are unsubstituted or substituted with substituents R^3b as defined below. According to one embodiment thereof, the carbocycle or heterocyde is unsubstituted.

According to still a further embodiment, R³ is a saturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbocycle or heterocyde, in particular three-, four-, five- or six- membered, wherein the heterocyde contains one, two, three or four heteroatoms selected from N, O and S, and wherein the carbocycle and heterocyde are unsubstituted or substituted with substituents R^3b as defined below. According to one embodiment thereof, the carbocycle or heterocyde is unsubstituted.

According to still another embodiment of formula I, R³ is a saturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbocycle, in particular three-, four-, five- or six- membered, wherein the carbocycle is unsubstituted or substituted by substituents R^3b as defined below. According to one embodiment thereof, the carbocycle is unsubstituted.

According to one embodiment, R³ is a 3-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R^3b. According to still another embodiment of formula I, it is substituted by R^3b.

According to one embodiment, R³ is a 3-membered saturated carbocycle, which is

unsubstituted such as cyclopropyl

According to one embodiment, R³ is a 3-membered saturated carbocycle, which is substituted by halogen, more specifically by F, such as C3H3F2.

According to one embodiment, R³ is a 3-membered saturated carbocycle, which is substituted by halogen. More specifically by CI, such as C3H3CI2.

According to one embodiment, R³ is a 4-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R^3b. According to still another embodiment of formula I, it is substituted by R^3b.

According to one embodiment, R³ is a 5-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R^3b. According to still another embodiment of formula I, it is substituted by R^3b.

According to one embodiment, R³ is a 6-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R^3b. According to still another embodiment of formula I, it is substituted by R^3b.

According to still another embodiment of formula I, R³ is a partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered heterocyde, in particular three-, four-, five- or six-membered, wherein the heterocyde contains one, two, three or four heteroatoms selected from N, O and S, and wherein the heterocyde is unsubstituted or substituted by substituents R^3b as defined below. According to one embodiment thereof, the heterocyde is unsubstituted.

According to still another embodiment of formula I, R³ is a saturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered heterocyde, in particular three-, four-, five- or six- membered, wherein the heterocyde contains one, two, three or four heteroatoms selected from N, O and S, and wherein the heterocyde is unsubstituted or substituted by substituents R^3b as defined below. According to one embodiment thereof, the heterocyde is unsubstituted.

According to still another embodiment of formula I, in the embodiments of R³ described above, the heterocycle contains preferably one, two or three, more specifically one or two heteroatoms selected from N, O and S. More specifically, the hetereocycle contains one heteroatom selected from N, O and S. In particular, the heterocycle contains one or two, in particular one O.

According to one embodiment, R³ is a 4-membered saturated heterocycle which contains 1 or 2 heteroatoms, in particular 1 heteroatom, from the group consisting of N, O and S, as ring members. According to one embodiment, the heterocycle contains one O as heteroatom. For example, the formed heterocycle is oxetane. According to one embodiment thereof, the heterocycle is unsubstituted, i.e. it does not carry any substituent R^3b. According to still another embodiment of formula I, it is substituted by R^3b.

According to still another embodiment of formula I, R³ is a 5-membered saturated heterocycle which contains 1 , 2 or 3, in particular 1 or 2, heteroatoms from the group consisting of N, O and S, as ring members. According to one embodiment, the heterocycle contains one O as heteroatom. According to one embodiment thereof, the heterocycle is unsubstituted, i.e. it does not carry any substituent R^3b. According to still another embodiment of formula I, it is substituted by R^3b.

According to still another embodiment of formula I, R³ is a 6-membered saturated heterocycle which contains 1 , 2 or 3, in particular 1 or 2, heteroatoms from the group consisting of N, O and S as ring members. According to one embodiment thereof, the heterocycle is unsubstituted, i.e. it does not carry any substituent R^3b. According to still another embodiment of formula I, it is substituted by R^3b. According to one specific embodiment thereof, said 6-membered saturated heterocycle contains 1 or 2, in particular 1 , heteroatom(s) O. According to one embodiment thereof, the respective 6-membered heterocycle is unsubstituted, i.e. it does not carry any substituent R^3b. According to still another embodiment of formula I, it is substituted by R^3b.

According to still another embodiment of formula I, R³ is phenyl-Ci-C6-alkyl, such as phenyl- CH2, wherein the phenyl moiety in each case is unsubstituted or substituted by one, two or three identical or different groups R^3b which independently of one another are selected from CN, halogen, Ci-C2-alkyl, Ci-C2-alkoxy, Ci-C2-halogenalkyl, Ci-C2-halogenalkoxy and S(0)_z-Ci-C6- alkyl, in particular from CN, F, CI, Br, CH₃, OCH₃, CF₃, CHF₂, OCHF₂, OCF₃ and S(0)₂CH₃.

According to still another embodiment of formula I, R³ is aryl, in particular phenyl, wherein the aryl or phenyl moiety in each case is unsubstituted or substituted by identical or different groups R^3b which independently of one another are selected from from CN, halogen, Ci-C2-alkyl, C1-C2- alkoxy, Ci-C2-halogenalkyl, Ci-C2-halogenalkoxy and S(0)_z-Ci-C6-alkyl, in particular from CN, F, CI, Br, CH3, OCH3, CF₃, CHF₂, OCHF₂, OCF₃. According to one embodiment, R³ is unsubstituted phenyl. According to another embodiment, R³ is phenyl, that is substituted by one, two or three, in particular one, halogen, in particular selected from F, CI and Br, more specifically selected from F and CI.

According to still another embodiment of formula I, R³ is a 5-membered heteroaryl such as pyr- rol-1-yl, pyrrol-2-yl, pyrrol-3-yl, thien-2-yl, thien-3-yl, furan-2-yl, furan-3-yl, pyrazol-1-yl, pyrazol- 3-yl, pyrazol-4-yl, pyrazol-5-yl, imidazol-1-yl, imidazol-2-yl, imidazol-4-yl, imidazol-5-yl, oxazol-2- yl, oxazol-4-yl, oxazol-5-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, 1 ,2,4-triazolyl-1 -yl, 1 ,2,4-triazol-3-yl 1 ,2,4-triazol-5-yl, 1 ,2,4-oxadiazol-3-yl, 1 ,2,4-oxadiazol-5-yl and 1 ,2,4-thiadiazol-3-yl,

1 ,2,4-thiadiazol-5-yl.

According to still another embodiment of formula I, R³ is a 6-membered heteroaryl, such as pyr- idin-2-yl, pyridin-3-yl, pyridin-4-yl, pyridazin-3-yl, pyridazin-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrazin-2-yl and 1 ,3,5-triazin-2-yl and 1 ,2,4-triazin-3-yl.

According to still another embodiment of formula I, R³ is Ci-C6-alkyl such as CH₃, C2H5, n- propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl which is substituted by at least one group R^3a, which independently of one another are selected from:

R ^a halogen, OH, CN, N0₂, SH, NH₂, NH(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂, NH(C(=0)Ci-C₄-alkyl), N(C(=0)Ci-C₄-alkyl)₂, NH-S0₂-R^x, Ci-C₆-alkoxy, Ci-C₄-halogenalkoxy, Ci-C₆-alkylthio, Ci-C₆- halogenalkylthio, S(0)_z-Ci-C₆-alkyl, S(0)_z-Ci-C₆-halogenalkyl, S(0)_z-aryl, CH(=0), C(=0)Ci-C₆- alkyl, C(=0)0(Ci-C₆-alkyl), C(=0)NH(Ci-C₆-alkyl), C(=0)N(Ci-C₆-alkyl)₂, CR'=NOR" a saturated or partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbocy- cle or heterocycle, five-, six- or ten-membered heteroaryl, an aryl or phenoxy, wherein in each case one or two CH₂ groups of the carbo- and heterocycle may be replaced by a group independently selected from C(=0) and C(=S), and wherein the heterocycle and heteroaryl contains independently one, two, three or four heteroatoms selected from N, O and S; wherein the car- bocyclic, heterocyclic, , heteroaryl, aryl and phenyl groups are independently unsubstituted or carry one, two, three, four or five substituents selected from the group consisting of halogen, OH, CN, N0₂, SH, NH₂, NH(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂, NH(C(=0)Ci-C₄-alkyl), N(C(=0)Ci-C₄- alkyl)₂, NH-S0₂-R^x, Ci-C₆-alkylthio, Ci-C₄-alkyl, Ci-C₄-halogenalkyl, Ci-C₄-alkoxy, Ci-C₄- halogenalkoxy, and S(0)z-Ci-C6-alkyl.

According to still another embodiment of formula I, R³ is CH₃ is substituted by at least one group R^3a, which independently of one another are selected from:

R^3a halogen, OH, CN, N0₂, SH, NH₂, NH(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂, NH(C(=0)Ci-C₄-alkyl), N(C(=0)Ci-C₄-alkyl)₂, NH-S0₂-R^x, Ci-C₆-alkoxy, Ci-C₄-halogenalkoxy, Ci-C₆-alkylthio, Ci-C₆- halogenalkylthio, S(0)_z-Ci-C₆-alkyl, S(0)_z-Ci-C₆-halogenalkyl, S(0)_z-aryl, CH(=0), C(=0)Ci-C₆- alkyl, C(=0)0(Ci-C₆-alkyl), C(=0)NH(Ci-C₆-alkyl), C(=0)N(Ci-C₆-alkyl)₂, CR'=NOR", a saturated or partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered car- bocycle or heterocycle, five-, six- or ten-membered heteroaryl, an aryl or phenoxy, wherein in each case one or two CH₂ groups of the carbo- and heterocycle may be replaced by a group independently selected from C(=0) and C(=S), and wherein the heterocycle and heteroaryl contains independently one, two, three or four heteroatoms selected from N, O and S; wherein the carbocyclic, heterocyclic, , heteroaryl, aryl and phenyl groups are independently unsubstituted or carry one, two, three, four or five substituents selected from the group consisting of halogen, OH, CN, N0₂, SH, NH₂, NH(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂, NH(C(=0)Ci-C₄-alkyl), N(C(=0)Ci-C₄- alkyl)₂, NH-S0₂-R^x, Ci-C₆-alkylthio, Ci-C₄-alkyl, Ci-C₄-halogenalkyl, Ci-C₄-alkoxy, Ci-C₄- halogenalkoxy, and S(0)z-Ci-C6-alkyl.

According to still another embodiment of formula I, R³ is C₂H₅ is substituted by at least one group R^3a, which independently of one another are selected from:

R ^a halogen, OH, CN, N0₂, SH, NH₂, NH(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂, NH(C(=0)Ci-C₄-alkyl), N(C(=0)Ci-C₄-alkyl)₂, NH-S0₂-R^x, Ci-C₆-alkoxy, Ci-C₄-halogenalkoxy, Ci-C₆-alkylthio, Ci-C₆- halogenalkylthio, S(0)_z-Ci-C₆-alkyl, S(0)_z-Ci-C₆-halogenalkyl, S(0)_z-aryl, CH(=0), C(=0)Ci-C₆- alkyl, C(=0)0(Ci-C₆-alkyl), C(=0)NH(Ci-C₆-alkyl), C(=0)N(Ci-C₆-alkyl)₂, CR'=NOR"a saturated or partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbocycle or heterocycle, five-, six- or ten-membered heteroaryl, an aryl or phenoxy, wherein in each case one or two CH₂ groups of the carbo- and heterocycle may be replaced by a group independently selected from C(=0) and C(=S), and wherein the heterocycle contains independently one, two, three or four heteroatoms selected from N, O and S; wherein the carbocyclic, heterocyclic, , heteroaryl, aryl and phenyl groups are independently unsubstituted or carry one, two, three, four or five substituents selected from the group consisting of halogen, OH, CN , NO2, SH, NH₂, NH(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂, NH(C(=0)Ci-C₄-alkyl), N(C(=0)Ci-C₄-alkyl)₂, NH-S0₂-R^x, Ci-C6-alkylthio, Ci-C₄-alkyl, Ci-C₄-halogenalkyl, Ci-C₄-alkoxy, Ci-C₄-halogenalkoxy, and S(0)z- d-Ce-alkyl.

According to a further particular embodiment, R³ is selected from Ci-C6-alkyl, C1-C6- halogenalkyl, phenyl-Ci-C6-alkyl, halogenphenyl-Ci-C6-alkyl, phenyl, halogenphenyl and three-, four-, five- or six-membered carbocycle and heterocycle, wherein the carbocycle and heterocycle is unsubstituted or carries one, two, three or four substituents R^3b as defined below. Accord- ing to one embodiment thereof, the carbocycle and heterocycle are unsubstituted. In a particular embodiment, R³ is selected from Ci-C6-alkyl, Ci-C6-halogenalkyl, phenyl-CH₂, halogenphenyl- CH₂, phenyl, halogenphenyl and three-, four-, five- or six-membered carbocycle and hetero- cacle, wherein the carbocycle and heterocylce unsubstituted or carries one, two, three or four substituents R^3b as defined below.

Particularly preferred embodiments of R³ according to the invention are in Table P3 below, wherein each line of lines P3-1 to P3-32 corresponds to one particular embodiment of the invention, wherein P3-1 to P3-32 are also in any combination with one another a preferred embodiment of the present invention. The connection point to the carbon atom, to which R³ is bound is marked with "#" in the drawings.

Table P3:

According to one embodiment of formula I, R⁴ is selected from R⁴ is in each case independently selected from halogen, OH , CN , N0₂, SH , Ci-C₆-alkylthio, N H₂, N H(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂, N H-S0₂-R^x, Ci-C₆-alkyl,_Ci-C₆-halogenalkyl, C₂-C₆-alkenyl, C₂-C₆-halogenalkenyl, C₂-C₆-alkynyl, C₂-C6-halogenalkynyl, Ci-C6-alkoxy, Ci-C6-halogenalkoxy, C₂-C6-alkenyloxy, C₂-C6-alkynyloxy, CH(=0), C(=0)CrC₆-alkyl, C(=0)0(C C₆-alkyl), C(=0) N H(C C₆-alkyl), C(=0)N(Ci-C₆-alkyl)₂, CR'=NOR", a saturated or partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbocycle or heterocycle, wherein in each case one or two CH₂ groups of the carbo- and heterocycle may be replaced by a group independently selected from C(=0) and C(=S), five- or six-membered heteroaryl and aryl; wherein the heterocycle and the heteroaryl contain independently one, two, three or four heteroatoms selected from N , O and S; wherein the heterocycle or heteroaryl contains one, two or three heteroatoms selected from N , O and S, and wherein R^x, R' and R" are defined below; and wherein the acyclic moieties of R⁴ are unsub- stituted or substituted with identical or different groups R^4a as defined below and wherein where- in the carbocycle, heterocycle, heteroaryl and aryl moieties are unsubstituted or substituted by substituents R^4b as defined below.

According to another embodiment of formula I, R⁴ is selected from Ci-C6-alkyl, Ci-Ce- halogenalkyI, CN , C₂-C6-alkenyl, C₂-C6-halogenalkenyl, C₂-C6-alkynyl, C₂-C6-halogenalkynyl, C3- C6-cycloalkyl, C3-C6-halogencycloalkyl, Ci-C6-alkylaryl, Ci-C6-alkyl-five- and six-membered het- eroaryl, five- and six-membered heteroaryl or aryl which is unsubstituted or substituted by halogen or Ci-C6-halogenalkyl, and wherein the acyclic moieties of R⁴ are unsubstituted or substituted with identical or different groups R^4a as defined below and wherein wherein the carbocycle, heterocycle, heteroaryl and aryl moieties are unsubstituted or substituted by substituents R^4b as defined below.

According to still another embodiment of formula I, R⁴ is selected from Ci-C6-alkyl, C1-C6- halogenalkyl, CN , C₂-C6-alkenyl, C₂-C6-halogenalkenyl, C₂-C6-alkynyl, C₂-C6-halogenalkynyl, C3- C6-cycloalkyl, C3-C6-halogencycloalkyl, Ci-C6-alkylaryl, phenyl, heteroaryl and C1-C6- alkylheteroaryl, wherein the heteroryl is most preferable pyridine, pyrimidine, thiophene, imidazole, triazol, oxadiazol; wherein the acyclic moieties of R⁴ are unsubstituted or substituted with identical or different groups R^4a as defined below and wherein wherein the carbocycle, hetero- cycle, heteroaryl and aryl moieties are unsubstituted or substituted by substituents R^4b as defined below.

According to still another embodiment of formula I, R⁴ is CN.

According to still another embodiment of formula I, R⁴ is Ci-C6-alkylthio, such as SCH3, SC2H5, Sn-propyl, Si-propyl, Sn-butyl, Si-butyl, Stert-butyl, Sn-pentyl, Si-pentyl, CH2SCH3 or

According to still another embodiment of formula I, R⁴ is Ci-C6-halogenalkylthio, such as SCF3, SCCI3, CH2SCF3 or CH2SCF3.

According to still another embodiment of formula I, R⁴ is Ci-C6-alkyl such as CH3, C2H5, n- propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl.

According to still another embodiment of formula I, R⁴ is Ci-C6-alkyl such as CH₃.

According to still another embodiment of formula I, R⁴ is Ci-C6-alkyl such as C2H5.

According to still another embodiment of formula I, R⁴ is Ci-C6-alkyl such as CH3, C2H5, n- propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl which is substituted by at least one group R^4a, which independently of one another are selected from:

R^4a halogen, OH, CN, N0₂, SH, NH₂, NH(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂, NH(C(=0)Ci-C₄-alkyl), N(C(=0)Ci-C₄-alkyl)₂, NH-S0₂-R^x, Ci-C₆-alkoxy, Ci-C₄-halogenalkoxy, Ci-C₆-alkylthio, Ci-C₆- halogenalkylthio, S(0)_z-Ci-C₆-alkyl, S(0)_z-CrC₆-halogenalkyl, S(0)_z-aryl, CH(=0), C(=0)d-C₆- alkyl, C(=0)0(C C₆-alkyl), C(=0)NH(C C₆-alkyl), C(=0)N(Ci-C₆-alkyl)₂, CR'=NOR" a saturated or partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbocy- cle or heterocycle, five-, six- or ten-membered heteroaryl, an aryl or phenoxy, wherein in each case one or two CH2 groups of the carbo- and heterocycle may be replaced by a group independently selected from C(=0) and C(=S), and wherein the heterocycle and heteroaryl contains independently one, two, three or four heteroatoms selected from N, O and S; wherein the car- bocyclic, heterocyclic, heteroaryl, aryl and phenyl groups are independently unsubstituted or carry one, two, three, four or five substituents selected from the group consisting of halogen,

OH, CN, N0₂, SH, NH₂, NH(CrC₄-alkyl), N(Ci-C₄-alkyl)₂, NH(C(=0)Ci-C₄-alkyl), N(C(=0)Ci-C₄- alkyl)₂, NH-S0₂-R^x, Ci-C₆-alkylthio, Ci-C₄-alkyl, Ci-C₄-halogenalkyl, Ci-C₄-alkoxy, Ci-C₄- halogenalkoxy, and S(0)z-Ci-C6-alkyl.

According to still another embodiment of formula I, R⁴ is CH3 is substituted by at least one group R^4a, which independently of one another are selected from:

R ^a halogen, OH, CN, N0₂, SH, NH₂, NH(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂, NH(C(=0)Ci-C₄-alkyl), N(C(=0)Ci-C₄-alkyl)₂, NH-S0₂-R^x, Ci-C₆-alkoxy, Ci-C₄-halogenalkoxy, Ci-C₆-alkylthio, Ci-C₆- halogenalkylthio, S(0)_z-Ci-C₆-alkyl, S(0)_z-C C₆-halogenalkyl, S(0)_z-aryl, CH(=0), C(=0)C C₆- alkyl, C(=0)0(C C₆-alkyl), C(=0)NH(C C₆-alkyl), C(=0)N(Ci-C₆-alkyl)₂, CR'=NOR", a saturat- ed or partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbocycle or heterocycle, five-, six- or ten-membered heteroaryl, an aryl or phenoxy, wherein in each case one or two CH2 groups of the carbo- and heterocycle may be replaced by a group independently selected from C(=0) and C(=S), and wherein the heterocycle and heteroaryl con- tains independently one, two, three or four heteroatoms selected from N, O and S; wherein the carbocyclic, heterocyclic, heteroaryl, aryl and phenyl groups are independently unsubstituted or carry one, two, three, four or five substituents selected from the group consisting of halogen, OH, CN, NO2, SH, NH₂, NH(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂, NH(C(=0)Ci-C₄-alkyl), N(C(=0)Ci-C₄- alkyl)₂, NH-S0₂-R^x, Ci-C₆-alkylthio, Ci-C₄-alkyl, Ci-C₄-halogenalkyl, Ci-C₄-alkoxy, Ci-C₄- halogenalkoxy, and S(0)z-Ci-C6-alkyl.

According to still another embodiment of formula I, R⁴ is C₂H₅ is substituted by at least one group R^4a, which independently of one another are selected from:

R ^a halogen, OH, CN, N0₂, SH, NH₂, NH(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂, NH(C(=0)Ci-C₄-alkyl), N(C(=0)Ci-C₄-alkyl)₂, NH-S0₂-R^x, Ci-C₆-alkoxy, Ci-C₄-halogenalkoxy, Ci-C₆-alkylthio, Ci-C₆- halogenalkylthio, S(0)_z-Ci-C₆-alkyl, S(0)_z-Ci-C₆-halogenalkyl, S(0)_z-aryl, CH(=0), C(=0)Ci-C₆- alkyl, C(=0)0(Ci-C₆-alkyl), C(=0)NH(Ci-C₆-alkyl), C(=0)N(Ci-C₆-alkyl)₂, CR'=NOR"a saturated or partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbocy- cle or heterocycle, five-, six- or ten-membered heteroaryl, an aryl or phenoxy, wherein in each case one or two CH₂ groups of the carbo- and heterocycle may be replaced by a group independently selected from C(=0) and C(=S), and wherein the heterocycle and heteroaryl contains independently one, two, three or four heteroatoms selected from N, O and S; wherein the carbocyclic, heterocyclic, heteroaryl, aryl and phenyl groups are independently unsubstituted or carry one, two, three, four or five substituents selected from the group consisting of halogen, OH, CN, N0₂, SH, NH₂, NH(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂, NH(C(=0)Ci-C₄-alkyl), N(C(=0)Ci-C₄- alkyl)₂, NH-S0₂-R^x, Ci-C₆-alkylthio, Ci-C₄-alkyl, Ci-C₄-halogenalkyl, Ci-C₄-alkoxy, Ci-C₄- halogenalkoxy, and S(0)z-Ci-C6-alkyl.

According to still another embodiment of formula I, R⁴ is CH₂CN.

According to still another embodiment of formula I, R⁴ is CH₂OH.

According to still another embodiment of formula I, R⁴ is Ci-C6-halogenalkyl, in particular Ci-C₄- halogenalkyl, more specifically Ci-C₂-halogenalkyl, such as CF3, CCI3, FCH₂, CICH₂, F₂CH, CI₂CH, CF₃CH₂, CCI₃CH₂ or CF₂CHF₂.

According to still another embodiment of formula I, R⁴ is CH₂F.

According to still another embodiment of formula I, R⁴ is CHF₂.

According to still another embodiment of formula I, R⁴ is CF₃.

According to still a further embodiment of formula I, R⁴ is C₂-C6-alkenyl, in particular C₂-C₄-alk- enyl, such as CH=CH₂, CH₂CH=CH₂ or C(CH₃)C=CH₂.

According to a further specific embodiment of formula I, R⁴ is C₂-C6-halogenalkenyl, in particular C₂-C₄-halogenalkenyl, more specifically C₂-C₃-halogenalkenyl such as CH=CHF, CH=CHCI, CH=CF₂, CH=CCI₂, CF=CF₂, CCI=CCI₂, CH₂CH=CHF, CH₂CH=CHCI, CH₂CH=CF₂,

According to still a further embodiment of formula I, R⁴ is C₂-C6-cycloalkenyl, in particular C₂-C₄- cycloalkenyl, such as CH=CH₂-cPr.

According to still a further embodiment of formula I, R⁴ is C₂-C6-alkynyl or C₂-C6-halogenalkynyl, in particular C₂-C₄-alkynyl or C₂-C₄-halogenalkynyl, such as C≡CH, C≡C-CI, C≡C-CH₃, CH₂- C≡CH, CH₂-C≡CCI or CH₂- C≡C-CH₃. According to still a further embodiment of formula I , R⁴ is C2-C6-cycloalkynyl in particular C2-C4- cycloalkynyl, such as C C-cPr.

According to a further specific embodiment of formula I , R⁴ is Ci-C6-alkoxy, in particular C1-C4- alkoxy, more specifically Ci-C2-alkoxy such as OCH3 or OCH2CH3.

According to a further specific embodiment of formula I , R⁴ is Ci-C6-alkyl-Ci-C6-alkoxy, in particular Ci-C4-alkyl-CrC4-alkoxy, more specifically Ci-C2-alkyl-CrC2-alkoxy, such as

CHzOCHs or CHzOCHzCHs.

According to a further specific embodiment of formula I , R⁴ is C2-C6-alkenyloxy, in particular C2- C4-alkenyloxy, more specifically Ci-C2-alkenyloxy such as OCH=CH2, OCH2CH=CH2

OC(CH₃)CH=CH₂, CH₂OCH=CH₂, or CH₂OCH₂CH=CH₂.

According to a further specific embodiment of formula I , R⁴ is C2-C6-alkynyloxy, in particular C2- C4-alkynyloxy, more specifically Ci-C2-alkynyloxy such as OC CH, OChbC CH or ChbOC CH

According to a further specific embodiment of formula I , R⁴ is Ci-C6-halogenalkoxy, in particular CrC4-halogenalkoxy, more specifically Ci-C2-halogenalkoxy such as OCF₃, OCHF₂, OCH₂F, OCCI3, OCHCI2 or OCH2CI, in particular OCF₃, OCHF₂, OCCI₃ or OCHCI₂.

According to a further specific embodiment of formula I , R⁴ is Ci-C6-alkyl-Ci-C6-halogenalkoxy, in particular Ci-C4-alkyl-Ci-C4-halogenalkoxy, more specifically Ci-C2-alkyl-Ci-C2-halogenalkoxy such as CH2OCF3, CH2OCHF2, CH2OCH2F, CH2OCCI3, CH2OCHCI2 or CH₂OCH₂CI, in particular CH2OCF3, CH₂OCHF₂, CH2OCCI3 or CH2OCHCI2.

According to a further specific embodiment of formula I , R⁴ is CH(=0), C(=0)Ci-C6-alkyl,

C(=0)0(Ci-C₆-alkyl), C(=0)NH(Ci-C₆-alkyl) or C(=0)N(Ci-C₆-alkyl)₂, wherein alkyl is CH₃, C2H5, n-propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl.

According to a further specific embodiment of formula I , R⁴ is CrC4-alkyl-CH(=0), Ci-C4-alkyl- C(=0)Ci-C₆-alkyl, Ci-C₄-alkyl-C(=0)0(Ci-C₆-alkyl), Ci-C₄-alkyl-C(=0)NH(Ci-C₆-alkyl) or C1-C4- alkyl-C(=0)N(Ci-C₆-alkyl)₂, especially CH₂CH(=0), CH₂C(=0)Ci-C₆-alkyl, CH₂C(=0)0(Ci-C₆- alkyl), CH₂C(=0)N H(Ci-C₆-alkyl) or CH₂C(=0)N(Ci-C₆-alkyl)₂ wherein alkyl is CH₃, C2H5, n- propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl.

According to a further specific embodiment of formula I , R⁴ is CR'=NOR" such as

C(CH₃)=NOCH₃, C(CH₃)=NOCH₂CH₃ or C(CH₃)=NOCF₃.

According to a further specific embodiment of formula I , R⁴ is Ci-C6-alkyl-NH(CrC4-alkyl) or Cr C6-alkyl-N(CrC4-alkyl)₂, wherein alkyl is CH₃, C2H5, n-propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl.

According to a further specific embodiment of formula I , R⁴ is Ci-C6-alkyl-S(0)_z-Ci-C6-alkyl, wherein alkyl is CH3, C2H5, n-propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl and z is 1 , 2 or 3.

According to a further specific embodiment of formula I , R⁴ is Ci-C6-alkyl-S(0)_z-Ci-C6- halogenalkyl, wherein halogenalkyl is CF3 or CHF2 and z is 1 , 2 or 3.

According to a further specific embodiment of formula I , R⁴ is Ci-C6-alkyl-S(0)_z-aryl, wherein the aryl or phenyl moiety in each case is unsubstituted or substituted by identical or different groups R^4b which independently of one another are selected from halogen, Ci-C2-alkyl, Ci-C2-alkoxy, Ci-C2-halogenalkyl, Ci-C2-halogenalkoxy and S(0)_z-Ci-C6-alkyl, in particular F, CI, Br, CH3, OCH3, CF3, CHF2, OCHF2, OCF3. According to one embodiment, R⁴ is unsubstituted phenyl. According to another embodiment, R⁴ is phenyl, that is substituted by one, two or three, in par- ticular one, halogen, in particular selected from F, CI and Br, more specifically selected from F and CI.

According to a further specific embodiment of formula I, R⁴ is Ci-C6-alkyl-NH-SC>2-R^x wherein R^x is Ci-C4-alkyl, Ci-C4-halogenalkyl, unsubstituted aryl or aryl that is substituted by one, two, three, four or five substituents R^x2 independently selected from Ci-C4-alkyl, halogen, OH, CN, Ci-C4-halogenalkyl, Ci-C4-alkoxy, or Ci-C4-halogenalkoxy, such as Ch NHSC^CFs or

According to still another embodiment of formula I, R⁴ is selected from Ci-C6-alkyl which is substituted, a saturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbocycle, in particular three-, four-, five- or six-membered, wherein the carbocycle is unsubstituted or sub- stituted by substituents R^4b as defined below. According to one embodiment thereof, the carbocycle is unsubstituted.

According to one embodiment, R⁴ is selected from Ci-C6-alkyl, especially CH2 which is substituted by a 3-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R^4b. According to still another embodiment of formula I, it is substituted by R^4b.

According to one embodiment, R⁴ is selected from Ci-C6-alkyl, especially CH2 which is substituted by a 4-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R^4b. According to still another embodiment of formula I, it is substituted by R^4b.

According to one embodiment, R⁴ is selected from Ci-C6-alkyl, especially CH2 which is substituted by a 5-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R^4b. According to still another embodiment of formula I, it is substituted by R^4b.

According to one embodiment, R⁴ is selected from Ci-C6-alkyl, especially CH2 which is substi- tuted by a 6-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R^4b. According to still another embodiment of formula I, it is substituted by R^4b.

According to a further specific embodiment of formula I, R⁴ is Ci-C6-alkyl, especially CH2 substituted by a 4-membered saturated heterocycle which contains 1 or 2 heteroatoms, in par- ticular 1 heteroatom, from the group consisting of N, O and S, as ring members. According to one embodiment, the heterocycle contains one O as heteroatom. For example, the formed heterocycle is oxetane. According to one embodiment thereof, the heterocycle is unsubstituted, i.e. it does not carry any substituent R^4b. According to still another embodiment of formula I, it is substituted by R^4b.

According to a further specific embodiment of formula I, R⁴ is Ci-C6-alkyl, especially CH2 substituted by a 5-membered saturated heterocycle which contains 1 , 2 or 3, in particular 1 or 2, heteroatoms from the group consisting of N, O and S, as ring members. According to one embodiment, the heterocycle contains one O as heteroatom. According to one embodiment thereof, the heterocycle is unsubstituted, i.e. it does not carry any substituent R^4b. According to still another embodiment of formula I, it is substituted by R^4b.

According to a further specific embodiment of formula I, R⁴ is Ci-C6-alkyl, especially Chb subsitited by a 6-membered saturated heterocycle which contains 1 , 2 or 3, in particular 1 or 2, heteroatoms from the group consisting of N, O and S as ring members. According to one embodiment thereof, the heterocycle is unsubstituted, i.e. it does not carry any substituent R^4b. According to still another embodiment of formula I, it is substituted by R^4b. According to one specific embodiment thereof, said 6-membered saturated heterocycle contains 1 or 2, in particular 1 , heteroatom(s) O. According to one embodiment thereof, the respective 6-membered heterocycle is unsubstituted, i.e. it does not carry any substituent R^4b. According to still another embodiment of formula I, it is substituted by R^4b.

According to a further specific embodiment of formula I, R⁴ is Ci-C6-alkyl, especially CH₂ substituted by a 5-membered saturated heterocycle which contains one N as ring member and optionally one or two groups Ch are replaced by C(=0).

According to still another embodiment of formula I, R⁴ is a partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbocycle, in particular three-, four-, five- or six-membered, wherein the carbocycle is unsubstituted or substituted by substituents R^4b as defined below. According to one embodiment thereof, the carbocycle is unsubstituted.

According to still another embodiment of formula I, R⁴ is a partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbocycle or heterocycle, in particular three-, four-, five- or six-membered, wherein the heterocycle contains one, two, three or four heteroatoms selected from N, O and S, and wherein the carbocycle and heterocycle are unsubstituted or substituted with substituents R^4b as defined below. According to one embodiment thereof, the carbocycle or heterocycle is unsubstituted.

According to still a further embodiment, R⁴ is a saturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbocycle or heterocycle, in particular three-, four-, five- or six- membered, wherein the heterocycle contains one, two, three or four heteroatoms selected from N, O and S, and wherein the carbocycle and heterocycle are unsubstituted or substituted with substituents R^4b as defined below. According to one embodiment thereof, the carbocycle or heterocycle is unsubstituted.

According to still another embodiment of formula I, R⁴ is a saturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbocycle, in particular three-, four-, five- or six- membered, wherein the carbocycle is unsubstituted or substituted by substituents R^4b as defined below. According to one embodiment thereof, the carbocycle is unsubstituted.

According to one embodiment, R⁴ is a 3-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R^4b. According to still another embodiment of formula I, it is substituted by R^4b.

According to one embodiment, R⁴ is a 3-membered saturated carbocycle, which is

unsubstituted such as cyclopropyl. According to one embodiment, R⁴ is a 3-membered saturated carbocycle, which is substituted by halogen, more specifically by F, such as C3H3F2.

According to one embodiment, R⁴ is a 3-membered saturated carbocycle, which is substituted by halogen. More specifically by CI, such as C3H3CI2.

According to one embodiment, R⁴ is a 4-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R^4b. According to still another embodiment of formula I, it is substituted by R^4b.

According to one embodiment, R⁴ is a 5-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R^4b. According to still another embodiment of formula I, it is substituted by R^4b.

According to one embodiment, R⁴ is a 6-membered saturated carbocycle. According to one embodiment thereof, the carbocycle is unsubstituted, i.e. it does not carry any substituent R^4b. According to still another embodiment of formula I, it is substituted by R^4b.

According to still another embodiment of formula I, R⁴ is a partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered heterocycle, in particular three-, four-, five- or six-membered, wherein the heterocycle contains one, two, three or four heteroatoms selected from N, O and S, and wherein the heterocycle is unsubstituted or substituted by substituents R^4b as defined below. According to one embodiment thereof, the heterocycle is unsubstituted.

According to still another embodiment of formula I, R⁴ is a saturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered heterocycle, in particular three-, four-, five- or six- membered, wherein the heterocycle contains one, two, three or four heteroatoms selected from N, O and S, and wherein the heterocycle is unsubstituted or substituted by substituents R^4b as defined below. According to one embodiment thereof, the heterocycle is unsubstituted.

According to still another embodiment of formula I, in the embodiments of R⁴ described above, the heterocycle contains preferably one, two or three, more specifically one or two heteroatoms selected from N, O and S. More specifically, the hetereocycle contains one heteroatom selected from N, O and S. In particular, the heterocycle contains one or two, in particular one O.

According to one embodiment, R⁴ is a 4-membered saturated heterocycle which contains 1 or 2 heteroatoms, in particular 1 heteroatom, from the group consisting of N, O and S, as ring mem- bers. According to one embodiment, the heterocycle contains one O as heteroatom. For example, the formed heterocycle is oxetane. According to one embodiment thereof, the heterocycle is unsubstituted, i.e. it does not carry any substituent R^4b. According to still another embodiment of formula I, it is substituted by R^4b.

According to still another embodiment of formula I, R⁴ is a 5-membered saturated heterocycle which contains 1 , 2 or 3, in particular 1 or 2, heteroatoms from the group consisting of N, O and S, as ring members. According to one embodiment, the heterocycle contains one O as heteroatom. According to one embodiment thereof, the heterocycle is unsubstituted, i.e. it does not carry any substituent R^4b. According to still another embodiment of formula I, it is substituted by R ^b.

According to still another embodiment of formula I, R⁴ is a 6-membered saturated heterocycle which contains 1 , 2 or 3, in particular 1 or 2, heteroatoms from the group consisting of N, O and S as ring members. According to one embodiment thereof, the heterocycle is unsubstituted, i.e. it does not carry any substituent R^4b. According to still another embodiment of formula I, it is substituted by R^4b. According to one specific embodiment thereof, said 6-membered saturated heterocycle contains 1 or 2, in particular 1 , heteroatom(s) O. According to one embodiment thereof, the respective 6-membered heterocycle is unsubstituted, i.e. it does not carry any substituent R^4b. According to still another embodiment of formula I, it is substituted by R^4b.

According to still another embodiment of formula I, R⁴ is phenyl-Ci-C6-alkyl, such as phenyl- CH2, wherein the phenyl moiety in each case is unsubstituted or substituted by one, two or three identical or different groups R^4b which independently of one another are selected from CN, hal- ogen, Ci-C2-alkyl, Ci-C2-alkoxy, Ci-C2-halogenalkyl, Ci-C2-halogenalkoxy and S(0)_z-Ci-C6- alkyl, in particular from CN, F, CI, Br, CH₃, OCH₃, CF₃, CHF₂, OCHF₂, OCF₃ and S(0)₂CH₃.

According to still another embodiment of formula I, R⁴ is aryl, in particular phenyl, wherein the aryl or phenyl moiety in each case is unsubstituted or substituted by identical or different groups R^4b which independently of one another are selected from from CN, halogen, Ci-C₂-alkyl, C₁-C₂- alkoxy, Ci-C₂-halogenalkyl, Ci-C₂-halogenalkoxy and S(0)_z-Ci-C6-alkyl, in particular from CN, F, CI, Br, CH3, OCH3, CF₃, CHF₂, OCHF₂, OCF₃. According to one embodiment, R⁴ is unsubstituted phenyl. According to another embodiment, R⁴ is phenyl, that is substituted by one, two or three, in particular one, halogen, in particular selected from F, CI and Br, more specifically selected from F and CI.

According to still another embodiment of formula I, R⁴ is a 5-membered heteroaryl such as pyr- rol-1-yl, pyrrol-2-yl, pyrrol-3-yl, thien-2-yl, thien-3-yl, furan-2-yl, furan-3-yl, pyrazol-1-yl, pyrazol- 3-yl, pyrazol-4-yl, pyrazol-5-yl, imidazol-1-yl, imidazol-2-yl, imidazol-4-yl, imidazol-5-yl, oxazol-2- yl, oxazol-4-yl, oxazol-5-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, 1 ,2,4-triazolyl-1 -yl, 1 ,2,4-triazol-3-yl 1 ,2,4-triazol-5-yl, 1 ,2,4-oxadiazol-3-yl, 1 ,2,4-oxadiazol-5-yl and 1 ,2,4-thiadiazol-3-yl,

1 ,2,4-thiadiazol-5-yl.

According to still another embodiment of formula I, R⁴ is a 6-membered heteroaryl, such as pyr- idin-2-yl, pyridin-3-yl, pyridin-4-yl, pyridazin-3-yl, pyridazin-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrazin-2-yl and 1 ,3,5-triazin-2-yl and 1 ,2,4-triazin-3-yl.

According to a further specific embodiment of formula I, R⁴ is Ci-C6-alkyl, especially CH₂ subsitited by a 5-membered saturated heteroaryl which contains 1 , 2 or 3, in particular 1 or 2, heteroatoms from the group consisting of N, O and S as ring members. According to one embodiment thereof, the heteroaryl is unsubstituted, i.e. it does not carry any substituent R^4b. According to still another embodiment of formula I, it is substituted by R^4b.

According to a further specific embodiment of formula I, R⁴ is Ci-C6-alkyl, especially CH2 subsitited by a 5-membered saturated heteroaryl which contains one N as ring member.

According to one embodiment thereof, the heteroaryl is unsubstituted, i.e. it does not carry any substituent R^4b. According to still another embodiment of formula I, it is substituted by R^4b.

According to a further specific embodiment of formula I, R⁴ is Ci-C6-alkyl, especially CH₂ subsitited by a 5-membered saturated heteroaryl which contains two N as ring members.

According to one embodiment thereof, the heteroaryl is unsubstituted, i.e. it does not carry any substituent R^4b. According to still another embodiment of formula I, it is substituted by R^4b. According to a further specific embodiment of formula I , R⁴ is Ci-C6-alkyl, especially Chb subsitited by a 5-membered saturated heteroaryl which contains three N as ring members. According to one embodiment thereof, the heteroaryl is unsubstituted, i.e. it does not carry any substituent R^4b. According to still another embodiment of formula I, it is substituted by R^4b. According to one specific embodiment thereof, said 5-membered saturated heterocycle contains 1 or 2, in particular 1 , heteroatom(s) O.

According to a further specific embodiment of formula I , R⁴ is Ci-C6-alkyl, especially CH₂ subsitited by a 5-membered saturated heteroaryl which contains one S as ring member.

According to a further specific embodiment of formula I , R⁴ is Ci-C6-alkyl, especially Chb subsitited by a 5-membered saturated heteroaryl which contains one S and one N as ring members. According to one embodiment thereof, the heteroaryl is unsubstituted, i.e. it does not carry any substituent R^4b. According to still another embodiment of formula I , it is substituted by R^4b. According to a further specific embodiment of formula I , R⁴ is Ci-C6-alkyl, especially CH₂ subsitited by a 5-membered saturated heteroaryl which contains one S and two N as ring members. According to one embodiment thereof, the heteroaryl is unsubstituted, i.e. it does not carry any substituent R^4b. According to still another embodiment of formula I , it is substituted by R^4b.

According to a further specific embodiment of formula I , R⁴ is Ci-C6-alkyl, especially Chb subsitited by a 5-membered saturated heteroaryl which contains one oxygen and one N as ring members. According to one embodiment thereof, the heteroaryl is unsubstituted, i.e. it does not carry any substituent R^4b. According to still another embodiment of formula I , it is substituted by R ^b.

According to a further specific embodiment of formula I , R⁴ is Ci-C6-alkyl, especially Chb subsitited by a 5-membered saturated heteroaryl which contains one oxygen and two N as ring members. According to one embodiment thereof, the heteroaryl is unsubstituted, i.e. it does not carry any substituent R^4b. According to still another embodiment of formula I , it is substituted by R .

According to a further specific embodiment of formula I , R⁴ is Ci-C6-alkyl, especially Chb subsitited by a 6-membered saturated heteroaryl which contains 1 , 2 or 3, in particular 1 or 2, heteroatoms from the group consisting of N, O and S as ring members. According to one embodiment thereof, the heteroaryl is unsubstituted, i.e. it does not carry any substituent R^4b. According to still another embodiment of formula I , it is substituted by R^4b.

According to a further specific embodiment of formula I , R⁴ is Ci-C6-alkyl, especially Chb subsitited by a 6-membered saturated heteroaryl which one N as ring member. According to one embodiment thereof, the heteroaryl is unsubstituted, i.e. it does not carry any substituent R^4b. According to still another embodiment of formula I , it is substituted by R^4b.

According to a further specific embodiment of formula I , R⁴ is Ci-C6-alkyl, especially CH₂ subsitited by a 6-membered saturated heteroaryl which two N as ring members. According to one embodiment thereof, the heteroaryl is unsubstituted, i.e. it does not carry any substituent R^4b. According to still another embodiment of formula I , it is substituted by R^4b. According to a further specific embodiment of formula I, R⁴ is Ci-C6-alkyl, especially Chb subsitited by a 10-membered saturated heteroaryl which contains 1 , 2 or 3, in particular 1 or 2, heteroatoms from the group consisting of N , O and S as ring members. According to one embodiment thereof, the heteroaryl is unsubstituted, i.e. it does not carry any substituent R^4b. According to still another embodiment of formula I, it is substituted by R^4b. According to one specific embodiment thereof, said 10-membered saturated heterocycle contains 1 or 2, in particular 1 , heteroatom(s) N .

According to a further specific embodiment of formula I, R⁴ is Ci-C6-alkyl, especially Chb subsitited by a 10-membered saturated heteroaryl which one N as ring members. According to one embodiment thereof, the heteroaryl is unsubstituted, i.e. it does not carry any substituent R^4b. According to still another embodiment of formula I, it is substituted by R^4b.

According to still another embodiment of formula I, R⁴ is Chb substituted by a 5-membered heteroaryl such as pyrrol-1-yl, pyrrol-2-yl, pyrrol-3-yl, thien-2-yl, thien-3-yl, furan-2-yl, furan-3-yl, pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, imidazol-1 -yl, imidazol-2-yl, imidazol-4-yl, imidazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, 1 ,2,4-triazolyl- 1-yl, 1 ,2,4-triazol-3-yl 1 ,2,4-triazol-5-yl, 1 ,2,4-oxadiazol-3-yl, 1 ,2,4-oxadiazol-5-yl and 1 ,2,4- thiadiazol-3-yl, 1 ,2,4-thiadiazol-5-yl.

According to still another embodiment of formula I, R⁴ is Chb substituted by a 6-membered het- eroaryl, such as pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyridazin-3-yl, pyridazin-4-yl, pyrimidin-2- yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrazin-2-yl and 1 ,3,5-triazin-2-yl and 1 ,2,4-triazin-3-yl.

According to a further particular embodiment, R⁴ is selected from Ci-C6-alkyl, C1-C6- halogenalkyl, CN , C2-C6-alkenyl, C2-C6-halogenalkenyl, C2-C6-alkynyl, C2-C6-halogenalkynyl, aryl, heteroaryl, three-, four-, five- or six-membered carbocycle and heterocycle, and Ci-C6-alkyl substituted by CN , three-, four-, five- or six-membered carbocycle and heterocycle, aryl and heteroaryl; wherein the carbocycle and heterocycle is unsubstituted or carries one, two, three or four substituents R^4b as defined below. According to one embodiment thereof, the carbocycle, heterocycle, heteroaryl and aryl are unsubstituted. In a particular embodiment, R⁴ is selected from Ci-C6-alkyl, Ci-C6-halogenalkyl, C2-C6-alkenyl, C2-C6-halogenalkenyl, C2-C6-alkynyl, C2-C6- halogenalkynyl, aryl, heteroaryl, cypropropyl and Ci-C6-alkyl substituted by aryl and heteroaryl; wherein the aryl and heteroaryl are unsubstituted or carries one, two, three or four substituents R^3b as defined below.

Particularly preferred embodiments of R⁴ according to the invention are in Table P4 below, wherein each line of lines P4-1 to P4-180 corresponds to one particular embodiment of the in- vention, wherein P4-1 to P4-180 are also in any combination with one another a preferred embodiment of the present invention. The connection point to the carbon atom, to which R⁴ is bound is marked with "#" in the drawings.

Table P4:

According to a further embodiment, R³ and R⁴ together with the carbon atom to which they are bound (marked with * in formula I) form a saturated or partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbocycle or heterocycle; wherein the heterocycle contains one, two, three or four heteroatoms selected from N, O and S, wherein the heteroatom N may carry one substituent R^N selected from Ci-C4-alkyl, Ci-C4-halogenalkyl and SC>2Ph, wherein Ph is unsubstituted phenyl or phenyl that is substituted by one, two or three substitu- ents selected from Ci-C4-alkyl, and wherein the heteroatom S may be in the form of its oxide SO or SO2, and wherein the carbocycle or heterocycle is unsubstituted or carries one, two, three or four substituents R³⁴ independently selected from CN, halogen, OH, CN, NO2, SH , NH2, Ci-C6-alkyl, Ci-C6-halogenalkyl, Ci-C6-alkoxy, Ci-C6-halogenalkoxy, Ci-C6-alkylthio, C1-C6- halogenalkylthio, Ci-C4-alkoxy-Ci-C4-alkyl, phenyl and phenoxy, wherein the phenyl groups are unsubstituted or carry one, two, three, four or five substituents R^34a selected from the group consisting of halogen, OH, CN , Ci-C4-alkyl, Ci-C4-halogenalkyl, Ci-C4-alkoxy and C1-C4- halogenalkoxy; and wherein in each case one or two CH2 groups of the carbo- or heterocycle may be replaced by a group independently selected from C(=0) and C(=S).

According to one embodiment, R³ and R⁴ together with the carbon atom to which they are bound (marked with * in formula I) form a saturated or partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered heterocycle that is unsubstituted or substituted. According to a further embodiment, the heterocycle formed by R³ and R⁴ is saturated.

According to a further embodiment, the heterocycle formed by R³ and R⁴ is a saturated unsub- stituted or substituted heterocycle, wherein the heterocycle contains one, two or three, more particularly one or two, specifically one, heteroatom(s) selected from NH, NR^N, O, S, S(=0) and S(=0)2, wherein R^N is defined and preferably defined above. According to one embodiment, this saturated heterocycle is unsubstituted. According to a further embodiment, the saturated heterocycle carries one, two, three or four substituents R³⁴. In one further particular embodiment, said heterocycle is four- or six-membered.

According to a further embodiment, the unsubstituted or substituted and saturated or partially unsaturated heterocycle is three-, four-, five- or six-membered and contains one, two or three, more particularly one or two, heteroatoms selected from NH, NR^N, O, S, S(=0) and S(=0)2, wherein R^N is as defined above or preferably selected from Ci-C2-alkyl, Ci-C2-halogenalkyl and SC>2Ph, wherein Ph is unsubstituted phenyl or phenyl that is substituted by one Ci-C2-alkyl. In one further particular embodiment, said heterocycle is four- or six-membered.

According to a further embodiment, the heterocycle formed by R³ and R⁴ contains one, two or three, more specifically one or two, heteroatoms selected from NH and NR^N, wherein R^N is as defined and preferably defined below, more particularly selected from Ci-C2-alkyl, C1-C2- halogenalkyl and S02Ph, wherein Ph is unsubstituted phenyl or phenyl that is substituted by one methyl. In one embodiment thereof, it contains one or two heteroatoms NH, in particular one NH. In another embodiment, it contains one or two heteroatoms NR^N, in particular one NR^N, wherein R^N in each case is as defined and preferably defined above.

According to a further embodiment, the heterocycle formed by R³ and R⁴ contains one, two or three, more specifically one or two, in particular one, heteroatom(s) selected from S, S(=0) and S(=0)2. In one embodiment thereof, it contains one or two heteroatoms S, in particular one S. In another embodiment, it contains one or two heteroatoms S(=0), in particular one S(=0). In still another embodiment, it contains one or two heteroatoms S(=0)2, in particular one S(=0)2.

According to a further embodiment, the heterocycle formed by R³ and R⁴ contains one or two heteroatoms O. In one embodiment thereof, it contains one heteroatom O. In another embodiment, it contains two heteroatoms O.

According to a further embodiment, the heterocycle formed by R³ and R⁴ is unsubstituted, i.e. it does not carry any substituent R³⁴. According to a further embodiment, it carries one, two, three or four R³⁴.

According to one particular embodiment, R³ and R⁴ together form a 4-membered saturated heterocycle which contains 1 or 2 heteroatoms, in particular 1 heteroatom, from the group consist- ing of NH, NR^N, O, S, S(=0) and S(=0)2, as ring members, wherein R^N is defined and preferably defined above. In one embodiment, the heterocycle contains one O as heteroatom. For example, the formed heterocycle is oxetane. According to one embodiment thereof, the heterocycle is unsubstituted, i.e. it does not carry any substituent R³⁴. According to a further embodiment, it carries one, two, three or four R³⁴.

According to a further particular embodiment, R³ and R⁴ together form a 5-membered saturated heterocycle which contains 1 , 2 or 3, in particular 1 or 2, heteroatoms from the group consisting of NH, NR^N, O, S, S(=0) and S(=0)2, as ring members, wherein R^N is as defined and preferably defined above. According to one embodiment thereof, the heterocycle is unsubstituted, i.e. it does not carry any substituent R³⁴. According to a further embodiment, it carries one, two, three or four R³⁴.

According to a further particular embodiment, R³ and R⁴ together form a 6-membered saturated heterocycle which contains 1 , 2 or 3, in particular 1 or 2, heteroatoms from the group consisting of NH, NR^N, O, S, S(=0) and S(=0)2, as ring members, wherein R^N is as defined and preferably defined below. According to one embodiment thereof, the heterocycle is unsubstituted, i.e. it does not carry any substituent R³⁴. According to a further embodiment, it carries one, two, three or four R³⁴. According to one specific embodiment thereof, said 6-membered saturated heterocycle contains 1 or 2 heteroatoms selected from NH and NR^N. According to a further specific embodiment thereof, said 6-membered saturated heterocycle contains 1 or 2 heteroatoms O. According to a further specific embodiment thereof, said 6-membered saturated heterocycle contains 1 or 2 heteroatoms selected from S, S(=0) and S(=0)2. According to one embodiment thereof, the respective 6-membered heterocycle is unsubstituted, i.e. it does not carry any substituent R³⁴. According to a further embodiment, it carries one, two, three or four R³⁴.

According to one further embodiment R³ together with R⁴ and with the carbon atom to which they are bound form a saturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered, in particular three-, four-, five- or six-membered carbocycle, more specifically five- or six- membered carbocycle, that is unsubstituted or carries one, two, three or four substituents R³⁴ as defined below. According to one embodiment thereof, R³ and R⁴ form a cyclopropyl, that is unsubstituted or carries one, two, three or four substituents R³⁴ as defined below. According to a further embodiment thereof, R³ and R⁴ form a cyclobutyl, that is unsubstituted or carries one, two, three or four substituents R³⁴ as defined below. According to still a further embodiment thereof, R³ and R⁴ form a cyclopentyl, that is unsubstituted or carries one, two, three or four substituents R³⁴ as defined below. According to still a further embodiment thereof, R³ and R⁴ form a cyclohexyl, that is unsubstituted or carries one, two, three or four substituents R³⁴ as defined below. According to still a further embodiment thereof, R³ and R⁴ form a cycloheptyl, that is unsubstituted or carries one, two, three or four substituents R³⁴ as defined below.

R³⁴ are the possible substituents for the carbo- or heterocycle formed by R³ and R⁴ and are independently selected from halogen, OH, CN, NO₂, SH, NH₂, Ci-C6-alkyl, Ci-C6-halogenalkyl, Ci-C6-alkoxy, Ci-C6-halogenalkoxy, Ci-C6-alkylthio, Ci-C6-halogenalkylthio, Ci-C4-alkoxy-Ci-C4- alkyl, phenyl and phenoxy, wherein the phenyl groups are unsubstituted or carry one, two, three, four or five substituents R^34a selected from the group consisting of halogen, OH, C1-C4- alkyl, Ci-C4-halogenalkyl, Ci-C4-alkoxy and Ci-C4-halogenalkoxy; and wherein in each case one or two CH2 groups of the carbo- or heterocycle may be replaced by a group independently selected from C(=0) and C(=S).

In one preferred embodiment, R³⁴ is in each case independently selected from halogen, OH, CN, SH, Ci-C6-alkyl, Ci-C6-halogenalkyl, Ci-C6-alkoxy, Ci-C6-halogenalkoxy and C1-C6- alkylthio. In one further preferred embodiment, R³⁴ is in each case independently selected from halogen, Ci-C6-alkyl and Ci-C6-halogenalkyl. In one further particular embodiment, R³⁴ is in each case independently selected from Ci-C6-alkyl, such as methyl and ethyl. R^N is the substituent of the heteroatom NR^N that is contained in the heterocycle formed by R³ and R⁴ in some of the inventive compounds. R^N is selected from Ci-C4-alkyl, Ci-C4-halogenalk and SC>2Ph, wherein Ph is unsubstituted phenyl or phenyl that is substituted by one, two or three substituents selected from Ci-C4-alkyl. In one preferred embodiment, R^N is in each case independently selected from Ci-C2-alkyl, Ci-C2-halogenalkyl and SC>2Ph, wherein Ph is unsubstituted phenyl or phenyl that is substituted by one methyl substituents. In one particular embodiment, R^N is in each case independently selected from Ci-C₂-alkyl, more particularly methyl. In one particular embodiment, R^N is in each case independently selected from S02Ph, wherein Ph is unsubstituted phenyl or phenyl that is substituted by one methyl.

Particularly preferred embodiments of combinations of R³ and R⁴ according to the invention are in Table P34 below, wherein each line of lines P34-1 to P34-155 corresponds to one particular embodiment of the invention, wherein P34-1 to P34-155 are also in any combination with one another a preferred embodiment of the present invention. The carbon atom, to which R³ and R⁴ are bound is marked with ^* in the drawings.

Table P34:

No. R³ R⁴

B-151

C H ₃

B-152 cyclobutyl

B-153 cyclopentyl

B-154 cyclohexyl

B-155 cycloheptyl

R^x in the substituent NH-S02-R^X is in each case independently selected from Ci-C4-alkyl, Ci-C₄- halogenalkyl, unsubstituted aryl and aryl that is substituted by one, two, three, four or five substituents R^x1 independently selected from Ci-C₄-alkyl. In particular, R^x is in each case independently selected from Ci-C₄-alkyl and phenyl that is substituted by one, two or three R^x1 independently selected from Ci-C2-alkyl, more specifically R^x is in each case independently selected from Ci-C₄-alkyl and phenyl that is substituted by one CH3., more specifically S02-R^x is the tosyl group ("Ts").

R^3a are the possible substituents for the the acyclic moieties of R³ and the R^3a are in each case independently selected from halogen, OH, CN, N0₂, SH, NH₂, NH(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂, NH(C(=0)Ci-C₄-alkyl), N(C(=0)Ci-C₄-alkyl)₂, Ci-C₆-alkoxy, C₃-C₆-cycloalkyl, C₃-C₆- halogencycloalkyl, Ci-C₄-halogenalkoxy, Ci-C6-alkylthio, Ci-C6-halogenalkylthio, S(0)_z-Ci-C6- alkyl, S(0)_z-Ci-C₆-halogenalkyl, S(0)_z-aryl, CH(=0), C(=0)Ci-C₆-alkyl, C(=0)OCi-C₆-alkyl, C(=0)NHCi-C₆-alkyl, C(=0)N(Ci-C₆-alkyl)₂, CR'=NOR", a saturated or partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbocycle or heterocycle, five-, six- or ten-membered heteroaryl, aryl, phenoxy; wherein in each case one or two CH₂ groups of the carbocycle and heterocycle may be replaced by a group independently selected from C(=0) and C(=S); wherein the heterocycle and heteroaryl contain independently one, two, three or four heteroatoms selected from N, O and S; wherein the carbocyclic, heterocyclic, aryl, phenyl and heteroaryl groups are independently unsubstituted or carry one, two, three, four or five substituents selected from the group consisting of halogen, OH, CN, NO2, SH, NH2, NH(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂, NH(C(=0)Ci-C₄-alkyl), N(C(=0)Ci-C₄-alkyl)₂, NH-S0₂-R^x, Ci-C₆-alkylthio, Ci- C₄-alkyl, Ci-C₄-halogenalkyl, Ci-C₄-alkoxy, Ci-C₄-halogenalkoxy and S(0)_z-Ci-C6-alkyl; wherein z is 0, 1 and 2;

In one preferred embodiment, R^3a is in each case independently selected from halogen, OH, CN, Ci-C6-alkoxy, Ci-C6-halogenalkoxy, heteroaryl, phenyl and halogenphenyl, wherein the halogenphenyl is substituted by halogen selected from the group consisting of F, CI and Br. In one further preferred embodiment, R^3a is in each case independently selected from halogen, heteroaryl, phenyl and halogenphenyl, wherein the halogenphenyl is substituted by halogen selected from the group consisting of F, CI and Br, in particular selected from F and CI.

In one further preferred embodiment, R^3a is in each case independently selected from halogen, CN, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, Ci-C4-halogenalkoxy, Ci-C6-alkylthio, phenyl, and heteroaryl; wherein the heteroaryl and phenyl is substituted by halogen selected from the group consisting of F, CI and Br or by Ci-C4-alkyl, Ci-C4-halogenalkyl, Ci-C4-alkoxy and C1-C4- halogenalkoxy. In one further preferred embodiment, R^3a is in each case independently selected from halogen heteroaryl and phenyl wherein the heteroaryl and phenyl is substituted by halogen selected from the group consisting of F, CI and Br, in particular selected from F and CI.

R^3b are the possible substituents for the carbocycle, heterocycle, heteroaryl and aryl moieties are independently selected from halogen, OH, CN, N0₂, SH, NH₂, NH(Ci-C₄-alkyl), N(Ci-C₄- alkyl)₂, NH(C(=0)Ci-C₄-alkyl), N(C(=0)Ci-C₄-alkyl)₂, NH-S0₂-R^x, Ci-C₄-alkyl, Ci-C₄-alkoxy, Ci- C4-halogenalkyl, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, Ci-C4-halogenalkoxy, C1-C6- alkylthio, Ci-C6-halogenalkylthio, S(0)_z-Ci-C6-alkyl, Ci-C4-alkoxy-Ci-C4-alkyl, phenyl and phe- noxy, wherein the phenyl groups are unsubstituted or substituted with substituents selected from the group consisting of halogen, OH, Ci-C4-alkyl, Ci-C4-haloalkyl, Ci-C4-alkoxy and C1-C4- halogenalkoxy.

In one preferred embodiment, R^3b is in each case independently selected from halogen, OH, CN, SH, Ci-C6-alkyl, Ci-C6-halogenalkyl, Ci-C6-alkoxy, Ci-C6-halogenalkoxy and C1-C6- alkylthio. In one further preferred embodiment, R^3b is in each case independently selected from halogen, Ci-C6-alkoxy, Ci-C6-halogenalkoxy and Ci-C6-halogenalkyl. In one further particular embodiment, R^3b is in each case independently selected from Ci-C6-alkyl, such as methyl and ethyl. In one further particular embodiment, R^3b is in each case independently selected from halogen, such as F, CI and Br.

R^4a are the possible substituents for the the acyclic moieties of R⁴ and the R^4a are in each case independently selected from halogen, OH, CN, N0₂, SH, NH₂, NH(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂, NH(C(=0)Ci-C₄-alkyl), N(C(=0)Ci-C₄-alkyl)₂, NH-S0₂-R*, Ci-C₆-alkoxy, C₃-C₆-cycloalkyl, C₃-C₆- halogencycloalkyl, Ci-C4-halogenalkoxy, Ci-C6-alkylthio, Ci-C6-halogenalkylthio, S(0)_z-Ci-C6- alkyl, S(0)_z-Ci-C₆-halogenalkyl, S(0)_z-aryl, CH(=0), C(=0)Ci-C₆-alkyl, C(=0)0(Ci-C₆-alkyl), C(=0)NH(Ci-C6-alkyl), CR'=NOR", a saturated or partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbocycle or heterocycle, five-, six- or ten-membered heteroaryl, aryl, phenoxy; wherein in each case one or two CH₂ groups of the carbocycle and heterocycle may be replaced by a group independently selected from C(=0) and C(=S); wherein the heterocycle and heteroaryl contain independently one, two, three or four heteroatoms selected from N, O and S; wherein the carbocyclic, heterocyclic, aryl, phenyl and heteroaryl groups are independently unsubstituted or carry one, two, three, four or five substituents select- ed from the group consisting of halogen, OH, CN, N0₂, SH, NH₂, NH(Ci-C₄-alkyl), N(Ci-C₄- alkyl)₂, NH(C(=0)Ci-C₄-alkyl), N(C(=0)Ci-C₄-alkyl)₂, NH-S0₂-R^x, Ci-C₆-alkylthio, Ci-C₄-alkyl, Ci-C4-halogenalkyl, Ci-C4-alkoxy, Ci-C4-halogenalkoxy and S(0)_z-Ci-C6-alkyl; wherein z is 0, 1 and 2;

According to one preferred embodiment, R^4a is in each case independently selected from halo- gen, OH, CN, NH(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂, NH-S0₂-R*, CH(=0), C(=0)Ci-C₆-alkyl, C(=0)0(Ci-C₆-alkyl), C(=0)NH(Ci-C₆-alkyl) and CR'=NOR".

According to one preferred embodiment, R^4a is in each case independently selected from OH, CN, CH(=0), C(=0)Ci-C₆-alkyl, C(=0)0(Ci-C₆-alkyl), C(=0)NH(Ci-C₆-alkyl) such as CN, CHO, C(0)0(CH₃) ,C0₂NH(CH₃) or C0₂N(CH₃)₂.

According to one preferred embodiment, R^4a is in each case independently selected from C1-C6- alkylthio, Ci-C₆-halogenalkylthio, S(0)_z-Ci-C₆-alkyl, S(0)_z-Ci-C₆-halogenalkyl, S(0)_z-aryl, such

According to one preferred embodiment, R^4a is in each case independently selected from N H(CrC₄-alkyl), N(C C₄-alkyl)₂, N H-S0₂-R*, such as N H (CH₃), N(CH₃)₂ or NHS0₂CH₃, NHS0₂CF₃.

According to one preferred embodiment, R^4a is in each case independently selected from C₃-C6- cycloalkyl, C₃-C6-halogencycloalkyl, such as cyclopropyl or fully or partially halogenated cyclo- propyl.

According to one preferred embodiment, R^4a is in each case independently selected from C1-C6- alkoxy, Ci-C₆-halogenalkoxy, such as OCF₃, OCH F₂, OCH₂F, OCCI₃, OCHCI₂ or OCH₂CI, in particular OCF₃, OCH F₂, OCCI₃ or OCHCI₂.

According to one preferred embodiment, R^4a is in each case independently selected from heter- ocycle, wherein the heterocycle is a satureated, two CH₂ groups are replaced by C(=0) and contains one N as a ring member.

According to one preferred embodiment, R^4a is in each case independently selected from aryl, wherein the aryl is substituted by halogen selected from the group consisting of F, CI , Br, CH₃, CH F₂, OCH₃, OCH Fs, CN or S0₂CH₃.

According to one prefer embodiment, R⁴ is unsubstituted 5- or 6-membered heteroaryl.

According to still a further embodiment, R⁴ is 5- or 6-membered heteroaryl substituted by halogen selected from the group consisting of F, CI, Br, CH₃, CH F₂, OCH₃, OCH F₃, CN or S0₂CH₃.

According to one preferred embodiment, R^4a is in each case independently selected from halogen, OH , CN , C₃-C6-cycloalkyl, C₃-C6-halogencycloalkyl and heterocycle, wherein the heterocy- clocycle is a satureated and contains one N as a ring member.

According to one preferred embodiment, R^4a is in each case independently selected from halogen, OH , CN , C₃-C6-cycloalkyl, C₃-C6-halogencycloalkyl and heterocycle, wherein the heterocycle is a satureated, one CH₂ group is replaced by C(=0) and contains one N as a ring member.

According to one preferred embodiment, R^4a is in each case independently selected from halo- gen, OH , CN , C₃-C6-cycloalkyl, C₃-C6-halogencycloalkyl and heterocycle, wherein the heretocy- clocycle is a satureated, two CH₂ groups are replaced by C(=0) and contains one N as a ring member.

According to one preferred embodiment, R^4a is in each case independently selected from halogen, OH , CN , Ci-C6-alkoxy, Ci-C6-halogenalkoxy, phenyl, aryl or heteroaryl; wherein the aryl and hteroaryl is substituted by halogen selected from the group consisting of F, CI, Br, CH₃, CH F₂, OCH₃, OCH F₃, CN or S0₂CH₃. According to one further preferred embodiment, R^4a is in each case independently selected from halogen, phenyl, halogenphenyl and heteroaryl, wherein the halogenphenyl is substituted by halogen selected from the group consisting of F, CI and Br, in particular selected from F and CI.

According to one further preferred embodiment, R^4a is in each case independently selected from halogen, CN, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, Ci-C6-alkoxy, Ci-C4-halogenalkoxy, Ci- C6-alkylthio, Ci-C6-halogenalkylthio, phenyl, wherein the phenyl is substituted by halogen selected from the group consisting of F, CI and Br or by Ci-C4-alkyl, Ci-C4-halogenalkyl, C1-C4- alkoxy and Ci-C4-halogenalkoxy. According to one further preferred embodiment, R^4a is in each case independently selected from halogen and phenyl wherein the phenyl is substituted by halogen selected from the group consisting of F, CI and Br, in particular selected from F and CI.

R^4b are the possible substituents for the carbocycle, heterocycle, heteroaryl and aryl moieties and are independently selected from halogen, OH, CN, N0₂, SH, NH₂, NH(Ci-C₄-alkyl), N(Ci-C₄- alkyl)₂, NH(C(=0)Ci-C₄-alkyl), N(C(=0)Ci-C₄-alkyl)₂, NH-S0₂-R^x, Ci-C₄-alkyl, Ci-C₄-alkoxy, Ci- C4-halogenalkyl, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, Ci-C4-halogenalkoxy, C1-C6- alkylthio, Ci-C6-halogenalkylthio, S(0)_z-Ci-C6-alkyl, Ci-C4-alkoxy-Ci-C4-alkyl, phenyl and phe- noxy, wherein the phenyl groups are unsubstituted or substituted with substituents selected from the group consisting of halogen, OH, Ci-C4-alkyl, Ci-C4-halogenalkyl, Ci-C4-alkoxy and Ci- C4-halogenalkoxy.

According to one preferred embodiment, R^4b is in each case independently selected from halogen, OH, CN, SH, Ci-C6-alkyl, Ci-C6-halogenalkyl, Ci-C6-alkoxy, Ci-C6-halogenalkoxy, C1-C6- alkylthio and S(0)_z-Ci-C6-alkyl. According to one further preferred embodiment, R^4b is in each case independently selected from halogen, Ci-C6-alkoxy, Ci-C6-halogenalkyl, C1-C6- halogenalkoxy and S(0)_z-Ci-C6-alkyl. According to one further particular embodiment, R^4b is in each case independently selected from Ci-C6-alkyl, such as methyl and ethyl. According to one further particular embodiment, R^4b is in each case independently selected from halogen, such as F, CI and Br. According to one further particular embodiment, R^4b is in each case independently selected from Ci-C6-alkoxy, such as OCH₃. According to one further particular embodiment, R^4b is in each case independently selected from Ci-C4-halogenalkoxy, such as OCHF₂ and OCF3. According to one further particular embodiment, R^4b is in each case independently selected from S(0)_z-Ci-C6-alkyl. such as S0₂CH3.

R⁵ according to the invention is hydrogen, halogen, OH, CN, N0₂, SH, NH₂, NH(Ci-C4-alkyl), N(Ci-C₄-alkyl)₂, NH-S0₂-R^x, C₂-C₆-alkyl, substituted Ci-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, Ci-C6-alkoxy, C3-C6-cycloalkyl, saturated or partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered heterocycle, five- or six-membered heteroaryl or aryl; wherein the heterocyle or heteroaryl contains one, two or three heteroatoms selected from N, O and S; and wherein R^x is defined above; and wherein the acyclic moieties of R⁵ are not further substituted or carry one, two, three or up to the maximum possible number of identical or different groups R^5a which independently of one another are selected from:

R^5a halogen, OH, CN, Ci-C₆-alkoxy, C₃-C₆-cycloalkyl, C₃-C₆-halogencycloalkyl, C1-C4- halogenalkoxy, Ci-C6-alkylthio and phenoxy, wherein the phenyl group is unsubstituted or carries one, two, three, four or five substituents R^55a selected from the group consisting of halogen, OH, Ci-C4-alkyl, Ci-C4-halogenalkyl, Ci-C4-alkoxy and Ci-C4-halogenalkoxy;

wherein the cycloalkyi, heterocyle, heteroaryl and aryl moieties of R⁵ are not further substituted or carry one, two, three, four, five or up to the maximum number of identical or different groups R^5b which independently of one another are selected from:

R⁵ halogen, OH, CN, Ci-C₄-alkyl, Ci-C₄-alkoxy, Ci-C₄-halogenalkyl, C₃-C₆-cycloalkyl, C₃-C₆- halogencycloalkyl, Ci-C4-halogenalkoxy and Ci-C6-alkylthio;

or R⁵ together with R⁶ and with the carbon atom to which they are bound with the carbon atom to which they are bound (marked with C^** in formula I) form a saturated or partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbo- or heterocycle; wherein the heterocycle contains one, two, three or four heteroatoms selected from N, O and S; wherein the heteroatom N may carry one substituent R^N selected from Ci-C4-alkyl, Ci-C4-halogenalkyl and SC>2Ph, wherein Ph is unsubstituted phenyl or phenyl that is substituted by one, two or three substituents selected from Ci-C4-alkyl, and wherein the heteroatom S may be in the form of its oxide SO or SO2; and wherein the carbocycle or heterocycle is unsubstituted or carries one, two, three or four substituents R⁵⁶ independently selected from CN, halogen, OH, CN, NO2, SH, NH2, Ci-C6-alkyl, Ci-C6-halogenalkyl, Ci-C6-alkoxy, Ci-C6-halogenalkoxy, Ci-C6-alkylthio, Ci-C6-halogenalkylthio, Ci-C4-alkoxy-Ci-C4-alkyl, phenyl and phenoxy; wherein the phenyl groups are unsubstituted or carry one, two, three, four or five substituents R^56a selected from the group consisting of CN, halogen, OH, Ci-C4-alkyl, Ci-C4-halogenalkyl, Ci-C4-alkoxy and C1-C4- halogenalkoxy; and wherein in each case one or two CH₂ groups of the carbo- or heterocycle may be replaced by a group independently selected from C(=0) and C(=S).

According to one embodiment, R⁵ is selected from hydrogen, halogen, OH, CN, NO2, SH, NH2, NH(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂, NH-S0₂-R^x, C₂-C₆-alkyl, substituted Ci-C₆-alkyl, C₂-C₆-alkenyl, C2-C6-alkynyl and Ci-C6-alkoxy; or R⁵ together with R⁶ and with the carbon atom to which they are bound form a saturated three-, four-, five- or six-membered carbocycle; wherein the carbocycle is unsubstituted or substituted by R⁵⁶ as defined below; in particular selected from hydrogen, F, CI, Br, OH, CN, NH₂, NH(C C₄-alkyl), N(Ci-C₄-alkyl)₂, NH-S0₂-R^x, C C₄-alkyl and d- C4-alkoxy; or R⁵ together with R⁶ and with the carbon atom to which they are bound form a saturated three-, four-, five- or six-membered carbocycle; wherein the carbocycle is unsubstituted or substituted by R⁵⁶ as defined below; and wherein R^x is as defined and preferably defined below; and wherein the acyclic moieties of R⁵ are not further substituted or carry one, two, three or up to the maximum possible number of identical or different groups R^5a as defined and preferably defined below.

According to one embodiment, R⁵ is selected from halogen, OH, CN, NO2, SH, NH2, NH(Ci-C4- alkyl), N(Ci-C₄-alkyl)₂, NH-S0₂-R^x, C₂-C₆-alkyl, C C₆-halogenalkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl and Ci-C6-alkoxy; or R⁵ together with R⁶ and with the carbon atom to which they are bound form a saturated three-, four-, five- or six-membered carbocycle; wherein the carbocycle is unsubstituted or substituted by R⁵⁶ as defined below; in particular selected from F, CI, Br, OH, CN, NH2, NH(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂, NH-S0₂-R^x, C₂-C₄-alkyl and Ci-C₄-alkoxy; or R⁵ together with R⁶ and with the carbon atom to which they are bound form a saturated three-, four-, five- or six- membered carbocycle; wherein the carbocycle is unsubstituted or substituted by R⁵⁶ as defined below; and wherein R^x is as defined and preferably defined below; and wherein the acyclic moieties of R⁵ are not further substituted or carry one, two, three or up to the maximum possible number of identical or different groups R^5a as defined and preferably defined below.

According to still a further embodiment, R⁵ is selected from hydrogen, halogen, OH, CN, C2-C6- alkyl, Ci-C6-halogenalkyl, and Ci-C6-alkoxy; or R⁵ together with R⁶ and with the carbon atom to which they are bound form a saturated three-, four-, five- or six-membered carbocycle; wherein the carbocycle is unsubstituted or substituted by R⁵⁶ as defined below; in particular selected from hydrogen, F, CI, Br, OH, CN, Ci-C4-alkyl and Ci-C4-alkoxy; or R⁵ together with R⁶ and with the carbon atom to which they are bound form a saturated three-, four-, five- or six-membered carbocycle; wherein the carbocycle is unsubstituted or substituted by R⁵⁶ as defined below; and wherein the acyclic moieties of R⁵ are not further substituted or carry one, two, three or up to the maximum possible number of identical or different groups R^5a as defined and preferably defined below.

According to still a further embodiment, R⁵ is selected from halogen, OH, CN C₁-C6- halogenalkyl and Ci-C6-alkoxy; or R⁵ together with R⁶ and with the carbon atom to which they are bound form a saturated three-, four-, five- or six-membered carbocycle; wherein the carbo- cycle is unsubstituted or substituted by R⁵⁶ as defined below; in particular selected from F, CI, Br, OH, CN, Ci-C4-alkyl and Ci-C4-alkoxy; or R⁵ together with R⁶ and with the carbon atom to which they are bound form a saturated three-, four-, five- or six-membered carbocycle; wherein the carbocycle is unsubstituted or substituted by R⁵⁶ as defined below; and wherein the acyclic moieties of R⁵ are not further substituted or carry one, two, three or up to the maximum possible number of identical or different groups R^5a as defined and preferably defined below.

According to a further embodiment, R⁵ is selected from hydrogen, F, CI, Br, OH, CN, C1-C4- halogenalkyl, Ci-C4-alkoxy and Ci-C6-halogenalkoxy; or R⁵ together with R⁶ and with the carbon atom to which they are bound form a saturated three-, four-, five- or six-membered, in particular 5- or 6-membered, carbocycle; in particular selected from hydrogen, F, CI, OH, Ci-C4-alkyl, Ci- C4-halogenalkyl, Ci-C4-alkoxy and Ci-C6-halogenalkoxy; or R⁵ together with R⁶ and with the carbon atom to which they are bound form a saturated three-, four-, five- or six-membered carbocycle, in particular 5- or 6-membered.

According to still a further embodiment, R⁵ is selected from F, CI, Br, OH, CN, Ci-C4-alkyl, Ci- C4-halogenalkyl, Ci-C4-alkoxy and Ci-C6-halogenalkoxy; or R⁵ together with R⁶ and with the carbon atom to which they are bound form a saturated three-, four-, five- or six-membered, in particular s- or 6-membered, carbocycle; in particular selected from F, CI, OH, Ci-C4-alkyl, Ci- C4-halogenalkyl, Ci-C4-alkoxy and Ci-C6-halogenalkoxy; or R⁵ together with R⁶ and with the carbon atom to which they are bound form a saturated three-, four-, five- or six-membered, in particular 5- or 6-membered, carbocycle.

According to a further embodiment, R⁵ is selected from hydrogen, NH₂, NH(Ci-C4-alkyl), N(Ci- C4-alkyl)₂ and NH-S02-R^X, wherein R^x is as defined and preferably defined below, in particular selected from hydrogen, NH₂, NH(Ci-C₂-alkyl), N(Ci-C₂-alkyl)₂ and NH-S0₂-R^x, wherein R^x is para-methyl-phenyl.

According to still a further embodiment, R⁵ is selected from NH₂, NH(Ci-C4-alkyl), N(Ci-C4-alkyl)₂ and NH-S0₂-R^x, wherein R^x is as defined and preferably defined below, in particular selected from NH₂, NH(Ci-C₂-alkyl), N(Ci-C₂-alkyl)₂ and NH-S0₂-R^x, wherein R^x is para-methyl-phenyl.

According to still a further embodiment, R⁵ is selected from hydrogen, C3-C6-cycloalkyl, five- or six-membered heteroaryl or aryl, in particular C3-C6-cycloalkyl, five- or six-membered heteroaryl or phenyl; wherein the heteroaryl contains one, two or three heteroatoms selected from N, O and S; and wherein the cycloalkyl, heteroaryl and aryl moieties are not further substituted or carry one, two, three, four, five or up to the maximum number of identical or different groups R^5b as defined and preferably defined below. According to still a further embodiment, R⁵ is selected from C3-C6-cycloalkyl, five- or six- membered heteroaryl or aryl, in particular C3-C6-cycloalkyl, five- or six-membered heteroaryl or phenyl; wherein the heteroaryl contains one, two or three heteroatoms selected from N, O and S; and wherein the cycloalkyl, heteroaryl and aryl moieties are not further substituted or carry one, two, three, four, five or up to the maximum number of identical or different groups R^5b as defined and preferably defined below.

According to one specific embodiment, R⁵ is hydrogen.

According to one further specific embodiment, R⁵ is hydrogen or halogen, in particular H, Br, F or CI, according to one embodiment it is H or F, according to a further embodiment, it is H or CI. According to one specific embodiment, R⁵ is halogen, in particular Br, F or CI, according to one embodiment it is F, according to a further embodiment, it is CI.

According to a further specific embodiment, R⁵ is H or OH . According to still a further specific embodiment, R⁵ is OH.

According to a further specific embodiment, R⁵ is hydrogen or C2-C6-alkyl, in particular hydrogen or C2-C4-alkyl, such as hydrogenor C2H_5.According to still a further specific embodiment, R⁵ is C2-C6-alkyl, in particular C2-C4-alkyl, such as C2H5.

According to a further specific embodiment, R⁵ is hydrogen or Ci-C6-halogenalkyl, in particular hydrogen or Ci-C₄-halogenalkyl, such as H, CF₃, CHF₂, CH₂F, CCI₃, CHCI2 or CH₂CI.

According to still a further specific embodiment, R⁵ is Ci-C6-halogenalkyl, in particular C1-C4- halogenalkyl, such as CF₃, CCI₃, FCH₂, CICH₂, F₂CH, CI₂CH, CF3CH2, CCI3CH2 or CF₂CHF₂. According to a further embodiment, R⁵ is hydrogen, C2-C6-alkenyl or C2-C6-halogenalkenyl, in particular hydrogen, C2-C₄-alkenyl or C2-C₄-halogenalkenyl, such as hydrogen or CH=CH₂.

According to still a further embodiment, R⁵ is C2-C6-alkenyl or C2-C6-halogenalkenyl, in particular C₂-C₄-alkenyl or C₂-C₄-halogenalkenyl, such as CH=CH₂, CH₂CH=CH₂,

C(CH₃)C=CH₂,CH=CHF, CH=CHCI, CH=CF₂, CH=CCI₂, CF=CF₂, CCI=CCI₂, CH₂CH=CHF, CH₂CH=CHCI, CH₂CH=CF₂, CH₂CH=CCI₂, CH₂CF=CF₂, CH₂CCI=CCI₂, CF₂CF=CF₂ or

CCI₂CCI=CCI₂.

According to a further embodiment, R⁵ is hydrogen, C2-C6-alkynyl or C2-C6-halogenalkynyl, in particular hydrogen, C2-C₄-alkynyl or C2-C₄-halogenalkynyl, such as hydrogen or C CH.

According to still a further embodiment, R⁵ is C2-C6-alkynyl or C2-C6-halogenalkynyl, in particular C₂-C₄-alkynyl or C₂-C₄-halogenalkynyl, such as C≡CH, C≡C-CI, C≡C-CH₃, CH₂-C≡CH, CH₂- C≡CCI or CH₂-C≡C-CH₃.

According to a further specific embodiment, R⁵ is hydrogen or Ci-C6-alkoxy, in particular hydrogen or Ci-C₄-alkoxy, more specifically hydrogen or Ci-C2-alkoxy such as H, OCH3 or

According to still a further specific embodiment, R⁵ is Ci-C6-alkoxy, in particular Ci-C₄-alkoxy, more specifically Ci-C2-alkoxy such as OCH3 or OCH2CH3.

According to a further specific embodiment, R⁵ is hydrogen or Ci-C6-halogenalkoxy, in particular hydrogen or CrC₄-halogenalkoxy, more specifically hydrogen or Ci-C2-halogenalkoxy such as H, OCFs, OCHF2, OCH2F, OCCIs, OCHC or OCH2CI, in particular H, OCF₃, OCHF2, OCCI₃ or OCHCI2.

According to still a further specific embodiment, R⁵ is Ci-C6-halogenalkoxy, in particular C1-C4- halogenalkoxy, more specifically Ci-C2-halogenalkoxy such as OCF3, OCHF2, OCH2F, OCCI3, OCHCb or OCH2CI, in particular OCF₃, OCHF₂, OCCI₃ or OCHCI₂.

According to a further specific embodiment R⁵ is hydrogen or C₃-C6-cycloalkyl, in particular hydrogen or cyclopropyl. According to still a further specific embodiment R⁵ is C₃-C6-cycloalkyl, in particular cyclopropyl.

In still a further specific embodiment, R⁵ is hydrogen or C3-C6-cycloalkyl, for example cyclopro- pyl, substituted by one, two, three or up to the maximum possible number of identical or different groups R^5b as defined and preferably defined below.

In still a further specific embodiment, R⁵ is C3-C6-cycloalkyl, for example cyclopropyl, substituted by one, two, three or up to the maximum possible number of identical or different groups R^5b as defined and preferably defined below.

According to a specific embodiment R⁵ is hydrogen or C₃-C6-halogencycloalkyl. In a special embodiment R⁵ is hydrogen or fully or partially halogenated cyclopropyl. According to a further specific embodiment R⁵ is C3-C6-halogencycloalkyl, in particular fully or partially halogenated cyclopropyl.

According to a further specific embodiment R⁵ is NH2, NH(Ci-C4-alkyl), N(Ci-C4-alkyl)2 or NH- S02-R^x, wherein R^x is Ci-C4-alkyl, Ci-C4-halogenalkyl, unsubstituted aryl or aryl that is substituted by one, two, three, four or five substituents R^x1 independently selected from Ci-C4-alkyl.

In one preferred embodiment, R⁵ is in each case independently selected from hydrogen, halogen, OH, CN, SH, C2-C6-alkyl, Ci-C6-halogenalkyl, Ci-C6-alkoxy, Ci-C6-halogenalkoxy and Ci- C6-alkylthio. In one further preferred embodiment, R⁵ is in each case independently selected from hydrogen, halogen, C2-C6-alkyl and Ci-C6-halogenalkyl. In one further particular embodiment, R⁵ is in each case independently selected from hydrogen and halogen. In one further particular embodiment, R⁵ is in each case independently selected from hydrogen and halogen, such as H, F, CI or Br.

R⁶ according to the invention is hydrogen, halogen, OH, CN, NO2, SH, NH2, NH(Ci-C4-alkyl), N(Ci-C₄-alkyl)₂, NH-S0₂-R^x, C₂-C₆-alkyl, substituted d-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, Ci-C6-alkoxy, C3-C6-cycloalkyl, saturated or partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered heterocycle, five- or six-membered heteroaryl or aryl; wherein the heterocyle or heteroaryl contains one, two or three heteroatoms selected from N, O and S; wherein the heteroatom N may carry one substituent R^N selected from Ci-C4-alkyl, C1-C4- halogenalkyl and S02Ph, wherein Ph is unsubstituted phenyl or phenyl that is substituted by one, two or three substituents selected from Ci-C4-alkyl, and wherein the heteroatom S may be in the form of its oxide SO or SO2; and wherein R^x is defined above; and wherein the acyclic moieties of R⁶ are not further substituted or carry one, two, three or up to the maximum possible number of identical or different groups R^6a which independently of one another are selected from:

R^6a halogen, OH, CN, d-Ce-alkoxy, Cs-Ce-cycloalkyl, Cs-Ce-halogencycloalkyl, C1-C4- halogenalkoxy, Ci-C6-alkylthio and phenoxy, wherein the phenyl group is unsubstituted or carries one, two, three, four or five substituents R^66a selected from the group consisting of halogen, OH, Ci-C4-alkyl, Ci-C4-halogenalkyl, Ci-C4-alkoxy and Ci-C4-halogenalkoxy;

wherein the cycloalkyl, heterocyle, heteroaryl and aryl moieties of R⁶ are not further substituted or carry one, two, three, four, five or up to the maximum number of identical or different groups R^6b which independently of one another are selected from:

R^6b CN, halogen, OH, CN, C C₄-alkyl, Ci-C₄-alkoxy, C C₄-halogenalkyl, C₃-C₆-cycloalkyl, C₃- C6-halogencycloalkyl, Ci-C4-halogenalkoxy and Ci-C6-alkylthio;

or R⁵ together with R⁶ and with the carbon atom to which they are bound with the carbon atom to which they are bound (marked with C^** in formula I) form a saturated or partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbo- or heterocycle; wherein the heterocycle contains one, two, three or four heteroatoms selected from N, O and S; wherein the heteroatom N may carry one substituent R^N selected from Ci-C4-alkyl, Ci-C4-halogenalkyl and S02Ph, wherein Ph is unsubstituted phenyl or phenyl that is substituted by one, two or three substituents selected from Ci-C4-alkyl, and wherein the heteroatom S may be in the form of its oxide SO or SO2; and wherein the carbocycle or heterocycle is unsubstituted or carries one, two, three or four substituents R⁵⁶ independently selected from halogen, OH, CN, NO2, SH, NH2, Ci-C6-alkyl, Ci-C6-halogenalkyl, Ci-C6-alkoxy, Ci-C6-halogenalkoxy, Ci-C6-alkylthio, C1-C6- halogenalkylthio, Ci-C4-alkoxy-Ci-C4-alkyl, phenyl and phenoxy; wherein the phenyl groups are unsubstituted or carry one, two, three, four or five substituents R^56a selected from the group consisting of CN, halogen, OH, Ci-C4-alkyl, Ci-C4-halogenalkyl, Ci-C4-alkoxy and C1-C4- halogenalkoxy; and wherein in each case one or two CH₂ groups of the carbo- or heterocycle may be replaced by a group independently selected from C(=0) and C(=S).

According to one embodiment, R⁶ is selected from hydrogen, halogen, OH, CN, NO2, SH, NH2, NH(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂, NH-S0₂-R^x, C₂-C₆-alkyl, Ci-C₆-halogenalkyl, C₂-C₆-alkenyl, C₂- C6-alkynyl and Ci-C6-alkoxy; or R⁵ together with R⁶ and with the carbon atom to which they are bound form a saturated three-, four-, five- or six-membered carbocycle; wherein the carbocycle is unsubstituted or substituted by R⁶⁶ as defined below; in particular selected from hydrogen, F, CI, Br, OH, CN, NH₂, NH(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂, NH-S0₂-R^x, Ci-C₄-alkyl and Ci-C₄-alkoxy; or R⁶ together with R⁶ and with the carbon atom to which they are bound form a saturated three- , four-, five- or six-membered carbocycle; wherein the carbocycle is unsubstituted or substituted by R⁶⁶ as defined below; and wherein R^x is as defined and preferably defined below; and wherein the acyclic moieties of R⁶ are not further substituted or carry one, two, three or up to the maximum possible number of identical or different groups R^6a as defined and preferably defined below.

According to one embodiment, R⁶ is selected from halogen, OH, CN, NO2, SH, NH2, NH(Ci-C4- alkyl), N(Ci-C₄-alkyl)₂, NH-S0₂-R^x, C₂-C₆-alkyl, Ci-C₆-halogenalkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl and Ci-C6-alkoxy; or R⁵ together with R⁶ and with the carbon atom to which they are bound form a saturated three-, four-, five- or six-membered carbocycle; wherein the carbocycle is unsubsti- tuted or substituted by R⁶⁶ as defined below; in particular selected from F, CI, Br, OH, CN, NH2, NH(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂, NH-S0₂-R^x, C₂-C₄-alkyl and Ci-C₄-alkoxy; or R⁶ together with R⁶ and with the carbon atom to which they are bound form a saturated three-, four-, five- or six- membered carbocycle; wherein the carbocycle is unsubstituted or substituted by R⁶⁶ as defined below; and wherein R^x is as defined and preferably defined below; and wherein the acyclic moieties of R⁶ are not further substituted or carry one, two, three or up to the maximum possible number of identical or different groups R^6a as defined and preferably defined below.

According to still a further embodiment, R⁶ is selected from hydrogen, halogen, OH, CN, C2-C6- alkyl Ci-C6-halogenalkyl and Ci-C6-alkoxy; or R⁵ together with R⁶ and with the carbon atom to which they are bound form a saturated three-, four-, five- or six-membered carbocycle; wherein the carbocycle is unsubstituted or substituted by R⁶⁶ as defined below; in particular selected from hydrogen, F, CI, Br, OH , CN, Ci-C4-alkyl and Ci-C4-alkoxy; or R⁵ together with R⁶ and with the carbon atom to which they are bound form a saturated three-, four-, five- or six-membered carbocycle; wherein the carbocycle is unsubstituted or substituted by R⁶⁶ as defined below; and wherein the acyclic moieties of R⁶ are not further substituted or carry one, two, three or up to the maximum possible number of identical or different groups R^6a as defined and preferably defined below.

According to still a further embodiment, R⁶ is selected from halogen, OH, CN C2-C6-alkyl, C1-C6- halogenalkyl, and Ci-C6-alkoxy; or R⁵ together with R⁶ and with the carbon atom to which they are bound form a saturated three-, four-, five- or six-membered carbocycle; wherein the carbocycle is unsubstituted or substituted by R⁶⁶ as defined below; in particular selected from F, CI, Br, OH, CN, C₂-C₆-alkyl, Ci-C₆-halogenalkyl and Ci-C₄-alkoxy; or R⁵ together with R⁶ and with the carbon atom to which they are bound form a saturated three-, four-, five- or six-membered carbocycle; wherein the carbocycle is unsubstituted or substituted by R⁶⁶ as defined below; and wherein the acyclic moieties of R⁶ are not further substituted or carry one, two, three or up to the maximum possible number of identical or different groups R^6a as defined and preferably defined below.

According to a further embodiment, R⁶ is selected from hydrogen, F, CI, Br, OH, CN, C2-C6- alkyl, Ci-C₄-halogenalkyl, Ci-C₄-alkoxy and Ci-C6-halogenalkoxy; or R⁵ together with R⁶ and with the carbon atom to which they are bound form a saturated three-, four-, five- or six- membered, in particular s- or 6-membered, carbocycle; in particular selected from hydrogen, F, CI, OH, C2-C6-alkyl, Ci-C₄-halogenalkyl, Ci-C₄-alkoxy and Ci-C6-halogenalkoxy; or R⁵ together with R⁶ and with the carbon atom to which they are bound form a saturated three-, four-, five- or six-membered carbocycle, in particular 5- or 6-membered.

According to still a further embodiment, R⁶ is selected from F, CI, Br, OH, CN , C2-C6-alkyl, Ci- C₄-halogenalkyl, Ci-C₄-alkoxy and Ci-C6-halogenalkoxy; or R⁵ together with R⁶ and with the carbon atom to which they are bound form a saturated three-, four-, five- or six-membered, in particular 5- or 6-membered, carbocycle; in particular selected from F, CI, OH , C2-C6-alkyl, Ci- C₄-halogenalkyl, Ci-C₄-alkoxy and Ci-C6-halogenalkoxy; or R⁵ together with R⁶ and with the carbon atom to which they are bound form a saturated three-, four-, five- or six-membered, in particular 5- or 6-membered, carbocycle.

According to a further embodiment, R⁶ is selected from hydrogen, NH_2, NH(Ci-C₄-alkyl), N(Ci- C₄-alkyl)2 and NH-S02-R^X, wherein R^x is as defined and preferably defined below, in particular selected from hydrogen, NH₂, NH(Ci-C₂-alkyl), N(Ci-C₂-alkyl)₂ and NH-S0₂-R^x, wherein R^x is para-methyl-phenyl. According to still a further embodiment, R⁶ is selected from NH2, NH(Ci-C4-alkyl), N(Ci-C4-alkyl)2 and NH-S02-R^X, wherein R^x is as defined and preferably defined below, in particular selected from NH2, NH(Ci-C₂-alkyl), N(Ci-C₂-alkyl)₂ and NH-S0₂-R^x, wherein R^x is para-methyl-phenyl.

According to still a further embodiment, R⁶ is selected from hydrogen, C3-C6-cycloalkyl, five- or six-membered heteroaryl or aryl, in particular C3-C6-cycloalkyl, five- or six-membered heteroaryl or phenyl; wherein the heteroaryl contains one, two or three heteroatoms selected from N, O and S; and wherein the cycloalkyl, heteroaryl and aryl moieties are not further substituted or carry one, two, three, four, five or up to the maximum number of identical or different groups R^6b as defined and preferably defined below.

According to still a further embodiment, R⁶ is selected from C3-C6-cycloalkyl, five- or six- membered heteroaryl or aryl, in particular C3-C6-cycloalkyl, five- or six-membered heteroaryl or phenyl; wherein the heteroaryl contains one, two or three heteroatoms selected from N, O and S; and wherein the cycloalkyl, heteroaryl and aryl moieties are not further substituted or carry one, two, three, four, five or up to the maximum number of identical or different groups R^6b as defined and preferably defined below.

According to one specific embodiment, R⁶ is hydrogen.

According to one further specific embodiment, R⁶ is hydrogen or halogen, in particular H, Br, F or CI, according to one embodiment it is H or F, according to a further embodiment, it is H or CI.

According to one specific embodiment, R⁶ is halogen, in particular Br, F or CI, according to one embodiment it is F, according to a further embodiment, it is CI.

According to a further specific embodiment, R⁶ is H or OH . According to still a further specific embodiment, R⁶ is OH.

According to a further specific embodiment, R⁶ is hydrogen or C2-C6-alkyl, in particular hydrogen or C2-C4-alkyl, such as hydrogenor C2Hs.According to still a further specific embodiment, R⁶ is C2-C6-alkyl, in particular C2-C4-alkyl, such as C2H5.

According to a further specific embodiment, R⁶ is hydrogen or Ci-C6-halogenalkyl, in particular hydrogen or Ci-C₄-halogenalkyl, such as H, CF₃, CHF₂, CH₂F, CCI₃, CHCI2 or CH₂CI.

According to still a further specific embodiment, R⁶ is Ci-C6-halogenalkyl, in particular C1-C4- halogenalkyl, such as CF₃, CCI₃, FCH₂, CICH₂, F₂CH, CI₂CH, CF3CH2, CCI3CH2 or CF₂CHF₂. According to a further embodiment, R⁶ is hydrogen, C2-C6-alkenyl or C2-C6-halogenalkenyl, in particular hydrogen, C2-C4-alkenyl or C2-C4-halogenalkenyl, such as hydrogen or CH=CH₂.

According to still a further embodiment, R⁶ is C2-C6-alkenyl or C2-C6-halogenalkenyl, in particular C₂-C₄-alkenyl or C₂-C₄-halogenalkenyl, such as CH=CH₂, CH₂CH=CH₂,

CCI₂CCI=CCI₂.

According to a further embodiment, R⁶ is hydrogen, C2-C6-alkynyl or C2-C6-halogenalkynyl, in particular hydrogen, C2-C4-alkynyl or C2-C4-halogenalkynyl, such as hydrogen or C CH, CH₂C≡CH.

According to still a further embodiment, R⁶ is C2-C6-alkynyl or C2-C6-halogenalkynyl, in particular C₂-C₄-alkynyl or C₂-C₄-halogenalkynyl, such as C≡CH, C≡C-CI, C≡C-CH₃, CH₂-C≡CH, CH₂- C≡CCI or CH₂- C≡C-CH₃.

According to a further specific embodiment, R⁶ is hydrogen or Ci-C6-alkoxy, in particular hydrogen or Ci-C₄-alkoxy, more specifically hydrogen or Ci-C₂-alkoxy such as H, OCH3 or OCH₂CH₃.

According to still a further specific embodiment, R⁶ is Ci-C6-alkoxy, in particular Ci-C₄-alkoxy, more specifically Ci-C₂-alkoxy such as OCH₃ or OCH₂CH₃.

According to a further specific embodiment, R⁶ is hydrogen or Ci-C6-halogenalkoxy, in particular hydrogen or Ci-C₄-halogenalkoxy, more specifically hydrogen or Ci-C₂-halogenalkoxy such as H, OCF₃, OCHF₂, OCH₂F, OCCI₃, OCHCI₂ or OCH₂CI, in particular H, OCF₃, OCHF₂, OCCI₃ or OCHCI₂.

According to still a further specific embodiment, R⁶ is Ci-C6-halogenalkoxy, in particular Ci-C₄- halogenalkoxy, more specifically Ci-C₂-halogenalkoxy such as OCF₃, OCHF₂, OCH₂F, OCCI₃, OCHCI₂ or OCH2CI, in particular OCF₃, OCHF₂, OCCI₃ or OCHCI₂.

According to a further specific embodiment R⁶ is hydrogen or C₃-C6-cycloalkyl, in particular hydrogen or cyclopropyl. According to still a further specific embodiment R⁶ is C₃-C6-cycloalkyl, in particular cyclopropyl.

In still a further specific embodiment, R⁶ is hydrogen or C₃-C6-cycloalkyl, for example cyclopropyl, substituted by one, two, three or up to the maximum possible number of identical or differ- ent groups R^6b as defined and preferably defined below.

In still a further specific embodiment, R⁶ is C₃-C6-cycloalkyl, for example cyclopropyl, substituted by one, two, three or up to the maximum possible number of identical or different groups R^6b as defined and preferably defined below.

According to a specific embodiment R⁶ is hydrogen or C₃-C6-halogencycloalkyl. In a special embodiment R⁶ is hydrogen or fully or partially halogenated cyclopropyl. According to a further specific embodiment R⁶ is C₃-C6-halogencycloalkyl, in particular fully or partially halogenated cyclopropyl.

According to a further specific embodiment R⁶ is NH₂, NH(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂ or NH- S0₂-R^x, wherein R^x is Ci-C₄-alkyl, Ci-C₄-halogenalkyl, unsubstituted aryl or aryl that is substi- tuted by one, two, three, four or five substituents R^x1 independently selected from Ci-C₄-alkyl.

In one preferred embodiment, R⁶ is in each case independently selected from hydrogen, halogen, OH, CN, SH, C₂-C6-alkyl, Ci-C6-halogenalkyl, Ci-C6-alkoxy, Ci-C6-halogenalkoxy and Ci- C6-alkylthio. In one further preferred embodiment, R⁶ is in each case independently selected from hydrogen, halogen, C₂-C6-alkyl and Ci-C6-halogenalkyl. In one further particular embodi- ment, R⁶ is in each case independently selected from hydrogen and halogen. In one further particular embodiment, R⁶ is in each case independently selected from hydrogen and halogen, such as H, F, CI or Br.

According to a further specific embodiment R⁵ together with R⁶ and with the carbon atom to which they are bound form a saturated or partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbo- or heterocycle wherein the heterocycle contains one, two, three or four heteroatoms selected from N, O and S, and wherein the carbocycle or heterocycle is unsubstituted or carries one, two, three or four substituents R⁵⁶ as defined below; and wherein in each case one or two Ch groups of the carbo- or heterocycle may be replaced by a group independently selected from C(=0) and C(=S).

According to one further embodiment R⁵ together with R⁶ and with the carbon atom to which they are bound form a saturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered, in particular five- or six-membered carbocycle, that is unsubstituted or carries one, two, three or four substituents R⁵⁶ as defined below. According to one embodiment thereof, R⁵ and R⁶ form a cyclopentyl, that is unsubstituted or carries one, two, three or four substituents R⁵⁶ as defined below. According to one embodiment thereof, R⁵ and R⁶ form a cyclohexyl, that is unsubstituted or carries one, two, three or four substituents R⁵⁶ as defined below.

According to one further embodiment R⁵ together with R⁶ and with the carbon atom to which they are bound form a saturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered, in particular three-, four-, five- or six-membered carbocycle, more specifically five- or six- membered carbocycle, that is unsubstituted or carries one, two, three or four substituents R⁵⁶ as defined below. According to one embodiment thereof, R⁵ and R⁶ form a cyclopropyl, that is unsubstituted or carries one, two, three or four substituents R⁵⁶ as defined below. According to a further embodiment thereof, R⁵ and R⁶ form a cyclobutyl, that is unsubstituted or carries one, two, three or four substituents R⁵⁶ as defined below. According to still a further embodiment thereof, R⁵ and R⁶ form a cyclopentyl, that is unsubstituted or carries one, two, three or four substituents R⁵⁶ as defined below. According to still a further embodiment thereof, R⁵ and R⁶ form a cyclohexyl, that is unsubstituted or carries one, two, three or four substituents R⁵⁶ as defined below.

According to still one further embodiment R⁵ together with R⁶ and with the carbon atom to which they are bound form a saturated or partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered, in particular five- or six-membered, heterocycle, wherein the heterocycle contains one, two, three or four, in particular one or two, heteroatoms selected from N, O and S, and wherein the heterocycle is unsubstituted or carries one, two, three or four substituents R⁵⁶ as defined below.

In one particular embodiment, R⁵ and R⁶ are independently selected from hydrogen, halogen and Ci-C6-alkyl, in particular selected from H, F, CI, Br and CH3, more specifically selected from H, F and CH_3. In a further embodiment, R⁵ and R⁶ are independently selected from halogen and Ci-C6-alkyl, in particular selected from H, F, CI, Br and CH₃, more specifically selected from F and CH₃.

In still a further embodiment, R⁵ and R⁶ are both hydrogen.

In still a further embodiment, R⁵ is hydrogen and R⁶ is not hydrogen and selected from the sub- stituents as defined above, in particular selected from halogen, OH, C2-C6-alkyl, C1-C6- halogenalkyl, Ci-C6-alkoxy and Ci-C6-halogenalkoxy, in particular selected from F, CI, Br, OH, C2H5, OCH3, OC2H5, CHF₂, CF₃, OCHF2 and OCF₃ more specifically selected from F, CI, Br and In still a further embodiment, R⁵ and R⁶ are both different from hydrogen and independently selected from the substituents as defined above, in particular selected from halogen, OH, C2-C6- alkyl and Ci-C6-alkoxy, in particular selected from F, CI, Br, OH, C2H5, OCH₃ and OC2H5, more specifically selected from F, CI, Br and C2H5.

In a further particular embodiment, R⁵ and R⁶ are independently selected from hydrogen, halo- gen and C2-C6-alkyl, or R⁵ and R⁶ together with the carbon atom to which they are bound form a saturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbocycle and heterocycle, in particular three, four-, five- or six-membered carbocycle and heterocycle, that is unsub- stituted or carries one, two, three or four substituents R⁵⁶ as defined below. In particular R⁵ and R⁶ are independently selected from H, F, CI, Br and C2H_5.or together with the carbon atom to which they are bound form a saturated three-, four-, five- or six-membered carbocycle, that is unsubstituted or carries one, two, three or four substituents R⁵⁶ as defined below.

In a further particular embodiment, R⁵ and R⁶ are independently selected from hydrogen, halogen and C2.-C6-alkyl, or R⁵ and R⁶ together with the carbon atom to which they are bound form a saturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbocycle and hetero- cycle,, in particular three, four-, five- or six-membered carbocycle and heterocycle, that is unsubstituted or carries one, two, three or four substituents R⁵⁶ as defined below. In particular R⁵ and R⁶ are independently selected from F, CI, Br and C2H5 or together with the carbon atom to which they are bound form a saturated three-, four-, five- or six-membered carbocycle and heterocycle, that is unsubstituted or carries one, two, three or four substituents R⁵⁶ as defined be- low.

R^x in the substituent NH-S02-R^X is in each case independently selected from Ci-C4-alkyl, C1-C4- halogenalkyl, unsubstituted aryl and aryl that is substituted by one, two, three, four or five substituents R^x1 independently selected from Ci-C4-alkyl. In particular, R^x is in each case independently selected from Ci-C4-alkyl and phenyl that is substituted by one, two or three R^x1 independently selected from Ci-C2-alkyl, more specifically R^x is in each case independently selected from Ci-C4-alkyl and phenyl that is substituted by one CH₃., more specifically S02-R^x is the tosyl group ("Ts").

R^5a are the possible substituents of the acyclic moieties of R⁵. There may be one, two, three or up to the maximum possible number of identical or different groups R^5a present, specifically, there are one, two, three or four, if at all. The R^5a are independently of one another selected from halogen, OH, CN, Ci-C6-alkoxy, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, C1-C4- halogenalkoxy, Ci-C6-alkylthio and phenoxy, wherein the phenyl group is unsubstituted or carries one, two, three, four or five, more specifically one, two or three, substituents R^55a selected from the group consisting of halogen, OH, Ci-C4-alkyl, Ci-C4-halogenalkyl, C1-C4- alkoxy and Ci-C4-halogenalkoxy, in particular selected from F, CI, OH, CH3, halomethyl, cyclopropyl, halogencyclopropyl, OCH3 and halogenmethoxy. In one embodiment, the R^55a are independently selected from halogen, in particular F, CI and Br, more specifically selected from F and CI.

According to one embodiment, R^5a are independently selected from halogen, OH, Ci-C2-alkoxy, Ci-C2-halogenalkoxy, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, in particular selected from F, CI, OH, cyclopropyl, halogencyclopropyl, OCH3 and halogenmethoxy.

According to one particular embodiment, R^5a are independently selected from halogen, in particular F, CI and Br, more specifically F and CI.

R^5b are the possible substituents of the cycloalkyi, heteroaryl and aryl moieties of R⁵. There may be one, two, three, four, five or up to the maximum number of identical or different groups R^5b, more specifically one, two or three, if at all. The R^5b are independently of one another selected from halogen, OH, CN, Ci-C4-alkyl, Ci-C4-alkoxy, Ci-C4-halogenalkyl, C3-C6-cycloalkyl, C3-C6- halogencycloalkyl, Ci-C4-halogenalkoxy and Ci-C6-alkylthio.

According to one embodiment, R^5b are independently selected from halogen, OH, CN, C1-C2- alkyl, Ci-C2-alkoxy, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, Ci-C2-halogenalkoxy and C1-C2- alkylthio, in particular selected from F, CI, CH₃, halogenmethyl, cyclopropyl, halogencyclopropyl, OCH3 and halogenmethoxy.

According to one particular embodiment, R^5b are independently selected from halogen and Ci- C2-alkyl, in particular from F, CI and CH3. Specifically, R^5b are selected from halogen.

R^6a are the possible substituents of the acyclic moieties of R⁶. There may be one, two, three or up to the maximum possible number of identical or different groups R^6a present, specifically, there are one, two, three or four, if at all. The R^6a are independently of one another selected from halogen, OH, CN, Ci-C6-alkoxy, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, C1-C4- halogenalkoxy, Ci-C6-alkylthio and phenoxy, wherein the phenyl group is unsubstituted or carries one, two, three, four or five, more specifically one, two or three, substituents R^66a selected from the group consisting of halogen, OH, Ci-C4-alkyl, Ci-C4-halogenalkyl, C1-C4- alkoxy and Ci-C4-halogenalkoxy, in particular selected from F, CI, OH, CH3, halomethyl, cyclopropyl, halogencyclopropyl, OCH3 and halogenmethoxy. In one embodiment, the R^66a are independently selected from halogen, in particular F, CI and Br, more specifically selected from F and CI.

According to one embodiment, R^6a are independently selected from halogen, OH, Ci-C2-alkoxy, Ci-C2-halogenalkoxy, C₃-C6-cycloalkyl, C₃-C6-halogencycloalkyl, in particular selected from F, CI, OH, cyclopropyl, halogencyclopropyl, OCH₃ and halogenmethoxy.

According to one particular embodiment, R^6a are independently selected from halogen, in particular F, CI and Br, more specifically F and CI.

R^6b are the possible substituents of the cycloalkyi, heteroaryl and aryl moieties of R⁶. There may be one, two, three, four, five or up to the maximum number of identical or different groups R^6b, more specifically one, two or three, if at all. The R^6b are independently of one another selected from halogen, OH, CN, Ci-C4-alkyl, Ci-C4-alkoxy, Ci-C4-halogenalkyl, C3-C6-cycloalkyl, C3-C6- halogencycloalkyl, Ci-C4-halogenalkoxy and Ci-C6-alkylthio.

According to one embodiment, R^6b are independently selected from halogen, OH, CN, C1-C2- alkyl, Ci-C2-alkoxy, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, Ci-C2-halogenalkoxy and C1-C2- alkylthio, in particular selected from F, CI, CH3, halogenmethyl, cyclopropyl, halogencyclopropyl, OCH3 and halogenmethoxy.

According to one particular embodiment, R^6b are independently selected from halogen and Ci- C2-alkyl, in particular from F, CI and CH3. Specifically, R^6b are selected from halogen.

R⁵⁶ are the possible substituents of the carbo- or heterocycle framed by R⁵ and R⁶. There may be one, two, three or four substituents R⁵⁶ present, if at all. R⁵⁶ are independently selected from halogen, OH, CN, N0₂, SH, NH₂, d-C₆-alkyl, C C₆-halogenalkyl, C C₆-alkoxy,

Ci-C6-halogenalkoxy, Ci-C6-alkylthio, Ci-C6-halogenalkylthio, CrC4-alkoxy-Ci-C4-alkyl, phenyl and phenoxy; wherein the phenyl groups are unsubstituted or carry one, two, three, four or five, in particular one, two or three, substituents R^56a selected from the group consisting of halogen, OH, Ci-C4-alkyl, Ci-C4-halogenalkyl, Ci-C4-alkoxy and Ci-C4-halogenalkoxy.

In one embodiment, R⁵⁶ are independently selected from halogen, OH, CN, Ci-C4-alkyl, Ci- C4-halogenalkyl, Ci-C4-alkoxy, Ci-C4-halogenalkoxy, Ci-C4-alkylthio, phenyl and phenoxy; wherein the phenyl groups are unsubstituted or carry one, two or three substituents R^56a selected from the group consisting of halogen, OH, CH₃, halogenmethyl, OCH₃ and

halogenmethoxy.

In a further embodiment, R⁵⁶ are independently selected from halogen, OH, CN, Ci-C2-alkyl, Ci- C2-halogenalkyl, Ci-C2-alkoxy and Ci-C2-halogenalkoxy, in particular selected from F, CI, OH, CH3, halogenmethyl, OCH3 and halogenmethoxy.

In one particular embodiment, R⁵⁶ are independently selected from halogen and Ci-C2-alkyl, in particular from F, CI and CH3. Specifically, R⁵⁶ are selected from halogen, such as F and CI.

Particularly preferred embodiments of the combination of R⁵ and R⁶ according to the invention are in Table P56 below, wherein each line of lines P56-1 to P56-125 corresponds to one particular embodiment of the invention, wherein P56-1 to P56-125 are also in any combination with one another a preferred embodiment of the present invention.

Table P56:

No. R⁵ R⁶ No. R⁵ R⁶

P56-31 H Br P56-69 OCH₃ i-C₃H₇

P56-32 F Br P56-70 OC2H5 i-C₃H₇

P56-33 CI Br P56-71 H OH

P56-34 Br Br P56-72 F OH

P56-35 C2H5 Br P56-73 CI OH

P56-36 n-C₃H₇ Br P56-74 Br OH

P56-37 i-C₃H₇ Br P56-75 C2H5 OH

P56-38 OH Br P56-76 n-C₃H₇ OH

P56-39 OCH3 Br P56-77 i-C₃H₇ OH

P56-40 OC2H5 Br P56-78 OH OH

P56-41 H C2H5 P56-79 OCH₃ OH

P56-42 F C2H5 P56-80 OC2H5 OH

P56-43 CI C2H5 P56-81 H OCH₃

P56-44 Br C2H5 P56-82 F OCH₃

P56-45 C2H5 C2H5 P56-83 CI OCH₃

P56-46 n-C₃H₇ C2H5 P56-84 Br OCH₃

P56-47 i-C₃H₇ C2H5 P56-85 C2H5 OCH₃

P56-48 OH C2H5 P56-86 n-C₃H₇ OCH₃

P56-49 OCH3 C2H5 P56-87 i-C₃H₇ OCH₃

P56-50 OC₂H₅ C2H5 P56-88 OH OCH₃

P56-51 H n-C₃H₇ P56-89 OCH₃ OCH₃

P56-52 F n-C₃H₇ P56-90 OC₂H₅ OCH₃

P56-53 CI n-C₃H₇ P56-91 H OC2H5

P56-54 Br n-C₃H₇ P56-92 F OC2H5

P56-55 C2H5 n-C₃H₇ P56-93 CI OC2H5

P56-56 n-C₃H₇ n-C₃H₇ P56-94 Br OC2H5

P56-57 i-C₃H₇ n-C₃H₇ P56-95 C2H5 OC2H5

P56-58 OH n-C₃H₇ P56-96 n-C₃H₇ OC2H5

P56-59 OCH₃ n-C₃H₇ P56-97 i-C₃H₇ OC2H5

P56-60 OC2H5 n-C₃H₇ P56-98 OH OC2H5

P56-61 H i-C₃H₇ P56-99 OCH₃ OC2H5

P56-62 F i-C₃H₇ P56-100 OC2H5 OC2H5

P56-63 CI i-C₃H₇ P56-101 cyclopropyl

P56-64 Br i-C₃H₇ P56-102 cyclobutyl

P56-65 C2H5 i-C₃H₇ P56-103 cyclopentyl

P56-66 n-C₃H₇ i-C₃H₇ P56-104 cyclohexyl

P56-67 i-C₃H₇ i-C₃H₇

P56-68 OH i-C₃H₇

R⁷ and R⁸ together with the carbon atoms to which they are bound together with the carbon atoms to which they are bound form a five- or six-membered heteroaryl; wherein the heteroaryl contains one, two or three heteroatoms selected from N, O and S, and wherein the heteroaryl carries zero, one, two, three or four substituents (R⁷⁸)₀, wherein o is 0, 1 , 2 or 3; and

R⁷⁸ are independently selected from are independently selected from halogen, OH, CN, NO2, SH, NH₂, NH(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂, NH(C(=0)Ci-C₄-alkyl), N(C(=0)Ci-C₄-alkyl)₂, NH-SO2- Rx, CH(=0), C(=0)Ci-C₆-alkyl, C(=0)NH(Ci-C₆-alkyl), CR'=NOR", Ci-C₆-alkyl, C₂-C₆-alkenyl, C2-C6-alkynyl, Ci-C6-alkoxy, Ci-C6-halogenalkoxy, C2-C6-alkenyloxy, C2-C6-alkynyloxy, C3-C6- cycloalkyl, C3-C6-cycloalkenyl, S(0)z-Ci-C6-alkyl, three-, four-, five- or six-membered saturated or partially unsaturated heterocycle, five- or six-membered heteroaryl and phenyl; wherein the heterocycle or heteroaryl contains one, two or three heteroatoms selected from N , O and S; wherein R' and R" are independently selected from Ci-C₄-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, saturated or partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered heterocycle, five- or six-membered heteroaryl or aryl; wherein the heterocycle or heteroaryl contains one, two or three heteroatoms selected from N, O and S, wherein z is 0, 1 or 2; and wherein R' and/or R" are independently unsubstituted or carry one, two or three R'" independently selected from halogen, OH, CN, N0₂, SH, NH₂, NH(C C₄-alkyl), N(C C₄-alkyl)₂, NH-S0₂-R^x, d-Ce-alkyl, C C₆-halogenalkyl, C₂-C₆-alkenyl, C₂-C₆-halogenalkenyl, C₂-C₆-alkynyl, C2-C6-halogenalkynyl, Ci-C6-alkoxy, Ci-C6-halogenalkoxy, C3-C6-cycloalkyl, C3-C6- halogencycloalkyl and phenyl; and wherein R^x is defined above; and wherein the acyclic moieties of R⁷⁸ are not further substituted or carry one, two, three or up to the maximum possible number of identical or different groups R^78a which independently of one another are selected from:

R^78a halogen, OH, CN, Ci-C₆-alkoxy, C₃-C₆-cycloalkyl, C₃-C₆-cycloalkenyl, C₃-C₆- halogencycloalkyl, C3-C6-halogencycloalkenyl, Ci-C₄-halogenalkoxy, Ci-C6-alkylthio, five- or six- membered heteroaryl, phenyl and phenoxy, wherein the heterorayl, phenyl and phenoxy group is unsubstituted or carries one, two, three, four or five substituents R^78a' selected from the group consisting of halogen, OH, Ci-C₄-alkyl, Ci-C₄-halogenalkyl, Ci-C₄-alkoxy and Ci-C₄- halogenalkoxy;

wherein the cyclic, phenyl, heterocyclic and heteroaryl moieties of R⁷⁸ are not further substituted or carry one, two, three, four, five or up to the maximum number of identical or different groups R78b _whj_ch independently of one another are selected from:

R^78b halogen, OH, CN, C C₄-alkyl, C C₄-alkoxy, Ci-C₄-halogenalkyl, C₃-C₆-cycloalkyl, C₃-C₆- halogencycloalkyl, Ci-C₄-halogenalkoxy and Ci-C6-alkylthio.

According to one embodiment, R⁷ and R⁸ together with the carbon atoms to which they are bound form a five- or six-membered heteroaryl; wherein the heteroaryl contains one or two heteroatoms selected from N, O and S, and wherein the heteroaryl carries zero, one or two substituents (R⁷⁸)₀, as defined and preferably defined herein, wherein o is 0, 1 or 2. According to one specific embodiment, o is 0. According to a further embodiment, o is 1 or 2. Particular embodiments thereof are listed in Table P78.

According to a further embodiment, R⁷ and R⁸ together with the carbon atoms to which they are bound form a five- or six-membered heteroaryl; wherein the heteroaryl contains one or two heteroatoms N, and wherein the heteroaryl carries zero, one or two substituents (R⁷⁸)₀, as defined and preferably defined herein, wherein o is 0, 1 or 2. According to one specific embodiment, o is 0. According to a further embodiment, o is 1 or 2. Particular embodiments thereof are listed in Table P78.

According to a further embodiment, R⁷ and R⁸ together with the carbon atoms to which they are bound form a five- or six-membered heteroaryl; wherein the heteroaryl contains one or two heteroatoms selected from S and O, and wherein the heteroaryl carries zero, one or two substituents (R⁷⁸)₀, as defined and preferably defined herein, wherein o is 0, 1 or 2. According to one specific embodiment, o is 0. According to a further embodiment, o is 1 or 2. Particular embodiments thereof are listed in Table P78.

According to a further embodiment, R⁷ and R⁸ together with the carbon atoms to which they are bound form a five- or six-membered heteroaryl; wherein the heteroaryl contains one heteroatom S, and wherein the heteroaryl carries zero, one or two substituents (R⁷⁸)₀, as defined and preferably defined herein, wherein o is 0, 1 or 2. According to one specific embodiment, o is 0. According to a further embodiment, o is 1 or 2. Particular embodiments thereof are listed in Table P78.

According to a further embodiment, R⁷ and R⁸ together with the carbon atoms to which they are bound form a five- or six-membered heteroaryl; wherein the heteroaryl contains one heteroatom O, and wherein the heteroaryl carries zero, one or two substituents (R⁷⁸)₀, as defined and preferably defined herein, wherein o is 0, 1 or 2. According to one specific embodiment, o is 0. According to a further embodiment, o is 1 or 2. Particular embodiments thereof are listed in Table P78.

According to one embodiment, R⁷ and R⁸ together with the carbon atoms to which they are bound form a five-membered heteroaryl; wherein the heteroaryl contains one or two

heteroatoms selected from N, O and S, and wherein the heteroaryl carries zero, one or two substituents (R⁷⁸)₀, as defined and preferably defined herein, wherein o is 0, 1 or 2. According to one specific embodiment, o is 0. According to a further embodiment, o is 1 or 2. Particular embodiments thereof are listed in Table P78.

heteroatoms N, and wherein the heteroaryl carries zero, one or two substituents (R⁷⁸)₀, as defined and preferably defined herein, wherein o is 0, 1 or 2. According to one specific embodiment, o is 0. According to a further embodiment, o is 1 or 2. Particular embodiments thereof are listed in Table P78.

heteroatoms selected from O and S, and wherein the heteroaryl carries zero, one or two substituents (R⁷⁸)₀, as defined and preferably defined herein, wherein o is 0, 1 or 2. According to one specific embodiment, o is 0. According to a further embodiment, o is 1 or 2. Particular embodiments thereof are listed in Table P78.

According to one embodiment, R⁷ and R⁸ together with the carbon atoms to which they are bound form a five-membered heteroaryl; wherein the heteroaryl contains one heteroatom S, and wherein the heteroaryl carries zero, one or two substituents (R⁷⁸)₀, as defined and preferably defined herein, wherein o is 0, 1 or 2. According to one specific embodiment, o is 0. According to a further embodiment, o is 1 or 2. According to one embodiment, R⁷ and R⁸ together with the carbon atoms to which they are bound form a five-membered heteroaryl; wherein the heteroaryl contains one heteroatom O, and wherein the heteroaryl carries zero, one or two substituents (R⁷⁸)₀, as defined and preferably defined herein, wherein o is 0, 1 or 2. According to one specific embodiment, o is 0. According to a further embodiment, o is 1 or 2. Particular embodiments thereof are listed in Table P78.

According to a further embodiment, R⁷ and R⁸ together with the carbon atoms to which they are bound form a six-membered heteroaryl; wherein the heteroaryl contains one or two heteroatoms selected from N, O and S, and wherein the heteroaryl carries zero, one or two substituents (R⁷⁸)o, as defined and preferably defined herein, wherein o is 0, 1 or 2. According to one specific embodiment, o is 0. According to a further embodiment, o is 1 or 2. Particular embodiments thereof are listed in Table P78.

According to a further embodiment, R⁷ and R⁸ together with the carbon atoms to which they are bound form a six-membered heteroaryl; wherein the heteroaryl contains one or two heteroatoms N, and wherein the heteroaryl carries zero, one or two substituents (R⁷⁸)₀, as defined and preferably defined herein, wherein o is 0, 1 or 2. According to one specific embodiment, o is 0. According to a further embodiment, o is 1 or 2. Particular embodiments thereof are listed in Table P78.

According to the invention, there can be zero, one, two or three R⁷⁸ present, namely for o is 0, 1 , 2 or 3.

According to one embodiment, o is 0.

According to a further embodiment, o is 1 .

According to a further embodiment, o is 2 or 3. According to one specific embodiment thereof, o is 2, according to a further specific embodiment, o is 3.

For every R⁷⁸ that is present in the inventive compounds, the following embodiments and preferences apply independently of the meaning of any other R⁷⁸ that may be present in the ring. Furthermore, the particular embodiments and preferences given herein for R⁷⁸ apply independently for each of o=1 , o=2 and o=3.

According to one specific embodiment, R⁷⁸ is halogen, in particular F, CI, Br or I, more specifically F, CI or Br, in particular F or CI.

According to still another embodiment of formula I, R⁷⁸ is F.

According to still another embodiment of formula I, R⁷⁸ is CI.

According to still another embodiment of formula I, R⁷⁸ is Br.

According to a further specific embodiment, R⁷⁸ is OH.

According to a further specific embodiment, R⁷⁸ is CN.

According to a further specific embodiment, R⁷⁸ is NO2.

According to still another embodiment of formula I, R⁷⁸ is SH.

According to still another embodiment of formula I, R⁷⁸ is NH₂. According to still another embodiment of formula I, R⁷⁸ is , NH(Ci-C4-alkyl), N(Ci-C4-alkyl)2, , NH(C(=0)(Ci-C₄-alkyl), N(C(=0)(Ci-C₄-alkyl)₂, wherein Ci-C₄-alkyl is CH₃, C₂H₅, n-propyl, i- propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl.

According to a further specific embodiment of formula I, R⁷⁸ is NH-S02-R^X such as NH-SO2-CH3, NH-SO2-CH2-CH3, NH-SO2-CF3 or NH-SO2-TS.

According to a further specific embodiment of formula I, R⁷⁸ is CH(=0), C(=0)CrC6-alkyl, C(=0)0(Ci-C₆-alkyl) or C(=0)NH(Ci-C₆-alkyl), wherein alkyl is CH₃, C₂H₅, n-propyl, i-propyl, n- butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl.

According to a further specific embodiment of formula I, R⁷⁸ is CR^'=NOR^" such as

C(CH₃)=NOCH₃, C(CH₃)=NOCH₂CH₃ or C(CH₃)=NOCF₃.

According to a further specific embodiment, R⁷⁸ is Ci-C6-alkyl, in particular Ci-C4-alkyl, such as CH₃, C2H5, n-propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl., in particular CH₃.

According to a further specific embodiment, R⁷⁸ is Ci-C6-halogenalkyl, in particular C1-C4- halogenalkyl, such as CF₃, CCI₃, FCH₂, CICH₂, F₂CH, CI₂CH, CF₃CH₂, CCI₃CH₂ or CF₂CHF₂. According to still a further embodiment, R⁷⁸ is C2-C6-alkenyl, in particular C2-C4-alkenyl, such as CH=CH₂ or CH₂ CH=CH₂.

According to still another embodiment of formula I R⁷⁸ is C₃-C6-cycloalkyl, in particular cyclopro- pyl.

According to still another embodiment of formula I, R⁷⁸ is C₃-C6-halogencycloalkyl. In a special embodiment R¹ is fully or partially halogenated cyclopropyl.

According to still a further embodiment, R⁷⁸ is C₃-C6-cycloalkyl-C2-C6-alkenyl, in particular C₃-C6- cycloalkyl-C2-C4-alkenyl, more specifically C₃-C6-cycloalkyl-C2-C₃-alkenyl, such as C₃H₅- CH=CH₂.

According to a further specific embodiment, R⁷⁸ is C2-C6-halogenalkenyl, in particular C2-C4- halogenalkenyl, more specifically C2-C₃-halogenalkenyl such as CH=CHF, CH=CHCI, CH=CF2, CH=CCI₂, CH₂CH=CHF, CH₂CH=CHCI, CH₂CH=CF₂, CH₂CH=CCI₂. CH₂CF=CF₂,

CH₂CCI=CCI₂. CF₂CF=CF₂ or CCI₂CCI=CCI₂.

According to still a further embodiment, R⁷⁸ is C2-C6-alkynyl, in particular C2-C4-alkynyl, more specifically C2-C₃-alkynyl, such as C≡CH.

According to still a further embodiment, R⁷⁸ is C2-C6-halogenalkynyl, in particular C2-C4- halogenalkynyl, more specifically C2-C₃-halogenalkynyl.

According to a further specific embodiment, R⁷⁸ is Ci-C6-alkoxy, in particular Ci-C4-alkoxy, more specifically Ci-C2-alkoxy such as OCH₃ or OCH2CH₃.

According to a further specific embodiment, R⁷⁸ is Ci-C6-halogenalkoxy, in particular C1-C4- halogenalkoxy, more specifically Ci-C2-halogenalkoxy such as OCF₃, OCHF2, OCH2F, OCCI₃, OCHCI2, OCH2CI and OCF2CHF2, in particular OCF₃, OCHF₂ and OCF₂CHF₂.

According to a further specific embodiment of formula I, R⁷⁸ is C2-C6-alkenyloxy, in particular C2- C4-alkenyloxy, more specifically Ci-C2-alkenyloxy such as OCH=CH₂, OCH2CH=CH₂. According to a further specific embodiment of formula I, R⁷⁸ is C2-C6-alkynyloxy, in particular C2- C4-alkynyloxy, more specifically Ci-C2-alkynyloxy such as OC CH

According to a further specific embodiment of formula I, R⁷⁸ is S(0)_z-Ci-C6-alkyl, wherein alkyl is CH3, C2H5, n-propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl and z is 1 , 2 or 3. According to a further specific embodiment of formula I, R⁷⁸ is S(0)_z-Ci-C6-halogenalkyl, wherein halogenalkyl is CF₃ or CHF₂ and z is 1 , 2 or 3.

According to still another embodiment of formula I, R⁷⁸ is a partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered heterocycle, in particular three-, four-, five- or six-membered, wherein the heterocycle contains one, two, three or four heteroatoms selected from N, O and S, and wherein the heterocycle is unsubstituted or substituted by substituents R^78b as defined below. According to one embodiment thereof, the heterocycle is unsubstituted.

According to still another embodiment of formula I, R⁷⁸ is a saturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered heterocycle, in particular three-, four-, five- or six- membered, wherein the heterocycle contains one, two, three or four heteroatoms selected from N, O and S, and wherein the heterocycle is unsubstituted or substituted by substituents R^78b as defined below. According to one embodiment thereof, the heterocycle is unsubstituted.

According to still another embodiment of formula I, in the embodiments of R⁷⁸ described above, the heterocycle contains preferably one, two or three, more specifically one or two heteroatoms selected from N, O and S. More specifically, the hetereocycle contains one heteroatom selected from N, O and S. In particular, the heterocycle contains one or two, in particular one O.

According to one embodiment, R⁷⁸ is a 4-membered saturated heterocycle which contains 1 or 2 heteroatoms, in particular 1 heteroatom, from the group consisting of N, O and S, as ring members. According to one embodiment, the heterocycle contains one O as heteroatom. For example, the formed heterocycle is oxetane. According to one embodiment thereof, the heterocycle is unsubstituted, i.e. it does not carry any substituent R^78b. According to still another embodiment of formula I, it is substituted by R^78b.

According to still another embodiment of formula I, R⁷⁸ is a 5-membered saturated heterocycle which contains 1 , 2 or 3, in particular 1 or 2, heteroatoms from the group consisting of N, O and S, as ring members. According to one embodiment, the heterocycle contains one O as heteroa- torn. According to one embodiment thereof, the heterocycle is unsubstituted, i.e. it does not carry any substituent R^78b. According to still another embodiment of formula I, it is substituted by

_R78b.

According to still another embodiment of formula I, R⁷⁸ is a 6-membered saturated heterocycle which contains 1 , 2 or 3, in particular 1 or 2, heteroatoms from the group consisting of N, O and S as ring members. According to one embodiment thereof, the heterocycle is unsubstituted, i.e. it does not carry any substituent R^78b. According to still another embodiment of formula I, it is substituted by R^78b. According to one specific embodiment thereof, said 6-membered saturated heterocycle contains 1 or 2, in particular 1 , heteroatom(s) O. According to one embodiment thereof, the respective 6-membered heterocycle is unsubstituted, i.e. it does not carry any substituent R^78b. According to still another embodiment of formula I, it is substituted by R^78b. According to still another embodiment of formula I, R⁷⁸ is phenyl-Ci-C6-alkyl, such as phenyl- CH2, wherein the phenyl moiety in each case is unsubstituted or substituted by one, two or three identical or different groups R^78b which independently of one another are selected from halogen, Ci-C2-alkyl, Ci-C2-alkoxy, Ci-C2-halogenalkyl and Ci-C2-halogenalkoxy, in particular CN, F, CI, Br, CH₃, OCH3, CHF₂, CF₃ OCHF₂, and OCF₃.

According to still a further specific embodiment, R⁷⁸ is unsubstituted phenyl or phenyl that is substituted by one, two, three or four R^78b, as defined and preferably herein. In particular, R⁷⁸ is unsubstituted phenyl or phenyl that is substituted by one, two, three or four R^78b, as defined herein. In one embodiment R⁷⁸ is unsubstituted phenyl.

According to still another embodiment of formula I, R⁷⁸ is a 5-membered heteroaryl such as pyrrol-1 -yl, pyrrol-2-yl, pyrrol-3-yl, thien-2-yl, thien-3-yl, furan-2-yl, furan-3-yl, pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, imidazol-1-yl, imidazol-2-yl, imidazol-4-yl, imidazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, 1 ,2,4-triazolyl-1 -yl, 1 ,2,4- triazol-3-yl 1 ,2,4-triazol-5-yl, 1 ,2,4-oxadiazol-3-yl, 1 ,2,4-oxadiazol-5-yl and 1 ,2,4-thiadiazol-3-yl, 1 ,2,4-thiadiazol-5-yl.

According to still another embodiment of formula I, R⁷⁸ is a 6-membered heteroaryl, such as pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyridazin-3-yl, pyridazin-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrazin-2-yl and 1 ,3,5-triazin-2-yl and 1 ,2,4-triazin-3-yl.

According to one further embodiment, R⁷⁸ is in each case independently selected from halogen, CN, Ci-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-C6-alkoxy, C3-C6-alkenyloxy, C3-C6-alkynyloxy, C3-C6-cycloalkyl, S(0)_z-CrC6-alkyl, three-, four-, five- or six-membered saturated or partially unsaturated heterocycle, five- or six-membered heteroaryl and phenyl; wherein the heterocycle or heteroaryl contains one, two or three heteroatoms selected from N, O and S; and wherein the acyclic moieties of R⁷⁸ are not further substituted or carry one, two, three or up to the maximum possible number of identical or different groups R^78a as defined and preferably defined herein, and wherein the heterocyclic, alicyclic, phenyl and heteroaryl moieties of R⁷⁸ are not further substituted or carry one, two, three, four, five or up to the maximum number of identical or different groups R^78b as defined and preferably defined herein.

According to one further embodiment, R⁷⁸ is in each case independently selected from halogen, CN, Ci-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-C6-alkoxy, Ci-C6-halogenalkoxy, C3-C6- alkenyloxy, C3-C6-alkynyloxy, C3-C6-cycloalkyl, S(0)_z-Ci-C6-alkyl, three-, four-, five- or six- membered saturated or partially unsaturated heterocycle, five- or six-membered heteroaryl and phenyl; wherein the heterocycle or heteroaryl contains one, two or three heteroatoms selected from N, O and S; and wherein the acyclic moieties of R⁷⁸ are not further substituted or carry one, two, three or up to the maximum possible number of identical or different groups R^78a as defined and preferably defined herein, and wherein the heterocyclic, alicyclic, phenyl and heteroaryl moieties of R⁷⁸ are not further substituted or carry one, two, three, four, five or up to the maximum number of identical or different groups R^78b as defined and preferably defined herein. Accordingto one specific embodiment, the acyclic and cyclic moieties of R⁷⁸ are not further substituted, according to another embodiment, the acyclic moieties of R⁷⁸ carry one, two, three or four identical or different groups R^78a as defined and preferably defined herein. According to a further embodiment, R⁷⁸ is in each case independently selected from halogen, CN, Ci-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-C6-alkoxy, C3-C6-alkenyloxy, C3-C6-alkynyloxy, C3-C6-cycloalkyl and S(0)_z-Ci-C6-alkyl, wherein the acyclic moieties of R⁷⁸ are not further substituted or carry one, two, three or up to the maximum possible number of identical or different groups R^78a as defined and preferably defined herein, and wherein the cycloalkyi moieties of R⁷⁸ are not further substituted or carry one, two, three, four, five or up to the maximum number of identical or different groups R^78b as defined and preferably defined herein.

According to a further embodiment, R⁷⁸ is in each case independently selected from halogen, CN, d-Ce-alkyl, , Ci-C₆-halogealkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, Ci-C₆-alkoxy, Ci-C₆- halogenalkoxy, C3-C6-alkenyloxy, C3-C6-alkynyloxy, C3-C6-cycloalkyl and S(0)_z-Ci-C6-alkyl, wherein the acyclic moieties of R⁷⁸ are not further substituted or carry one, two, three or up to the maximum possible number of identical or different groups R^78a as defined and preferably defined herein, and wherein the cycloalkyi moieties of R⁷⁸ are not further substituted or carry one, two, three, four, five or up to the maximum number of identical or different groups R^78b as defined and preferably defined herein. Accordingto one specific embodiment, the acyclic and cyclic moieties of R⁷⁸ are not further substituted, according to another embodiment, the acyclic moieties of R⁷⁸ carry one, two, three or four identical or different groups R^78a as defined and preferably defined herein.

According to still a further embodiment, R⁷⁸ is in each case independently selected from halo- gen, Ci-C6-alkyl and Ci-C6-alkoxy, wherein the acyclic moieties of R⁷⁸ are not further substituted or carry one, two, three or up to the maximum possible number of identical or different groups R^78a defined and preferably defined herein.

According to still a further embodiment, R⁷⁸ is in each case independently selected from CN, halogen, Ci-C6-alkyl, Ci-C6-halogealkyl, Ci-C6-alkoxy and Ci-C6-halogenalkoxy, wherein the acyclic moieties of R⁷⁸ are not further substituted or carry one, two, three or up to the maximum possible number of identical or different groups R^78a defined and preferably defined herein. Accordingto one specific embodiment, the acyclic and cyclic moieties of R⁷⁸ are not further substituted, according to another embodiment, the acyclic moieties of R⁷⁸ carry one, two, three or four identical or different groups R^78a as defined and preferably defined herein.

R^78a are the possible substituents for the acyclic moieties of R⁷⁸. R^78a is independently selected from halogen, OH, CN, Ci-C6-alkoxy, C₃-C6-cycloalkyl, C₃-C6-cycloalkenyl, C₃-C6- halogencycloalkyl, C3-C6-halogencycloalkenyl, Ci-C4-halogenalkoxy, Ci-C6-alkylthio, five- or six- membered heteroaryl, phenyl and phenoxy, wherein the heterorayl, phenyl and phenoxy group is unsubstituted or carries one, two, three, four or five substituents R^78a' selected from the group consisting of halogen, OH, Ci-C4-alkyl, Ci-C4-halogenalkyl, Ci-C4-alkoxy and C1-C4- halogenalkoxy.

According to one embodiment R^78a is independently selected from halogen, Ci-C6-alkoxy, C3- C6-cycloalkyl, C3-C6-halogencycloalkyl and Ci-C4-halogenalkoxy. Specifically, R^78a is

independently selected from F, CI, Br, I, Ci-C2-alkoxy, cyclopropyl, 1 -F-cyclopropyl, 1-CI- cyclopropyl, 1 ,1 -F2-cyclopropyl, 1 ,1-Cl2-cyclopropyl and Ci-C2-halogenalkoxy.

According to a further embodiment, R^78a is independently halogen, in particular selected from F, CI, Br and I, more specifically F, CI and Br. R^78b are the possible substituents for the cycloalkyi, heterocyclyl, heteroaryl and phenyl moieties of R⁷⁸. R^78b according to the invention is independently selected from halogen, OH, CN, C1-C4- alkyl, Ci-C4-alkoxy, Ci-C4-halogenalkyl, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, C1-C4- halogenalkoxy and Ci-C6-alkylthio.

According to one embodiment thereof R^78b is independently selected from halogen, CN, C1-C4- alkyl, Ci-C4-alkoxy, Ci-C4-halogenalkyl and Ci-C4-halogenalkoxy, in particular halogen, C1-C4- alkyl and Ci-C₄-alkoxy. Specifically, R^78b is independently selected from F, CI, CN, CH₃, OCH₃ and halogenmethoxy.

Particularly preferred embodiments of R⁷ and R⁸, optionally substituted by (R⁷⁸)₀, according to the invention are in Table P78 below, wherein each line of lines P78-1 to P78-40 corresponds to one particular embodiment of the invention, wherein P78-1 to P78-40 are also in any combination with one another a preferred embodiment of the present invention. Thereby, the positions of the heteroaryls marked with "#" represents the connection points (carbon atoms 5' and 6' in formula I) with the remaining skeleton of the compounds of formula I :

R⁹ is in each case independently selected from hydrogen, OH, CH(=0), C(=0)CrC6-alkyl, C(=0)C₂-C₆-alkenyl, C(=0)C₃-C₆-cycloalkyl, C(=0)0(C C₆-alkyl), C(=0)0(C₂-C₆-alkenyl), C(=0)0(C₂-C₆-alkynyl), C(=0)0(C₃-C₆-cycloalkyl), C(=0)NH(Ci-C₆-alkyl), C(=0)NH(C₂-C₆- alkenyl), C(=0)NH(C₂-C₆-alkynyl), C(=0) NH(C₃-C₆-cycloalkyl), CH(=S), C(=S)Ci-C₆-alkyl, C(=S)C₂-C₆-alkenyl, C(=S)C₂-C₆-alkynyl, C(=S)C₃-C₆-cycloalkyl, , C(=S)0(Ci-C₆-alkyl),

C(=S)0(C₂-C₆-alkenyl), C(=S)0(C₂-C₆-alkynyl), C(=S)0(C₃-C₆-cycloalkyl), C(=S)NH(Ci-C₆- alkyl), C(=S)NH(C₂-C₆-alkenyl), C(=S)NH(C₂-C₆-alkynyl), C(=S)NH(C₃-C₆-cycloalkyl), Ci-C₆- alkyl, Ci-C4-halogenalkyl, C₃-C6-cycloalkyl, C₃-C6-halogencycloalkyl, Ci-C4-alkoxy, C1-C4- halogenalkoxy, OR^Y, Ci-C6-alkylthio, Ci-C6-halogenalkylthio, C₂-C6-alkenyl, C₂-C6- halogenalkenyl C₂-C6-alkynyl, C₂-C6-halogenalkynyl, S(0)z-Ci-C6-alkyl, S(0)z-Ci-C6- halogenalkyl, S(0)z-Ci-C₆-alkoxy, S(0)_z-C₂-C₆-alkenyl, S(0)_z-C₂-C₆-alkynyl, S(0)z-aryl, S0₂- NH(Ci-C₆-alkyl), S0₂-NH(Ci-C₆-halogenalkyl), S0₂-NH-aryl, tri-(Ci-C₆ alkyl)silyl and di-(Ci-C₆ alkoxy)phosphoryl), , five- or six-membered heteroaryl and aryl; wherein the heteroaryl contains one, two or three heteroatoms selected from N, O and S; wherein the aryl groups are unsubsti- tuted or carry one, two, three, four or five substituents selected from the group consisting of CN, halogen, OH, Ci-C4-alkyl, Ci-C4-halogenalkyl, Ci-C4-alkoxy and Ci-C4-halogenalkoxy;

R^Y is Ci-C6-alkyl, Ci-C6-halogenalkyl, C₂-C6-alkenyl, C₂-C6-halogenalkenyl, C₂-C6-alkynyl, C₂-C6- halogenalkynyl, C₃-C6-cycloalkyl, C₃-C6-halogencycloalkyl, phenyl and phenyl-Ci-C6-alkyl;

wherein the phenyl groups are unsubstituted or carry one, two, three, four or five substituents selected from the group consisting of CN, halogen, OH, Ci-C4-alkyl, Ci-C4-halogenalkyl, C1-C4- alkoxy and Ci-C4-halogenalkoxy;

R^9a is the subtituent of the acyclic moieties of R⁹. The acyclic moieties of R⁹ are not further substituted or carry one, two, three or up to the maximum possible number of identical or different groups R^9a which independently of one another are selected from halogen, OH, CN, Ci-C6-alkoxy, C3-C6-cycloalkyl, C3-C6-cycloalkenyl, C3-C6-halogencycloalkyl, C3-C6- halogencycloalkenyl, Ci-C4-halogenalkoxy, Ci-C6-alkylthio, five- or six-membered heteroaryl, phenyl and phenoxy, wherein the heteroaryl, phenyl and phenoxy group is unsubstituted or carries one, two, three, four or five substituents R^78a' selected from the group consisting of halogen, OH, Ci-C4-alkyl, Ci-C4-halogenalkyl, Ci-C4-alkoxy and Ci-C4-halogenalkoxy;

R^9b is the subtituyend of cycloalkyl, phenyl, heterocyclic and heteroaryl moieties of R⁹. The alicyclic, phenyl, heterocyclic and heteroaryl moieties of R⁹ are not further substituted or carry one, two, three, four, five or up to the maximum number of identical or different groups R^9b which independently of one another are selected from halogen, OH, CN , Ci-C4-alkyl, C1-C4- alkoxy, Ci-C4-halogenalkyl, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, Ci-C4-halogenalkoxy and d-Ce-alkylthio.

According to one embodiment of formula I, R⁹ is H.

According to still another embodiment of formula I, R⁹ is OH.

According to a further specific embodiment of formula I, R⁹ is CH(=0).

According to a further specific embodiment of formula I, R⁹ is C(=0)Ci-C6-alkyl, C(=0)0(Ci-C6- alkyl), C(=0)NH(Ci-C₆-alkyl) or C(=0)N(Ci-C₆-alkyl)₂, wherein alkyl is CH₃, C2H5, n-propyl, i- propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl.

According to a further specific embodiment of formula I, R⁹ is C(=0)C2-C6-alkenyl, C(=0)0(C₂- Ce-alkenyl), C(=0)NH(C₂-C₆-alkenyl) or C(=0)N(C₂-C₆-alkenyl)₂), wherein alkenyl is CH=CH₂, CH₂CH=CH₂.

According to a further specific embodiment of formula I, R⁹ is C(=0)C₂-C6-alkynyl, C(=0)0(C₂- Ce-alkynyl), C(=0)NH(C₂-C₆-alkynyl) or C(=0)N(C₂-C₆-alkynyl)₂, wherein alkynyl is C≡CH_, CH₂C≡CH.

According to a further specific embodiment of formula I, R⁹ is C(=0)C3-C6-cycloalkyl,

C(=0)0(C₃-C₆-cycloalkyl), C(=0)N H(C₃-C₆-cycloalkyl) or C(=0)N(C₃-C₆-cycloalkyl)₂,, wherein cycloalkyl is cyclopropyl (C3H7) or cyclobutyl (C4H9).

According to a further specific embodiment of formula I, R⁹ is CH(=S).

According to a further specific embodiment of formula I, R⁹ is C(=S)Ci-C6-alkyl, C(=S)0(Ci-C6- alkyl), C(=S)NH(C C₆-alkyl) or C(=S)N(C C₆-alkyl)₂, wherein alkyl is CH₃, C₂H₅, n-propyl, i- propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl.

According to a further specific embodiment of formula I, R⁹ is C(=S)C₂-C6-alkenyl, C(=S)0(C₂- Ce-alkenyl), C(=S)NH(C₂-C₆-alkenyl) or C(=S)N(C₂-C₆-alkenyl)₂„ wherein alkenyl is CH=CH₂, CH₂CH=CH₂.

According to a further specific embodiment of formula I, R⁹ is C(=S)0(C₂-C6-alkynyl),

C(=S)NH(C₂-C₆-alkynyl) or C(=S)N(C₂-C₆-alkynyl)₂, wherein alkynyl is C≡CH, CH₂C≡CH.

According to a further specific embodiment of formula I, R⁹ is C(=S)C3-C6-cycloalkyl,

C(=S)0(C₃-C6-cycloalkyl) or C(=S)N(C₃-C6-cycloalkyl)₂, wherein cycloalkyl is cyclopropyl (C₃H7) or cyclobutyl (C4H9). According to still another embodiment of formula I, R⁹ is Ci-C6-alkyl, such as CH3, C2H5, n- propyl, i-propyl, n-butyl, i-butyl, tert-butyl, n-pentyl or i-pentyl.

According to still another embodiment of formula I, R⁹ is Ci-C6-alkyl, in particular Ci-C4-alkyl, such as CH3, C2H5, n-propyl, i-propyl.

According to still another embodiment of formula I, R⁹ is Ci-C6-halogenalkyl, in particular C1-C4- halogenalkyl, such as CF₃, CCI₃, FCH₂, CICH₂, F₂CH, CI₂CH, CF₃CH₂, CCI₃CH₂ or CF₂CHF₂.

According to still another embodiment of formula I R⁹ is C3-C6-cycloalkyl, in particular cyclopro- pyl.

According to still another embodiment of formula I, R⁹ is C3-C6-halogencycloalkyl. In a special embodiment R^9b is fully or partially halogenated cyclopropyl, such as 1 -F-cyclopropyl, 1 -CI- cyclopropyl, 1 ,1 -F₂-cyclopropyl, 1 ,1-CI₂-cyclopropyl .

According to still another embodiment of formula I, R⁹ is Ci-C4-alkoxy and Ci-C4-halogenalkoxy, in particular Ci-C₃-alkoxy, Ci-C₃-halogenalkoxy, such as CH₂OCH₃, CH₂OCF₃ or CH₂OCHF₂.

According to a further specific embodiment of formula I, R⁹ is OR^Y wherein R^Y is Ci-C6-alkyl, Ci- C6-halogenalkyl, C₂-C6-alkenyl, C₂-C6-halogenalkenyl, C₂-C6-alkynyl, C₂-C6-halogenalkynyl, C₃- C6-cycloalkyl, C₃-C6-halogencycloalkyl, phenyl and phenyl-Ci-C6-alkyl; wherein the phenyl groups are unsubstituted or carry one, two, three, four or five substituents selected from the group consisting of CN, halogen, OH, Ci-C4-alkyl, Ci-C4-halogenalkyl, Ci-C4-alkoxy and C1-C4- halogenalkoxy;

According to a further specific embodiment of formula I, R⁹ is OR^Y, wherein R^Y is Ci-C6-alkyl, in particular Ci-C4-alkyl, more specifically Ci-C₂-alkyl. R⁹ is such as OCH₃ or OCH₂CH₃.

According to a further specific embodiment of formula I, R⁹ is OR^Y wherein R^Y is C1-C6- halogenalkyl, in particular Ci-C4-halogenalkyl, more specifically Ci-C₂-halogenalkyl. R⁹ is such as OCF₃, OCHF₂, OCH₂F, OCCI₃, OCHCI₂ or OCH₂CI, in particular OCF₃, OCHF₂, OCCI₃ or OCHCI₂.

According to a further specific embodiment of formula I, R⁹ is OR^Y, wherein R^Y C₂-C6-alkenyl, in particular C₂-C4-alkenyl, more specifically Ci-C₂-alkenyl. R⁹ is such as OCH=CH₂,

OCH₂CH=CH₂.

According to a further specific embodiment of formula I, R⁹ is OR^Y, wherein R^Y C₂-C6-alkynyl, in particular C₂-C6-alkynyl, in particular C₂-C4-alkynyl, more specifically Ci-C₂-alkynyl. R⁹ is such as OC≡CH

According to still another embodiment of formula I, R⁹ is OR^Y, wherein R^Y is C₃-C6- halogencycloalkyl. In a special embodiment R¹ is fully or partially halogenated cyclopropyl.

According to still another embodiment of formula I, R⁹ is is OR^Y, wherein R^Y and phenyl; wherein the phenyl groups are unsubstituted or carry one, two, three, four or five substituents selected from the group consisting of CN, halogen, OH, Ci-C4-alkyl, Ci-C4-halogenalkyl, Ci-C4-alkoxy and Ci-C4-halogenalkoxy.

According to still another embodiment of formula I, R⁹ is is OR^Y wherein R^Y phenyl-Ci-C6-alkyl, such as phenyl-CH₂, herein the phenyl groups are unsubstituted or carry one, two, three, four or five substituents selected from the group consisting of CN, halogen, OH, Ci-C4-alkyl, C1-C4- halogenalkyl, Ci-C4-alkoxy and Ci-C4-halogenalkoxy. R⁹ is such as OChbPh.

According to still a further embodiment of formula I, R⁹ is C2-C6-alkenyl, in particular C2-C4-alk- enyl, such as CH=CH₂, C(CH₃)=CH₂, CH₂CH=CH₂.

According to a further specific embodiment of formula I, R⁹ is C2-C6-halogenalkenyl, in particular C₂-C4-halogenalkenyl, more specifically C₂-C3-halogenalkenyl such as CH=CHF, CH=CHCI, CH=CF₂, CH=CCI₂, CH₂CH=CHF, CH₂CH=CHCI, CH₂CH=CF₂, CH₂CH=CCI₂, CF₂CH=CF₂, CCI₂CH=CCI₂, CF₂CF=CF₂, CCI₂CCI=CCI₂.

According to still a further embodiment of formula I, R⁹ is C2-C6-alkynyl or C2-C6-halogenalkynyl, in particular C2-C4-alkynyl or C2-C4-halogenalkynyl, such as C CH,

According to still another embodiment of formula I, R⁹ is S(0)z-Ci-C6-alkyl such as SCH3, S(=0) CH₃, S(0)₂CH₃.

According to still another embodiment of formula I, R⁹ is S(0)z-Ci-C6-halogenalkyl such as

SCF3, S(=0)CF₃, S(0)₂CF₃, SCHF₂, S(=0)CHF₂, S(0)₂CHF₂.

According to still another embodiment of formula I, R⁹ is S(0)z-aryl such as S-phenyl, S(=0) phenyl, S(0)2phenyl, wherein the phenyl group is unsubstituted or carries one, two, three, four or five substituents R^78a' selected from the group consisting of halogen, OH, Ci-C4-alkyl, C1-C4- halogenalkyl, Ci-C4-alkoxy and Ci-C4-halogenalkoxy;

According to still another embodiment of formula I, R⁹ is S(0)z-C2-C6-alkenyl such as

SCH=CH₂, S(=0)CH=CH₂, S(0)₂CH=CH₂, SCH₂CH=CH₂, S(=0)CH₂CH=CH₂,

S(0)₂CH₂CH=CH₂ .

According to still another embodiment of formula I, R⁹ is S(0)z-C₂-C6-alkynyl such as SC CH, S(=0)C≡CH, S(0)₂C≡CH, SCH₂C≡CH, S(=0)CH₂C≡CH, S(0)₂CH₂C≡CH.

According to still another embodiment of formula I, R⁹ is S02-NH(Ci-C6-alkyl), is Ci-C6-alkyl, in particular Ci-C₄-alkyl, more specifically Ci-C₂-alkyl. R⁹ is such as SO2NHCH3 or SO2NHCH2CH3.

According to still another embodiment of formula I, R⁹ is S02-NH(Ci-C6-halogenalkyl), wherein Ci-C6-halogenalkyl, in particular Ci-C4-halogenalkyl, more specifically Ci-C2-halogenalkyl. R⁹ is such as SO2NHCF3, SO2NHCHF2, SO2NHCH2F, SO2NHCCI3, SO2NHCHCI2 or SO2NHCH2CI, in particular SO2NHCF3, SO2NHCHF2, SO2NHCCI3 or SO2NHCHCI2.

According to still another embodiment of formula I, R⁹ is S02-NHaryl, wherein the aryl groups are unsubstituted or carry one, two, three, four or five substituents selected from the group consisting of CN, halogen, OH, Ci-C4-alkyl, Ci-C4-halogenalkyl, Ci-C4-alkoxy and C1-C4- halogenalkoxy. . R⁹ is such as S02NHPh.

According to still another embodiment of formula I, R⁹ is tri-(Ci-C6 alkyl)silyl, in particular C1-C4- alkyl, such as CH₃. or C2H5. R⁹ is such as OSi(CH₃)₃

According to still another embodiment of formula I, R⁹ is di-(Ci-C6 alkoxy)phosphoryl), in particular Ci-C₄-alkoxy, such as OCH₃. or OC2H5. R⁹ is such as OPO(OCH₃)₂.

According to still another embodiment of formula I, R⁹ is phenyl-Ci-C6-alkyl, such as phenyl- CH₂, wherein the phenyl moiety in each case is unsubstituted or substituted by one, two or three identical or different groups R^9b which independently of one another are selected from halogen, Ci-C2-alkyl, Ci-C2-alkoxy, Ci-C2-halogenalkyl and Ci-C2-halogenalkoxy, in particular F, CI, Br, CH₃, OCHs, CF₃ and OCF₃.

According to still another embodiment of formula I , R⁹ is aryl, in particular phenyl, wherein the aryl or phenyl moiety in each case is unsubstituted or substituted by identical or different groups R^9b which independently of one another are selected from halogen, Ci-C2-alkyl, Ci-C2-alkoxy, Ci-C2-halogenalkyl and Ci-C2-halogenalkoxy, in particular F, CI, Br, CH₃, OCH₃, CF₃ and OCF₃. According to one embodiment, R⁹ is unsubstituted phenyl. According to another embodiment, R⁹ is phenyl, that is substituted by one, two or three, in particular one, halogen, in particular se- lected from F, CI and Br, more specifically selected from F and CI.

According to still another embodiment of formula I , R⁹ is a 5-membered heteroaryl such as pyr- rol-1-yl, pyrrol-2-yl, pyrrol-3-yl, thien-2-yl, thien-3-yl, furan-2-yl, furan-3-yl, pyrazol-1-yl, pyrazol- 3-yl, pyrazol-4-yl, pyrazol-5-yl, imidazol-1-yl, imidazol-2-yl, imidazol-4-yl, imidazol-5-yl, oxazol-2- yl, oxazol-4-yl, oxazol-5-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, 1 ,2,4-triazolyl-1 -yl, 1 ,2,4-triazol-3-yl 1 ,2,4-triazol-5-yl, 1 ,2,4-oxadiazol-3-yl, 1 ,2,4-oxadiazol-5-yl and 1 ,2,4-thiadiazol-3-yl,

1 ,2,4-thiadiazol-5-yl.

According to still another embodiment of formula I , R⁹ is a 6-membered heteroaryl such as pyri- din-2-yl, pyridin-3-yl, pyridin-4-yl, pyridazin-3-yl, pyridazin-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrazin-2-yl and 1 ,3,5-triazin-2-yl and 1 ,2,4-triazin-3-yl.

According to still another embodiment of formula I , R⁹ is in each case independently selected from H, halogen, OH, CN , Ci-C6-alkyl, Ci-C6-halogenalkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6- alkoxy, Ci-C6-halogenalkoxy, C3-C6-alkenyloxy, C3-C6-alkynyloxy and C3-C6-cycloalkyl wherein the acyclic moieties of R⁹ are unsubstituted or substituted with identical or different groups R^9a as defined and preferably defined herein, and wherein the carbocyclic, phenyl and heteroaryl moieties of R⁹ are unsubstituted or substituted with identical or different groups R^9b as defined and preferably defined herein.

According to still another embodiment of formula I , R⁹ is in each case independently selected from H, halogen, OH, CN , d-Ce-alkyl, C2-Ce-alkenyl, C2-Ce-alkynyl, Ci-Ce-alkoxy, C3-C6- alkenyloxy, C3-C6-alkynyloxy and C3-C6-cycloalkyl, wherein the acyclic moieties of R⁹ are unsubstituted or substituted with identical or different groups R^9a as defined and preferably defined herein, and wherein the cycloalkyl moieties of R⁹ are unsubstituted or substituted with identical or different groups R^9b as defined and preferably defined herein.

According to still another embodiment of formula I , R⁹ is in each case independently selected from H and OR^Y, wherein R^Y is most preferably Ci-C6-alkyl, Ci-C6-halogenalkyl, C2-C6-alkenyl, C2-C6-halogenalkenyl, C2-C6-alkynyl, C2-C6-halogenalkynyl, phenyl and phenyl-Ci-C6-alkyl; wherein the phenyl groups are unsubstituted or carry one, two, three, four or five substituents selected from the group consisting of CN , halogen, OH, Ci-C4-alkyl, Ci-C4-halogenalkyl, C1-C4- alkoxy and Ci-C4-halogenalkoxy.

According to still another embodiment of formula I , R⁹ is in each case independently selected from H and OR^Y, wherein R^Y is most preferably C2-C6-alkenyl, C2-C6-alkynyl, phenyl and phenyl- Ci-C6-alkyl; wherein the phenyl groups are unsubstituted or carry one, two, three, four or five substituents selected from the group consisting of CN, halogen, Ci-C4-alkyl, Ci-C4-halogenalkyl, Ci-C4-alkoxy and Ci-C4-halogenalkoxy.

According to still another embodiment of formula I, R⁹ is in each case independently selected from H, CH(=0), C(=0)Ci-C₆-alkyl, C(=0)0(Ci-C₆-alkyl) and C(=0)NH(Ci-C₆-alkyl), C(=0)N(Ci- C₆-alkyl)₂, C(=0)C₂-C₆-alkenyl, C(=0)0(C₂-C₆-alkenyl), C(=0)NH(C₂-C₆-alkenyl), C(=0)N(C₂-C₆- alkenyl)_2, C(=0)C₂-C₆-alkynyl, C(=0)0(C₂-C₆-alkynyl), C(=0)NH(C₂-C₆-alkynyl), C(=0)N(C₂-C₆- alkynyl)₂C(=0)C₃-C₆-cycloalkyl, C(=0)0(C₃-C₆-cycloalkyl), C(=0)NH(C₃-C₆-cycloalkyl) and C(=0)N(C3-C6-cycloalkyl)₂, wherein the acyclic moieties of R⁹ are unsubstituted or substituted with identical or different groups R^9a as defined and preferably defined herein, and wherein the cycloalkyi moieties of R⁹ are unsubstituted or substituted with identical or different groups R^9b as defined and preferably defined herein.

According to still another embodiment of formula I, R⁹ is in each case independently selected from H, C(=0)Ci-C₆-alkyl, C(=0)0(Ci-C₆-alkyl), C(=0)NH(Ci-C₆-alkyl), C(=0)N(Ci-C₆-alkyl)₂, C(=0)C₂-C₆-alkenyl, C(=0)0(C₂-C₆-alkenyl), C(=0)NH(C₂-C₆-alkenyl), C(=0)N(C₂-C₆-alkenyl)_2, wherein the acyclic moieties of R⁹ are unsubstituted or substituted with identical or different groups R^9a as defined and preferably defined herein, and wherein the cycloalkyi moieties of R⁹ are unsubstituted or substituted with identical or different groups R^9b as defined and preferably defined herein.

According to still another embodiment of formula I, R⁹ is in each case independently selected from H, S(0)z-Ci-C₆-alkyl, S(0)_z-Ci-C₆-halogenalkyl, S(0)_z -Ci-C₆-alkoxy, S(0)_z-C₂-C₆-alkenyl, S(0)_z-C₂-C6-alkynyl, S(0)_zaryl, wherein the acyclic moieties of R⁹ are unsubstituted or substituted with identical or different groups R^9a as defined and preferably defined herein, and wherein the aryl moieties of R⁹ are unsubstituted or substituted with identical or different groups R^9b as defined and preferably defined herein.

According to still another embodiment of formula I, R⁹ is in each case independently selected from H, S0₂-NH(Ci-C₆-alkyl), S0₂-NH(Ci-C₆-halogenalkyl), SO^NHphenyl, wherein the acyclic moieties of R⁹ are unsubstituted or substituted with identical or different groups R^9a as defined and preferably defined herein, and wherein the aryl moieties of R⁹ are unsubstituted or substituted with identical or different groups R^9b as defined and preferably defined herein.

According to one embodiment R^9a is independently selected from halogen, Ci-C6-alkoxy, C3-C6- cycloalkyl, C3-C6-halogencycloalkyl and Ci-C4-halogenalkoxy. Specifically, R^9a is independently selected from F, CI, Br, I, Ci-C₂-alkoxy, cyclopropyl, 1 -F-cyclopropyl, 1-CI-cyclopropyl, 1 ,1 -F₂- cyclopropyl, 1 ,1 -CI₂-cyclopropyl and Ci-C₂-halogenalkoxy.

According to still another embodiment of formula I, R^9a is independently halogen, in particular selected from F, CI, Br and I, more specifically F, CI and Br.

R^9b are the possible substituents for the cycloalkyi, heteroaryl and phenyl moieties of R⁹. R^9b according to the invention is independently selected from halogen, OH, CN, Ci-C4-alkyl, C1-C4- alkoxy, Ci-C4-halogenalkyl, C₃-C6-cycloalkyl, C₃-C6-halogencycloalkyl, Ci-C4-halogenalkoxy and d-Ce-alkylthio.

According to one embodiment thereof R^9b is independently selected from halogen, CN, C1-C4- alkyl, Ci-C4-alkoxy, Ci-C4-halogenalkyl and Ci-C4-halogenalkoxy, in particular halogen, C1-C4- alkyl and Ci-C4-alkoxy. Specifically, R^9b is independently selected from F, CI, CN, CH3, CHF2, CFsOCHs and halogenmethoxy.

Particularly preferred embodiments of R⁹ according to the invention are in Table P13 below, wherein each line of lines P13-1 to P3-50corresponds to one particular embodiment of the in- vention, wherein P13-1 to P3-50 are also in any combination with one another a preferred embodiment of the present invention. The connection point to the carbon atom, to which R⁹ is bound is marked with "#" in the drawings.

Table P9:

Preferred embodiments of the present invention are the following compounds I.A, I.B and I.C. In these formulae, the substituents R¹ , m, R², n, R³, R⁴, R⁵, R⁶, R⁷⁸, o and R⁹ are independently as defined above or preferably defined herein:

I.A I.B

I.C

Preferred embodiments of the present invention are the following compounds I.A-1 , I.A-2, I.A-3, I.A-4, I.B-1 , I.B-2, I.B-3, I.B-4, and I.C-1 , I.C-2, I.C-3, I.C-4. In these formulae, the substituents R⁷⁸, o and R⁹ are independently as defined above or preferably defined herein:

In particular with a view to their use, according to one embodiment, preference is given to the compounds of the formulae compounds I.A-1 , I.A-2, I.A-3, I.A-4, I.B-1 , I.B-2, I.B-3, I.B-4, and I.C-1 , I.C-2, I.C-3, I.C-4 that that are compiled in the Tables 1 a to 9a. Each of the groups mentioned for a substituent in the tables is furthermore per se, independently of the combination in which it is mentioned, a particularly preferred aspect of the substituent in question.

Table 1 a Compounds of the formula I.A-1 , I.A-2, I.A-3, I.A-4 in which o is 0 and the meaning of R⁹ for each individual compound corresponds in each case to one line of Table A (compounds I.A-1.1 a.A-1 to I.A-1 .1 a.A-28, I.A-2.1 a.A-1 to I.A-2.1 a.A-28, I.A-3.1 a.A-1 to I.A-3.1 a.A- 28, I.A-4.1 a.A-1 to I.A-4.1 a.A-28).

Table 2a Compounds of the formula I.A-1 , I.A-2, I.A-3, I.A-4 in which R⁷⁸ is 3"-CI and the meaning of R⁹ for each individual compound corresponds in each case to one line of Table A (compounds I.A-1.2a.A-1 to I.A-1.2a.A-28, I.A-2.2a.A-1 to I.A-2.2a.A-28, I.A-3.2a.A-1 to I.A- 3.2a.A-28, I.A-4.2a.A-1 to I.A-4.2a.A-28).

Table 3a Compounds of the formula I.B-1 , I.B-2, I.B-3, I.B-4 in which o is 0 and the meaning of R⁹ for each individual compound corresponds in each case to one line of Table A (compounds I.B-1.3a.A-1 to I.B-1 .3a.A-28, I.B-2.3a.A-1 to I.B-2.3a.A-28, I.B-3.3a.A-1 to I.B-3.3a.A- 28, I.B-4.3a.A-1 to I.B-4.3a.A-28).

Table 4a Compounds of the formula I.B-1 , I.B-2, I.B-3, I.B-4 in which R⁷⁸ is 3"-CI and the meaning of R⁹ for each individual compound corresponds in each case to one line of Table A (compounds I.B-1.4a.A-1 to I.B-1.4a.A-28, I.B-2.4a.A-1 to I.B-2.4a.A-28, I.B-3.4a.A-1 to I.B- 3.4a.A-28, I.B-4.4a.A-1 to I.B-4.4a.A-28).

Table 5a Compounds of the formula I.C-1 , I.C-2, I.C-3, I.C-4 in which o is 0 and the meaning of R⁹ for each individual compound corresponds in each case to one line of Table A (com- pounds I.C-1 .5a.A-1 to I.C-1 .5a.A-28, I.C-2.5a.A-1 to I.C-2.5a.A-28, I.C-3.5a.A-1 to I.C-3.5a.A- 28, I.C-4.5a.A-1 to I.C-4.5a.A28).

Table 6a Compounds of the formula I.C-1 , I.C-2, I.C-3, I.C-4 in which R⁷⁸ is 3"-CI and the meaning of R⁹ for each individual compound corresponds in each case to one line of Table A (compounds I.C-1 .6a.A-1 to I.C-1.6a.A-28, I.C-2.6a.A-1 to I.C-2.6a.A-28, I.C-3.6a.A-1 to I.C- 3.6a.A-28, I.C-4.6a.A-1 to I.C-4.6a.A-28).

Table 7a Compounds of the formula I.A-1 , I.A-2, I.A-3, I.A-4 in which R⁷⁸ is 3"-F and the meaning of R⁹ for each individual compound corresponds in each case to one line of Table A (compounds I.A-1.7a.A-1 to I.A-1.7a.A-28, I.A-2.7a.A-1 to I.A-2.7a. A-28, I.A-3.7a.A-1 to I.A- 3.7a.A-28, I.A-4.7a.A-1 to I.A-4.7a.A-28).

Table 8a Compounds of the formula I.B-1 , I.B-2, I.B-3, I.B-4 in which R⁷⁸ is 3"-F and the meaning of R⁹ for each individual compound corresponds in each case to one line of Table A (compounds I.B-1.8a.A-1 to I.B-1.8a.A-28, I.B-2.8a.A-1 to I.B-2.8a.A-28, I.B-3.8a.A-1 to I.B- 3.8a.A-28, I.B-4.8a.A-1 to I.B-4.8a.A-28).

Table 9a Compounds of the formula I.C-1 , I.C-2, I.C-3, I.C-4 in which R⁷⁸ is 3"-F and the meaning of R⁹ for each individual compound corresponds in each case to one line of Table A (compounds I.C-1 .9a.A-1 to I.C-1.9a.A-28, I.C-2.9a.A-1 to I.C-2.9a.A-28, I.C-3.9a.A-1 to I.C- 3.9a.A-28, I.C-4.9a.A-1 to I.C-4.9a.A-28). Table 1

Preferred embodiments of the present invention are the following compounds XI .A, XI. B and XI. C. In these formulae, the substituents R¹, m, R², n, R³, R⁴, R⁵, R⁶, R⁷⁸ and o are independentl as defined above or preferably defined herein:

xi-c

Preferred embodiments of the present invention are the following compounds XI.A-1 , XI.A-2,

XI.A-3, XI.A-4, XI.B-1 , XI.B-2, XI.B-3, XI.B-4 and XI.C-1 . XI.C-2, XI.C-3, XI.C-4. In these formulae, the substituents R³ and R⁴ are independently as defined above or preferably defined herein:

In particular with a view to their use, according to one embodiment, preference is given to the compounds of the formulae compounds XI.A-1 , XI.A-2, XI.A-3, XI.A-4, XI.B-1 , XI.B-2, XI.B-3, XI.B-4 and XI.C-1 , XI.C-2, XI.C-3, XI.C-4. that are compiled in the Tables 1 a to 9a. Each of the groups mentioned for a substituent in the tables is furthermore per se, independently of the combination in which it is mentioned, a particularly preferred aspect of the substituent in question.

Table 1 a Compounds of the formula XI.A-1 , XI.A-2, XI.A-3, XI.A-4 in which o is 0 and the meaning for the combination of R³ and R⁴ for each individual compound corresponds in each case to one line of Table B (compounds XI.A-1 .1 a. B-1 to XI.A-1 .1 a. B-132, XI.A-2.1 a. B-1 to XI.A-2.1 a. B-132, XI.A-3.1 a.B-1 to XI.A-3.1 a. B-132, XI.A-4.1 a.B-1 to XI.A-4.1 a.B-132).

Table 2a Compounds of the formula XI.A-1 , XI.A-2, XI.A-3, XI.A-4 in which R⁷⁸ is 3"-CI and the meaning for the combination of R³ and R⁴ for each individual compound corresponds in each case to one line of Table B (compounds XI.A-1 .2a. B-1 to XI.A-1.2a. B-132, XI.A-2.2a.B-1 to XI.A-2.2a.B-132, XI.A-3.2a.B-1 to XI.A-3.2a. B-132, XI.A-4.2a.B-1 to XI.A-4.2a.B-132).

Table 3a Compounds of the formula XI.B-1 , XI.B-2, XI.B-3, XI.B-4 in which o is 0 and the meaning for the combination of R³ and R⁴ for each individual compound corresponds in each case to one line of Table B (compounds XI.B-1 .3a. B-1 to XI.B-1 .3a. B-132, XI.B-2.3a. B-1 to XI.B-2.3a.B-132, XI.B-3.3a.B-1 to XI. B-3.3a. B-132, XI.B-4.3a.B-1 to XI.B-4.3a.B-132).

Table 4a Compounds of the formula XI.B-1 , XI.B-2, XI.B-3, XI.B-4 in which R⁷⁸ is 3"-CI and the meaning for the combination of R³ and R⁴ for each individual compound corresponds in each case to one line of Table B (compounds XI.B-1 .4a. B-1 to XI. B-1.4a. B-132, XI.B-2.4a.B-1 to XI.B-2.4a.B-132, XI.B-3.4a.B-1 to XI. B-3.4a. B-132, XI.B-4.4a.B-1 to XI.B-4.4a.B-132). Table 5a Compounds of the formula XI.C-1 , XI.C-2, XI.C-3, XI.C-4 in which o is 0 and the meaning for the combination of R³ and R⁴ for each individual compound corresponds in each case to one line of Table B (compounds XI.C-1.5a. B-1 to XI.C-1 .5a. B-132, XI.C-2.5a. B-1 to XI.C-2.5a.B-132, XI.C-3.5a.B-1 to XI.C-3.5a.B-132, XI.C-4.5a.B-1 to XI.C-4.5a.B-132).

Table 6a Compounds of the formula XI.C-1 , XI.C-2, XI.C-3, XI.C-4 in which R⁷⁸ is 3"-CI and the meaning for the combination of R³ and R⁴ for each individual compound corresponds in each case to one line of Table B (compounds XI.C-1.6a. B-1 to XI .C-1.6a. B-132, XI.C-2.6a. B-1 to XI.C-2.6a.B-132, XI.C-3.6a.B-1 to XI.C-3.6a.B-132, XI.C-4.6a.B-1 to XI.C-4.6a.B-132).

Table 7a Compounds of the formula XI.A-1 , XI.A-2, XI.A-3, XI.A-4 in which R⁷⁸ is 3"-F and the meaning for the combination of R³ and R⁴ for each individual compound corresponds in each case to one line of Table B (compounds XI.A-1 .7a. B-1 to XI.A-1 .7a. B-132, XI.A-2.7a. B-1 to XI.A-2.7a.B-132, XI.A-3.7a.B-1 to XI.A-3.7a.B-132, XI.A-4.7a.B-1 to XI.A-4.7a.B-132).

Table 8a Compounds of the formula XI. B-1 , XI.B-2, XI.B-3, XI.B-4 in which R⁷⁸ is 3"-F and the meaning for the combination of R³ and R⁴ for each individual compound corresponds in each case to one line of Table B (compounds XI. B-1 .8a. B-1 to XI. B-1 .8a. B-132, XI.B-2.8a. B-1 to XI.B-2.8a.B-132, XI.B-3.8a.B-1 to XI. B-3.8a. B-132, XI.B-4.8a.B-1 to XI.B-4.8a.B-132).

Table 9a Compounds of the formula XI.C-1 , XI.C-2, XI.C-3, XI.C-4 in which R⁷⁸ is 3"-F and the meaning for the combination of R³ and R⁴ for each individual compound corresponds in each case to one line of Table B (compounds XI.C-1.9a. B-1 to XI .C-1.9a. B-132, XI.C-2.9a. B-1 to XI.C-2.9a.B-132, XI.C-3.9a.B-1 to XI.C-3.9a.B-132, XI.C-4.9a.B-1 to XI.C-4.9a.B-132).

Table B

The compounds I and the compositions according to the invention, respectively, are suitable as fungicides. They are distinguished by an outstanding effectiveness against a broad spectrum of phytopathogenic fungi, including soil-borne fungi, which derive especially from the classes of the Plasmodiophoromycetes, Peronosporomycetes (syn. Oomycetes), Chytridiomycetes, Zygomycetes, Ascomycetes, Basidiomycetes and Deuteromycetes (syn. Fungi imperfecti). Some are systemically effective and they can be used in crop protection as foliar fungicides, fungicides for seed dressing and soil fungicides. Moreover, they are suitable for controlling harmful fungi, which inter alia occur in wood or roots of plants.

The compounds I and the compositions according to the invention are particularly important in the control of a multitude of phytopathogenic fungi on various cultivated plants, such as cereals, e. g. wheat, rye, barley, triticale, oats or rice; beet, e. g. sugar beet or fodder beet; fruits, such as pomes, stone fruits or soft fruits, e. g. apples, pears, plums, peaches, almonds, cherries, strawberries, raspberries, blackberries or gooseberries; leguminous plants, such as lentils, peas, alfalfa or soybeans; oil plants, such as rape, mustard, olives, sunflowers, coconut, cocoa beans, castor oil plants, oil palms, ground nuts or soybeans; cucurbits, such as squashes, cucumber or melons; fiber plants, such as cotton, flax, hemp or jute; citrus fruit, such as oranges, lemons, grapefruits or mandarins; vegetables, such as spinach, lettuce, asparagus, cabbages, carrots, onions, tomatoes, potatoes, cucurbits or paprika; lauraceous plants, such as avocados, cinnamon or camphor; energy and raw material plants, such as corn, soybean, rape, sugar cane or oil palm; corn; tobacco; nuts; coffee; tea; bananas; vines (table grapes and grape juice grape vines); hop; turf; sweet leaf (also called Stevia); natural rubber plants or ornamental and forestry plants, such as flowers, shrubs, broad-leaved trees or evergreens, e. g. conifers; and on the plant propagation material, such as seeds, and the crop material of these plants.

Preferably, compounds I and compositions thereof, respectively are used for controlling a multitude of fungi on field crops, such as potatoes sugar beets, tobacco, wheat, rye, barley, oats, rice, corn, cotton, soybeans, rape, legumes, sunflowers, coffee or sugar cane; fruits; vines; ornamentals; or vegetables, such as cucumbers, tomatoes, beans or squashes.

The term "plant propagation material" is to be understood to denote all the generative parts of the plant such as seeds and vegetative plant material such as cuttings and tubers (e. g. potatoes), which can be used for the multiplication of the plant. This includes seeds, roots, fruits, tubers, bulbs, rhizomes, shoots, sprouts and other parts of plants, including seedlings and young plants, which are to be transplanted after germination or after emergence from soil. These young plants may also be protected before transplantation by a total or partial treatment by immersion or pouring.

Preferably, treatment of plant propagation materials with compounds I and compositions there- of, respectively, is used for controlling a multitude of fungi on cereals, such as wheat, rye, barley and oats; rice, corn, cotton and soybeans.

The term "cultivated plants" is to be understood as including plants which have been modified by breeding, mutagenesis or genetic engineering including but not limiting to agricultural biotech products on the market or in development (cf. http://cera-gmc.org/, see GM crop database therein). Genetically modified plants are plants, which genetic material has been so modified by the use of recombinant DNA techniques that under natural circumstances cannot readily be obtained by cross breeding, mutations or natural recombination. Typically, one or more genes have been integrated into the genetic material of a genetically modified plant in order to improve certain properties of the plant. Such genetic modifications also include but are not limited to targeted post-translational modification of protein(s), oligo- or polypeptides e. g. by glycosylation or polymer additions such as prenylated, acetylated or farnesylated moieties or PEG moieties.

Plants that have been modified by breeding, mutagenesis or genetic engineering, e. g. have been rendered tolerant to applications of specific classes of herbicides, such as auxin herbi- cides such as dicamba or 2,4-D; bleacher herbicides such as hydroxylphenylpyruvate dioxy- genase (HPPD) inhibitors or phytoene desaturase (PDS) inhibitors; acetolactate synthase (ALS) inhibitors such as sulfonyl ureas or imidazolinones; enolpyruvylshikimate-3-phosphate synthase (EPSPS) inhibitors, such as glyphosate; glutamine synthetase (GS) inhibitors such as glufosinate; protoporphyrinogen-IX oxidase inhibitors; lipid biosynthesis inhibitors such as acetyl CoA carboxylase (ACCase) inhibitors; or oxynil (i. e. bromoxynil or ioxynil) herbicides as a result of conventional methods of breeding or genetic engineering. Furthermore, plants have been made resistant to multiple classes of herbicides through multiple genetic modifications, such as resistance to both glyphosate and glufosinate or to both glyphosate and a herbicide from another class such as ALS inhibitors, HPPD inhibitors, auxin herbicides, or ACCase inhibitors. These herbicide resistance technologies are e. g. described in Pest Managem. Sci. 61 , 2005, 246; 61 , 2005, 258; 61 , 2005, 277; 61 , 2005, 269; 61 , 2005, 286; 64, 2008, 326; 64, 2008, 332; Weed Sci. 57, 2009, 108; Austral. J. Agricult. Res. 58, 2007, 708; Science 316, 2007, 1 185; and references quoted therein. Several cultivated plants have been rendered tolerant to herbicides by conventional methods of breeding (mutagenesis), e. g. Clearfield^® summer rape (Canola, BASF SE, Germany) being tolerant to imidazolinones, e. g. imazamox, or ExpressSun^® sunflowers (DuPont, USA) being tolerant to sulfonyl ureas, e. g. tribenuron. Genetic engineering methods have been used to render cultivated plants such as soybean, cotton, corn, beets and rape, tolerant to herbicides such as glyphosate and glufosinate, some of which are commercially available under the trade names RoundupReady^® (glyphosate-tolerant, Monsanto, U.S.A.), Cul- tivance^® (imidazolinone tolerant, BASF SE, Germany) and LibertyLink^® (glufosinate-tolerant, Bayer CropScience, Germany).

Furthermore, plants are also covered that are by the use of recombinant DNA techniques capable to synthesize one or more insecticidal proteins, especially those known from the bacterial genus Bacillus, particularly from Bacillus thuringiensis, such as δ-endotoxins, e. g. CrylA(b), CrylA(c), CrylF, CrylF(a2), CryllA(b), CrylllA, CrylllB(bl ) or Cry9c; vegetative insecticidal proteins (VIP), e. g. VIP1 , VIP2, VIP3 or VIP3A; insecticidal proteins of bacteria colonizing nematodes, e. g. Photorhabdus spp. or Xenorhabdus spp.; toxins produced by animals, such as scorpion toxins, arachnid toxins, wasp toxins, or other insect-specific neurotoxins; toxins pro- duced by fungi, such Streptomycetes toxins, plant lectins, such as pea or barley lectins; agglutinins; proteinase inhibitors, such as trypsin inhibitors, serine protease inhibitors, patatin, cystatin or papain inhibitors; ribosome-inactivating proteins (RIP), such as ricin, maize-RIP, abrin, luffin, saporin or bryodin; steroid metabolism enzymes, such as 3-hydroxysteroid oxidase, ecdyster- oid-IDP-glycosyl-transferase, cholesterol oxidases, ecdysone inhibitors or HMG-CoA-reductase; ion channel blockers, such as blockers of sodium or calcium channels; juvenile hormone esterase; diuretic hormone receptors (helicokinin receptors); stilbene synthase, bibenzyl synthase, chitinases or glucanases. In the context of the present invention these insecticidal proteins or toxins are to be understood expressly also as pre-toxins, hybrid proteins, truncated or otherwise modified proteins. Hybrid proteins are characterized by a new combination of protein domains, (see, e. g. WO 02/015701 ). Further examples of such toxins or genetically modified plants capable of synthesizing such toxins are disclosed, e. g., in EP-A 374 753, WO 93/007278, WO 95/34656, EP-A 427 529, EP-A 451 878, WO 03/18810 und WO 03/52073. The methods for producing such genetically modified plants are generally known to the person skilled in the art and are described, e. g. in the publications mentioned above. These insecticidal proteins contained in the genetically modified plants impart to the plants producing these proteins tolerance to harmful pests from all taxonomic groups of arthropods, especially to beetles (Coelop- tera), two-winged insects (Diptera), and moths (Lepidoptera) and to nematodes (Nematoda). Genetically modified plants capable to synthesize one or more insecticidal proteins are, e. g., described in the publications mentioned above, and some of which are commercially available such as YieldGard^® (corn cultivars producing the Cry1 Ab toxin), YieldGard^® Plus (corn cultivars producing CrylAb and Cry3Bb1 toxins), Starlink^® (corn cultivars producing the Cry9c toxin), Herculex^® RW (corn cultivars producing Cry34Ab1 , Cry35Ab1 and the enzyme phosphinothri- cin-N-acetyltransferase [PAT]); NuCOTN^® 33B (cotton cultivars producing the Cry1 Ac toxin), Bollgard^® I (cotton cultivars producing the CrylAc toxin), Bollgard^® II (cotton cultivars producing CrylAc and Cry2Ab2 toxins); VIPCOT^® (cotton cultivars producing a VIP-toxin); NewLeaf^® (potato cultivars producing the Cry3A toxin); Bt-Xtra^®, NatureGard^®, KnockOut^®, BiteGard^®, Pro- tecta^®, Bt1 1 (e. g. Agrisure^® CB) and Bt176 from Syngenta Seeds SAS, France, (corn cultivars producing the CrylAb toxin and PAT enyzme), MIR604 from Syngenta Seeds SAS, France (corn cultivars producing a modified version of the Cry3A toxin, c.f. WO 03/018810), MON 863 from Monsanto Europe S.A., Belgium (corn cultivars producing the Cry3Bb1 toxin), IPC 531 from Monsanto Europe S.A., Belgium (cotton cultivars producing a modified version of the CrylAc toxin) and 1507 from Pioneer Overseas Corporation, Belgium (corn cultivars producing the Cry1 F toxin and PAT enzyme).

Furthermore, plants are also covered that are by the use of recombinant DNA techniques capable to synthesize one or more proteins to increase the resistance or tolerance of those plants to bacterial, viral or fungal pathogens. Examples of such proteins are the so-called "pathogenesis- related proteins" (PR proteins, see, e. g. EP-A 392 225), plant disease resistance genes (e. g. potato cultivars, which express resistance genes acting against Phytophthora infestans derived from the Mexican wild potato Solanum bulbocastanum) or T4-lysozym (e. g. potato cultivars capable of synthesizing these proteins with increased resistance against bacteria such as Er- winia amylvora). The methods for producing such genetically modified plants are generally known to the person skilled in the art and are described, e. g. in the publications mentioned above. Furthermore, plants are also covered that are by the use of recombinant DNA techniques capable to synthesize one or more proteins to increase the productivity (e. g. bio mass production, grain yield, starch content, oil content or protein content), tolerance to drought, salinity or other growth-limiting environmental factors or tolerance to pests and fungal, bacterial or viral patho- gens of those plants.

Furthermore, plants are also covered that contain by the use of recombinant DNA techniques a modified amount of substances of content or new substances of content, specifically to improve human or animal nutrition, e. g. oil crops that produce health-promoting long-chain omega-3 fatty acids or unsaturated omega-9 fatty acids (e. g. Nexera^® rape, DOW Agro Sciences, Cana- da).

Furthermore, plants are also covered that contain by the use of recombinant DNA techniques a modified amount of substances of content or new substances of content, specifically to improve raw material production, e. g. potatoes that produce increased amounts of amylopectin (e. g. Amflora^® potato, BASF SE, Germany).

The compounds I and compositions thereof, respectively, are particularly suitable for controlling the following plant diseases:

Albugo spp. (white rust) on ornamentals, vegetables (e. g. A. Candida) and sunflowers (e. g. A. tragopogonis); Alternaria spp. (Alternaria leaf spot) on vegetables, rape (A. brassico/a or brassi- cae), sugar beets (A tenuis), fruits, rice, soybeans, potatoes (e. g. A. so/an/ or A. alternata), tomatoes (e. g. A. solani or A. alternata) and wheat; Aphanomyces spp. on sugar beets and vegetables; Ascochyta spp. on cereals and vegetables, e. g. A. tritici (anthracnose) on wheat and A. horde/ on barley; Bipolar/s and Drechslera pp. (teleomorph: Cochliobolus spp.), e. g. Southern leaf blight (D. maydisj or Northern leaf blight (B. zeicola) on corn, e. g. spot blotch (B. sorokiniana) on cereals and e. g. B. oryzae on rice and turfs; Blumeria (formerly Erysiphe) graminis (powdery mildew) on cereals (e. g. on wheat or barley); Botrytis cinerea (teleomorph: Botryotinia fucke/iana: grey mold) on fruits and berries (e. g. strawberries), vegetables (e. g. lettuce, carrots, celery and cabbages), rape, flowers, vines, forestry plants and wheat; Bremia lactucae (downy mildew) on lettuce; Ceratocystis (syn. Ophiostoma) spp. (rot or wilt) on broad- leaved trees and evergreens, e. g. C. ί///77/^' (Dutch elm disease) on elms; Cercospora spp. (Cer- cospora leaf spots) on corn (e. g. Gray leaf spot: C. zeae-maydis), rice, sugar beets (e. g. C. bet/cola), sugar cane, vegetables, coffee, soybeans (e. g. C. sojina or C. kikuchii) and rice; Cladosporium spp. on tomatoes (e. g. C. fulvum. leaf mold) and cereals, e. g. C. herbarum (black ear) on wheat; Claviceps purpurea (ergot) on cereals; Cochliobolus (anamorph: Helmin- thosporium of Bipolaris) spp. (leaf spots) on corn (C. carbonum), cereals (e. g. C. sativus, ana- morph: B. sorokiniana) and rice (e. g. C. miyabeanus, anamorph: H. oryzae); Colletotrichum

(teleomorph: Giomereiia) spp. (anthracnose) on cotton (e. g. C. gossypil), corn (e. g. C. gramini- <%>/#/Anthracnose stalk rot), soft fruits, potatoes (e. g. C. coccodes. black dot), beans (e. g. C. lindemuthianum) and soybeans (e. g. C. truncatum or C. gloeosporioides); Cortici urn spp., e. g. C. sasak/i (sheath blight) on rice; Corynespora cassiicola (leaf spots) on soybeans and orna- mentals; Cycloconium spp., e. g. C. oleaginum on olive trees; Cylindrocarpon spp. (e. g. fruit tree canker or young vine decline, teleomorph: Nectria or Neonectria spp.) on fruit trees, vines (e. g. C. liriodendri, teleomorph: Neonectria liriodendri. Black Foot Disease) and ornamentals; Dematophora (teleomorph: Rosellinia) necatrix (root and stem rot) on soybeans; Diaporthe spp., e. g. D. phaseolorum (damping off) on soybeans; Drechslera (syn. Helminthosporium, teleomorph: Pyrenophora) spp. on corn, cereals, such as barley (e. g. D. teres, net blotch) and wheat (e. g. D. tritici-repentis. tan spot), rice and turf; Esca (dieback, apoplexy) on vines, caused by Formitiporia (syn. Phellinus) punctata, F. mediterranea, Phaeomoniella chlamydospora (earlier Phaeoacremonium chlamydosporum), Phaeoacremonium aleophilum and/or Botryosphaeria obtusa, Elsinoe spp. on pome fruits (E. pyri), soft fruits (E. veneta: anthracnose) and vines (E. ampe/ina: anthracnose); Entyloma oryzae (leaf smut) on rice; Epicoccum spp. (black mold) on wheat; Erysiphe spp. (powdery mildew) on sugar beets {E. betae), vegetables (e. g. E. pisl), such as cucurbits (e. g. E. cichoracearum), cabbages, rape (e. g. E. cruciferarum); Eutypa lata (Eutypa canker or dieback, anamorph: Cytosporina lata, syn. Libertella blepharis) on fruit trees, vines and ornamental woods; Exserohilum (syn. Helminthosporium) spp. on corn (e. g. E. turci- cum); Fusarium (teleomorph: Gibberella) spp. (wilt, root or stem rot) on various plants, such as F. graminearum or F. culmorum (root rot, scab or head blight) on cereals (e. g. wheat or barley), F. oxysporum on tomatoes, F. so/ani( sp. glycines now syn. F. virguliforme ) and F. tucumani- ae and F. brasiliense each causing sudden death syndrome on soybeans, and F. verticillioides on corn; Gaeumannomyces graminis (take-all) on cereals (e. g. wheat or barley) and corn; Gibberella soo. on cereals (e. g. G. zeae) and rice (e. g. G. fujikuror. Bakanae disease); Giomereiia cingulata on vines, pome fruits and other plants and G gossypiion cotton; Grainstaining complex on rice; G 'uignardia bidwellii (black rot) on vines; Gymnosporangium spp. on rosaceous plants and junipers, e. g. G. sabinae (rust) on pears; Helminthosporium spp. (syn. Drechslera, teleomorph: Cochiioboius) on corn, cereals and rice; Hemileia spp., e. g. H. vastatrix (coffee leaf rust) on coffee; Isariopsis clavispora (syn. Cladosporium vitis) on vines; Macrophomina phaseolina (syn. phaseo/ή (root and stem rot) on soybeans and cotton; Microdochium (syn. Fusarium) nivale (pink snow mold) on cereals (e. g. wheat or barley); Microsphaera diffusa (powdery mildew) on soybeans; Monilinia spp., e. g. M. laxa, M. fructicola and M. fructigena (bloom and twig blight, brown rot) on stone fruits and other rosaceous plants; Mycosphaerella spp. on cereals, bananas, soft fruits and ground nuts, such as e. g. M. graminicola (anamorph: Septoria tritici, Septoria blotch) on wheat or M. fijiensis (black Sigatoka disease) on bananas; Peronospora spp. (downy mildew) on cabbage (e. g. P. brassicae), rape (e. g. P. parasitica), onions (e. g. P. destructor), tobacco {P. tabacina) and soybeans (e. g. P. manshurica);

Phakopsora pachyrhizi and P. meibomiae (soybean rust) on soybeans; Phialophora spp. e. g. on vines (e. g. P. tracheiphila and P. tetraspora) and soybeans (e. g. P. gregata: stem rot); Phoma lingam (root and stem rot) on rape and cabbage and P. betae (root rot, leaf spot and damping-off) on sugar beets; Phomopsis spp. on sunflowers, vines (e. g. P. viticola: can and leaf spot) and soybeans (e. g. stem rot: P. phaseoli, teleomorph: Diaporthe phaseolorum); Phy- soderma maydis (brown spots) on corn; Phytophthora spp. (wilt, root, leaf, fruit and stem root) on various plants, such as paprika and cucurbits (e. g. P. capsici), soybeans (e. g. P.

megasperma, syn. P. sojae), potatoes and tomatoes (e. g. P. infestans: late blight) and broad- leaved trees (e. g. P. ramorum. sudden oak death); Plasmodiophora brassicae (club root) on cabbage, rape, radish and other plants; Plasmopara spp., e. g. P. viticola (grapevine downy mildew) on vines and P. ha/stediion sunflowers; Podosphaera spp. (powdery mildew) on rosaceous plants, hop, pome and soft fruits, e. g. P. leucotricha on apples; Po/ymyxa spp., e. g. on cereals, such as barley and wheat (P. graminis) and sugar beets (P. betae) and thereby transmitted viral diseases; Pseudocercosporella herpotrichoides (eyespot, teleomorph: Tapes/a yal- lundae) on cereals, e. g. wheat or barley; Pseudoperonospora (downy mildew) on various plants, e. g. P. cubens/s on cucurbits or P. hum/// on hop; Pseudopezicula tracheiphila (red fire disease or .rotbrenner', anamorph: Phialophora) on vines; Puccinia spp. (rusts) on various plants, e. g. P. triticina (brown or leaf rust), P. striiformis (stripe or yellow rust), P. horde/^' (dwarf rust), P. graminis (stem or black rust) or P. recondita (brown or leaf rust) on cereals, such as e. g. wheat, barley or rye, P. kuehnii (orange rust) on sugar cane and P. asparagio asparagus; Pyrenophora (anamorph: Drechslera) tritici-repentis (tan spot) on wheat or P. teres (net blotch) on barley; Pyricu/aria spp., e. g. P. oryzae (teleomorph: Magnaporthe grisea, rice blast) on rice and P. grisea on turf and cereals; Pythium spp. (damping-off) on turf, rice, corn, wheat, cotton, rape, sunflowers, soybeans, sugar beets, vegetables and various other plants (e. g. P. ultimum or P. aphanidermatum); Ramularia spp., e. g. R. collo-cygni (Ramularia leaf spots, Physiological leaf spots) on barley and R. bet/cola on sugar beets; Rhizoctonia spp. on cotton, rice, potatoes, turf, corn, rape, potatoes, sugar beets, vegetables and various other plants, e. g. R. solani (root and stem rot) on soybeans, R. solani (sheath blight) on rice or R. cerealis (Rhizoctonia spring blight) on wheat or barley; Rhizopus sto/on/fer (b\ack mold, soft rot) on strawberries, carrots, cabbage, vines and tomatoes; Rhynchosporium secalis (scald) on barley, rye and triticale; Sa- rocladium oryzae and S. attenuatum (sheath rot) on rice; Sclerotinia spp. (stem rot or white mold) on vegetables and field crops, such as rape, sunflowers (e. g. S. sclerotiorum) and soybeans (e. g. S. ro/fs/ior S. sclerotiorum); Septoria spp. on various plants, e. g. S. glycines (brown spot) on soybeans, S. tritici (Septoria blotch) on wheat and S. (syn. Stagonospora) no- dorum (Stagonospora blotch) on cereals; Uncinula (syn. Erysiphe) necator (powdery mildew, anamorph: Oidium tucker!) on vines; Setospaeria spp. (leaf blight) on corn (e. g. S. turcicum, syn. Helminthosporium turcicum) and turf; Sphacelotheca spp. (smut) on corn, (e. g. S. reiliana: head smut), sorghum und sugar cane; Sphaerotheca fuliginea (powdery mildew) on cucurbits; Spongospora subterranea (powdery scab) on potatoes and thereby transmitted viral diseases; Stagonospora spp. on cereals, e. g. S. nodorum (Stagonospora blotch, teleomorph: Lepto- sphaeria [syn. Phaeosphaer/a] nodorum) on wheat; Synchytrium endobioticum on potatoes (potato wart disease); Taphrina spp., e. g. T. deformans (leaf curl disease) on peaches and T. pruni (plum pocket) on plums; Thielaviopsis spp. (black root rot) on tobacco, pome fruits, vegetables, soybeans and cotton, e. g. T. basicola (syn. Chalara elegans); Tilletia spp. (common bunt or stinking smut) on cereals, such as e. g. T. tritici(syn. T. caries, wheat bunt) and T. controversa (dwarf bunt) on wheat; Typhula incarnata (grey snow mold) on barley or wheat; Urocystis spp., e. g. U. occulta (stem smut) on rye; Uromyces spp. (rust) on vegetables, such as beans (e. g. U. appendiculatus, syn. U. phaseoli) and sugar beets (e. g. U. betae); Ustilago spp. (loose smut) on cereals (e. g. U. nuda and U. avaenae), corn (e. g. U. maydis. corn smut) and sugar cane; Venturis spp. (scab) on apples (e. g. V. inaequalis) and pears; and Verticillium spp. (wilt) on various plants, such as fruits and ornamentals, vines, soft fruits, vegetables and field crops, e. g. V. dah/iae on strawberries, rape, potatoes and tomatoes.

The compounds I and compositions thereof, respectively, are also suitable for controlling harm- ful fungi in the protection of stored products or harvest and in the protection of materials.

The term "protection of materials" is to be understood to denote the protection of technical and non-living materials, such as adhesives, glues, wood, paper and paperboard, textiles, leather, paint dispersions, plastics, cooling lubricants, fiber or fabrics, against the infestation and de- struction by harmful microorganisms, such as fungi and bacteria. As to the protection of wood and other materials, the particular attention is paid to the following harmful fungi: Ascomycetes such as Ophiostoma spp., Ceratocystis spp., Aureobasidium pullulans, Sclerophoma spp., Chaetomium spp., Humicola pp., Petriella spp., Trichurus spp.; Basidiomycetes such as Coni- ophora pp., Coriolus spp., Gloeophyllum spp., Lentinus spp., Pleurotus spp., Poria spp., Ser- pu/a spp. and Tyromyces spp., Deuteromycetes such as Aspergillus spp., Cladosporium spp., Penicillium spp., Trichoderma spp., Alternaria spp., Paecilomyces spp. and Zygomycetes such as Mucorspp., and in addition in the protection of stored products and harvest the following yeast fungi are worthy of note: Candida spp. and Saccharomyces cerevisae.

The method of treatment according to the invention can also be used in the field of protecting stored products or harvest against attack of fungi and microorganisms. According to the present invention, the term "stored products" is understood to denote natural substances of plant or animal origin and their processed forms, which have been taken from the natural life cycle and for which long-term protection is desired. Stored products of crop plant origin, such as plants or parts thereof, for example stalks, leafs, tubers, seeds, fruits or grains, can be protected in the freshly harvested state or in processed form, such as pre-dried, moistened, comminuted, ground, pressed or roasted, which process is also known as post-harvest treatment. Also falling under the definition of stored products is timber, whether in the form of crude timber, such as construction timber, electricity pylons and barriers, or in the form of finished articles, such as furniture or objects made from wood. Stored products of animal origin are hides, leather, furs, hairs and the like. The combinations according the present invention can prevent disadvantageous effects such as decay, discoloration or mold. Preferably "stored products" is understood to denote natural substances of plant origin and their processed forms, more preferably fruits and their processed forms, such as pomes, stone fruits, soft fruits and citrus fruits and their pro- cessed forms.

The compounds I and compositions thereof, respectively, may be used for improving the health of a plant. The invention also relates to a method for improving plant health by treating a plant, its propagation material and/or the locus where the plant is growing or is to grow with an effective amount of compounds I and compositions thereof, respectively.

The term "plant health" is to be understood to denote a condition of the plant and/or its products which is determined by several indicators alone or in combination with each other such as yield (e. g. increased biomass and/or increased content of valuable ingredients), plant vigor (e. g. improved plant growth and/or greener leaves ("greening effect")), quality (e. g. improved content or composition of certain ingredients) and tolerance to abiotic and/or biotic stress. The above identified indicators for the health condition of a plant may be interdependent or may result from each other.

The compounds of formula I can be present in different crystal modifications whose biological activity may differ. They are likewise subject matter of the present invention.

The compounds I are employed as such or in form of compositions by treating the fungi or the plants, plant propagation materials, such as seeds, soil, surfaces, materials or rooms to be protected from fungal attack with a fungicidally effective amount of the active substances. The application can be carried out both before and after the infection of the plants, plant propagation materials, such as seeds, soil, surfaces, materials or rooms by the fungi.

Plant propagation materials may be treated with compounds I as such or a composition comprising at least one compound I prophylactically either at or before planting or transplanting.

The invention also relates to agrochemical compositions comprising an auxiliary and at least one compound I according to the invention.

An agrochemical composition comprises a fungicidally effective amount of a compound I. The term "effective amount" denotes an amount of the composition or of the compounds I, which is sufficient for controlling harmful fungi on cultivated plants or in the protection of materials and which does not result in a substantial damage to the treated plants. Such an amount can vary in a broad range and is dependent on various factors, such as the fungal species to be controlled, the treated cultivated plant or material, the climatic conditions and the specific compound I used.

The compounds I, their N-oxides and salts can be converted into customary types of agrochemical compositions, e. g. solutions, emulsions, suspensions, dusts, powders, pastes, granules, pressings, capsules, and mixtures thereof. Examples for composition types are suspensions (e. g. SC, OD, FS), emulsifiable concentrates (e. g. EC), emulsions (e. g. EW, EO, ES, ME), capsules (e. g. CS, ZC), pastes, pastilles, wettable powders or dusts (e. g. WP, SP, WS, DP, DS), pressings (e. g. BR, TB, DT), granules (e. g. WG, SG, GR, FG, GG, MG), insecticidal articles (e. g. LN), as well as gel formulations for the treatment of plant propagation materials such as seeds (e. g. GF). These and further compositions types are defined in the "Catalogue of pesticide formulation types and international coding system", Technical Monograph No. 2, 6^th Ed. May 2008, CropLife International.

The compositions are prepared in a known manner, such as described by Mollet and Grube- mann, Formulation technology, Wiley VCH, Weinheim, 2001 ; or Knowles, New developments in crop protection product formulation, Agrow Reports DS243, T&F Informa, London, 2005.

Suitable auxiliaries are solvents, liquid carriers, solid carriers or fillers, surfactants, dispersants, emulsifiers, wetters, adjuvants, solubilizers, penetration enhancers, protective colloids, adhesion agents, thickeners, humectants, repellents, attractants, feeding stimulants, compatibilizers, bactericides, anti-freezing agents, anti-foaming agents, colorants, tackifiers and binders.

Suitable solvents and liquid carriers are water and organic solvents, such as mineral oil fractions of medium to high boiling point, e. g. kerosene, diesel oil; oils of vegetable or animal origin; aliphatic, cyclic and aromatic hydrocarbons, e. g. toluene, paraffin, tetrahydronaphthalene, alkylated naphthalenes; alcohols, e. g. ethanol, propanol, butanol, benzyl alcohol, cyclohexanol; glycols; DMSO; ketones, e. g. cyclohexanone; esters, e. g. lactates, carbonates, fatty acid es- ters, gamma-butyrolactone; fatty acids; phosphonates; amines; amides, e. g. N-methyl pyrroli- done, fatty acid dimethyl amides; and mixtures thereof.

Suitable solid carriers or fillers are mineral earths, e. g. silicates, silica gels, talc, kaolins, limestone, lime, chalk, clays, dolomite, diatomaceous earth, bentonite, calcium sulfate, magnesium sulfate, magnesium oxide; polysaccharides, e. g. cellulose, starch; fertilizers, e. g. ammonium sulfate, ammonium phosphate, ammonium nitrate, ureas; products of vegetable origin, e. g. cereal meal, tree bark meal, wood meal, nutshell meal, and mixtures thereof. Suitable surfactants are surface-active compounds, such as anionic, cationic, nonionic and amphoteric surfactants, block polymers, polyelectrolytes, and mixtures thereof. Such surfactants can be used as emulsifier, dispersant, solubilizer, wetter, penetration enhancer, protective colloid, or adjuvant. Examples of surfactants are listed in McCutcheon's, Vol.1 : Emulsifiers & De- tergents, McCutcheon's Directories, Glen Rock, USA, 2008 (International Ed. or North American Ed.).

Suitable anionic surfactants are alkali, alkaline earth or ammonium salts of sulfonates, sulfates, phosphates, carboxylates, and mixtures thereof. Examples of sulfonates are alkylaryl sulfonates, diphenyl sulfonates, alpha-olefin sulfonates, lignin sulfonates, sulfonates of fatty acids and oils, sulfonates of ethoxylated alkylphenols, sulfonates of alkoxylated arylphenols, sulfonates of condensed naphthalenes, sulfonates of dodecyl- and tridecylbenzenes, sulfonates of naphthalenes and alkyl naphthalenes, sulfosuccinates or sulfosuccinamates. Examples of sulfates are sulfates of fatty acids and oils, of ethoxylated alkylphenols, of alcohols, of ethoxylated alcohols, or of fatty acid esters. Examples of phosphates are phosphate esters. Examples of carboxylates are alkyl carboxylates, and carboxylated alcohol or alkylphenol ethoxylates.

Suitable nonionic surfactants are alkoxylates, N-substituted fatty acid amides, amine oxides, esters, sugar-based surfactants, polymeric surfactants, and mixtures thereof. Examples of alkoxylates are compounds such as alcohols, alkylphenols, amines, amides, arylphenols, fatty acids or fatty acid esters which have been alkoxylated with 1 to 50 equivalents. Ethylene oxide and/or propylene oxide may be employed for the alkoxylation, preferably ethylene oxide. Examples of N-substituted fatty acid amides are fatty acid glucamides or fatty acid alkanolamides. Examples of esters are fatty acid esters, glycerol esters or monoglycerides. Examples of sugar- based surfactants are sorbitans, ethoxylated sorbitans, sucrose and glucose esters or al- kylpolyglucosides. Examples of polymeric surfactants are home- or copolymers of vinyl pyrroli- done, vinyl alcohols, or vinyl acetate.

Suitable cationic surfactants are quaternary surfactants, for example quaternary ammonium compounds with one or two hydrophobic groups, or salts of long-chain primary amines. Suitable amphoteric surfactants are alkylbetains and imidazolines. Suitable block polymers are block polymers of the A-B or A-B-A type comprising blocks of polyethylene oxide and polypropylene oxide, or of the A-B-C type comprising alkanol, polyethylene oxide and polypropylene oxide. Suitable polyelectrolytes are polyacids or polybases. Examples of polyacids are alkali salts of polyacrylic acid or polyacid comb polymers. Examples of polybases are polyvinyl amines or polyethylene amines.

Suitable adjuvants are compounds, which have a negligible or even no pesticidal activity them- selves, and which improve the biological performance of the compound I on the target. Examples are surfactants, mineral or vegetable oils, and other auxiliaries. Further examples are listed by Knowles, Adjuvants and additives, Agrow Reports DS256, T&F Informa UK, 2006, chapter 5.

Suitable thickeners are polysaccharides (e. g. xanthan gum, carboxymethyl cellulose), inorganic clays (organically modified or unmodified), polycarboxylates, and silicates.

Suitable bactericides are bronopol and isothiazolinone derivatives such as alkylisothiazolinones and benzisothiazolinones.

Suitable anti-freezing agents are ethylene glycol, propylene glycol, urea and glycerin. Suitable anti-foaming agents are silicones, long chain alcohols, and salts of fatty acids.

Suitable colorants (e. g. in red, blue, or green) are pigments of low water solubility and water- soluble dyes. Examples are inorganic colorants (e. g. iron oxide, titan oxide, iron hexacyanofer- rate) and organic colorants (e. g. alizarin-, azo- and phthalogencyanine colorants).

Suitable tackifiers or binders are polyvinyl pyrrolidones, polyvinyl acetates, polyvinyl alcohols, polyacrylates, biological or synthetic waxes, and cellulose ethers.

Examples for composition types and their preparation are:

i) Water-soluble concentrates (SL, LS)

10-60 wt% of a compound I and 5-15 wt% wetting agent (e. g. alcohol alkoxylates) are dis- solved in water and/or in a water-soluble solvent (e. g. alcohols) ad 100 wt%. The active substance dissolves upon dilution with water.

ii) Dispersible concentrates (DC)

5-25 wt% of a compound I and 1-10 wt% dispersant (e. g. polyvinyl pyrrolidone) are dissolved in organic solvent (e. g. cyclohexanone) ad 100 wt%. Dilution with water gives a disper- sion.

iii) Emulsifiable concentrates (EC)

15-70 wt% of a compound I and 5-10 wt% emulsifiers (e. g. calcium dodecylben- zenesulfonate and castor oil ethoxylate) are dissolved in water-insoluble organic solvent (e. g. aromatic hydrocarbon) ad 100 wt%. Dilution with water gives an emulsion.

iv) Emulsions (EW, EO, ES)

5-40 wt% of a compound I and 1 -10 wt% emulsifiers (e. g. calcium dodecylbenzenesulfonate and castor oil ethoxylate) are dissolved in 20-40 wt% water-insoluble organic solvent (e. g. aromatic hydrocarbon). This mixture is introduced into water ad 100 wt% by means of an emulsifying machine and made into a homogeneous emulsion. Dilution with water gives an emulsion. v) Suspensions (SC, OD, FS)

In an agitated ball mill, 20-60 wt% of a compound I are comminuted with addition of 2-10 wt% dispersants and wetting agents (e. g. sodium lignosulfonate and alcohol ethoxylate), 0.1- 2 wt% thickener (e. g. xanthan gum) and water ad 100 wt% to give a fine active substance suspension. Dilution with water gives a stable suspension of the active substance. For FS type composition up to 40 wt% binder (e. g. polyvinyl alcohol) is added.

vi) Water-dispersible granules and water-soluble granules (WG, SG)

50-80 wt% of a compound I are ground finely with addition of dispersants and wetting agents (e. g. sodium lignosulfonate and alcohol ethoxylate) ad 100 wt% and prepared as water- dispersible or water-soluble granules by means of technical appliances (e. g. extrusion, spray tower, fluidized bed). Dilution with water gives a stable dispersion or solution of the active substance.

vii) Water-dispersible powders and water-soluble powders (WP, SP, WS)

50-80 wt% of a compound I are ground in a rotor-stator mill with addition of 1 -5 wt% disper- sants (e. g. sodium lignosulfonate), 1-3 wt% wetting agents (e. g. alcohol ethoxylate) and solid carrier (e. g. silica gel) ad 100 wt%. Dilution with water gives a stable dispersion or solution of the active substance.

viii) Gel (GW, GF)

In an agitated ball mill, 5-25 wt% of a compound I are comminuted with addition of 3-10 wt% dispersants (e. g. sodium lignosulfonate), 1 -5 wt% thickener (e. g. carboxymethyl cellulose) and water ad 100 wt% to give a fine suspension of the active substance. Dilution with water gives a stable suspension of the active substance.

ix) Microemulsion (ME)

5-20 wt% of a compound I are added to 5-30 wt% organic solvent blend (e. g. fatty acid dimethyl amide and cyclohexanone), 10-25 wt% surfactant blend (e. g. alcohol ethoxylate and arylphenol ethoxylate), and water ad 100 %. This mixture is stirred for 1 h to produce spontaneously a thermodynamically stable microemulsion.

x) Microcapsules (CS)

An oil phase comprising 5-50 wt% of a compound I, 0-40 wt% water insoluble organic solvent (e. g. aromatic hydrocarbon), 2-15 wt% acrylic monomers (e. g. methylmethacrylate, methacrylic acid and a di- or triacrylate) are dispersed into an aqueous solution of a protective colloid (e. g. polyvinyl alcohol). Radical polymerization results in the formation of poly(meth)acrylate microcapsules. Alternatively, an oil phase comprising 5-50 wt% of a compound I according to the in- vention, 0-40 wt% water insoluble organic solvent (e. g. aromatic hydrocarbon), and an isocya- nate monomer (e. g. diphenylmethene-4,4'-diisocyanatae) are dispersed into an aqueous solution of a protective colloid (e. g. polyvinyl alcohol). The addition of a polyamine (e. g. hexameth- ylenediamine) results in the formation of polyurea microcapsules. The monomers amount to 1 - 10 wt%. The wt% relate to the total CS composition.

xi) Dustable powders (DP, DS)

1 -10 wt% of a compound I are ground finely and mixed intimately with solid carrier (e. g. finely divided kaolin) ad 100 wt%.

xii) Granules (GR, FG)

0.5-30 wt% of a compound I is ground finely and associated with solid carrier (e. g. silicate) ad 100 wt%. Granulation is achieved by extrusion, spray-drying or fluidized bed.

xiii) Ultra-low volume liquids (UL)

1 -50 wt% of a compound I are dissolved in organic solvent (e. g. aromatic hydrocarbon) ad 100 wt%.

The compositions types i) to xiii) may optionally comprise further auxiliaries, such as 0.1-1 wt% bactericides, 5-15 wt% anti-freezing agents, 0.1 -1 wt% anti-foaming agents, and 0.1 -1 wt% colorants.

The agrochemical compositions generally comprise between 0.01 and 95%, preferably between 0.1 and 90%, more preferably between 1 and 70%, and in particular between 10 and 60%, by weight of active substance. The active substances are employed in a purity of from 90% to 100%, preferably from 95% to 100% (according to NMR spectrum).

For the purposes of treatment of plant propagation materials, particularly seeds, solutions for seed treatment (LS), Suspoemulsions (SE), flowable concentrates (FS), powders for dry treat- ment (DS), water-dispersible powders for slurry treatment (WS), water-soluble powders (SS), emulsions (ES), emulsifiable concentrates (EC), and gels (GF) are usually employed. The compositions in question give, after two-to-tenfold dilution, active substance concentrations of from 0.01 to 60% by weight, preferably from 0.1 to 40%, in the ready-to-use preparations. Application can be carried out before or during sowing. Methods for applying compound I and compositions thereof, respectively, onto plant propagation material, especially seeds, include dressing, coating, pelleting, dusting, and soaking as well as in-furrow application methods. Preferably, compound I or the compositions thereof, respectively, are applied on to the plant propagation material by a method such that germination is not induced, e. g. by seed dressing, pelleting, coating and dusting.

When employed in plant protection, the amounts of active substances applied are, depending on the kind of effect desired, from 0.001 to 2 kg per ha, preferably from 0.005 to 2 kg per ha, more preferably from 0.05 to 0.9 kg per ha, and in particular from 0.1 to 0.75 kg per ha.

In treatment of plant propagation materials such as seeds, e. g. by dusting, coating or drenching seed, amounts of active substance of from 0.1 to 1000 g, preferably from 1 to 1000 g, more preferably from 1 to 100 g and most preferably from 5 to 100 g, per 100 kilogram of plant propagation material (preferably seeds) are generally required.

When used in the protection of materials or stored products, the amount of active substance applied depends on the kind of application area and on the desired effect. Amounts customarily applied in the protection of materials are 0.001 g to 2 kg, preferably 0.005 g to 1 kg, of active substance per cubic meter of treated material.

Various types of oils, wetters, adjuvants, fertilizer, or micronutrients, and further pesticides (e. g. herbicides, insecticides, fungicides, growth regulators, safeners, biopesticides) may be added to the active substances or the compositions comprising them as premix or, if appropriate not until immediately prior to use (tank mix). These agents can be admixed with the compositions according to the invention in a weight ratio of 1 :100 to 100:1 , preferably 1 :10 to 10:1 .

A pesticide is generally a chemical or biological agent (such as pestidal active ingredient, compound, composition, virus, bacterium, antimicrobial or disinfectant) that through its effect deters, incapacitates, kills or otherwise discourages pests. Target pests can include insects, plant path- ogens, weeds, mollusks, birds, mammals, fish, nematodes (roundworms), and microbes that destroy property, cause nuisance, spread disease or are vectors for disease. The term "pesticide" includes also plant growth regulators that alter the expected growth, flowering, or reproduction rate of plants; defoliants that cause leaves or other foliage to drop from a plant, usually to facilitate harvest; desiccants that promote drying of living tissues, such as unwanted plant tops; plant activators that activate plant physiology for defense of against certain pests; safeners that reduce unwanted herbicidal action of pesticides on crop plants; and plant growth promoters that affect plant physiology e.g. to increase plant growth, biomass, yield or any other quality parameter of the harvestable goods of a crop plant.

The user applies the composition according to the invention usually from a predosage device, a knapsack sprayer, a spray tank, a spray plane, or an irrigation system. Usually, the agrochemical composition is made up with water, buffer, and/or further auxiliaries to the desired applica- tion concentration and the ready-to-use spray liquor or the agrochemical composition according to the invention is thus obtained. Usually, 20 to 2000 liters, preferably 50 to 400 liters, of the ready-to-use spray liquor are applied per hectare of agricultural useful area.

According to one embodiment, individual components of the composition according to the invention such as parts of a kit or parts of a binary or ternary mixture may be mixed by the user himself in a spray tank or any other kind of vessel used for applications (e. g. seed treater drums, seed pelleting machinery, knapsack sprayer) and further auxiliaries may be added, if appropriate.

Consequently, one embodiment of the invention is a kit for preparing a usable pesticidal composition, the kit comprising a) a composition comprising component 1 ) as defined herein and at least one auxiliary; and b) a composition comprising component 2) as defined herein and at least one auxiliary; and optionally c) a composition comprising at least one auxiliary and optionally a further active component 3) as defined herein.

Mixing the compounds I or the compositions comprising them in the use form as fungicides with other fungicides results in many cases in an expansion of the fungicidal spectrum of activity being obtained or in a prevention of fungicide resistance development. Furthermore, in many cases, synergistic effects are obtained.

The following list of pesticides II (e. g. pesticidally-active substances and biopesticides), in conjunction with which the compounds I can be used, is intended to illustrate the possible combinations but does not limit them:

A) Respiration inhibitors

Inhibitors of complex III at Q₀ site: azoxystrobin (A.1 .1 ), coumethoxystrobin (A.1.2), coumoxystrobin (A.1 .3), dimoxystrobin (A.1.4), enestroburin (A.1.5), fenaminstrobin (A.1 .6), fenoxystrobin/flufenoxystrobin (A.1.7), fluoxastrobin (A.1 .8), kresoxim-methyl (A.1 .9), man- destrobin (A.1 .10), metominostrobin (A.1 .1 1 ), orysastrobin (A.1 .12), picoxystrobin (A.1.13), pyraclostrobin (A.1.14), pyrametostrobin (A.1.15), pyraoxystrobin (A.1.16), trifloxystrobin

(A.1 .17), 2-(2-(3-(2,6-dichlorophenyl)-1-methyl-allylideneaminooxymethyl)-phenyl)- 2-methoxyimino-N-methyl-acetamide (A.1 .18), pyribencarb (A.1.19), triclopyricarb/chloro- dincarb (A.1.20), famoxadone (A.1 .21 ), fenamidone (A.1.21 ), methyl-/V-[2-[(1 ,4-dimethyl- 5-phenyl-pyrazol-3-yl)oxylmethyl]phenyl]-N-methoxy-carbamate (A.1 .22), 1-[2-[[1 -(4- chlorophenyl)pyrazol-3-yl]oxymethyl]-3-methyl-phenyl]-4-methyl-tetrazol-5-one (A.1.25),

( ;2£^:)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]-oxy-2-methoxyimino-/V,3-dimethyl-pent-3- enamide (A.1 .34), (Z;2£)-5-[1-(4-chlorophenyl)pyrazol-3-yl]oxy-2-methoxyimino-/V,3- dimethyl-pent-3-enamide (A.1.35), pyriminostrobin (A.1.36), bifujunzhi (A.1 .37), 2-(ortho- ((2,5-dimethylphenyl-oxymethylen)phenyl)-3-methoxy-acrylic acid methylester (A.1 .38); - inhibitors of complex III at Q, site: cyazofamid (A.2.1 ), amisulbrom (A.2.2),

[(6S,7R,8R)-8-benzyl-3-[(3-hydroxy-4-methoxy-pyridine-2-carbonyl)amino]-6-methyl-4,9-di- oxo-1 ,5-dioxonan-7-yl] 2-methylpropanoate (A.2.3 fenpicoxamid (A.2.4);

- inhibitors of complex II: benodanil (A.3.1 ), benzovindiflupyr (A.3.2), bixafen (A.3.3), boscalid (A.3.4), carboxin (A.3.5), fenfuram (A.3.6), fluopyram (A.3.7), flutolanil (A.3.8), fluxapyroxad (A.3.9), furametpyr (A.3.10), isofetamid (A.3.1 1 ), isopyrazam (A.3.12), mepronil (A.3.13), ox- ycarboxin (A.3.14), penflufen (A.3.15), penthiopyrad (A.3.16), pydiflumetofen (A.3.17), pyra- ziflumid (A.3.18), sedaxane (A.3.19), tecloftalam (A.3.20), thifluzamide (A.3.21 ), inpyrfluxam (A.3.22), /V-[(22)-2-[3-chloro-5-(2-cyclopropylethynyl)-2-pyridyl]-2-isopropoxyimino-ethyl]-3- (difluoromethyl)-1 -methyl-pyrazole-4-carboxamide (A.3.23), fluindapyr (A.3.28), methyl (E)-2- [2-[(5-cyano-2-methyl-phenoxy)methyl]phenyl]-3-methoxy-prop-2-enoate (A.3.30), isoflu- cypram (A.3.31 ), 2-(difluoromethyl)-N-(1 ,1 ,3-trimethyl-indan-4-yl)pyridine-3-carboxamide (A.3.32), 2-(difluoromethyl)-N-[(3R)-1 ,1 ,3-trimethylindan-4-yl]pyridine-3-carboxamide

(A.3.33), 2-(difluoromethyl)-N-(3-ethyl-1 ,1-dimethyl-indan-4-yl)pyridine-3-carboxamide (A.3.34), 2-(difluoromethyl)-N-[(3R)-3-ethyl-1 ,1-dimethyl-indan-4-yl]pyridine-3-carboxamide (A.3.35), 2-(difluoromethyl)-N-(1 ,1 -dimethyl-3-propyl-indan-4-yl)pyridine-3-carboxamide (A.3.36), 2-(difluoromethyl)-N-[(3R)-1 ,1 -dimethyl-3-propyl-indan-4-yl]pyridine-3-carboxamide (A.3.37), 2-(difluoromethyl)-N-(3-isobutyl-1 ,1-dimethyl-indan-4-yl)pyridine-3-carboxamide (A.3.38), 2-(difluoromethyl)-N-[(3R)-3-isobutyl-1 ,1-dimethyl-indan-4-yl]pyridine-3- carboxamide (A.3.39);

- other respiration inhibitors: diflumetorim (A.4.1 ); nitrophenyl derivates: binapacryl (A.4.2), dinobuton (A.4.3), dinocap (A.4.4), fluazinam (A.4.5), meptyldinocap (A.4.6), ferimzone

(A.4.7); organometal compounds: fentin salts, e. g. fentin-acetate (A.4.8), fentin chloride (A.4.9) or fentin hydroxide (A.4.10); ametoctradin (A.4.1 1 ); silthiofam (A.4.12);

B) Sterol biosynthesis inhibitors (SBI fungicides)

- C14 demethylase inhibitors: triazoles: azaconazole (B.1.1 ), bitertanol (B.1.2), bromu- conazole (B.1.3), cyproconazole (B.1.4), difenoconazole (B.1.5), diniconazole (B.1.6), dini- conazole-M (B.1.7), epoxiconazole (B.1 .8), fenbuconazole (B.1 .9), fluquinconazole (B.1.10), flusilazole (B.1.1 1 ), flutriafol (B.1.12), hexaconazole (B.1.13), imibenconazole (B.1 .14), ip- conazole (B.1.15), metconazole (B.1.17), myclobutanil (B.1.18), oxpoconazole (B.1 .19), paclobutrazole (B.1.20), penconazole (B.1.21 ), propiconazole (B.1.22), prothioconazole (B.1.23), simeconazole (B.1 .24), tebuconazole (B.1.25), tetraconazole (B.1.26), triadimefon (B.1.27), triadimenol (B.1 .28), triticonazole (B.1.29), uniconazole (B.1.30), 2-(2,4- difluorophenyl)-1 ,1 -difluoro-3-(tetrazol-1-yl)-1 -[5-[4-(2,2,2-trifluoroethoxy)phenyl]- 2-pyridyl]propan-2-ol (B.1.31 ), 2-(2,4-difluorophenyl)-1 ,1-difluoro-3-(tetrazol-1 -yl)- 1 -[5-[4-(trifluoromethoxy)phenyl]-2-pyridyl]propan-2-ol (B.1.32), ipfentrifluconazole (B.1 .37), mefentrifluconazole (B.1.38),2-(chloromethyl)-2-methyl-5-(p-tolylmethyl)-1 -(1 ,2,4-triazol-1- ylmethyl)cyclopentanol (B.1.43); imidazoles: imazalil (B.1.44), pefurazoate (B.1 .45), prochlo- raz (B.1 .46), triflumizol (B.1.47); pyrimidines, pyridines and piperazines: fenarimol (B.1.49), pyrifenox (B.1 .50), triforine (B.1 .51 ), [3-(4-chloro-2-fluoro-phenyl)-5-(2,4-di- fluorophenyl)isoxazol-4-yl]-(3-pyridyl)methanol (B.1 .52);

- Delta 14-reductase inhibitors: aldimorph (B.2.1 ), dodemorph (B.2.2), dodemorph-acetate

(B.2.3), fenpropimorph (B.2.4), tridemorph (B.2.5), fenpropidin (B.2.6), piperalin (B.2.7), spi- roxamine (B.2.8); - Inhibitors of 3-keto reductase: fenhexamid (B.3.1 );

- Other Sterol biosynthesis inhibitors: chlorphenomizole (B.4.1 );

C) Nucleic acid synthesis inhibitors

- phenylamides or acyl amino acid fungicides: benalaxyl (C.1.1 ), benalaxyl-M (C.1 .2), kiralaxyl (C.1 .3), metalaxyl (C.1 .4), metalaxyl-M (C.1 .5), ofurace (C.1 .6), oxadixyl (C.1 .7);

- other nucleic acid synthesis inhibitors: hymexazole (C.2.1 ), octhilinone (C.2.2), oxolinic acid (C.2.3), bupirimate (C.2.4), 5-fluorocytosine (C.2.5), 5-fluoro-2-(p-tolylmethoxy)pyrimidin- 4-amine (C.2.6), 5-fluoro-2-(4-fluorophenylmethoxy)pyrimidin-4-amine (C.2.7), 5-fluoro- 2-(4-chlorophenylmethoxy)pyrimidin-4 amine (C.2.8);

D) Inhibitors of cell division and cytoskeleton

- tubulin inhibitors: benomyl (D.1 .1 ), carbendazim (D.1 .2), fuberidazole (D1.3), thiabendazole (D.1 .4), thiophanate-methyl (D.1 .5), 3-chloro-4-(2,6-difluorophenyl)-6-methyl-5-phenyl-pyri- dazine (D.1 .6), 3-chloro-6-methyl-5-phenyl-4-(2,4,6-trifluorophenyl)pyridazine (D.1 .7), N-eth- yl-2-[(3-ethynyl-8-methyl-6-quinolyl)oxy]butanamide (D.1.8), N-ethyl-2-[(3-ethynyl-8-methyl- 6-quinolyl)oxy]-2-methylsulfanyl-acetamide (D.1 .9), 2-[(3-ethynyl-8-methyl-6-quinolyl)oxy]- N-(2-fluoroethyl)butanamide (D.1 .10), 2-[(3-ethynyl-8-methyl-6-quinolyl)oxy]-N-(2-fluoroeth- yl)-2-methoxy-acetamide (D.1 .1 1 ), 2-[(3-ethynyl-8-methyl-6-quinolyl)oxy]-N-propyl-butanam- ide (D.1 .12), 2-[(3-ethynyl-8-methyl-6-quinolyl)oxy]-2-methoxy-N-propyl-acetamide (D.1.13), 2-[(3-ethynyl-8-methyl-6-quinolyl)oxy]-2-methylsulfanyl-N-propyl-acetamide (D.1.14), 2-[(3-ethynyl-8-methyl-6-quinolyl)oxy]-N-(2-fluoroethyl)-2-methylsulfanyl-acetamide (D.1.15), 4-(2-bromo-4-fluoro-phenyl)-N-(2-chloro-6-fluoro-phenyl)-2,5-dimethyl-pyrazol-3-amine (D.1 .16);

- other cell division inhibitors: diethofencarb (D.2.1 ), ethaboxam (D.2.2), pencycuron (D.2.3), fluopicolide (D.2.4), zoxamide (D.2.5), metrafenone (D.2.6), pyriofenone (D.2.7);

E) Inhibitors of amino acid and protein synthesis

- methionine synthesis inhibitors: cyprodinil (E.1 .1 ), mepanipyrim (E.1.2), pyrimethanil (E.1.3);

- protein synthesis inhibitors: blasticidin-S (E.2.1 ), kasugamycin (E.2.2), kasugamycin hydro- chloride-hydrate (E.2.3), mildiomycin (E.2.4), streptomycin (E.2.5), oxytetracyclin (E.2.6);

F) Signal transduction inhibitors

- MAP / histidine kinase inhibitors: fluoroimid (F.1.1 ), iprodione (F.1.2), procymidone (F.1 .3), vinclozolin (F.1 .4), fludioxonil (F.1 .5);

- G protein inhibitors: quinoxyfen (F.2.1 );

G) Lipid and membrane synthesis inhibitors

- Phospholipid biosynthesis inhibitors: edifenphos (G.1.1 ), iprobenfos (G.1 .2), pyrazophos (G.1.3), isoprothiolane (G.1.4);

- lipid peroxidation: dicloran (G.2.1 ), quintozene (G.2.2), tecnazene (G.2.3), tolclofos-methyl (G.2.4), biphenyl (G.2.5), chloroneb (G.2.6), etridiazole (G.2.7);

- phospholipid biosynthesis and cell wall deposition: dimethomorph (G.3.1 ), flumorph (G.3.2), mandipropamid (G.3.3), pyrimorph (G.3.4), benthiavalicarb (G.3.5), iprovalicarb (G.3.6), valifenalate (G.3.7);

- compounds affecting cell membrane permeability and fatty acides: propamocarb (G.4.1 );

- inhibitors of oxysterol binding protein: oxathiapiprolin (G.5.1 ), 2-{3-[2-(1 -{[3,5-bis(difluoro- methyl-1 H-pyrazol-1 -yl]acetyl}piperidin-4-yl)-1 ,3-thiazol-4-yl]-4,5-dihydro-1 ,2-oxazol-5-yl}- phenyl methanesulfonate (G.5.2), 2-{3-[2-(1 -{[3, 5-bis(difluoromethyl)-1 H-pyrazol-1 -yl]- acetyl}piperidin-4-yl) 1 ,3-thiazol-4-yl]-4,5-dihydro-1 ,2-oxazol-5-yl}-3-chlorophenyl methanesulfonate (G.5.3), 4-[1-[2-[3-(difluoromethyl)-5-methyl-pyrazol-1-yl]acetyl]-4-piperidyl]-N-te- tralin-1-yl-pyridine-2-carboxamide (G.5.4), 4-[1-[2-[3,5-bis(difluoromethyl)pyrazol-1 -yl]acetyl]- 4-piperidyl]-N-tetralin-1-yl-pyridine-2-carboxamide (G.5.5), 4-[1 -[2-[3-(difluoromethyl)-5-(tri- fluoromethyl)pyrazol-1 -yl]acetyl]-4-piperidyl]-N-tetralin-1-yl-pyridine-2-carboxamide (G.5.6), 4-[1-[2-[5-cyclopropyl-3-(difluoromethyl)pyrazol-1 -yl]acetyl]-4-piperidyl]-N-tetralin-1 -yl- pyridine-2-carboxamide (G.5.7), 4-[1 -[2-[5-methyl-3-(trifluoromethyl)pyrazol-1-yl]acetyl]-4-pi- peridyl]-N-tetralin-1 -yl-pyridine-2-carboxamide (G.5.8), 4-[1 -[2-[5-(difluoromethyl)-3-(trifluoro- methyl)pyrazol-1-yl]acetyl]-4-piperidyl]-N-tetralin-1 -yl-pyridine-2-carboxamide (G.5.9),

4-[1-[2-[3,5-bis(trifluoromethyl)pyrazol-1-yl]acetyl]-4-piperidyl]-N-tetralin-1-yl-pyridine-2-car- boxamide (G.5.10), (4-[1 -[2-[5-cyclopropyl-3-(trifluoromethyl)pyrazol-1-yl]acetyl]-4-piperidyl]- N-tetralin-1 -yl-pyridine-2-carboxamide (G.5.1 1 );

H) Inhibitors with Multi Site Action

- inorganic active substances: Bordeaux mixture (H.1 .1 ), copper (H.1 .2), copper acetate

(H.1 .3), copper hydroxide (H.1 .4), copper oxychloride (H.1.5), basic copper sulfate (H.1.6), sulfur (H.1 .7);

- thio- and dithiocarbamates: ferbam (H.2.1 ), mancozeb (H.2.2), maneb (H.2.3), metam

(H.2.4), metiram (H.2.5), propineb (H.2.6), thiram (H.2.7), zineb (H.2.8), ziram (H.2.9);

- organochlorine compounds: anilazine (H.3.1 ), chlorothalonil (H.3.2), captafol (H.3.3), captan (H.3.4), folpet (H.3.5), dichlofluanid (H.3.6), dichlorophen (H.3.7), hexachlorobenzene (H.3.8), pentachlorphenole (H.3.9) and its salts, phthalide (H.3.10), tolylfluanid (H.3.1 1 );

- guanidines and others: guanidine (H.4.1 ), dodine (H.4.2), dodine free base (H.4.3),

guazatine (H.4.4), guazatine-acetate (H.4.5), iminoctadine (H.4.6), iminoctadine-triacetate (H.4.7), iminoctadine-tris(albesilate) (H.4.8), dithianon (H.4.9), 2,6-dimethyl-1 H,5H- [1 ,4]dithiino[2,3-c:5,6-c']dipyrrole-1 ,3,5,7(2H,6H)-tetraone (H.4.10);

I) Cell wall synthesis inhibitors

- inhibitors of glucan synthesis: validamycin (1.1 .1 ), polyoxin B (1.1.2);

- melanin synthesis inhibitors: pyroquilon (1.2.1 ), tricyclazole (1.2.2), carpropamid (I.2.3), dicy- clomet (I.2.4), fenoxanil (I.2.5);

J) Plant defence inducers

- acibenzolar-S-methyl (J.1 .1 ), probenazole (J.1.2), isotianil (J.1.3), tiadinil (J.1.4), prohexadi- one-calcium (J.1.5); phosphonates: fosetyl (J.1.6), fosetyl-aluminum (J.1 .7), phosphorous acid and its salts (J.1 .8), potassium or sodium bicarbonate (J.1.9), 4-cyclopropyl-N-(2,4- dimethoxyphenyl)thiadiazole-5-carboxamide (J.1 .10); K) Unknown mode of action

- bronopol (K.1.1 ), chinomethionat (K.1 .2), cyflufenamid (K.1 .3), cymoxanil (K.1 .4), dazomet (K.1.5), debacarb (K.1.6), diclocymet (K.1.7), diclomezine (K.1 .8), difenzoquat (K.1 .9), di- fenzoquat-methylsulfate (K.1.10), diphenylamin (K.1 .1 1 ), fenitropan (K.1.12), fenpyrazamine (K.1.13), flumetover (K.1.14), flusulfamide (K.1 .15), flutianil (K.1.16), harpin (K.1 .17), metha- sulfocarb (K.1 .18), nitrapyrin (K.1.19), nitrothal-isopropyl (K.1.20), tolprocarb (K.1.21 ), oxin- copper (K.1.22), proquinazid (K.1.23), tebufloquin (K.1.24), tecloftalam (K.1 .25), triazoxide (K.1.26), N'-(4-(4-chloro-3-trifluoromethyl-phenoxy)-2,5-dimethyl-phenyl)-N-ethyl-N-methyl formamidine (K.1.27), N'-(4-(4-fluoro-3-trifluoromethyl-phenoxy)-2,5-dimethyl-phenyl)-N-eth- yl-N-methyl formamidine (K.1 .28), N'-[4-[[3-[(4-chlorophenyl)methyl]-1 ,2,4-thiadiazol-5-yl]- oxy]-2,5-dimethyl-phenyl]-N-ethyl-N-methyl-formamidine (K.1.29), N'-(5-bromo-6-indan-2-yl- oxy-2-methyl-3-pyridyl)-N-ethyl-N-methyl-formamidine (K.1.30), N'-[5-bromo-6-[1 -(3,5-diflu- orophenyl)ethoxy]-2-methyl-3-pyridyl]-N-ethyl-N-methyl-formamidine (K.1 .31 ), N'-[5-bromo- 6-(4-isopropylcyclohexoxy)-2-methyl-3-pyridyl]-N-ethyl-N-methyl-formamidine (K.1.32), N'-[5-bromo-2-methyl-6-(1-phenylethoxy)-3-pyridyl]-N-ethyl-N-methyl-formamidine (K.1.33), N'-(2-methyl-5-trifluoromethyl-4-(3-trimethylsilanyl-propoxy)-phenyl)-N-ethyl-N-methyl formamidine (K.1.34), N'-(5-difluoromethyl-2-methyl-4-(3-trimethylsilanyl-propoxy)-phenyl)-N-ethyl- N-methyl formamidine (K.1.35), 2-(4-chloro-phenyl)-N-[4-(3,4-dimethoxy-phenyl)-isoxazol- 5-yl]-2-prop-2-ynyloxy-acetamide (K.1 .36), 3-[5-(4-chloro-phenyl)-2,3-dimethyl-isoxazolidin- 3-yl]-pyridine (pyrisoxazole) (K.1 .37), 3-[5-(4-methylphenyl)-2,3-dimethyl-isoxazolidin-3 yl]- pyridine (K.1.38), 5-chloro-1 -(4,6-dimethoxy-pyrimidin-2-yl)-2-methyl-1 H-benzoimidazole (K.1.39), ethyl (Z)-3-amino-2-cyano-3-phenyl-prop-2-enoate (K.1 .40), picarbutrazox (K.1.41 ), pentyl N-[6-[[(Z)-[(1 -methyltetrazol-5-yl)-phenyl-methylene]amino]oxymethyl]-2-pyridyl]carba- mate (K.1 .42), but-3-ynyl N-[6-[[(Z)-[(1-methyltetrazol-5-yl)-phenyl-methylene]amino]oxy- methyl]-2-pyridyl]carbamate (K.1.43), 2-[2-[(7,8-difluoro-2-methyl-3-quinolyl)oxy]-6-fluoro- phenyl]propan-2-ol (K.1 .44), 2-[2-fluoro-6-[(8-fluoro-2-methyl-3-quinolyl)oxy]phen-yl]propan- 2-ol (K.1.45), quinofumelin (K.1 .47), 9-fluoro-2,2-dimethyl-5-(3-quinolyl)- 3H-1 ,4-benzoxazepine (K.1 .49), 2-(6-benzyl-2-pyridyl)quinazoline (K.1.50), 2-[6-(3-fluoro- 4-methoxy-phenyl)-5-methyl-2-pyridyl]quinazoline (K.1.51 ), 3-[(3,4-dichloroisothiazol- 5-yl)methoxy]-1 ,2-benzothiazole 1 ,1 -dioxide (K.1 .52), N'-(2,5-dimethyl-4-phenoxy-phenyl)-N- ethyl-N-methyl-formamidine (K.1 .53), pyrifenamine (K.1.54);

M) Growth regulators

abscisic acid (M.1.1 ), amidochlor, ancymidol, 6-benzylaminopurine, brassinolide, butralin, chlormequat, chlormequat chloride, choline chloride, cyclanilide, daminozide, dikegulac, dime- thipin, 2,6-dimethylpuridine, ethephon, flumetralin, flurprimidol, fluthiacet, forchlorfenuron, gib- berellic acid, inabenfide, indole-3-acetic acid , maleic hydrazide, mefluidide, mepiquat, mepiquat chloride, naphthaleneacetic acid, N-6-benzyladenine, paclobutrazol, prohexadione, prohexadi- one-calcium, prohydrojasmon, thidiazuron, triapenthenol, tributyl phosphorotrithioate,

2,3,5-tri-iodobenzoic acid , trinexapac-ethyl and uniconazole;

N) Herbicides from classes N.1 to N.15

N.1 Lipid biosynthesis inhibitors: alloxydim, alloxydim-sodium, butroxydim, clethodim,

clodinafop, clodinafop-propargyl, cycloxydim, cyhalofop, cyhalofop-butyl, diclofop, diclofop- methyl, fenoxaprop, fenoxaprop-ethyl, fenoxaprop-P, fenoxaprop-P-ethyl, fluazifop, fluazifop- butyl, fluazifop-P, fluazifop-P-butyl, haloxyfop, haloxyfop-methyl, haloxyfop-P, haloxyfop-P- methyl, metamifop, pinoxaden, profoxydim, propaquizafop, quizalofop, quizalofop-ethyl, quizalofop-tefuryl, quizalofop-P, quizalofop-P-ethyl, quizalofop-P-tefuryl, sethoxydim, tepra- loxydim, tralkoxydim, 4-(4'-chloro-4-cyclo^-,propyl-2'-fluoro[1 ,1 '-biphenyl]-3-yl)-5-hydroxy- 2,2,6,6-tetramethyl-2H-pyran-3(6H)-one (CAS 1312337-72-6); 4-(2',4'-dichloro-4- cyclopropyl[1 ,1 '-biphenyl]-3-yl)-5-hydroxy-2,2,6,6-tetramethyl-2H-pyran-3(6H)-one (CAS 1312337-45-3); 4-(4'-chloro-4-ethyl-2'-fluoro[1 ,1 '-biphenyl]-3-yl)-5-hydroxy-2,2,6,6- tetramethyl-2H-pyran-3(6H)-one (CAS 1033757-93-5); 4-(2',4'-Dichloro-4-ethyl[1 ,1 '- biphenyl]-3-yl)-2,2,6,6-tetramethyl-2H-pyran-3,5(4H,6H)-dione (CAS 1312340-84-3); 5- (acetyloxy)-4-(4'-chloro-4-cyclopropyl-2'-fluoro[1 ,1 '-biphenyl]-3-yl)-3,6-dihydro-2,2,6,6- tetramethyl-2H-pyran-3-one (CAS 1312337-48-6); 5-(acetyloxy)-4-(2^',4'-dichloro-4- cyclopropyl- [1 ,1 '-biphenyl]-3-yl)-3,6-dihydro-2,2,6,6-tetramethyl-2H-pyran-3-one; 5- (acetyloxy)-4-(4'-chloro-4-ethyl-2'-fluoro[1 ,1 '-biphenyl]-3-yl)-3,6-dihydro-2,2,6,6-tetramethyl- 2H-pyran-3-one (CAS 1312340-82-1 ); 5-(acetyloxy)-4-(2',4'-dichloro-4-ethyl[1 ,1 '-biphenyl]-3- yl)-3,6-dihydro-2,2,6,6-tetramethyl-2H-pyran-3-one (CAS 1033760-55-2); 4-(4'-chloro-4- cyclopropyl-2'-fluoro[1 ,1 '-biphenyl]-3-yl)-5,6-dihydro-2,2,6,6-tetramethyl-5-oxo-2H-pyran-3-yl carbonic acid methyl ester (CAS 1312337-51 -1 ); 4-(2^',4'-dichloro -4-cyclopropyl- [1 ,1 '- biphenyl]-3-yl)-5,6-dihydro-2,2,6,6-tetramethyl-5-oxo-2H-pyran-3-yl carbonic acid methyl es- ter; 4-(4'-chloro-4-ethyl-2'-fluoro[1 ,1 '-biphenyl]-3-yl)-5,6-dihydro-2,2,6,6-tetramethyl-5-oxo-

2H-pyran-3-yl carbonic acid methyl ester (CAS 1312340-83-2); 4-(2',4'-dichloro-4-ethyh[1 ,1 '- biphenyl]-3-yl)-5,6-dihydro-2,2,6,6-tetramethyl-5-oxo-2H-pyran-3-yl carbonic acid methyl ester (CAS 1033760-58-5); benfuresate, butylate, cycloate, dalapon, dimepiperate, EPTC, esprocarb, ethofumesate, flupropanate, molinate, orbencarb, pebulate, prosulfocarb, TCA, thiobencarb, tiocarbazil, triallate and vernolate;

ALS inhibitors: amidosulfuron, azimsulfuron, bensulfuron, bensulfuron-methyl, chlorimuron, chlorimuron-ethyl, chlorsulfuron, cinosulfuron, cyclosulfamuron, ethametsulfuron, ethamet- sulfuron-methyl, ethoxysulfuron, flazasulfuron, flucetosulfuron, flupyrsulfuron, flupyrsulfuron- methyl-sodium, foramsulfuron, halosulfuron, halosulfuron-methyl, imazosulfuron, iodosulfu- ron, iodosulfuron-methyl-sodium, iofensulfuron, iofensulfuron-sodium, mesosulfuron, met- azosulfuron, metsulfuron, metsulfuron-methyl, nicosulfuron, orthosulfamuron, oxasulfuron, primisulfuron, primisulfuron-methyl, propyrisulfuron, prosulfuron, pyrazosulfuron, pyrazosul- furon-ethyl, rimsulfuron, sulfometuron, sulfometuron-methyl, sulfosulfuron, thifensulfuron, thifensulfuron-methyl, triasulfuron, tribenuron, tribenuron-methyl, trifloxysulfuron, triflusulfu- ron, triflusulfuron-methyl, tritosulfuron, imazamethabenz, imazamethabenz-methyl, imaza- mox, imazapic, imazapyr, imazaquin, imazethapyr; cloransulam, cloransulam-methyl, di- closulam, flumetsulam, florasulam, metosulam, penoxsulam, pyrimisulfan and pyroxsulam; bispyribac, bispyribac-sodium, pyribenzoxim, pyriftalid, pyriminobac, pyriminobac-methyl, py- rithiobac, pyrithiobac-sodium, 4-[[[2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]phenyl]methyl]amino]- benzoic acid-1-methyhethyl ester (CAS 420138-41 -6), 4-[[[2-[(4,6-dimethoxy-2- pyrimidinyl)oxy]phenyl]-"methyl]amino]-benzoic acid propyl ester (CAS 420138-40-5), N-(4- bromophenyl)-2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]benzenemethanamine (CAS 420138-01 - 8); flucarbazone, flucarbazone-sodium, propoxycarbazone, propoxycarbazone-sodium, thiencarbazone, thiencarbazone-methyl; triafamone; N.3 Photosynthesis inhibitors: amicarbazone; chlorotriazine; ametryn, atrazine, chloridazone, cyanazine, desmetryn, dimethametryn,hexazinone, metribuzin, prometon, prometryn, pro- pazine, simazine, simetryn, terbumeton, terbuthylazin, terbutryn, trietazin; chlorobromuron, chlorotoluron, chloroxuron, dimefuron, diuron, fluometuron, isoproturon, isouron, linuron, metamitron, methabenzthiazuron, metobenzuron, metoxuron, monolinuron, neburon, sidu- ron, tebuthiuron, thiadiazuron, desmedipham, karbutilat, phenmedipham, phenmedipham- ethyl, bromofenoxim, bromoxynil and its salts and esters, ioxynil and its salts and esters, bromacil, lenacil, terbacil, bentazon, bentazon-sodium, pyridate, pyridafol, pentanochlor, propanil; diquat, diquat-dibromide, paraquat, paraquat-dichloride, paraquat-dimetilsulfate; N.4 protoporphyrinogen-IX oxidase inhibitors: acifluorfen, acifluorfen-sodium, azafenidin, ben- carbazone, benzfendizone, bifenox, butafenacil, carfentrazone, carfentrazone-ethyl, chlor- methoxyfen, cinidon-ethyl, fluazolate, flufenpyr, flufenpyr-ethyl, flumiclorac, flumiclorac- pentyl, flumioxazin, fluoroglycofen, fluoroglycofen-ethyl, fluthiacet, fluthiacet-methyl, fome- safen, halosafen, lactofen, oxadiargyl, oxadiazon, oxyfluorfen, pentoxazone, profluazol, py- raclonil, pyraflufen, pyraflufen-ethyl, saflufenacil, sulfentrazone, thidiazimin, tiafenacil, triflu- dimoxazin, ethyl [3-[2-chloro-4-fluoro-5-(1-methyl-6-trifluoromethyl-2,4-dioxo-1 ,2,3,4-te- trahydropyrimidin-3-yl)phenoxy]-2-pyridyloxy]acetate (CAS 353292-31-6), N-ethyl-3-(2,6-di- chloro-4-trifluoro-methylphenoxy)-5-methyl-1 H-pyrazole-1 -carboxamide (CAS 452098-92-9), N tetrahydrofurfuryl-3-(2,6-dichloro-4-trifluoromethylphenoxy)-5-methyl-1 H-pyrazole-1 -car- boxamide (CAS 915396-43-9), N-ethyl-3-(2-chloro-6-fluoro-4-trifluoromethyhphenoxy)-

5- methyl-1 H-pyrazole-1 -carboxamide (CAS 452099-05-7), N tetrahydro->furfuryl-3-(2-chloro-

6- fluoro-4-trifluoro^-,methylphenoxy)-5-methyl-1 H-pyrazole-1 -carboxamide (CAS 452100-03- 7), 3-[7-fluoro-3-oxo-4-(prop-2-ynyl)-3,4-dihydro-2H-benzo[1 ,4]oxazin-6-yl]-1 ,5-dimethyl- 6-thioxo-[1 ,3,5]triazinan-2,4-dione (CAS 451484-50-7), 2-(2,2,7-trifluoro-3-oxo-4-prop-2-ynyl- 3,4-dihydro-2H-benzo[1 ,4]oxazin-6-yl)-4,5,6,7-tetrahydro-isoindole-1 ,3-dione (CAS 13001 18- 96-0), 1-methyl-6-trifluoro-"methyl-3-(2,2,7-tri-fluoro-3-oxo-4-prop-2-ynyl-3,4-dihydro-2H-ben- zo[1 ,4]oxazin-6-yl)-1 H-pyrimidine-2,4-dione (CAS 13041 13-05-0), methyl (E)-4-[2-chloro- 5-[4-chloro-5-(difluoromethoxy)-1 H-methyl-pyrazol-3-yl]-4-fluoro-phenoxy]-3-methoxy-but- 2-enoate (CAS 948893-00-3), 3-[7-chloro-5-fluoro-2-(trifluoromethyl)-1 H-benzimidazol-4-yl]- 1 -methyl-6-(trifluoromethyl)-1 H-pyrimidine-2,4-dione (CAS 212754-02-4);

N.5 Bleacher herbicides: beflubutamid, diflufenican, fluridone, flurochloridone, flurtamone,

norflurazon, picolinafen, 4-(3-trifluoromethyhphenoxy)-2-(4-trifluoromethylphen- yl)-"pyrimidine (CAS 180608-33-7); benzobicyclon, benzofenap, bicyclopyrone, clomazone, fenquintrione, isoxaflutole, mesotrione, pyrasulfotole, pyrazolynate, pyrazoxyfen, sulcotrione, tefuryltrione, tembotrione, tolpyralate, topramezone; aclonifen, amitrole, flumeturon;

N.6 EPSP synthase inhibitors: glyphosate, glyphosate-isopropylammonium, glyposate- potassium, glyphosate-trimesium (sulfosate);

N.7 Glutamine synthase inhibitors: bilanaphos (bialaphos), bilanaphos-sodium, glufosinate, glufosinate-P, glufosinate-ammonium;

N.8 DHP synthase inhibitors: asulam;

N.9 Mitosis inhibitors: benfluralin, butralin, dinitramine, ethalfluralin, fluchloralin, oryzalin,

pendimethalin, prodiamine, trifluralin; amiprophos, amiprophos-methyl, butamiphos; chlor- thai, chlorthal-dimethyl, dithiopyr, thiazopyr, propyzamide, tebutam; carbetamide, chlorprop- ham, flamprop, flamprop-isopropyl, flamprop-methyl, flamprop-M-isopropyl, flamprop-M- methyl, propham;

N.10 VLCFA inhibitors: acetochlor, alachlor, butachlor, dimethachlor, dimethenamid, dimethen- amid-P, metazachlor, metolachlor, metolachlor-S, pethoxamid, pretilachlor, propachlor, prop- isochlor, thenylchlor, flufenacet, mefenacet, diphenamid, naproanilide, napropamide, napro- pamide-M, fentrazamide, anilofos, cafenstrole, fenoxasulfone, ipfencarbazone, piperophos, pyroxasulfone, isoxazoline compounds of the formulae 11.1 , II.2, II.3, II.4, II.5, II.6, II.7, II.8 and II.9

N.1 1 Cellulose biosynthesis inhibitors: chlorthiamid, dichlobenil, flupoxam, indaziflam, isoxaben, triaziflam, 1 -cyclohexyl-5-pentafluorphenyloxy-14-[1 ,2,4,6]thiatriazin-3-ylamine (CAS

175899-01-1 );

N.12 Decoupler herbicides: dinoseb, dinoterb, DNOC and its salts;

N.13 Auxinic herbicides: 2,4-D and its salts and esters, clacyfos, 2,4-DB and its salts and esters, aminocyclopyrachlor and its salts and esters, aminopyralid and its salts such as amino- pyralid-dimethylammonium, aminopyralid-tris(2-hydroxypropyl)ammonium and its esters, benazolin, benazolin-ethyl, chloramben and its salts and esters, clomeprop, clopyralid and its salts and esters, dicamba and its salts and esters, dichlorprop and its salts and esters, di- chlorprop-P and its salts and esters, fluroxypyr, fluroxypyr-butometyl, fluroxypyr-meptyl, ha- lauxifen and its salts and esters (CAS 943832-60-8); MCPA and its salts and esters, MCPA- thioethyl, MCPB and its salts and esters, mecoprop and its salts and esters, mecoprop-P and its salts and esters, picloram and its salts and esters, quinclorac, quinmerac, TBA (2,3,6) and its salts and esters, triclopyr and its salts and esters, 4-amino-3-chloro-6-(4- chloro-2-fluoro-3-methoxyphenyl)-5-fluoropyridine-2-carboxylic acid, benzyl 4-amino-3- chloro-6-(4-chloro-2-fluoro-3-methoxyphenyl)-5-fluoropyridine-2-carboxylate (CAS 1390661- 72-9);

N.14 Auxin transport inhibitors: diflufenzopyr, diflufenzopyr-sodium, naptalam and naptalam- sodium;

N.15 Other herbicides: bromobutide, chlorflurenol, chlorflurenol-methyl, cinmethylin, cumyluron, cyclopyrimorate (CAS 499223-49-3) and its salts and esters, dalapon, dazomet, difenzoquat, difenzoquat-metilsulfate, dimethipin, DSMA, dymron, endothal and its salts, etobenzanid, flurenol, flurenol-butyl, flurprimidol, fosamine, fosamine-ammonium, indanofan, maleic hy- drazide, mefluidide, metam, methiozolin (CAS 403640-27-7), methyl azide, methyl bromide, methyl-dymron, methyl iodide, MSMA, oleic acid, oxaziclomefone, pelargonic acid, pyributi- carb, quinoclamine, tridiphane;

O) Insecticides from classes 0.1 to 0.29

0.1 Acetylcholine esterase (AChE) inhibitors: aldicarb, alanycarb, bendiocarb, benfuracarb, butocarboxim, butoxycarboxim, carbaryl, carbofuran, carbosulfan, ethiofencarb, fenobucarb, formetanate, furathiocarb, isoprocarb, methiocarb, methomyl, metolcarb, oxamyl, pirimicarb, propoxur, thiodicarb, thiofanox, trimethacarb, XMC, xylylcarb and triazamate; acephate, aza- methiphos, azinphos-ethyl, azinphosmethyl, cadusafos, chlorethoxyfos, chlorfenvinphos, chlormephos, chlorpyrifos, chlorpyrifos-methyl, coumaphos, cyanophos, demeton-S-methyl, diazinon, dichlorvos/ DDVP, dicrotophos, dimethoate, dimethylvinphos, disulfoton, EPN, ethion, ethoprophos, famphur, fenamiphos, fenitrothion, fenthion, fosthiazate, heptenophos, imicyafos, isofenphos, isopropyl O-(methoxyaminothio-phosphoryl) salicylate, isoxathion, malathion, mecarbam, methamidophos, methidathion, mevinphos, monocrotophos, naled, omethoate, oxydemeton-methyl, parathion, parathion-methyl, phenthoate, phorate, phosa- lone, phosmet, phosphamidon, phoxim, pirimiphos- methyl, profenofos, propetamphos, pro- thiofos, pyraclofos, pyridaphenthion, quinalphos, sulfotep, tebupirimfos, temephos, terbufos, tetrachlorvinphos, thiometon, triazophos, trichlorfon, vamidothion;

0.2 GABA-gated chloride channel antagonists: endosulfan, chlordane; ethiprole, fipronil,

flufiprole, pyrafluprole, pyriprole;

0.3 Sodium channel modulators: acrinathrin, allethrin, d-cis-trans allethrin, d-trans allethrin, bifenthrin, bioallethrin, bioallethrin S-cylclopentenyl, bioresmethrin, cycloprothrin, cyfluthrin, beta-cyfluthrin, cyhalothrin, lambda-cyhalothrin, gamma-cyhalothrin, cypermethrin, alpha- cypermethrin, beta-cypermethrin, theta-cypermethrin, zeta-cypermethrin, cyphenothrin, del- tamethrin, empenthrin, esfenvalerate, etofenprox, fenpropathrin, fenvalerate, flucythrinate, flumethrin, tau-fluvalinate, halfenprox, heptafluthrin, imiprothrin, meperfluthrin, metofluthrin, momfluorothrin, permethrin, phenothrin, prallethrin, profluthrin, pyrethrin (pyrethrum), resmethrin, silafluofen, tefluthrin, tetramethylfluthrin, tetramethrin, tralomethrin and trans- fluthrin; DDT, methoxychlor;

0.4 Nicotinic acetylcholine receptor agonists (nAChR): acetamiprid, clothianidin, cycloxaprid, dinotefuran, imidacloprid, nitenpyram, thiacloprid, thiamethoxam;

4,5-dihydro-/V-nitro-1-(2-oxiranylmethyl)-1 A -imidazol-2-amine, (2£)-1-[(6-chloropyridin-3- y methyl^/V^nitro^-pentylidenehydrazinecarboximidamide; 1-[(6-chloropyridin-3-yl)methyl]- 7-methyl-8-nitro-5-propoxy-1 ,2,3,5,6,7-hexahydroimidazo[1 ,2-a]pyridine; nicotine; sul- foxaflor, flupyradifurone, triflumezopyrim;

0.5 Nicotinic acetylcholine receptor allosteric activators: spinosad, spinetoram;

0.6 Chloride channel activators: abamectin, emamectin benzoate, ivermectin, lepimectin, mil- bemectin;

0.7 Juvenile hormone mimics: hydroprene, kinoprene, methoprene; fenoxycarb, pyriproxyfen;

0.8 miscellaneous non-specific (multi-site) inhibitors: methyl bromide and other alkyl halides; chloropicrin, sulfuryl fluoride, borax, tartar emetic;

0.9 Chordotonal organ TRPV channel modulators: pymetrozine, flonicamid, flonicamid;

O.10 Mite growth inhibitors: clofentezine, hexythiazox, diflovidazin; etoxazole;

0.1 1 Microbial disruptors of insect midgut membranes: Bacillus thuringiensis, Bacillus sphaeri- cus and the insecticdal proteins they produce: Bacillus thuringiensis subsp. israelensis, Bacillus sphaericus, Bacillus thuringiensis subsp. aizawai, Bacillus thuringiensis subsp.

kurstaki, Bacillus thuringiensis subsp. tenebrionis, the Bt crop proteins: CrylAb, CrylAc, Cryl Fa, Cry2Ab, mCry3A, Cry3Ab, Cry3Bb, Cry34/35Ab1 ;

0.12 Inhibitors of mitochondrial ATP synthase: diafenthiuron; azocyclotin, cyhexatin, fenbutatin oxide, propargite, tetradifon;

0.13 Uncouplers of oxidative phosphorylation via disruption of the proton gradient: chlorfenapyr, DNOC, sulfluramid;

0.14 Nicotinic acetylcholine receptor (nAChR) channel blockers: bensultap, cartap hydrochlo- ride, thiocyclam, thiosultap sodium;

0.15 Inhibitors of the chitin biosynthesis type 0: bistrifluron, chlorfluazuron, diflubenzuron, flu- cycloxuron, flufenoxuron, hexaflumuron, lufenuron, novaluron, noviflumuron, teflubenzuron, triflumuron;

0.16 Inhibitors of the chitin biosynthesis type 1 : buprofezin;

0.17 Moulting disruptors: cyromazine;

0.18 Ecdyson receptor agonists: methoxyfenozide, tebufenozide, halofenozide, fufenozide, chromafenozide;

0.19 Octopamin receptor agonists: amitraz; O.20 Mitochondrial complex III electron transport inhibitors: hydramethylnon, acequinocyl, fluacrypyrim, bifenazate;

0.21 Mitochondrial complex I electron transport inhibitors: fenazaquin, fenpyroximate, pyrimidif- en, pyridaben, tebufenpyrad, tolfenpyrad; rotenone;

0.22 Voltage-dependent sodium channel blockers: indoxacarb, metaflumizone, 2-[2-(4-cyano- phenyl)-1-[3-(trifluoromethyl)phenyl]ethylidene]-N-[4-(difluoromethoxy)phenyl]-hydrazine- carboxamide, N-(3-chloro-2-methylphenyl)-2-[(4-chlorophenyl)-[4-[methyl(methylsulfonyl)- amino]phenyl]methylene]-hydrazinecarboxamide;

0.23 Inhibitors of the of acetyl CoA carboxylase: spirodiclofen, spiromesifen, spirotetramat, spi- ropidion;

0.24 Mitochondrial complex IV electron transport inhibitors: aluminium phosphide, calcium

phosphide, phosphine, zinc phosphide, cyanide;

0.25 Mitochondrial complex II electron transport inhibitors: cyenopyrafen, cyflumetofen;

0.26 Ryanodine receptor-modulators: flubendiamide, chlorantraniliprole, cyantraniliprole, cycla- niliprole, tetraniliprole; (R)-3-chloro-N1 -{2-methyl-4-[1 ,2,2,2 -tetrafluoro-l-(trifluoromethyl)- ethyl]phenyl}-N2-(1 -methyl-2-methylsulfonylethyl)phthalamide, (S)-3-chloro-N1-{2-methyl-4- [1 ,2,2,2-tetrafluoro-1 -(trifluoromethyl)ethyl]phenyl}-N2-(1-methyl-2-methylsulfonylethyl)- phthalamide, methyl-2-[3,5-dibromo-2-({[3-bromo-1-(3-chloropyridin-2-yl)-1 H-pyrazol-5-yl]- carbonyl}amino)benzoyl]-1 ,2-dimethylhydrazinecarboxylate; N-[4,6-dichloro-2-[(diethyl- lambda-4-sulfanylidene)carbamoyl]-phenyl]-2-(3-chloro-2-pyridyl)-5-(trifluoromethyl)pyrazole- 3-carboxamide; N-[4-chloro-2-[(diethyl-lambda-4-sulfanylidene)carbamoyl]-6-methyl-phenyl]- 2-(3-chloro-2-pyridyl)-5-(trifluoromethyl)pyrazole-3-carboxamide; N-[4-chloro-2-[(di-2-propyl- lambda-4-sulfanylidene)carbamoyl]-6-methyl-phenyl]-2-(3-chloro-2-pyridyl)-5-(trifluorometh- yl)pyrazole-3-carboxamide; N-[4,6-dichloro-2-[(di-2-propyl-lambda-4-sulfanylidene)carba- moyl]-phenyl]-2-(3-chloro-2-pyridyl)-5-(trifluoromethyl)pyrazole-3-carboxamide; N-[4,6-di- bromo-2-[(diethyl-lambda-4-sulfanylidene)carbamoyl]-phenyl]-2-(3-chloro-2-pyridyl)-5-(tri- fluoromethyl)pyrazole-3-carboxamide; N-[2-(5-amino-1 ,3,4-thiadiazol-2-yl)-4-chloro-6-meth- ylphenyl]-3-bromo-1 -(3-chloro-2-pyridinyl)-1 H-pyrazole-5-carboxamide; 3-chloro-1-(3-chloro- 2-pyridinyl)-N-[2,4-dichloro-6-[[(1-cyano-1 -methylethyl)amino]carbonyl]phenyl]-1 H-pyrazole- 5-carboxamide; 3-bromo-N-[2,4-dichloro-6-(methylcarbamoyl)phenyl]-1-(3,5-dichloro-2-pyri- dyl)-1 H-pyrazole-5-carboxamide; N-[4-chloro-2-[[(1 ,1 -dimethylethyl)amino]carbonyl]-6-meth- ylphenyl]-1 -(3-chloro-2-pyridinyl)-3-(fluoromethoxy)-1 H-pyrazole-5-carboxamide; cyhalodi- amide;

0.27: Chordotonal organ Modulators - undefined target site: flonicamid;

0.28. insecticidal active compounds of unknown or uncertain mode of action: afidopyropen, afoxolaner, azadirachtin, amidoflumet, benzoximate, broflanilide, bromopropylate, chinome- thionat, cryolite, dicloromezotiaz, dicofol, flufenerim, flometoquin, fluensulfone, fluhexafon, fluopyram, fluralaner, metoxadiazone, piperonyl butoxide, pyflubumide, pyridalyl, tioxazafen, 1 1-(4-chloro-2,6-dimethylphenyl)-12-hydroxy-1 ,4-dioxa-9-azadispiro[4.2.4.2]-tetradec-1 1 -en- 10-one, 3-(4'-fluoro-2,4-dimethylbiphenyl-3-yl)-4-hydroxy-8-oxa-1-azaspiro[4.5]dec-3-en-2- one, 1 -[2-fluoro-4-methyl-5-[(2,2,2-trifluoroethyl)sulfinyl]phenyl]-3-(trifluoromethyl)-1 H-1 ,2,4- triazole-5-amine, Bacillus firmus, flupyrimin, (fluxametamide; 5-[3-[2,6-dichloro-4-(3,3- dichloroallyloxy)phenoxy]propoxy]-1 H-pyrazole; 3-(benzoylmethylamino)-N-[2-bromo-4- [1 ,2,2,3,3,3-hexafluoro-1-(trifluoromethyl)propyl]-6-(trifluoromethyl)phenyl]-2-fluoro- benzamide; 3-(benzoylmethylamino)-2-fluoro-N-[2-iodo-4-[1 ,2,2,2-tetrafluoro-1 -

(trifluoromethyl)ethyl]-6-(trifluoromethyl)phenyl]-benzamide; N-[3-[[[2-iodo-4-[1 ,2,2,2- tetrafluoro-1-(trifluoromethyl)ethyl]-6-(trifluoromethyl)phenyl]amino]carbonyl]ph

methyl-benzamide; N-[3-[[[2-bromo-4-[1 ,2,2,2-tetrafluoro-1-(trifluoromethyl)ethyl]-6- (trifluoromethyl)phenyl]amino]carbonyl]-2-fluorophenyl]-4-fluoro-N-methyl-benzam

4-fluoro-N-[2-fluoro-3-[[[2-iodo-4-[1 ,2,2,2-tetrafluoro-1 -(trifluoromethyl)ethyl]-6-(trifluoro- methyl)phenyl]amino]carbonyl]phenyl]-N-methyl-benzamide; 3-fluoro-N-[2-fluoro-3-[[[2-iodo- 4-[1 ,2,2,2-tetrafluoro-1-(trifluoromethyl)ethyl]-6(trifluoromethyl)phenyl]amino]carb^ yl]-N-methyl-benzamide; 2-chloro-N-[3-[[[2-iodo-4-[1 ,2,2,2-tetrafluoro-1-(trifluoromethyl)- ethyl]-6-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]-3-pyridinecarboxamide; 4-cyano- N-[2-cyano-5-[[2,6-dibromo-4-[1 ,2,2,3,3,3-hexafluoro-1-(trifluoromethyl)propyl]phenyl]carba- moyl]phenyl]-2-methyl-benzamide; 4-cyano-3-[(4-cyano-2-methyl-benzoyl)amino]-N-[2,6-di- chloro-4-[1 ,2,2,3,3,3-hexafluoro-1-(trifluoromethyl)propyl]phenyl]-2-fluoro-benzamide;

N-[5-[[2-chloro-6-cyano-4-[1 , 2,2,3, 3,3-hexafluoro-1-(trifluoromethyl)propyl]phenyl]carba- moyl]-2-cyano-phenyl]-4-cyano-2-methyl-benzamide; N-[5-[[2-bromo-6-chloro-4-[2,2,2-tri- fluoro-1 -hydroxy-1 -(trifluoromethyl)ethyl]phenyl]carbamoyl]-2-cyano-phenyl]-4-cyano-

2-methyl-benzamide; N-[5-[[2-bromo-6-chloro-4-[1 ,2,2,3,3,3-hexafluoro-1 -(trifluoromethyl)- propyl]phenyl]carbamoyl]-2-cyano-phenyl]-4-cyano-2-methyl-benzamide; 4-cyano-N-[2-cy- ano-5-[[2,6-dichloro-4-[1 ,2,2,3,3,3-hexafluoro-1 -(trifluoromethyl)propyl]phenyl]carbamoyl]- phenyl]-2-methyl-benzamide; 4-cyano-N-[2-cyano-5-[[2,6-dichloro-4-[1 ,2,2,2-tetrafluoro- 1 -(trifluoromethyl)ethyl]phenyl]carbamoyl]phenyl]-2-methyl-benzamide; N-[5-[[2-bromo-

6-chloro-4-[1 ,2,2,2-tetrafluoro-1 -(trifluoromethyl)ethyl]phenyl]carbamoyl]-2-cyano-phenyl]-

4- cyano-2-methyl-benzamide; 2-(1 ,3-dioxan-2-yl)-6-[2-(3-pyridinyl)-5-thiazolyl]-pyridine; 2-[6-[2-(5-fluoro-3-pyridinyl)-5-thiazolyl]-2-pyridinyl]-pyrimidine; 2-[6-[2-(3-pyridinyl)-5-thi- azolyl]-2-pyridinyl]-pyrimidine; N-methylsulfonyl-6-[2-(3-pyridyl)thiazol-5-yl]pyridine-2-car- boxamide; N-methylsulfonyl-6-[2-(3-pyridyl)thiazol-5-yl]pyridine-2-carboxamide; N-ethyl- N-[4-methyl-2-(3-pyridyl)thiazol-5-yl]-3-methylthio-propanamide; N-methyl-N-[4-methyl- 2-(3-pyridyl)thiazol-5-yl]-3-methylthio-propanamide; N,2-dimethyl-N-[4-methyl-2-(3-pyridyl)- thiazol-5-yl]-3-methylthio-propanamide; N-ethyl-2-methyl-N-[4-methyl-2-(3-pyridyl)thiazol-

5- yl]-3-methylthio-propanamide; N-[4-chloro-2-(3-pyridyl)thiazol-5-yl]-N-ethyl-2-methyl- 3-methylthio-propanamide; N-[4-chloro-2-(3-pyridyl)thiazol-5-yl]-N,2-dimethyl-3-methylthio- propanamide; N-[4-chloro-2-(3-pyridyl)thiazol-5-yl]-N-methyl-3-methylthio-propanamide; N-[4-chloro-2-(3-pyridyl)thiazol-5-yl]-N-ethyl-3-methylthio-propanamide; 1 -[(6-chloro-3-pyri- dinyl)methyl]-1 ,2,3,5,6,7-hexahydro-5-methoxy-7-methyl-8-nitro-imidazo[1 ,2-a]pyridine; 1 -[(6-chloropyridin-3-yl)methyl]-7-methyl-8-nitro-1 ,2,3,5,6,7-hexahydroimidazo[1 ,2-a]pyridin- 5-ol; 1 -isopropyl-N,5-dimethyl-N-pyridazin-4-yl-pyrazole-4-carboxamide; 1 -(1 ,2-dimethyl- propyl)-N-ethyl-5-methyl-N-pyridazin-4-yl-pyrazole-4-carboxamide; N,5-dimethyl-N-pyridazin- 4-yl-1 -(2,2,2-trifluoro-1-methyl-ethyl)pyrazole-4-carboxamide; 1-[1 -(1 -cyanocyclopropyl)eth- yl]-N-ethyl-5-methyl-N-pyridazin-4-yl-pyrazole-4-carboxamide; N-ethyl-1 -(2 -fluoro-1 -methyl- propyl)-5-methyl-N-pyridazin-4-yl-pyrazole-4-carboxamide; 1 -(1 ,2-dimethylpropyl)-N,5-di- methyl-N-pyridazin-4-yl-pyrazole-4-carboxamide; 1-[1 -(1 -cyanocyclopropyl)ethyl]-N,5-di- methyl-N-pyridazin-4-yl-pyrazole-4-carboxamide; N-methyl-1-(2-fluoro-1 -methyl-propyl]- 5-methyl-N-pyridazin-4-yl-pyrazole-4-carboxamide; 1-(4,4-difluorocyclohexyl)-N-ethyl- 5-methyl-N-pyridazin-4-yl-pyrazole-4-carboxamide; 1-(4,4-difluorocyclohexyl)-N,5-dimethyl- N-pyridazin-4-yl-pyrazole-4-carboxamide, N-(1-methylethyl)-2-(3-pyridinyl)-2H-indazole- 4-carboxamide; N-cyclopropyl-2-(3-pyridinyl)-2H-indazole-4-carboxamide; N-cyclohexyl- 2-(3-pyridinyl)-2H-indazole-4-carboxamide; 2-(3-pyridinyl)-N-(2,2,2-trifluoroethyl)-2H-inda- zole-4-carboxamide; 2-(3-pyridinyl)-N-[(tetrahydro-2-furanyl)methyl]-2H-indazole-5-carbox- amide; methyl 2-[[2-(3-pyridinyl)-2H-indazol-5-yl]carbonyl]hydrazinecarboxylate; N-[(2,2-di- fluorocyclopropyl)methyl]-2-(3-pyridinyl)-2H-indazole-5-carboxamide; N-(2,2-difluoropropyl)- 2-(3-pyridinyl)-2H-indazole-5-carboxamide; 2-(3-pyridinyl )-N-(2-pyrimidinylmethyl )-2H-in- dazole-5-carboxamide; N-[(5-methyl-2-pyrazinyl)methyl]-2-(3-pyridinyl)-2H-indazole-5-car- boxamide, tyclopyrazoflo; N-[3-chloro-1 -(3-pyridyl)pyrazol-4-yl]-N-ethyl-3-(3,3,3- trifluoropropylsulfinyl)propanamide; N-[3-chloro-1-(3-pyridyl)pyrazol-4-yl]-3-[(2,2-di- fluorocyclopropyl)methylsulfanyl]-N-ethyl-propanamide; N-[3-chloro-1 -(3-pyridyl)pyrazol-

4-yl]-3-[(2,2-difluorocyclopropyl)methylsulfinyl]-N-ethyl-propanamide; sarolaner, lotilaner, N- [4-chloro-3-[[(phenylmethyl)amino]carbonyl]phenyl]-1-methyl-3-(1 ,1 ,2,2,2-pentafluoroethyl)- 4-(trifluoromethyl)-1 A -pyrazole-5-carboxamide; M. UN.22a 2-(3-ethylsulfonyl-2-pyridyl)-3- methyl-6-(trifluoromethyl)imidazo[4,5-b]pyridine, 2-[3-ethylsulfonyl-5-(trifluoromethyl)-2- pyridyl]-3-methyl-6-(trifluoromethyl)imidazo[4,5-b]pyridine, 4-[5-(3,5-dichlorophenyl)-5-(tri- fluoromethyl)-4A isoxazol-3-yl]-N-[(4 t -2-ethyl-3-oxo-isoxazolidin-4-yl]-2-methyl-benzamide, 4-[5-(3,5-dichloro-4-fluoro-phenyl)-5-(trifluoromethyl)-4 isoxazol-3-yl]-/V-[(4 )-2-ethyl-3-oxo- isoxazolidin-4-yl]-2-methyl-benzamide; N[4-chloro-3-(cyclopropylcarbamoyl)phenyl]-2- methyl-5-(1 ,1 ,2,2,2-pentafluoroethyl)-4-(trifluoromethyl)pyrazole-3-carboxamide, /V-[4-chloro- 3-[(1-cyanocyclopropyl)carbamoyl]phenyl]-2-methyl-5-(1 ,1 ,2,2,2-pentafluoroethyl)-4- (trifluoromethyl)pyrazole-3-carboxamide; acynonapyr; benzpyrimoxan; chloro-/V-(1- cyanocyclopropyl)-5-[1-[2-methyl-5-(1 ,1 ,2,2,2-pentafluoroethyl)-4-(trifluoromethyl)pyrazol-3- yl]pyrazol-4-yl]benzamide. The active substances referred to as component 2, their preparation and their activity e. g. against harmful fungi is known (cf.: http://www.alanwood.net/pesticides/); these substances are commercially available. The compounds described by lUPAC nomenclature, their preparation and their pesticidal activity are also known (cf. Can. J. Plant Sci. 48(6), 587-94, 1968;

EP-A 141 317; EP-A 152 031 ; EP-A 226 917; EP-A 243 970; EP-A 256 503; EP-A 428 941 ; EP-A 532 022; EP-A 1 028 125; EP-A 1 035 122; EP-A 1 201 648; EP-A 1 122 244,

JP 2002316902; DE 19650197; DE 10021412; DE 102005009458; US 3,296,272;

US 3,325,503; WO 98/46608; WO 99/14187; WO 99/24413; WO 99/27783; WO 00/29404;

WO 00/46148; WO 00/65913; WO 01/54501 ; WO 01/56358; WO 02/22583; WO 02/40431 ;

WO 03/10149; WO 03/1 1853; WO 03/14103; WO 03/16286; WO 03/53145; WO 03/61388; WO 03/66609; WO 03/74491 ; WO 04/49804; WO 04/83193; WO 05/120234; WO 05/123689;

WO 05/123690; WO 05/63721 ; WO 05/87772; WO 05/87773; WO 06/15866; WO 06/87325;

WO 06/87343; WO 07/82098; WO 07/90624, WO 10/139271 , WO 1 1/028657, WO 12/168188,

WO 07/006670, WO 1 1/77514; WO 13/047749, WO 10/069882, WO 13/047441 , WO 03/16303, WO 09/90181 , WO 13/007767, WO 13/010862, WO 13/127704, WO 13/024009, WO 13/24010, WO 13/047441 , WO 13/162072, WO 13/092224, WO 1 1/135833, CN 1907024, CN 1456054, CN 103387541 , CN 1309897, WO 12/84812, CN 1907024, WO 09094442, WO 14/60177, WO 13/1 16251 , WO 08/013622, WO 15/65922, WO 94/01546, EP 2865265, WO 07/129454, WO 12/16551 1 , WO 1 1/081 174, WO 13/47441 ).

The present invention furthermore relates to agrochemical compositions comprising a mixture of at least one compound I (component 1 ) and at least one further active substance useful for plant protection, e. g. selected from the groups A) to O) (component 2), in particular one fur- ther fungicide, e. g. one or more fungicide from the groups A) to K), as described above, and if desired one suitable solvent or solid carrier. Those mixtures are of particular interest, since many of them at the same application rate show higher efficiencies against harmful fungi. Furthermore, combating harmful fungi with a mixture of compounds I and at least one fungicide from groups A) to K), as described above, is more efficient than combating those fungi with indi- vidual compounds I or individual fungicides from groups A) to K).

By applying compounds I together with at least one active substance from groups A) to O) a synergistic effect can be obtained, i.e. more then simple addition of the individual effects is obtained (synergistic mixtures).

This can be obtained by applying the compounds I and at least one further active substance simultaneously, either jointly (e. g. as tank-mix) or seperately, or in succession, wherein the time interval between the individual applications is selected to ensure that the active substance applied first still occurs at the site of action in a sufficient amount at the time of application of the further active substance(s). The order of application is not essential for working of the present invention.

When applying compound I and a pesticide II sequentially the time between both applications may vary e. g. between 2 hours to 7 days. Also a broader range is possible ranging from 0.25 hour to 30 days, preferably from 0.5 hour to 14 days, particularly from 1 hour to 7 days or from 1.5 hours to 5 days, even more preferred from 2 hours to 1 day.

In the binary mixtures and compositions according to the invention the weight ratio of the component 1 ) and the component 2) generally depends from the properties of the active components used, usually it is in the range of from 1 :10,000 to 10,000:1 , often it is in the range of from 1 :100 to 100:1 , regularly in the range of from 1 :50 to 50: 1 , preferably in the range of from 1 :20 to 20:1 , more preferably in the range of from 1 :10 to 10:1 , even more preferably in the range of from 1 :4 to 4:1 and in particular in the range of from 1 :2 to 2:1 .

According to further embodiments of the binary mixtures and compositions, the weight ratio of the component 1 ) and the component 2) usually is in the range of from 1000:1 to 1 :1 , often in the range of from 100: 1 to 1 :1 , regularly in the range of from 50:1 to 1 :1 , preferably in the range of from 20:1 to 1 :1 , more preferably in the range of from 10:1 to 1 :1 , even more preferably in the range of from 4:1 to 1 :1 and in particular in the range of from 2:1 to 1 :1 .

According to a further embodiments of the binary mixtures and compositions, the weight ratio of the component 1 ) and the component 2) usually is in the range of from 1 :1 to 1 :1000, often in the range of from 1 :1 to 1 :100, regularly in the range of from 1 :1 to 1 :50, preferably in the range of from 1 :1 to 1 :20, more preferably in the range of from 1 :1 to 1 :10, even more preferably in the range of from 1 :1 to 1 :4 and in particular in the range of from 1 :1 to 1 :2.

In the ternary mixtures, i.e. compositions according to the invention comprising the component 1 ) and component 2) and a compound III (component 3), the weight ratio of component 1 ) and component 2) depends from the properties of the active substances used, usually it is in the range of from 1 :100 to 100:1 , regularly in the range of from 1 :50 to 50:1 , preferably in the range of from 1 :20 to 20:1 , more preferably in the range of from 1 :10 to 10:1 and in particular in the range of from 1 :4 to 4:1 , and the weight ratio of component 1 ) and component 3) usually it is in the range of from 1 :100 to 100:1 , regularly in the range of from 1 :50 to 50:1 , preferably in the range of from 1 :20 to 20:1 , more preferably in the range of from 1 :10 to 10:1 and in particular in the range of from 1 :4 to 4:1.

Any further active components are, if desired, added in a ratio of from 20:1 to 1 :20 to the component 1 ).

These ratios are also suitable for inventive mixtures applied by seed treatment.

Preference is also given to mixtures comprising as component 2) at least one active substance selected from inhibitors of complex III at Q₀ site in group A), more preferably selected from compounds (A.1.1 ), (A.1.4), (A.1.8), (A.1.9), (A.1.10), (A.1 .12), (A.1.13), (A.1 .14), (A.1.17), (A.1 .21 ), (A.1.25), ( (A.1 .34) and (A.1 .35); particularly selected from (A.1.1 ), (A.1.4), (A.1.8), (A.1 .9), (A.1 .13), (A.1.14), (A.1 .17), (A.1.25), (A.1 .34) and (A.1 .35).

Preference is also given to mixtures comprising as component 2) at least one active substance selected from inhibitors of complex III at Q, site in group A), more preferably selected from compounds (A.2.1 ), (A.2.3) and (A.2.4); particularly selected from (A.2.3) and (A.2.4).

Preference is also given to mixtures comprising as component 2) at least one active substance selected from inhibitors of complex II in group A), more preferably selected from compounds (A.3.2), (A.3.3), (A.3.4), (A.3.7), (A.3.9), (A.3.1 1 ), (A.3.12), (A.3.15), (A.3.16), (A.3.17), (A.3.18), (A.3.19), (A.3.20), (A.3.21 ), (A.3.22), (A.3.23), ( (A.3.28), (A.3.31 ), (A.3.32), (A.3.33), (A.3.34), (A.3.35), (A.3.36), (A.3.37), (A.3.38) and (A.3.39); particularly selected from (A.3.2), (A.3.3), (A.3.4), (A.3.7), (A.3.9), (A.3.12), (A.3.15), (A.3.17), (A.3.19), (A.3.22), (A.3.23), ), (A.3.31 ), (A.3.32), (A.3.33), (A.3.34), (A.3.35), (A.3.36), (A.3.37), (A.3.38) and (A.3.39).

Preference is also given to mixtures comprising as component 2) at least one active substance selected from other respiration nhibitors in group A), more preferably selected from compounds (A.4.5) and (A.4.1 1 ); in particular (A.4.1 1 ).

Preference is also given to mixtures comprising as component 2) at least one active substance selected from C14 demethylase inhibitors in group B), more preferably selected from compounds (B.1 .4), (B.1 .5), (B.1 .8), (B.1 .10), (B.1.1 1 ), (B.1 .12), (B.1.13), (B.1 .17), (B.1.18), (B.1 .21 ), (B.1.22), (B.1.23), (B.1 .25), (B.1.26), (B.1 .29), (B.1.34), (B.1 .37), (B.1.38), (B.1 .43) and (B.1 .46); particularly selected from (B.1.5), (B.1.8), (B.1 .10), (B.1.17), (B.1.22), (B.1.23), (B.1 .25), (B.1.33), (B.1 .34), (B.1.37), (B.138), (B.1.43) and (B.1.46).

Preference is also given to mixtures comprising as component 2) at least one active substance selected from Delta 14-reductase inhibitors in group B), more preferably selected from compounds (B.2.4), (B.2.5), (B.2.6) and (B.2.8); in particular (B.2.4).

Preference is also given to mixtures comprising as component 2) at least one active substance selected from phenylamides and acyl amino acid fungicides in group C), more preferably se- lected from compounds (C.1 .1 ), (C.1 .2), (C.1.4) and (C.1.5); particularly selected from (C.1 .1 ) and (C.1.4).

Preference is also given to mixtures comprising as component 2) at least one active substance selected from other nucleic acid synthesis inhibitors in group C), more preferably selected from compounds (C.2.6),(C.2.7) and (C.2.8).

Preference is also given to mixtures comprising as component 2) at least one active substance selected from group D), more preferably selected from compounds (D.1.1 ), (D.1 .2), (D.1.5), (D.2.4) and (D.2.6); particularly selected from (D.1 .2), (D.1.5) and (D.2.6).

Preference is also given to mixtures comprising as component 2) at least one active substance selected from group E), more preferably selected from compounds (E.1.1 ), (E.1.3), (E.2.2) and (E.2.3); in particular (E.1.3).

Preference is also given to mixtures comprising as component 2) at least one active substance selected from group F), more preferably selected from compounds (F.1.2), (F.1.4) and (F.1.5).

Preference is also given to mixtures comprising as component 2) at least one active substance selected from group G), more preferably selected from compounds (G.3.1 ), (G.3.3), (G.3.6), (G.5.1 ), (G.5.2), (G.5.3), (G.5.4), (G.5.5), G.5.6), G.5.7), (G.5.8), (G.5.9), (G.5.10) and (G.5.1 1 ); particularly selected from (G.3.1 ), (G.5.1 ), (G.5.2) and (G.5.3).

Preference is also given to mixtures comprising as component 2) at least one active substance selected from group H), more preferably selected from compounds (H.2.2), (H.2.3), (H.2.5), (H.2.7), (H.2.8), (H.3.2), (H.3.4), (H.3.5), (H.4.9) and (H.4.10); particularly selected from (H.2.2), (H.2.5), (H.3.2), (H.4.9) and (H.4.10).

Preference is also given to mixtures comprising as component 2) at least one active substance selected from group I), more preferably selected from compounds (1.2.2) and (I.2.5).

Preference is also given to mixtures comprising as component 2) at least one active substance selected from group J), more preferably selected from compounds (J.1 .2), (J.1.5) and (J.1 .8); in particular (J.1.5).

Preference is also given to mixtures comprising as component 2) at least one active substance selected from group K), more preferably selected from compounds (K.1.41 ), (K.1 .42), (K.1.44), (K.1 .45), (K.1.47) and (K.1.49); particularly selected from (K.1 .41 ), (K.1.44), (K.1 .45), (K.1.47) and (K.1 .49).

The mixtures of active substances can be prepared as compositions comprising besides the active ingredients at least one inert ingredient (auxiliary) by usual means, e. g. by the means given for the compositions of compounds I. Concerning usual ingredients of such compositions reference is made to the explanations given for the compositions containing compounds I.

I. Synthesis examples With due modification of the starting compounds, the procedures shown in the synthesis examples below were used to obtain further compounds I. The resulting compounds, together with physical data, are listed in Table I below

Example 1 Synthesis of 4,4-difluoro-7-(8-fluoro-3-quinolyl)-5,5-dimethyl-6,7-dihydrothieno[2,3- c]pyridine (I-2):

350 mg (8,0 mmol) of sodium borohydride were added dropwise at 0 °C to a solution of 0,3 g (1 ,0 mmol) 4,4-difluoro-7-(8-fluoro-3-quinolyl)-5,5-dimethyl-thieno[2,3-c]pyridine in 25 ml. in MeOH. The reaction mixture was allowed to warm to room temperature and stirred overnight, before dilution with ethyl acetate. The organic phase was washed with sat. Na2CC>3 solution and water, dried over Na2S0₄ and concentrated. The residue was purified via MPLC with a mixture of water/Acetonitrile to yield 63 mg (21 %) of the title compound as an oil.

H NMR (CDCIs, δ in ppm): 9.0 (s, 1 H); 8,2 (s, 1 H); 7,7 (t, 1 H); 7,6 (dt, 1 H); 7,5 (dd, 1 H); 7,4-7,2 (m, 2H); 6,5 (d, 2H); 5,3 (s, 1 H); 1 ,6 (s, 3H); 1 ,4 (s, 3H).

^*HPLC-MS: R_t = 1 ,07 min; M⁺+H=349,0

Example 2 Synthesis of 7-(7,8-difluoro-3-quinolyl)-4,4-difluoro-5,5-dimethyl-6,7- dihydrothieno[2,3-c]pyridine (I-6):

3 ml. acetic acid was added dropwise at room temperature to a solution of 0,3 g (1 ,0 mmol) 7- (7,8-difluoro-3-quinolyl)-4,4-difluoro-5,5-dimethyl-thieno[2,3-c]pyridine in 10 mL in MeOH. Then, 0,155 g (2,0 mmol) sodium cyanoborohydride was added. The reaction mixture was stirred at room temperature overnight before dilution with ethyl acetate. The organic phase was washed with sat. Na2CC>3 solution and water, dried over Na2S0₄ and concentrated. The residue was purified via MPLC with a mixture of water/Acetonitrile to yield 0,302 g (100%) of the title compound as an oil.

¹H NMR (CDCIs, δ in ppm):9.0 (s, 1 H); 8,1 (s, 1 H); 7,6 (m, 1 H); 7,5 (m, 1 H); 7,2 (dd, 1 H); 7,3 (dd, 1 H); 5,6 (dd, 1 H); 1 ,9 (br s, 1 H); 1.3 (s, 6H)

^*HPLC-MS: R_t = 1 ,093 min; M⁺+H=367,0

Example 3: Synthesis of 7-(7,8-difluoro-3-quinolyl)-4,4-difluoro-5,5,6-trimethyl-7H-thieno[2,3- c]pyridine (1-1 1 )

To a solution of 7-(7,8-difluoro-3-quinolyl)-4,4-difluoro-5,5-dimethyl-6,7-dihydrothieno[2,3- c]pyridine (0.430 g, 1.174 mmol) in acetonitrile 7.5 mL., formaldehyde (10 mL, 1 1 .737 mmol) and NaCNBH₃ (0.221 g, 3.521 mmol) were added. The reaction mixture was allowed to react at room temperature overhicht, then 0.725 mL acetic acid were added. The reaction was diluted with EtOAc, and quenched with 1 M NaOH sol. The organic phase was washed with sat. Na2C03 solution and water, dried over Na2S0₄ and concentrated. The residue was crystalized using DIPE to yield 85 mg (18 %) of the title compound as a white solid (Mp = 149 °C)

H NMR (CDCIs, δ in ppm): 9.0 (s, 1 H); 8,1 (s, 1 H); 7,6 (m, 1 H); 7,4 td, 1 H); 7,2 (dd, 1 H); 7,1 (dd, 1 H); 4,8 (dd, 1 H); 2,2 (s, 3H); 1 ,4 (s, 3H); 1.2 (s, 3H)

^*HPLC-MS: R_t = 1 ,315 min; M⁺+H=381 Example 4: Synthesis of 1-[7-(7,8-difluoro-3-quinolyl)-4,4-difluoro-5,5-dimethyl-7H-thieno[2,3- c]pyridin-6-yl]ethenone (1-13)

To a solution of 7-(7,8-difluoro-3-quinolyl)-4,4-difluoro-5,5-dimethyl-6,7-dihydrothieno[2,3- c]pyridine (0.430 g, 1.174 mmol) in 7 ml. CH2CI2, 3 ml. pyridine and 3 mL acetyl chloride were added. The reaction mixture was heated for 2 h at 90 °C in microwave. The reaction was diluted with EtOAc, and quenched with sat. NH₄CI sol. The organic phase was washed with sat.

Na2CC>3 solution and water, dried over Na2S0₄ and concentrated. The residue via column chroatography to yield 1 12 mg (21 %) of the title compound as a brown oil 1H NMR (CDCI₃, δ in ppm): 9.0 (s, 1 H); 8,1 (s, 1 H); 7,6 (m, 1 H); 7,5 (td, 1 H); 7,4 (d, 1 H); 7,2 (d, 1 H); 6,5 (s, 1 H); 2,2 (s, 3H); 2,1 (s, 3H); 1 ,4 (s, 3H).

^*HPLC-MS: R_t = 1 ,213 min; M⁺+H=408,9 Table I:

The positions of the heteroaryls given as "R⁷+R⁸" marked with "#" represents the connection points (carbon atoms 5' and 6' in formula I) with the remaining skeleton of the compounds of formula:

^*HPLC-MS: HPLC-column Kinetex XB C18 1 ,7μ (50 x 2,1 mm); eluent: acetonitrile / water +

0.1 % TFA (5 gradient from 5:95 to 100 : 0 in 1 .5 min at 60°C, flow gradient from 0.8 to 1 .0 ml/min in 1.5 min). MS: Quadrupol Electrospray lonisation, 80 V (positive mode).

II. Biological trials

Microtest

The active compounds were formulated separately as a stock solution having a concentration of 10000 ppm in dimethyl sulfoxide.

Example - 1 Activity against the grey mold Botrytis cinerea in the microtiterplate test

The stock solutions were mixed according to the ratio, pipetted onto a micro titer plate (MTP) and diluted with water to the stated concentrations. A spore suspension of Botrci cinerea in an aqueous biomalt or yeast-bactopeptone-sodiumacetate solution was then added. The plates were placed in a water vapor-saturated chamber at a temperature of 18°C. Using an absorption photometer, the MTPs were measured at 405 nm 7 days after the inoculation.

In this test, the samples which had been treated with 2 ppm of the active substance from exam- pies 1-1 , 1-2, 1-3, I-5, and I-6 respectively, showed up to at most 3 % growth of the pathogen. In this test, the sample which had been treated with 31 ppm of the active substance from examples I-4, I-5, I-6, I-7 and I-8 showed up to at most 9 % growth of the pathogen.

Example 2 - Activity against rice blast Pyricularia oryzae in the microtiterplate test

The stock solutions were mixed according to the ratio, pipetted onto a micro titer plate (MTP) and diluted with water to the stated concentrations. A spore suspension of Pyricularia oryzae in an aqueous biomalt or yeast-bactopeptone-glycerine solution was then added. The plates were placed in a water vapor-saturated chamber at a temperature of 18°C. Using an absorption photometer, the MTPs were measured at 405 nm 7 days after the inoculation.

In this test, the samples which had been treated with 2 ppm of the active substance from exam- pies 1-1 , 1-3, I-5, and I-6 respectively, showed up to at most 5 % growth of the pathogen.

In this test, the sample which had been treated with 31 ppm of the active substance from example I-4, I-5, I-6, I-7 and I-8 showed up to at most 15 % growth of the pathogen. Example 3 - Activity against leaf blotch on wheat caused by Septoria tritici

The stock solutions were mixed according to the ratio, pipetted onto a micro titer plate (MTP) and diluted with water to the stated concentrations. A spore suspension of Septoria tritici Ίη an aqueous biomalt or yeast-bactopeptone-glycerine solution was then added. The plates were placed in a water vapor-saturated chamber at a temperature of 18°C. Using an absorption pho- tometer, the MTPs were measured at 405 nm 7 days after the inoculation.

In this test, the samples which had been treated with 82 ppm of the active substance from examples 1-1 , I-2, I-5, and I-6 respectively, showed up to at most 18 % growth of the pathogen. In this test, the samples which had been treated with 8 ppm of the active substance from examples I-5, I-6, I-7 and I-8 respectively, showed up to at most 6 % growth of the pathogen.

Example 4 - Activity against Fusarium culmorum in the microtiterplate test

The stock solutions were mixed according to the ratio, pipetted onto a micro titer plate (MTP) and diluted with water to the stated concentrations. A spore suspension of Fusarium culmorum in an aqueous biomalt or yeast-bactopeptone-glycerine solution was then added. The plates were placed in a water vapor-saturated chamber at a temperature of 18°C. Using an absorption photometer, the MTPs were measured at 405 nm 7 days after the inoculation.

In this test, the samples which had been treated with 31 ppm of the active substance from examples I-5, I-6, I-7 and I-8 respectively, showed up to at most 2 % growth of the pathogen.

The measured parameters were compared to the growth of the active compound-free control variant (100%) and the fungus-free and active compound-free blank value to determine the relative growth in % of the pathogens in the respective active compounds.

Green House

The spray solutions were prepared in several steps:

The stock solution were prepared: a mixture of acetone and/or dimethylsulfoxide and the wetting agent/emulsifier Wettol, which is based on ethoxylated alkylphenoles, in a relation (volume) solvent-emulsifier of 99 to 1 was added to 25 mg of the compound to give a total of 5 ml.

Water was then added to total volume of 100 ml.

This stock solution was diluted with the described solvent-emulsifier-water mixture to the given concentration.

Example 1 - Long lasting control of Botrytis cinereaon leaves of green pepper

Young seedlings of green pepper were grown in pots to the 4 to 5 leaf stage. These plants were sprayed to run-off with an aqueous suspension, containing the concentration of active ingredient or their mixture mentioned in the table below. The plants were then cultivated in the greenhouse for 7 days and then inoculated with an aqueous biomalt solution containing the spore suspension of Botrytis cinerea. Then the plants were immediately transferred to a humid chamber. After 5 days at 22 to 24°C and a relative humidity close to 100 % the extent of fungal attack on the leaves was visually assessed as % diseased leaf area.

In this test, plants which had been treated with 32 ppm of the active substance from examples I- 1 , I-2 and I-3 respectively, showed up to at most 7 % diseased leaf area compared to 90 % diseased leaf area by untreated plants.

In this test, plants which had been treated with 250 ppm of the active substance from examples I-7 and I-8 respectively, showed up to at most 1 % diseased leaf area compared to 90 % diseased leaf area by untreated plants.

Example 2 - Preventative fungicidal control of Botrytis cinerea on leaves of green pepper

Young seedlings of green pepper were grown in pots to the 4 to 5 leaf stage. These plants were sprayed to run-off with an aqueous suspension, containing the concentration of active ingredient or their mixture mentioned in the table below. The next day the plants were inoculated with an aqueous biomalt or DOB media solution containing the spore suspension of Botrytis cinerea. Then the plants were immediately transferred to a humid chamber. After 5 days at 22 to 24· C and a relative humidity close to 100 % the extent of fungal attack on the leaves was visually assessed as % diseased leaf area.

In this test, plants which had been treated with 250 ppm of the active substance from examples I-7 and I-8 respectively, showed up to at most 0 % diseased leaf area compared to 90 % diseased leaf area by untreated plants.

Example 3 - Control of culm rot on pearl millet caused by Fusanum culmorum

Pot-grown pearl millet seedlings were sprayed to run-off with an aqueous suspension, containing the concentration of active ingredient or their mixture as described below. Seven days later the plants were inoculated with a spore suspension of Fusarium culmorum in an aqueous biomalt or DOB media solution. Then the trial plants were immediately transferred to a humid chamber. After 6 days at 23-25°C and a relative humidity close to 100 % the extent of fungal attack on the leaves was visually assessed as % diseased leaf area. In this test, plants which had been treated with 250 ppm of the active substance from examples I-7 and I-8 respectively, showed up to at most 1 % diseased leaf area compared to 80 % diseased leaf area by untreated plants.

Claims

1. Compounds of the formula I

wherein

m is 0, 1 , 2, 3 or 4;

R¹ is in each case independently selected from halogen, OH, CN, NO2, SH, N H2,

R^1a halogen, OH, CN, Ci-C6-alkoxy, C₃-C6-cycloalkyl, C₃-C6-halogencycloalkyl, Ci- C₄-halogenalkoxy, Ci-C6-alkylthio and phenoxy, wherein the phenyl group is unsubstituted or carries one, two, three, four or five substituents R^11a selected from the group consisting of halogen, OH, Ci-C₄-alkyl, Ci-C₄-halogenalkyl, Ci- C₄-alkoxy and Ci-C₄-halogenalkoxy;

R^{1 b} halogen, OH, CN, Ci-C₄-alkyl, Ci-C₄-alkoxy, d-C₄-halogenalkyl, C₃-C₆- cycloalkyl, C3-C6-halogencycloalkyl, Ci-C₄-halogenalkoxy and Ci-C6-alkylthio; n is 0, 1 or 2;

R² is in each case independently selected from the substituents as defined for R¹ , wherein the possible substituents for R² are R^2a and R^2b , respectively, which correspond to R^1a and R^{1 b}, respectively; R³,R⁴ are independently selected from halogen, OH, CN, N0₂, SH, Ci-C₆-alkylthio, NH₂,

NH(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂, NH-S0₂-R^x, Ci-C₆-alkyl,_Ci-C₆-halogenalkyl, C₂-C₆- alkenyl, C₂-C6-halogenalkenyl, C₂-C6-alkynyl, C₂-C6-halogenalkynyl, Ci-C6-alkoxy, Ci-C6-halogenalkoxy, C₂-C6-alkenyloxy, C₂-C6-alkynyloxy, CH(=0), C(=0)Ci-C6- alkyl, C(=0)0(Ci-C₆-alkyl), C(=0)NH(Ci-C₆-alkyl), C(=0)N(Ci-C₆-alkyl)₂,

CR'=NOR", a saturated or partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbocycle or heterocycle, wherein in each case one or two CH₂ groups of the carbo- and heterocycle may be replaced by a group independently selected from C(=0) and C(=S), five- or six-membered heteroaryl and ar- yl; wherein the heterocycle and the heteroaryl contain independently one, two, three or four heteroatoms selected from N, O and S; and wherein R' and R" are independently selected from H, Ci-C₄-alkyl, C₂-C6-alkenyl, C₂-C6-alkynyl, saturated or partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbo- and heterocycle, five- or six-membered heteroaryl or aryl; wherein the heter- ocycle or heteroaryl contains one, two or three heteroatoms selected from N, O and

S, and wherein R' and R" are independently unsubstituted or substituted by R'" which is independently selected from halogen, OH, CN, N0₂, SH, NH₂, NH(Ci-C₄- alkyl), N(Ci-C₄-alkyl)₂, NH-S0₂-R^x, Ci-C₆-alkyl, Ci-C₆-halogenalkyl, C₂-C₆-alkenyl, C₂-C6-halogenalkenyl, C₂-C6-alkynyl, C₂-C6-halogenalkynyl, Ci-C6-alkoxy, C1-C6- halogenalkoxy, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl and phenyl; or wherein the acyclic moieties of R³ and R⁴ are independently not further substituted or carry one, two, three or up to the maximum possible number of identical or different groups R^3a or R^4a, respectively, which independently of one another are selected from:

NH(C(=0)Ci-C₄-alkyl), N(C(=0)Ci-C₄-alkyl)₂, NH-S0₂-R^x, Ci-C₆-alkoxy, Ci-C₄-halogenalkoxy, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, C1-C6- alkylthio, Ci-C₆-halogenalkylthio, S(0)_z-Ci-C₆-alkyl, S(0)_z-Ci-C₆- halogenalkyl, S(0)_z-aryl, CH(=0), C(=0)C C₆-alkyl, C(=0)0(Ci-C₆-alkyl), C(=0)NH(CrC₆-alkyl), C(=0)N(C C₆-alkyl)₂, CR'=NOR", a saturated or partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten- membered carbocycle or heterocycle, five-, six- or ten-membered heteroaryl, aryl, phenoxy; wherein in each case one or two CH₂ groups of the carbocycle and heterocycle may be replaced by a group independently selected from C(=0) and C(=S); wherein the heterocycle and heteroaryl contain independently one, two, three or four heteroatoms selected from N, O and S; wherein the carbocyclic, heterocyclic, aryl, phenyl and heteroaryl groups are independently unsubstituted or carry one, two, three, four or five substituents selected from the group consisting of halogen, OH, CN, N0₂, SH, NH₂, NH(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂, NH(C(=0)Ci-C₄- alkyl), N(C(=0)Ci-C₄-alkyl)₂, NH-S0₂-R^x, Ci-C₆-alkylthio, Ci-C₄-alkyl, Ci- C₄-halogenalkyl, Ci-C₄-alkoxy, Ci-C₄-halogenalkoxy and S(0)_z-Ci-C6- alkyl;

z is 0, 1 and 2;

NH(C(=0)Ci-C₄-alkyl), N(C(=0)Ci-C₄-alkyl)₂, NH-S0₂-R^X, Ci-C₄-alkyl, Ci- C₄-alkoxy, Ci-C₄-halogenalkyl, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, Ci-C₄-halogenalkoxy, d-Ce-alkylthio, Ci-Ce-halogenalkylthio, S(0)_z-Ci-

C6-alkyl, Ci-C₄-alkoxy-Ci-C₄-alkyl, phenyl and phenoxy, wherein the phenyl groups are unsubstituted or carry one, two, three, four or five substitu- ents selected from the group consisting of halogen, OH, Ci-C₄-alkyl, Ci- C₄-halogenalkyl, Ci-C₄-alkoxy and Ci-C₄-halogenalkoxy;

and wherein R^x R' and R" is as defined above;

or R³, R⁴ together with the carbon atom to which they are bound (marked with ^* in formula I) form a saturated or partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbocycle or heterocycle; wherein the heterocycle contains one, two, three or four heteroatoms selected from N, O and S, wherein the heteroa- torn N may carry one substituent R^N selected from Ci-C₄-alkyl, Ci-C₄-halogenalkyl and S0₂Ph, wherein Ph is unsubstituted phenyl or phenyl that is substituted by one, two or three substituents selected from CrC₄-alkyl, and wherein the heteroatom S may be in the form of its oxide SO or S0₂, and wherein the carbocycle or heterocycle is unsubstituted or carries one, two, three or four substituents R³⁴ independently selected from halogen, OH, CN, N0₂, SH, NH₂, d-Ce-alkyl, Ci-C₆-halogenalkyl, Ci-

C6-alkoxy, Ci-C6-halogenalkoxy, Ci-C6-alkylthio, Ci-C6-halogenalkylthio, Ci-C₄- alkoxy-Ci-C₄-alkyl, phenyl and phenoxy, wherein the phenyl groups are unsubstituted or carry one, two, three, four or five substituents R^34a selected from the group consisting of CN, halogen, OH, Ci-C₄-alkyl, Ci-C₄-halogenalkyl, Ci-C₄-alkoxy and CrC₄-halogenalkoxy; and wherein in each case one or two CH₂ groups of the carbo- or heterocycle may be replaced by a group independently selected from C(=0) and C(=S);

5 is hydrogen, halogen, OH, CN, N0₂, SH, NH₂, NH(Ci-C₄-alkyl), N(Ci-C₄-alkyl)₂, NH- S0₂-R^x, C₂-C₆-alkyl, substituted d-Ce-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, Ci-C₆- alkoxy, C3-C6-cycloalkyl, saturated or partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered heterocycle, five- or six-membered heteroaryl or aryl; wherein the heterocycle or heteroaryl contains one, two or three heteroatoms selected from N, O and S; and wherein R^x is defined above; and

wherein the acyclicmoieties of R⁵ are not further substituted or carry one, two, three or up to the maximum possible number of identical or different groups R^5a which independently of one another are selected from: R^5a halogen, OH , CN , Ci-C6-alkoxy, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, Ci- C4-halogenalkoxy, Ci-C6-alkylthio and phenoxy, wherein the phenyl group is unsubstituted or carries one, two, three, four or five substituents R^55a selected from the group consisting of halogen, OH , Ci-C4-alkyl, Ci-C4-halogenalkyl, Ci- C4-alkoxy and Ci-C4-halogenalkoxy;

R^5b halogen, OH , CN , Ci-C₄-alkyl, Ci-C₄-alkoxy, Ci-C₄-halogenalkyl, C₃-C₆- cycloalkyl, C3-C6-halogencycloalkyl, Ci-C4-halogenalkoxy and Ci-C6-alkylthio;

or R⁵ and R⁶ together with the carbon atom to which they are bound (marked with C** in formula I) form a saturated or partially unsaturated three-, four-, five-, six-, seven-, eight-, nine-, or ten-membered carbo- or heterocyde; wherein the heterocyde contains one, two, three or four heteroatoms selected from N , O and S, wherein the heteroatom N may carry one substituent R^N selected from Ci-C4-alkyl, C1-C4- halogenalkyl and S02Ph, wherein Ph is unsubstituted phenyl or phenyl that is substituted by one, two or three substituents selected from Ci-C4-alkyl, and wherein the heteroatom S may be in the form of its oxide SO or SO2, and wherein the carbocycle or heterocyde is unsubstituted or carries one, two, three or four substituents R⁵⁶ independently selected from halogen, OH , CN , NO2, SH , NH2, Ci- C6-alkyl, Ci-C6-halogenalkyl, Ci-C6-alkoxy, Ci-C6-halogenalkoxy, Ci-C6-alkylthio, Ci- C6-halogenalkylthio, Ci-C4-alkoxy-Ci-C4-alkyl, phenyl and phenoxy; wherein the phenyl groups are unsubstituted or carry one, two, three, four or five substituents R^56a selected from the group consisting of CN , halogen, OH , Ci-C4-alkyl, C1-C4- halogenalkyl, Ci-C4-alkoxy and Ci-C4-halogenalkoxy; and wherein in each case one or two CH₂ groups of the carbo- or heterocyde may be replaced by a group independently selected from C(=0) and C(=S);

and

o is 0, 1 , 2 or 3; and

R⁷⁸ are independently selected from halogen, OH , CN , NO2, SH , N H₂,

N H(CrC₄-alkyl), N(Ci-C₄-alkyl)₂, N H(C(=0)d-C₄-alkyl), N(C(=0)C C₄- alkyl)₂, N H-S0₂-R^x, CH(=0), C(=0)Ci-C₆-alkyl, C(=0) N H(Ci-C₆-alkyl), CR'=NOR", d-Ce-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, Ci-C₆-alkoxy, Ci- C6-halogenalkoxy, C2-C6-alkenyloxy, C2-C6-alkynyloxy, C3-C6-cycloalkyl, C3-C6-cycloalkenyl, S(0)z-Ci-C6-alkyl, three-, four-, five- or six-membered saturated or partially unsaturated heterocycle, five- or six-membered heteroaryl and phenyl; wherein the heterocycle or heteroaryl contains one, two or three heteroatoms selected from N, O and S; wherein the heterocycle or heteroaryl contains one, two or three heteroatoms selected from N, O and S; wherein z, R' and R" is as defined above;

R^78a halogen, OH, CN, Ci-C₆-alkoxy, C₃-C₆-cycloalkyl, C₃-C₆- cycloalkenyl, C3-C6-halogencycloalkyl, C3-C6-halogencycloalkenyl, Ci-C4-halogenalkoxy, Ci-C6-alkylthio, five- or six-membered heteroaryl, phenyl and phenoxy, wherein the heterorayl, phenyl and phenoxy group is unsubstituted or carries one, two, three, four or five substituents R^78a' selected from the group consisting of halogen, OH, Ci-C4-alkyl, Ci-C4-halogenalkyl, Ci-C4-alkoxy and C1-C4- halogenalkoxy;

wherein the cyclic, phenyl, heterocyclic and heteroaryl moieties of R⁷⁸ are not further substituted or carry one, two, three, four, five or up to the maximum number of identical or different groups R^78b which

independently of one another are selected from:

R^78b halogen, OH, CN, Ci-C₄-alkyl, Ci-C₄-alkoxy, C C₄-halogenalkyl, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, Ci-C4-halogenalkoxy and Ci-C6-alkylthio;

is in each case independently selected from hydrogen, OH, CH(=0), C(=0)Ci-C6- alkyl, C(=0)C₂-C₆-alkenyl, C(=0)C₂-C₆-alkynyl, C(=0)C₃-C₆-cycloalkyl, C(=0)0(Ci- Ce-alkyl), C(=0)0(C₂-C₆-alkenyl), C(=0)0(C₂-C₆-alkynyl), C(=0)0(C₃-C₆- cycloalkyl), C(=0)NH(Ci-C₆-alkyl), C(=0)NH(C₂-C₆-alkenyl), C(=0)NH(C₂-C₆- alkynyl), C(=0)NH(C₃-C₆-cycloalkyl), C(=0)N(Ci-C₆-alkyl)₂, C(=0)N(C₂-C₆- alkenyl)₂, C(=0)N(C₂-C₆-alkynyl)₂, C(=0)N(C₃-C₆-cycloalkyl)₂, CH(=S), C(=S)C C₆- alkyl, C(=S)C₂-C₆-alkenyl, C(=S)C₂-C₆-alkynyl, C(=S)C₃-C₆-cycloalkyl, C(=S)0(Ci- Ce-alkyl), C(=S)0(C₂-C₆-alkenyl), C(=S)0(C₂-C₆-alkynyl), C(=S)0(C₃-C₆- cycloalkyl), C(=S)NH(Ci-C₆-alkyl), C(=S)NH(C₂-C₆-alkenyl), C(=S)NH(C₂-C₆- alkynyl), C(=S)NH(C₃-C₆-cycloalkyl), C(=S)N(Ci-C₆-alkyl)₂, C(=S)N(C₂-C₆-alkenyl)₂, C(=S)N(C₂-C₆-alkynyl)₂, C(=S)N(C₃-C₆-cycloalkyl)₂, Ci-C₆-alkyl, Ci-C₄-halogenalkyl, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, Ci-C4-alkoxy, Ci-C4-halogenalkoxy, OR^Y, Ci-C6-alkylthio, Ci-C6-halogenalkylthio, C2-C6-alkenyl, C2-C6-halogenalkenyl C₂-C₆-alkynyl, C₂-C₆-halogenalkynyl, S(0)z-C C₆-alkyl, S(0)_z-CrC₆-halogenalkyl, S(0)_z-Ci-C₆-alkoxy, S(0)_z-C₂-C₆-alkenyl, S(0)_z-C₂-C₆-alkynyl, S(0)_zaryl, SO2- NH(Ci-C₆-alkyl), S0₂-NH(Ci-C₆-halogenalkyl), S0₂-NH-aryl, tri-(Ci-C₆ alkyl)silyl and di-(Ci-C6 alkoxy)phosphoryl), five- or six-membered heteroaryl and aryl; wherein the heteroaryl contains one, two or three heteroatoms selected from N, O and S; wherein the aryl groups are unsubstituted or carry one, two, three, four or five substituents selected from the group consisting of CN , halogen, OH , C1-C4- alkyl, Ci-C4-halogenalkyl, Ci-C4-alkoxy and Ci-C4-halogenalkoxy;

R^Y is Ci-C6-alkyl, Ci-C6-halogenalkyl, C2-C6-alkenyl, C2-C6-halogenalkenyl, C2-C6- alkynyl, C2-C6-halogenalkynyl, C₃-C6-cycloalkyl, C₃-C6-halogencycloalkyl, phenyl and phenyl-Ci-C6-alkyl; wherein the phenyl groups are unsubstituted or carry one, two, three, four or five substituents selected from the group consisting of CN , halogen, OH , Ci-C4-alkyl, Ci-C4-halogenalkyl, Ci-C4-alkoxy and C1-C4- halogenalkoxy;

R^9a halogen, OH , CN , Ci-C₆-alkoxy, C₃-C₆-cycloalkyl, C₃-C₆- cycloalkenyl, C3-C6-halogencycloalkyl, C₃-C6-halogencycloalkenyl, Ci-C4-halogenalkoxy, Ci-C6-alkylthio, five- or six-membered heteroaryl, phenyl and phenoxy, wherein the heterorayl, phenyl and phenoxy group is unsubstituted or carries one, two, three, four or five substituents R^78a' selected from the group consisting of halogen, OH , Ci-C4-alkyl, Ci-C4-halogenalkyl, Ci-C4-alkoxy and C1-C4- halogenalkoxy;

R^9b halogen, OH , CN , Ci-C₄-alkyl, Ci-C₄-alkoxy, Ci-C₄-halogenalkyl, C3-C6-cycloalkyl, C3-C6-halogencycloalkyl, Ci-C4-halogenalkoxy and Ci-C6-alkylthio; and the N-oxides and the agriculturally acceptable salts thereof.

The compounds of claim 1 wherein R³ and R⁴ are independently selected from Ci-C4-alkyl or Ci-C4-halogenalkyl.

The compounds of any one of claims 1 to 2, wherein R³ is in each case independently selected from Ci-C4-alkyl or Ci-C4-halogenalkyl and R⁴ is in each case independently selected from Ci-C6-alkyl, Ci-C6-halogenalkyl, CN , Ci-C6-halogenalkyl, C2-C6-alkenyl, C2-C6-halogenalkenyl, C3-C6-cycloalkenyl, C2-C6-alkynyl, C2-C6-halogenalkynyl, C3-C6- cycloalkynyl, CH(=0), C(=0)Ci-C₆-alkyl, C(=0)0(Ci-C₆-alkyl), CR'=NOR", C₃-C₆- halogencycloalkyl, a saturated three-, four-, five-, six-, membered carbocycle or hetero- cycle, a five- or six-membered heteroaryl or aryl; and Ci-C6-alkyl substituted by CN , Ci- Ce-alkoxy, Ci-C₄-halogenalkoxy, Ci-C₆-alkylthio, S(0)_z-Ci-C₆-alkyl, N H-S0₂-R^x, N H(Ci- Ce-alkyl), N(Ci-C₆-alkyl)₂, CH(=0), C(=0)Ci-C₆-alkyl, C(=0)0(Ci-C₆-alkyl), a saturated three-, four-, five-, six-, membered carbocycle or heterocycle, a five- or six-membered heteroaryl or aryl.

The compounds of any one of claims 1 to 3, wherein wherein R³ is in each case independently selected from Ci-C4-alkyl or Ci-C4-halogenalkyl and R⁴ is in each case independently selected from Ci-C6-alkyl, Ci-C6-halogenalkyl, C2-C6-alkenyl, C2-C6- halogenalkenyl, C2-C6-alkynyl, C2-C6-halogenalkynyl, C3-C6-cycloalkyl, C3-C6- halogencycloalkyl, a five- or six-membered heteroaryl or aryl; and Ci-C6-alkyl substituted by a five- or six-membered heteroaryl or aryl.

The compounds of any one of claims 1 to 4, wherein R⁵ and R⁶ independently are hydrogen.

The compounds of any one of claims 1 to 4, wherein R⁵ and R⁶ independently are halogen.

The compounds of any one of claims 1 to 6, wherein R⁷ and R⁸ together with the carbon atoms to which they are bound form a five-membered heteroaryl; wherein the heteroaryl contains one, two or three heteroatoms selected from N, O and S, and wherein the heteroaryl carries zero, one, two, three or four substituents (R⁷⁸)₀.

The compounds of any one of claims 1 to 7, wherein R⁹ is hydrogen, C(=0)Ci-C6-alkyl, C(=0)OCi-C₆-alkyl, C(=0)NHCi-C₆-alkyl, S(0)_z-Ci-C₆-alkyl, S(0)_z-aryl, S0₂-NH(Ci-C₆- alkyl), OR^Y, or Ci-C₄-alkyl.

A process for the synthesis of compounds I of claim 1 , comprising the step of:

a) reacting a compound XI

XI

wherein all substituents are as defined in claim 1 with the proviso that R³ and R⁴ together with the carbon to which they are bond can not form a carbocycle or heterocycle. 10. The intermediate compounds XI as defined in claim 9.

1 1. A composition, comprising one compound of formula I, as defined in any of the claims 1 to 8, an N-oxide or an agriculturally acceptable salt thereof.

12. The composition according to claim 1 1 , comprising additionally a further active substance.

13. A use of a compound of the formula I, as defined in any of the claims 1 to 8, and/or of an agriculturally acceptable salt thereof or of the compositions, as defined in any of the claims 1 1 or 12, for combating phytopathogenic fungi.

4. A method for combating phytopathogenic fungi, comprising treating the fungi or the materials, plants, the soil or seeds to be protected against fungal attack with an effective amount of at least one compound of formula I, as defined in any of the claims 1 to 8 or with a composition, as defined in any of the claims 1 1 or 12.

5. Seed, coated with at least one compound of the formula I, as defined in any of the

claims 1 to 8, and/or an agriculturally acceptable salt thereof or with a composition, as defined in any of the claims 1 1 or 12, in an amount of from 0.1 to 10 kg per 100 kg of seed.